<SEC-DOCUMENT>0001213900-25-073743.txt : 20250808
<SEC-HEADER>0001213900-25-073743.hdr.sgml : 20250808
<ACCEPTANCE-DATETIME>20250808170044
ACCESSION NUMBER:		0001213900-25-073743
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250808
DATE AS OF CHANGE:		20250808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		251199288

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ea0249439-10q_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<html xmlns:atnm="http://www.actiniumpharma.com/20250630" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-8060">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="ixv-34"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric><b>&#160;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-8061">June 30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-8062">2025</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-50"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric><b>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from __________ to __________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-61"><b>001-36374</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-67"><b>ACTINIUM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-77"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-82"><span style="font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-100"><b>100 Park Ave., 23<sup>rd</sup> Floor</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-8063">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-8064">NY</ix:nonNumeric> </b></p></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-107"><span style="font-size: 10pt"><b>10017</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-8065">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-8066">677-3870</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="width: 2%">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-146"><span style="font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-151"><span style="font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-8067">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-8068">Yes</ix:nonNumeric> &#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-8069">Yes</ix:nonNumeric> &#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="background-color: white"> <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="background-color: white"> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-189"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span><span style="font-size: 10pt">&#160;</span></td> <td><span style="font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-197"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="background-color: white"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-205"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric><span style="font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards, provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;Yes
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-218"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>&#160;No</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of August 8, 2025: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8070">31,195,891</ix:nonFraction></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; width: 8%"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; width: 84%"><span style="font-size: 10pt"><a href="#a_002">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_003">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_004">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_005">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_008">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_009">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_010">Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_011">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_012">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="#a_013">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><b><a href="#a_014">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. UNAUDITED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion
of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at
June 30, 2025 and December 31, 2024, and the results of operations and cash flows for the three months and six months ended June 30, 2025
and 2024, respectively, have been made. Certain information and footnote disclosures normally included in financial statements prepared
in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested
that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s
audited financial statements for the year ended December 31, 2024 in the Company&#8217;s Annual Report on Form 10-K. The results of operations
for the three months and six months ended June 30, 2025 are not necessarily indicative of the operating results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8071">59,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8072">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-8073">1,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-8074">1,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-8075">61,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-8076">74,506</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-8077">985</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-8078">891</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-8079">271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-8080">364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8081">329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8082">324</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8083">1,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8084">1,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8085">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-8086">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-8087">63,017</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-8088">76,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8089">7,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8090">7,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8091">589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8092">569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8093">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-8094">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8095">8,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-8096">8,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8097">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8098">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Long-term operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8099">685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8100">984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Long-term finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8101">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-8102">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-8103">44,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-8104">44,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8105"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8106">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8107"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8108">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-8109"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-8110"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8111"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8112">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8113"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-8114">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8115"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-8116">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-8117"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8118">31,195,891</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-8119"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-8120">31,195,891</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-8121">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-8122">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-8123">417,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-8124">408,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-8125">398,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-8126">375,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8127">19,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8128">32,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-8129">63,017</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-8130">76,899</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Other revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="-sec-ix-hidden: hidden-fact-15; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Research and development, net of reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-8131">4,879</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-8132">8,825</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-8133">12,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-8134">15,460</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-8135">2,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-8136">3,593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-8137">11,562</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-8138">6,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-8139">7,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-8140">12,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-8141">24,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-8142">22,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8143">7,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8144">12,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8145">24,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8146">22,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-8147">625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-8148">1,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-8149">1,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-8150">1,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-8151">625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-8152">1,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-8153">1,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-8154">1,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8155">6,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8156">11,353</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8157">22,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8158">20,023</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-8159"><ix:nonFraction contextRef="c12" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-8160">0.22</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-8161"><ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-8162">0.38</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-8163"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-8164">0.73</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-8165"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-8166">0.69</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-8167"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-8168">31,195,891</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-8169"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-8170">30,103,063</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-8171"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-8172">31,195,891</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-8173"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-8174">28,994,775</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2025 to June
30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><b>Stockholders</b>&#8217;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold">Balance, January 1, 2025</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8175">31,195,891</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8176">31</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8177">408,553</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8178">375,826</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8179">32,758</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8180">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8181">8,874</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8182">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8183">15,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Balance, March 31, 2025</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8184">31,195,891</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8185">31</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8186">417,427</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8187">391,764</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8188">25,694</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8189">197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8190">197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8191">6,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8192">6,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Balance, June 30, 2025</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8193">31,195,891</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8194">31</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8195">417,624</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8196">398,642</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8197">19,013</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2024 to June
30, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold">Balance, January 1, 2024</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8198">27,634,213</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8199">28</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8200">373,934</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8201">337,583</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8202">36,379</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8203">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8204">1,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-8205">1,752,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8206">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8207">14,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8208">14,695</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-8209">10,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-8210">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-8211">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8212">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8213">8,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Balance, March 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8214">29,396,411</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8215">29</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8216">390,081</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8217">346,253</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8218">43,857</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8219">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-8220">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-8221">1,154,191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8222">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8223">9,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-8224">9,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8225">11,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8226">11,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance, June 30, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-8227">30,550,602</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8228">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8229">401,410</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-8230">357,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-8231">43,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Cash flows used in operating activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8232">22,816</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-8233">20,023</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-8234">9,071</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-8235">2,752</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-8236">409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd" id="ixv-8237">405</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-8238">501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-8239">555</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-8240">147</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd" id="ixv-8241">1,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-8242">278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-8243">259</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-8244">12,966</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-8245">15,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-8246">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-8247">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows used in/provided by financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-8248">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-8249">5</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-8250">24,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-8251">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in/provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd" id="ixv-8252">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-8253">24,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-8254">12,971</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-8255">9,365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8256">73,228</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8257">76,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8258">60,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8259">86,355</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-2199"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyPolicyTextBlock" id="ixv-2203"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;,
or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production,
final drug product manufacturing, preclinical research and development (&#8220;R&amp;D&#8221;) and clinical development. We are deploying
our technologies, capabilities and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation
radiotherapies. We are focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline
of clinical and preclinical stage targeted radiotherapy product candidates are directed against validated cancer targets for indications
in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed
by currently available treatment options.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-2207"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-2211"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates" id="ixv-2215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-2220"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-2225"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-2244"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8260">59,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-8261">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8262">329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-8263">324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8264">60,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-8265">73,228</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-2294"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-2298"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-2302"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. There
was no revenue for the three and six months ended June 30, 2025 and June 30, 2024, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="ixv-2333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-2338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenuePolicyTextBlock" id="ixv-2344"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the six months ended June 30, 2025 and June
30, 2024, respectively.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-2379"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-2384"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-2388"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-8266">For the three and six months ended
June 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</ix:nonNumeric></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8267">240</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8268">5,420</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8269">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8270">305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8271">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8272">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8273">547</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-8274">5,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-2444"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740):
Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments
in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income
tax disclosures. The Company is required to disclose additional information regarding reconciling items equal to or greater than five
percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required
to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds
received). <span style="background-color: white">The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. The Company adopted this standard effective
January 1, 2025 and will report on it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company
will update all required disclosures pursuant to ASU 2023-09 at that time.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="ixv-2468"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting
periods, including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual
reporting period. The Company is evaluating the impact of ASU 2024-03 on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-2483"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c57" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd" id="ixv-8275">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="atnm:NetSalesPercentage" scale="-2" unitRef="pure" id="ixv-8276">2</ix:nonFraction>% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who intend to file an amended Securities Complaint on or before August 25, 2025. The Defendants
have not yet responded to the Securities Complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court has not yet entered that stipulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_LeasesTextBlock-c0_cont_1" escape="true" name="atnm:LeasesTextBlock" id="ixv-2513"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription" id="ixv-8277">5 years 2 months</ix:nonNumeric>, with an expiration
date of <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-8278">July 30, 2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="6" unitRef="usd" id="ixv-8279">0.6</ix:nonFraction> million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-2525"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-8280">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-8281">173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-8282">346</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-8283">346</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-8284">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-8285">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-8286">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-8287">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-8288">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-8289">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-8290">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-8291">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-8292">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-8293">6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="atnm_LeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-8294">313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-8295">306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-8296">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-8297">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-8298">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-8299">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_1" escape="true" name="atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" id="ixv-2804"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Weighted average remaining lease term:</span></td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-size: 10pt">Operating leases</span></td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-8300">2.1</ix:nonNumeric> years</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Finance Leases</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-8301">1.5</ix:nonNumeric> years</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. <ix:continuation continuedAt="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_2" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_1">Below is information on the weighted average discount rates used at the time that the leases were evaluated:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-8303">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-8304">6.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:LesseeLeaseLiabilityMaturityTableTextBlock" id="ixv-2848"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding six months ended June 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-8305">318</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-8306">6</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-8307">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-8308">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-8309">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-8310">1,341</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-8311">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-8312">67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-8313">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-8314">1,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-8315">16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock" id="ixv-2927"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the six months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $<ix:nonFraction contextRef="c60" decimals="-6" format="ixt:num-dot-decimal" name="atnm:NonRefundablePaymentReceived" scale="6" unitRef="usd" id="ixv-8316">35</ix:nonFraction> million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="atnm_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-8317"><ix:nonFraction contextRef="c3" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-8318">35</ix:nonFraction></ix:nonFraction> million at
June 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval of Iomab-B
or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-2954"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c61" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-8319">200</ix:nonFraction> million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock
are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#8220;Prior
Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911),
which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration
Statement, including a base prospectus which covers the offering, issuance and sale of up to $<ix:nonFraction contextRef="c62" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" unitRef="usd" id="ixv-8320">500</ix:nonFraction> million of common stock, preferred stock,
warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum
aggregate offering price of $<ix:nonFraction contextRef="c62" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-8321">200</ix:nonFraction> million of common stock that may be issued and sold under the Amended Sales Agreement. On March 31, 2025,
upon filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, the Company became subject to General
Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock in a registered primary offering using
Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month period so long as its public float remains
below $<ix:nonFraction contextRef="c63" decimals="-6" format="ixt:num-dot-decimal" name="atnm:AggregateMarketValueOfCommonStock" scale="6" unitRef="usd" id="ixv-8322">75</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the six months ended June 30, 2025. During the six months ended June 30, 2024, the Company sold <ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-8323">2.9</ix:nonFraction> million
shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-8324">25.2</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceedFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-8325">24.7</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-2965"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-8326">5,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8327">6.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c76" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-8328">7.04</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-8329">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8330">1.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-8331">4,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8332">6.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-8333">240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8334">6.66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-8335">6.04</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, June 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-8336">166</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8337">7.36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-8338">5.14</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2025, the Company granted newly hired employees options to purchase <ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-8339">26</ix:nonFraction> thousand shares of common stock with an exercise price
ranging from $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-8340">1.06</ix:nonFraction> to $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-8341">1.43</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="ixv-8342">10 years</ix:nonNumeric>, and a vesting period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-8343">4</ix:nonNumeric> years. The stock options had an aggregated fair value
of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="3" unitRef="usd" id="ixv-8344">29</ix:nonFraction> thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from <ix:nonFraction contextRef="c67" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-8345">4.0</ix:nonFraction>% to <ix:nonFraction contextRef="c68" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-8346">4.5</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-8347">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-8348">90.1</ix:nonFraction>% to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" unitRef="pure" id="ixv-8349">90.7</ix:nonFraction>%, and
(4) <span style="-sec-ix-hidden: hidden-fact-67">zero</span> expected dividends. During the six months ended June 30, 2024, the Company granted options to purchase <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares" id="ixv-8350">1,000</ix:nonFraction> shares.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of <ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" unitRef="shares" id="ixv-8351">4.9</ix:nonFraction> million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="6" unitRef="usd" id="ixv-8352">8.8</ix:nonFraction> million in stock option compensation expense for the six months
ended June 30, 2025. During the six months ended June 30, 2024, the Company recorded stock option compensation expense of $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-8353">2.4</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2025
was $<ix:nonFraction contextRef="c71" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-8354">0.3</ix:nonFraction> million related to unvested stock options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-8355">2.2</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-3150"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-8356">300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-8357">5.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c72" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-8358">300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-8359">5.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c72" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="6" unitRef="usd" id="ixv-8360">1.8</ix:nonFraction> million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at June 30, 2025 of $<ix:nonFraction contextRef="c72" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-8361">0.1</ix:nonFraction>
million is expected to be expensed over <ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-8362">0.1</ix:nonNumeric> years. During the six months ended June 30, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $<ix:nonFraction contextRef="c73" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-8363">0.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c74" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-8364">0.3</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-3229"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-8365">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8366">17.33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c79" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-8367">4.46</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-8368">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8369">17.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-8370">4.00</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares" id="ixv-8371">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-8372">17.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" id="ixv-8373">4.00</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENT NOTICE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form
10-Q and other reports filed by the Company from time to time with the Securities and Exchange Commission contains or may contain certain
forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company&#8217;s
management as well as estimates and assumptions made by Company&#8217;s management. Readers are cautioned not to place undue reliance
on these forward-looking statements, which are only predictions and speak only as of the date hereof. For this purpose, any statements
contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements.
&#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended to identify forward-looking
statements. &#160;These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within our control. &#160;These factors include but are not limited to economic
conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition
from much larger competitors; technological advances and failure to successfully develop business relationships. Although we believe that
the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update
any of the forward-looking statements to conform these statements to actual results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers.
Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production, final drug product manufacturing,
preclinical research and development (&#8220;R&amp;D&#8221;) and clinical development. We are deploying our technologies, capabilities
and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation radiotherapies. We are
focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline of clinical and preclinical
stage targeted radiotherapy product candidates are directed against validated cancer targets for indications in hematology, solid tumors
and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed by currently available treatment
options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Our Targeted Radiotherapy Candidate Pipeline</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are advancing two clinical stage product candidates and one preclinical
stage product candidate that are directed against validated cancer targets. Actimab-A is our most advanced clinical-stage product candidate
that we are actively developing and is intended to address the significant unmet medical needs of patients with myeloid malignancies,
including acute myeloid leukemia (&#8220;AML&#8221;) and myelodysplastic syndromes (&#8220;MDS&#8221;). We are also evaluating Actimab-A&#8217;s
potential to synergize with PD-1 immune checkpoint inhibitors (&#8220;ICIs&#8221;) in solid tumor indications through the depletion of
immune cells known as myeloid derived suppressor cells (&#8220;MDSCs&#8221;). We recently announced our ATNM-400 program, a novel preclinical,
non-prostate specific-membrane antigen (&#8220;non-PSMA&#8221;) targeting, first-in-class radiotherapy utilizing the Actinium-225 (&#8220;Ac-225&#8221;)
radioisotope payload intended for patients with prostate cancer directed against a novel radiotherapy target and thereby differentiated
from Lu-177-PSMA-617, the active agent used in Pluvicto<sup>&#174;</sup>, a blockbuster approved prostate cancer radiotherapy and the majority
of radiotherapies in development for prostate cancer. Iomab-ACT is a next-generation targeted conditioning agent we are developing with
the intent to improve patient access to, and outcomes with, cellular therapies such as CAR-T for various blood cancer indications and
gene therapies for non-malignant hematologic disorders such as sickle cell disease (&#8220;SCD&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategic Pipeline Prioritization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to commit a significant portion of our current
and future resources to the development and advancement of our targeted radiotherapy solid tumor pipeline candidates as well as solid
tumor focused R&amp;D efforts. In the first quarter of 2025, we announced ATNM-400, our first solid tumor focused program, which we are
developing for prostate cancer. In addition, we announced our solid tumor initiative with Actimab-A in combination with PD-1 immune checkpoint
inhibitors for head and neck squamous cell carcinoma (&#8220;HNSCC&#8221;) and non-small cell lung cancer (&#8220;NSCLC&#8221;). We believe
solid tumors represent large addressable markets and there remains high unmet needs in several indications that are not addressed by currently
available therapies. We will continue to advance Actimab-A in a focused manner as a therapeutic for hematology indications including supporting
our CRADA with the NCI and Iomab-ACT as a targeted conditioning agent for cell and gene therapies while simultaneously seeking strategic
development partners or collaborators for these programs. There have been significant changes in senior leadership at the United States
Food &amp; Drug Administration (&#8220;FDA&#8221;) and other government agencies including the Center for Biologics Evaluation and Research
(&#8220;CBER&#8221;). We believe these changes could impact the FDA&#8217;s approach toward approving therapies in part based on their
perception of value and their cost benefit profile. There have also been funding cuts to healthcare spending and at governmental healthcare
agencies such as the National Institutes of Health (&#8220;NIH&#8221;) and National Cancer Institute (&#8220;NCI&#8221;). We have a Cooperative
Research and Development Agreement (&#8220;CRADA&#8221;) with the NCI for the development of Actimab-A, and while currently not the case,
in the future there could be funding cuts to the NCI may cause delays, and/or pauses or termination of clinical trials under our CRADA.
As previously announced, we are actively seeking a strategic partner for Iomab-B in the U.S. As part of our strategic pipeline prioritization,
we may seek to partner, divest, spin-out, or out-license Iomab-B, Actimab-A and Iomab-ACT individually or collectively for all non-solid
tumor indications. We believe, in aggregate, the clinical data from these hematology and cellular therapy focused programs is supportive
of a partnering approach, which if successful, may yield greater value as the Company focuses on its solid tumor development efforts utilizing
existing resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented first ever preclinical data for ATNM-400, a novel, first-in-class
non-Prostate Specific Mature Antigen (&#8220;PSMA&#8221;) Ac-225 targeted radiotherapy at the American Association for Cancer Research
(&#8220;AACR&#8221;) Annual Meeting in April 2025 highlighting that ATNM-400&#8217;s target is implicated in prostate cancer biology,
disease progression and resistance to therapies. The data also showed that ATNM-400 was more efficacious than Lu-177-PSMA-617, the active
agent used in Pluvicto<sup>&#174;</sup>, an FDA approved targeted radiotherapy, in prostate cancer models, and is highly efficacious in
overcoming Lu-177-PSMA-617 resistance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented data at AACR in
                                                                                                                                                                 April 2025 highlighting the mutation agnostic antileukemic activity of Actimab-A against the most prevalent and actionable mutations
                                                                                                                                                                 in AML including FLT3, NPM1, KMT2A and TP53;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presented additional
                                                                                                                                                                 ATNM-400 preclinical data at the Society of Nuclear Medicine and Molecular Imaging (&#8220;SNMMI&#8221;) Annual Meeting in June 2025
                                                                                                                                                                 showing superior efficacy to enzalutamide (Xtandi<sup>&#174;</sup>), an androgen receptor inhibitor (&#8220;ARPI&#8221;) therapy,
                                                                                                                                                                 ATNM-400&#8217;s ability to overcome resistance to enzalutamide and synergistic potential in combination with
                                                                                                                                                                 enzalutamide;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrolled first patient in the Iomab-ACT commercial CAR-T investigator sponsored trial at the University of Texas Southwestern Medical Center; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalized protocol for Phase 2/3 trial for Iomab-B in agreement with
the FDA with approval to initiate the Phase 2 portion of the trial; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: justify">Presented additional ATNM-400 preclinical data at the Targeted Radiopharmaceuticals
Summit (&#8220;TRP&#8221;) in July 2025 showing tumor-specific uptake of ATNM-400 via PET images and enhanced, robust tumor control and
improved survival compared to Lu-177-PSMA-617, the active agent used in Pluvicto<sup>&#174;</sup>. Additionally, ATNM-400 showed enhanced
and tumor control in enzalutamide resistance prostate cancer models and enhanced efficacy in combination with enzalutamide with follow-up
ongoing.</td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hematology Therapeutic Program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is being developed as a targeted radiotherapeutic to leverage
the Ac-225 isotope payload directed against CD33, a target expressed ubiquitously in patients with AML, MDS and other myeloid malignancies.
We are attempting to leverage the mutation-agnostic ability of Ac-225 to establish Actimab-A as a backbone therapy in myeloid malignancies,
which are extremely heterogenous and radiosensitive, as a single agent or in combinations with chemotherapy, targeted agents, cellular
therapy and immunotherapy. Actimab-A has been studied in over 150 patients as a single agent and in combination with other modalities.
This clinical experience is informing our current clinical development strategy for Actimab-A. We plan to initiate a Phase 2/3 trial with
Actimab-A in combination with the chemotherapy regimen CLAG-M in patients with r/r AML based on promising results with this combination
in a Phase 1b trial. In addition to our internal development efforts, we entered into a Cooperative Research and Development Agreement
(&#8220;CRADA&#8221;) with the National Cancer Institute (&#8220;NCI&#8221;) in February 2023 for the development of Actimab-A for AML
and other myeloid malignancies. The first Actimab-A trial initiated under the CRADA is being conducted in patients with frontline AML
in combination with Venetoclax, an oral Bcl-2 inhibitor and ASTX-727, an oral hypomethylating agent (&#8220;HMA&#8221;) developed by Taiho
Oncology, an Otsuka Holdings company. To date, there has been broad interest from investigators through the NCI CRADA to study Actimab-A
in a variety of hematology indications that we believe may support our partnering efforts given the potential to expand the addressable
market opportunity for Actimab-A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Solid Tumor Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is our newest
targeted radiotherapy program that we are advancing for prostate cancer. We believe ATNM-400 is uniquely positioned to overcome key
limitations of current standards of care in prostate cancer, including Lu-177-PSMA-617 (Pluvicto<sup>&#174;</sup>) and the ARPI
therapy enzalutamide (Xtandi<sup>&#174;</sup>). Pluvicto<sup>&#174;</sup> is a PSMA directed targeted radiotherapy that uses the
beta-particle emitting radioisotope Lutetium-177 (&#8220;Lu-177&#8221;) that is approved for patients with metastatic prostate
cancer. Pluvicto<sup>&#174;</sup> is marketed and sold by Novartis and generated sales of approximately $1.39 billion in 2024.
ATNM-400 is differentiated from Lu-177-PSMA-617 such as Pluvicto<sup>&#174;</sup> as it targets a different marker than PSMA, which
has been shown to be overexpressed in patients with prostate cancer and its expression is sustained post- Lu-177-PSMA-617 treatment.
In addition, ATNM-400 uses the alpha-particle emitter Ac-225, which is more potent than Lu-177 but has a shorter path length, which
could result in fewer off-target effects such as xerostomia or dry mouth as PSMA is expressed in the salivary glands.
ATNM-400&#8217;s target is also implicated in resistance to androgen receptor (&#8220;AR&#8221;) inhibition. Our preclinical data
has shown that ATNM-400 is effective in preclinical prostate cancer models resistant to the ARPI enzalutamide and has additive
efficacy when used in combination with enzalutamide, suggesting flexibility in sequencing or combination regimens. Enzalutamide
(Xtandi<sup>&#174;</sup>) is approved for three stages of prostate cancer and is marketed and sold by Astellas and Pfizer with sales
of $5.9 billion in 2024. Given the biology of the antigen targeted by ATNM-400, the precise and potent cell-killing of Ac-225 and
our preclinical data to date, we believe ATNM-400 has transformative potential to address unmet needs in prostate cancer for
Lu-177-PSMA-617 and enzalutamide ineligible patients, after patients become resistant to Lu-177-PSMA-617 or enzalutamide, in
combination and even as an alternative treatment option.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to ATNM-400, we
have active R&amp;D efforts leveraging our in-house preclinical development and translational research capabilities that are primarily
focused on supporting our ATNM-400 preclinical program, the Actimab-A and Iomab-ACT clinical programs and advancing several preclinical
programs for solid tumor indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also initiated our
Actimab-A solid tumor program that will combine Actimab-A with PD-1 checkpoint inhibitors. We initiated this program to evaluate if Actimab-A
can deplete CD33 expressing MDSCs and hence improve patient outcomes in combination with PD-1 ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and
OPDIVO<sup>&#174;</sup>. The Actimab-A solid tumor program is comprised of several controlled, head-to-head clinical trials that will evaluate
the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus
OPDIVO<sup>&#174;</sup>&#160;alone. The initial tumors that are being targeted are Head and Neck Squamous Cell Carcinoma (&#8220;HNSCC&#8221;)
and Non-Small Cell Lung Cancer (&#8220;NSCLC&#8221;) with a separate trial for each indication.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Targeted Conditioning Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is our next-generation
targeted conditioning agent directed against CD45, a target expressed widely across the hematopoietic system including normal nucleated
immune cells such as lymphocytes that are relevant to this program and uses the Iodine-131(&#8220;I-131&#8221;) radioisotope payload.
We are developing Iomab-ACT as conditioning for cell and gene therapies in both malignant and non-malignant hematologic indications. Iomab-ACT
utilizes non-myeloablative doses of I-131, to not fully deplete the patient&#8217;s bone marrow and immune system with the goal of improving
patient access and outcomes for potentially curative cell and gene therapies by replacing the need for the non-targeted, chemotherapy-based
conditioning regimens that are currently used. Iomab-ACT is currently being studied in three clinical trials. These trials include Iomab-ACT
with a commercial CAR-T therapy, Iomab-ACT prior to allogeneic bone marrow transplant for patients with SCD, which could potentially inform a trial design
with gene therapy for SCD, and Iomab-ACT with a novel investigational CD19 CAR-T therapy.&#160;In May 2025, we announced that the first
patient was enrolled in the Iomab-ACT commercial CAR-T trial at the University of Texas Southwest Medical Center (&#8220;UTSW&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We previously advanced our targeted conditioning program Iomab-B through
the Phase 3 Study of Iomab-B in Elderly Relapsed and Refractory AML (&#8220;SIERRA&#8221;) trial, a 153 patient, randomized multi-center
trial conducted in the United States and Canada. Iomab-B is comprised of the anti-CD45 monoclonal antibody apamistamab with myeloablative
doses of I-131 intended to enable patient access to bone marrow transplant (&#8220;BMT&#8221;), the only potentially curative treatment
option for patients with r/r AML. At this time, we are seeking a strategic partner for Iomab-B to conduct an additional clinical trial
based on feedback from the FDA. We have finalized the protocol for this additional Phase 2/3 trial in agreement with the FDA and have
authorization to initiate the Phase 2 portion of this trial. As previously disclosed and noted above, Actinium also has a License Agreement
with Immedica, granting Immedica the exclusive product rights for commercialization of Iomab-B in certain countries in the EUMENA region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Targeted Radiotherapy Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actimab-A: Mutation Agnostic Mechanism of Action
with Backbone Therapy Potential in Myeloid Malignancies including AML and high-risk MDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A <i>(Ac-225-lintuzumab
satetraxetan) </i>is our most advanced radiotherapeutic product candidate in development for patients with myeloid malignancies. To our
knowledge, Actimab-A is the only CD33 targeting radiotherapy in clinical development. We are focused on developing Actimab-A as both a
monotherapy and in combination with other treatment regimens to leverage both the potential mechanistic synergies of radiation and its
mutation agnostic cell-killing ability. In addition to our internal development efforts, we entered into a CRADA with the NCI in February
2023 for the development of Actimab-A for AML and other myeloid malignancies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to establish Actimab-A
as a backbone therapy, leveraging the broad expression of CD33 in myeloid malignancies such as AML and MDS, which, like most blood cancers,
are highly sensitive to radiation. AML is a highly heterogenous, mutation-rich cancer with over 70 identified driver genetic mutations.
However, there are only approved therapies for four mutations including FLT3, IDH1 &amp; IDH2, and KMT2A. CD33 is expressed regardless
of other mutations being present. The Ac-225 isotope payload that we utilize with Actimab-A emits potent alpha-particles with high linear
energy that kill cells via double strand DNA breaks for which there is no known resistance or repair mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development strategy is
to exploit these properties of Actimab-A to address the unmet needs of patients with myeloid malignancies across the treatment journey
including the frontline, relapsed/refractory and maintenance settings. To accomplish this, we are leveraging our clinical development
experience, clinical data and preclinical work supporting Actimab-A&#8217;s mutation agnostic capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + CLAG-M Pivotal Phase 2/3 Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have aligned with the FDA
on a randomized pivotal Phase 2/3 trial to compare Actimab-A + CLAG-M to CLAG-M alone in patients with r/r AML. Based on our interactions
with the FDA, this trial will first complete a Phase 2 portion where the Actimab-A dose will be optimized in combination with CLAG-M.
Once the optimized Actimab-A dose is determined, we expect the trial will advance to the Phase 3 portion of the study, which may reduce
time and resources required compared to separate Phase 2 and Phase 3 studies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint of the
Phase 3 trial will be Overall Survival. Event-Free Survival (&#8220;EFS&#8221;) and other efficacy measures as well as safety also being
evaluated. We are actively seeking potential strategic partners or collaborators to advance this trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A NCI CRADA Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, we entered into a
CRADA with NCI to develop Actimab-A for the treatment of patients with AML and other hematologic malignancies. The NCI will serve as the
regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A. The CRADA will provide support for
and may accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel
combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s clinical development team, where we
have the right to review and approve all protocols and have full rights to all data. The NCI CRADA provides for us to supply Actimab-A
and for NCI to cover all clinical trial execution and development expenses, which we believe will be a cost-efficient approach as opposed
to a Company sponsored trial and may therefore spare our balance sheet. The NCI Cancer Therapy Evaluation Program (&#8220;CTEP&#8221;),
which sponsors approximately two thirds of all combination cancer studies, will accept Letters of Intent (&#8220;LOIs&#8221;) or concepts
for Phase 1, 2 or 3 studies of Actimab-A in AML and other hematological malignancies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, the NCI announced
that its myeloMATCH program was officially open to patient enrollment across the U.S. and Canada. MyeloMATCH is a portfolio of clinical
trials to test precision medicine treatments for adults with AML or MDS being designed and led by four leading cancer research organizations
including the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer
Research Network in collaboration with the NCI National Clinical Trials Network (&#8220;NCTN&#8221;). Collectively, the myeloMATCH program
expects to open trials at hundreds of cancer care sites across the U.S. and Canada with the goal of enrolling 5,000 or more patients over
the next several years. Under our CRADA with the NCI, Actimab-A is part of the myeloMATCH program and may be included in future clinical
trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A, Venetoclax &amp; ASTX-727 &#8211;
Frontline AML Triplet Phase 1b Combination Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we
announced the initiation of the first clinical trial to be conducted under our CRADA by NCI. The trial will evaluate the triplet
combination comprised of Actimab-A, Venetoclax and ASTX-727, a novel oral HMA developed by Taiho Oncology, an Otsuka Holdings
company, in frontline AML patients. Venetoclax in combination with HMAs (Ven-HMA) is approved for patients with newly diagnosed AML.
We believe this trial is supported by our Actimab-A + Venetoclax combination trial that showed that the combination was
well-tolerated and showed supportive anti-leukemic activity. The frontline AML triplet trial is expected to enroll up to 48 patients
who are newly diagnosed with AML that are age 75 and above and not eligible for intensive chemotherapy. The trial will evaluate
various dose levels of Actimab-A along with dosing regimens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional clinical trial concepts for Actimab-A have been submitted
through our CRADA. We believe this supports the differentiated profile of Actimab-A for hematologic and solid tumor indications and presents
an opportunity to expand Actimab-A&#8217;s addressable market for a potential partner or collaborator.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Data Supporting Actimab-A&#8217;s Mutation Agnostic Profile</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To leverage Actimab-A&#8217;s
mutation agnostic capabilities and support its broad development, we have conducted preclinical experiments studying Actimab-A in combination
with targeted agents including Bcl-2 inhibitors, FLT-3 inhibitors, IDH inhibitors, menin inhibitors for NPM1 and KMT2A AML, chemotherapies
such as azacitidine and in cell lines expressing TP53 mutations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2025, we presented
data at the AACR annual meeting preclinical data demonstrating that the combination of Actimab-A with standard of care targeted AML therapies
including menin and FLT3 inhibitors and the HMA azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3,
NPM1, KMT2A and TP53 mutations. Additionally, in animal models, Actimab-A significantly enhanced tumor growth inhibition, prolonged the
duration of response and survival when combined with the menin inhibitor revumenib, and potentiated AML cell killing in combination with
the FLT3 inhibitor gilteritinib and HMA azacitidine. We expect to present additional data supporting Actimab-A&#8217;s mutation agnostic
capabilities and backbone potential at future scientific and medical conferences. In addition, we will continue to explore potential clinical
trials under our CRADA with NCI, investigator-initiated trials or under our sponsorship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 Program: Novel, First-in-Class, Non-PSMA Targeting Ac-225
Radiotherapy for Prostate Cancer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is a novel antibody
radioconjugate designed to deliver the potent alpha-emitter Ac-225 to prostate cancer cells by targeting a non-PSMA, disease-driving protein
overexpressed in advanced and treatment-resistant disease. Unlike PSMA-targeted agents that primarily serve as imaging and targeting tools,
the ATNM-400 target is directly implicated in tumor progression, survival signaling, and resistance to AR inhibition. This target is markedly
overexpressed in advanced, treatment-refractory prostate cancer and is associated with faster progression to castration resistance and
poorer overall survival in metastatic castrate resistant prostate cancer (&#8220;mCRPC&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that ATNM-400 is uniquely positioned to overcome key limitations
of current standards of care in prostate cancer, including Lu-177-PSMA-617 (Pluvicto<sup>&#174;</sup>) and the ARPI enzalutamide (Xtandi<sup>&#174;</sup>).
By selectively targeting ARPI-resistant tumor populations and delivering potent Ac-225 alpha radiation, we believe that ATNM-400 has the
potential to achieve deep, durable responses in patients with limited treatment options. With a differentiated mechanism of action, we
believe that ATNM-400 represents a potential first-in-class targeted radiotherapy designed to extend survival and address the significant
unmet need in mCRPC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preclinical Highlights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In vitro and in vivo studies have established ATNM-400&#8217;s robust
therapeutic activity and unique resistance-overcoming potential:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Mechanism of Action:</b>
ATNM-400 selectively binds and internalizes in human prostate cancer cells expressing
the target protein, inducing potent cytotoxicity via alpha radiation from the Ac-225 isotope, which causes irreversible double-stranded
DNA breaks and targeted tumor cell death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Sustained and
specific tumor uptake: </b>The ATNM-400 antibody showed sustained tumor uptake up to 216 hours with rapid clearance from normal
tissues in prostate cancer in vivo models. PET imaging confirmed tumor-specific uptake, which was blocked with unlabeled cold
antibody.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_002.jpg" style="height: 200px; width: 600px"/></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Superior to
PSMA-targeted Therapies:</b> In direct head-to-head studies, ATNM-400 demonstrated greater in vitro
cytotoxicity and in vivo tumor growth inhibition compared to both Lu-177-PSMA-617 and 225Ac-PSMA-617 in prostate cancer preclinical models.
Unlike PSMA, which loses target expression upon treatment with Lu-177-PSMA-617 (the active agent in Pluvicto<sup>&#174;</sup>), the target
for ATNM-400 is sustained post-Lu-177-PSMA-617 treatment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <img alt="" src="image_003.jpg" style="height: 170px; width: 600px"/> </p><div>



</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Robust Tumor Control,
Improved Survival and Superior Efficacy After Lu-177-PSMA-617 Resistance:</b> ATNM-400 outperformed Lu-177-PSMA-617, the active agent in Pluvicto&#174;, significantly
improved survival and had robust anti-tumor activity in preclinical prostate cancer models. It remained effective in both in vitro and
in vivo models with acquired Lu-177-PSMA-617 resistance, highlighting its potential in resistant disease settings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><img alt="" src="image_004.jpg" style="width: 650px"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Superior Tumor Control Activity Post-Enzalutamide:</b> ATNM-400 remained effective in preclinical
prostate cancer models resistant to the ARPI enzalutamide, highlighting its utility post-AR pathway treatment failure.</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img alt="" src="image_005.jpg" style="width: 650px"/></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Enhanced Efficacy Supports Combination Therapy Potential:</b> ATNM-400 demonstrated additive
efficacy when used in combination with AR-targeting agents such as enzalutamide in both in vitro and in vivo preclinical studies in prostate
cancer models, suggesting flexibility in sequencing or combination regimens. Also 40% of prostate cancer tumor-bearing animals had complete
cures.</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><img alt="" src="image_008.jpg" style="width: 650px"/></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are continuing to study and advance ATNM-400 and expect to have
further updates on this program in the second half of 2025. We intend to demonstrate ATNM-400&#8217;s potential to treat prostate cancer
that has become resistant to commonly used therapies such as Lu-177-PSMA-617 (the active agent in Pluvicto<sup>&#174;</sup>) and enzalutamide to improve
outcomes with mCRPC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 Market Opportunity in Prostate Cancer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approximately 313,780 men in the United States are expected to be diagnosed
with prostate cancer in 2025, accounting for approximately 30% of all cancer diagnoses in men according to the American Cancer Society.
Prostate cancer is by far the most diagnosed cancer in men in the United States and is the same in 118 of 185 countries. Of those diagnosed
with prostate cancer, approximately 5-7% exhibited metastatic disease at initial diagnosis, and among those exhibiting localized prostate
cancer, approximately 20-30% will progress to metastatic disease. A majority of metastatic prostate cancer patients receive hormone therapy
such as ARPI therapy, as prostate cancer cells rely on androgen hormones for growth. In the U.S., approximately 40,000&#8211;60,000 mCRPC
patients annually progress after ARPI therapy, which as a class generated sales of greater than $10 billion in 2024 including Xtandi<sup>&#174;</sup>
(&gt;$5.9 billion) Erleada<sup>&#174;</sup> (&gt;$2.9 billion), and Nubeqa<sup>&#174;</sup> (&gt;$1.7 billion), highlighting a significant
unmet need. Unlike localized diseased, there are currently no known cures for metastatic prostate cancer &#8211; there are only treatments
to slow the progression of disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the approval of the targeted radiotherapy Pluvicto<sup>&#174;</sup>
(lutetium Lu 177 vipivotide tetraxetan; active agent: Lu-177-PSMA-617) for post-taxane mCRPC in March 2022, targeted-radiotherapy has
become a prominent component of the metastatic prostate cancer treatment paradigm. Pluvicto<sup>&#174;</sup>, marketed globally by Novartis,
generated approximately $1.39 billion in sales in 2024 and approximately $825M in the first half of 2025. In March 2025, the total addressable
market for Pluvicto<sup>&#174;</sup> essentially doubled to approximately 44,000 patients with its approval in mCRPC after treatment with
ARPI therapy and prior to taxane. Subsequently, in June 2025, Novartis announced that Pluvicto<sup>&#174;</sup> reached the primary endpoint
in the Phase 3 PSMAddition study in metastatic hormone sensitive prostate cancer (&#8220;mHSPC&#8221;) and expects to file an FDA submission
in the second half of 2025. An approval would add approximately 42,500 additional patients to the addressable market for Pluvicto<sup>&#174;</sup>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the only approved targeted
radiotherapy moving up in the prostate cancer treatment paradigm and very few differentiated products in clinical development, a significant
opportunity exists in the post-Pluvicto<sup>&#174;</sup> setting. Currently, over 20 PSMA-targeted radiotherapies are in various stages
of development, of which few offer a substantial efficacy advantage compared to Pluvicto<sup>&#174;</sup>. Re-treatment with PSMA-targeting
agents has not yet been supported substantially in clinical trials and could be less effective than targeting a different antigen due
to potential reduction of PSMA surface expression as well as increased tumor heterogeneity following initial PSMA-targeted therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 targets a non-PSMA tumor antigen that is implicated in disease
progression, shorter time to hormone therapy resistance such as ARPI therapy and poorer survival outcomes. We have demonstrated that ATNM-400&#8217;s
differentiated target is expressed and druggable following ARPI therapy and PSMA radiotherapy. We believe ATNM-400 can therefore target
a significant subset of the mCRPC patient population with aggressive disease who progressed on second generation ARPIs or have had no
response to or progressed on Lu-177 labelled PSMA-targeted therapy. ATNM-400 utilizes the alpha-particle emitter Ac-225, which is more
potent than Lu-177, and due to Ac-225&#8217;s short path length, could result in fewer off-target effects. As ATNM-400 does not target
PSMA, xerostomia or dry mouth, which can be a significant quality of life issue for patients with metastatic prostate cancer receiving
PSMA-targeted radiotherapies as PSMA is expressed on salivary glands, would not be expected. Additionally, the antigen targeted by ATNM-400
is implicated in a pathway leading to ARPI-resistance in mCRPC patients; therefore, along with the tumor suppressing ability of Ac-225,
ATNM-400 displays a compelling mechanism for synergy with ARPIs. As a result, we believe ATNM-400 has the potential to address critical
gaps in prostate cancer treatment as a monotherapy or in combination or sequenced with other therapeutic modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actimab-A Solid Tumor Program: Potential Pan
Solid Tumor Therapy in Combination with PD-1 Checkpoint Inhibitors Including KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> by Depleting
Myeloid Derived Suppressor Cells </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the significant
number of patients treated with PD-1 ICIs, there is extensive data in the medical literature on outcomes in these patients. PD-1
ICIs have significantly improved patient outcomes across several solid tumor indications, however, not all patients have robust or
durable responses. Multiple therapeutic modalities have been studied in combination with PD-1 ICIs in attempt to improve patient
outcomes, but few combinations have produced a sufficient clinical benefit or have been approved. To our knowledge, our Actimab-A
solid tumor program is the only CD33 targeted radiotherapy being evaluated in combination with PD-1 ICIs. The rationale for studying
Actimab-A in combination with either KEYTRUDA<sup>&#174;</sup> or OPDIVO<sup>&#174;</sup> is based on the premise that depleting
MDSCs with Actimab-A may improve the efficacy of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MDSCs are immune-suppressive
cells that help tumors evade immune detection and promote disease progression. They are overexpressed in the tumor microenvironment in
several different solid tumors and associated with poor outcomes. They work by multiple mechanisms but most relevant to PD-1 inhibitors
which work by keeping T-cells active is that MDSCs prevent T-cells from recognizing and attacking cancer cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>Potential Mechanistic Synergy
of Actimab-A with PD-1 ICI&#8217;s</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies have shown that MDSCs
are overexpressed in patients with cancers. For instance, a study by Bronte et al., in patients with NSCLC receiving ICIs evaluated the
role of immune cells on patient outcomes. In this study, MDSCs were the only immune cell subtype to show a statistically significant association
with tumor response. The median level of MDSCs was determined to be 1.9% with patients above that level being classified as &#8220;High-MDSC&#8221;
and patients below that level being classified as &#8220;Low-MDSC&#8221;. In this study, only Low-MDSC patients had a clinical response,
with no responses observed in High-MDSC patients and over 80% of High-MDSC patients having progressive disease. In addition, Low-MDSC
patients had a statistically significantly improvement in progression-free survival (&#8220;PFS&#8221;) of 8.39 months compared to 1.94
months in High-MDSC patients and OS of 15.15 months compared to 3.03 months in High-MDSC patients.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b>Low MDSC&#8217;s Associated
with Statistically Significant Improvement in PFS and OS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is considerable preclinical
scientific evidence in the literature that depleting MDSCs could be a viable strategy in improving the outcomes of PD-1 directed immunotherapy,
however, there have been no viable clinical approaches that have been tried successfully to our knowledge.&#160; MDSCs are known to express
the CD33 antigen which is the target of Actimab-A.&#160; Actinium has also generated published and unpublished preclinical data showing
that Actimab-A can selectively deplete MDSCs in solid tumors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there is strong
scientific rationale supporting the potential for Actimab-A to deplete CD33 expressing MDSCs and hence improve patient outcomes with PD-1
ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and OPDIVO<sup>&#174;</sup>. Our Actimab-A solid tumor program is expected to be comprised of
several controlled, head-to-head clinical trials that will evaluate the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus
KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus OPDIVO<sup>&#174;</sup>&#160;alone. The initial
tumors that are being targeted are HSNCC and NSCLC with a separate trial for each indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patient population
for these trials will be adults with PD-L1 expression and locally advanced metastatic HNSCC or NSCLC randomized to either Actimab-A
alone or Actimab-A with a specific checkpoint inhibitor. The objective of each trial would be to evaluate the safety and
tolerability as well as following endpoints including ORR, PFS and OS. Further, the following biomarker data would be collected
including the pattern of depletion of CD33+ MDSCs and T-cell activity in peripheral blood. We are advancing these trials and expect initial proof of concept data in the first
half of 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Iomab-ACT Program: Potential Universal Targeted
Conditioning Agent for Cell &amp; Gene Therapies to Improve Patient Access and Outcomes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opportunity exists for
better conditioning regimens in the area of cellular therapies beyond the non-targeted chemotherapy-based regimens that are used currently.
We are working on a next-generation targeted conditioning program, Iomab-ACT, for the rapidly growing cell and gene therapy market, as
well as BMT conditioning for non-malignant hematologic indications such as SCD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are studying Iomab-ACT in collaboration with Memorial Sloan Kettering
Cancer Center (&#8220;MSKCC&#8221;), for conditioning prior to CAR-T therapy for patients with relapsed or refractory B-cell acute lymphoblastic
leukemia (&#8220;B-ALL&#8221;) or diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). This study, funded by a NIH grant, is the first
study of its kind to use CD45 targeted radiotherapy conditioning with CAR-T therapy. At the 2024 Tandem Meetings | Transplantation &amp;
Cellular Therapy Meetings of ASTCT and CIBMTR, we presented results from the ongoing Phase 1 trial. No patients (0/4) developed Immune
Effector Cell-Associated Neurotoxicity Syndrome (&#8220;ICANS&#8221;) of any grade, a major safety measure of the study, as ICANS is observed
in 25% or more of patients with r/r B-ALL and DLBCL treated with various CAR T-cell products and negligible incidence of cytokine release
syndrome (&#8220;CRS&#8221;). Additionally, Iomab-ACT demonstrated transient depletion of peripheral blood lymphocytes and monocytes.
Persistence of CAR T-cells up to 8 weeks and minimal non-hematologic toxicities have been observed to date. These results prompted us
to explore additional clinical trials with Iomab-ACT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have initiated an investigator-sponsored
trial studying Iomab-ACT as targeted conditioning prior to patients receiving an FDA approved commercial CAR-T therapy at UTSW. To our
knowledge, this is the first trial to study a targeted radiotherapy conditioning agent with a commercial CAR-T therapy. Given the robust
clinical data that exists with commercial CAR-T therapies, we believe this trial may demonstrate the potential for Iomab-ACT to improve
outcomes over current chemotherapy conditioning regimens, which we are seeking to replace and provide patients better access to CAR-T.
In May 2025, we announced that the first patient was enrolled in this trial, which will enroll up to 30 patients. The primary objectives
of this study are safety, tolerability and efficacy. Secondary objectives will evaluate incidences of CRS and ICANS as well as the persistence
and expansion of CAR-T cells, which has been associated with improved efficacy and patient outcomes. If successful, we believe this Phase
1b/2 trial could support a pivotal trial, which could be initiated as early as 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is also being studied in an investigator-led clinical trial
as targeted conditioning prior to a BMT for patients with SCD in collaboration with Columbia University. SCD is a rare, debilitating and
life-threatening blood disorder with significant unmet need that affects approximately 100,000 people in the U.S. Patients with sickle
cell disease have a mutation that causes red blood cells to develop a crescent or &#8220;sickle&#8221; shape, which restrict the flow
in blood vessels and limit oxygen delivery to the body&#8217;s tissues, leading to severe pain and organ damage called vaso-occlusive
events (&#8220;VOEs&#8221;) or vaso-occlusive crises (&#8220;VOCs&#8221;). The recurrence of these events or crises can lead to life-threatening
disabilities and/or early death. A BMT is a potentially curative treatment option for patients with sickle cell disease, particularly
in patients who have had complications such as strokes, acute chest crises or recurring pain crises due to their disease. Patient recruitment
for the Phase 1 trial has commenced and this trial can enroll up to 24 patients with interim data updates expected. If safety is demonstrated,
the trial is expected to inform a clinical trial to evaluate Iomab-ACT as a targeted conditioning agent prior to gene therapy for which
there are two approved agents for patients with sickle cell disease, Casgevy<sup>&#174;</sup> (Vertex Pharmaceuticals, Inc.) and Lyfgenia<sup>&#8482;</sup>
(Bluebird Bio, Inc.).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to continue to develop Iomab-ACT based on early encouraging
results, ultimately with the value proposition of improving overall access and outcomes for patients who need cellular or gene therapies.
We believe an opportunity exists for Iomab-ACT to potentially generate significant revenue, if it can provide one or more clinical benefits
related to lower CRS, less ICANS (neurotoxicity), longer duration of response or a higher overall success rate of cellular therapy due
to benefits of targeted conditioning.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Iomab-B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
February 2023, Actinium announced that the SIERRA trial met the primary endpoint with statistical significance, as 22% of patients (13/76)
on the Iomab-B arm achieved durable Complete Remission (&#8220;dCR&#8221;) compared to 0% of patients (0/77) on the control arm resulting
in a p-value of &lt;0.0001. The SIERRA trial met the secondary endpoint of Event-Free Survival (&#8220;EFS&#8221;) with a 78% reduction
in the probability of an event (Hazard Ratio=0.22, p&lt;0.0001 for both per protocol and ITT basis). EFS at 180 days for the Iomab-B arm
was 28% compared to 0.2% for the control arm. In the SIERRA trial, an event was defined as one of the following: a patient not achieving
CR/CRp or crossing over, patient not receiving BMT, a patient relapsing or death. The SIERRA trial did not, however, meet the secondary
endpoint in achieving a statistically significant improvement in OS in the intent to treat (&#8220;ITT&#8221;) population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 5, 2024, Actinium announced that it concluded both its clinical and Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) interactions
with the FDA regarding the BLA pathway for Iomab-B based on the SIERRA trial results. As previously disclosed, we had received positive
feedback from the FDA regarding our CMC package for Iomab-B and were also assigned a BLA number. However, in the third quarter of 2024,
the FDA provided definitive feedback that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, despite (a) the
SIERRA trial meeting the primary endpoint of dCR with statistical significance (p-value&lt;0.0001) and other positive secondary endpoints
including Event Free Survival (&#8220;EFS&#8221;) and safety, and (b) our presentation of several additional analyses from the SIERRA
study, including long-term follow-up demonstrating a trend towards improved overall survival and evidence of survival benefit in patients
with high-risk TP53 mutations, to support Iomab-B&#8217;s impact on overall survival. The FDA indicated that demonstrating an overall
survival benefit in a randomized head-to-head trial is necessary and has advised us to conduct a study to evaluate allogeneic BMT using
Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (&#8220;Flu/TBI&#8221;) versus allogeneic
BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This proposed additional study differs from the SIERRA
trial, which allowed physician&#8217;s choice of salvage chemotherapies and heterogenous conditioning regimens in the control arm. Additionally,
the proposed new study will not allow patients to cross over from the control arm, which was allowed in the SIERRA trial and confounded
the overall survival analysis in the ITT patient population, as nearly 60% of patients crossed over from the control arm.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Actinium continued interactions with the FDA in 2024 to further discuss
the specifics of the additional head-to-head clinical trial required by the FDA, including the patient population, which the FDA had suggested
could include all adult r/r AML patients. The FDA also requires that a Phase 2 dose optimization trial demonstrating safety and efficacy
be completed to calculate the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24
Gy of radiation to the liver as was done in the SIERRA trial based on several interactions we had with the FDA before starting the SIERRA
trial. In the second quarter of 2025, Actinium conducted another meeting with the FDA. Based on this meeting, Actinium has reached agreement
with the FDA on a Phase 2/3 clinical trial protocol and has been authorized by FDA to initiate the Phase 2 portion of the trial. We are
actively seeking a strategic partner for Iomab-B in the U.S. to execute the Phase 2/3 clinical trial. This planned study will be conducted
to establish dose optimization and evaluate allogeneic BMT using Iomab-B plus a reduced intensity conditioning regimen of Flu/TBI versus
allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. The study population will be all adult
patients aged 18 and above with active AML with blasts counts between 5 and 20 percent. This is a broader patient population than the
patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above and with blast counts that exceeded 20 percent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered
into a License Agreement with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights
for commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable
payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. Immedica is responsible for regulatory submissions in the EUMENA region, and we continue to retain commercialization
rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R&amp;D and Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D capabilities have
the potential to yield differentiated, high-value targeted radiotherapy programs that demonstrate our experience across multiple validated
cancer targets and isotopes and cover broad areas of focus leveraging our clinical development experience across hematology, targeted
conditioning, solid tumors, and next-generation radiotherapies. We have internal R&amp;D capabilities with our research laboratory capable
of executing in vitro and in vivo experiments and translational research. We are working on several preclinical programs which include
novel approaches to validated cancer targets, as well as novel targets that we believe show immense potential for radiotherapeutic approaches.
Preclinical pharmacology studies with our targeted radiotherapeutics, such as HER2, CD33 and CD38, have shown strong improvement in tumor
growth inhibition in various preclinical tumor models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently believe that
our targeted radiotherapies, which utilize biologic molecules, are less likely than small molecules to face pricing pressure and negotiation
from the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), given that small molecules are at risk for pricing negotiations seven years
after approval compared to eleven years for biologics with negotiated prices taking effect two years after selection. Further, a drug
or biological product that has an orphan drug designation, which our Actimab-A and Iomab-B programs both have, for only one rare disease
or condition will be excluded from the IRA&#8217;s price negotiations requirements until such time the biological products has designations
for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease
or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for
selection for negotiation. In addition, regulatory barriers for generic large molecule biologic based targeted radiotherapies are much
higher than for small molecule radioligands such as those under development or approved, namely, Pluvicto<sup>&#174;</sup>, Lutathera<sup>&#174;</sup>,
and Xofigo<sup>&#174;</sup>. Generic versions of certain radiopharmaceuticals utilizing peptides, which are considered small molecules,
have been submitted to the FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;) pathway. To our knowledge, only the biosimilar approach pertains to large molecule biologic-based
radiotherapies filed under 351(k) BLA pathway. The regulatory pathway for a biosimilar is much more comprehensive than the pathway for
generics, and it has not been proven that biosimilars are interchangeable with the innovator&#8217;s large molecule biologic targeted
radiotherapy. In addition, we are not aware of any regulations that would require us to provide Actimab-A or Iomab-ACT, including their
respective mAbs, lintuzumab and apamistamab, to any third party or potential competitor. Despite the above, we are aware that one or more
of the policies or regulations that afford our pipeline candidates market protections may change in the future and that one or more of
our product candidates may be disadvantaged by such change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to expand our capabilities
and technologies across therapeutic modalities, linker technologies and in vivo cancer models, and build visibility through presentations
at key conferences and publications in journals of high impact. Our R&amp;D efforts are centered on the advancement of key programs with
a robust &#8220;fast-to-clinic&#8221; approach. Underpinning our development programs is our expanded patent portfolio of approximately
240 issued patents and pending patent applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Proprietary Ac-225 Cyclotron Manufacturing
Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our in-depth, long-term
experience in clinical development of Ac-225 based radiopharmaceuticals, we have developed an end-to-end technology solution for producing
Ac-225 that has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods. This patented technology
has been used to produce Ac-225 in a cyclotron that is essentially identical to that derived from a Th-229 generator and has the potential
to be a lower-cost, commercially scalable higher-yielding approach. Importantly, the Ac-225 material produced by our proprietary method
contains no long-lived contaminants and less than 0.001% Actinium-227 (&#8220;Ac-227&#8221;). Using the cyclotron-produced Ac-225 technology
may allow for large commercial scale production with estimated cost of goods sold including capital expenditures and operational costs
for a single cyclotron facility to be several times less expensive than the price of currently available Ac-225 material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our extensive know-how related to this production technology is supported
by 5 issued patents in the U.S. and 33 issued patents internationally and covers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">End-to-end solution including processing and recycling of Radium-226 starting material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Production of up to 100 mCi of Ac-225 per production cycle</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Utilization of a medium energy cyclotron</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Expected cost 10 to 20 times lower than currently available material</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Radiochemical purity &gt; 99%</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Radioisotopic purity 99.8% with no long-lived contaminants and &lt;0.001% Ac-227</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our Ac-2225 based Actimab-A and ATNM-400 programs
and the rapidly increasing number of Ac-225 based programs in development, we believe that we are well positioned to leverage this technology
to produce Ac-225 to address the growing clinical and potential commercial demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Supply Chain</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has established significant
manufacturing and supply chain expertise, having delivered over 500 doses for 18 clinical trials at 45 large cancer hospitals and have
never missed a dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe this experience
provides us with insights that are highly relevant to the unique manufacturing and distribution requirements of radiotherapeutics. Due
to the short half-life of radioisotopes, our finished drug products are shipped &#8220;hot&#8221; and must be administered within days.
Actinium has established core competencies in the process of manufacturing radiotherapeutics, coordinating with the hospital&#8217;s care
team, and delivering &#8220;just-in-time&#8221; doses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to establish our own
manufacturing capabilities and intend to commence the build-out of a facility in the second half of 2025. We believe that having in-house
manufacturing will provide enhanced control, flexibility and scalability to serve our current and planned clinical trials and R&amp;D
efforts as well as potential future activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Isotope supply is critical
for the manufacturing of radiotherapeutics, and we have engaged several sources for the procurement of alpha (e.g., Ac-225) and beta (e.g.,
I-131 and Lu-177) emitters. We also have multiple isotope supply agreements and qualified vendors in place to supply isotopes for our
active and planned clinical trials. In March 2025, we announced that we entered into&#160;Ac-225 supply agreement with Eckert &amp; Ziegler,
a leading specialist in isotope-related components for nuclear medicine and radiation therapy, to support our comprehensive development
including U.S. and international clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has commercial agreements
with Contract Development and Manufacturing Organizations (&#8220;CDMOs&#8221;) with significant experience in mAb and final radio-labeled
drug products. Our finished drug product CDMOs are located in the U.S. and have experience in the international supply of radiotherapies.
We have scaled deliberately for manufacturing flexibility&#160;and are currently qualifying additional CDMOs to ensure readily available
drug product upon FDA approval and the ability to ramp up rapidly to meet commercial demand.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established an actively
managed end-to-end supply chain that encompasses isotope sourcing through drug administration at the point of care to execute our clinical
trials. Our end-to-end supply chain did not miss a patient dose in our international, 24-site SIERRA Phase 3 clinical trial, including
40 additional patients that crossed over from the control arm to receive Iomab-B. We believe we have a thorough understanding and working
knowledge of the intricacies required to manufacture and distribute radiotherapies. Through our clinical experience with Iomab-B and Actimab-A,
we have developed a wealth of proprietary knowledge to enable coordination between Actinium and all key stakeholders including, but not
limited to hematologists/oncologists, infusion center and in patient rooms, nuclear medicine and radiology, hot labs and radio-pharmacies,
and radiation safety committees, among others.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is supported by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted
radiotherapies and their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and
scheduling, radionuclide warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 2025, our patent portfolio is comprised of approximately
240 issued patents and pending patent applications worldwide, which we believe constitutes a valuable business asset. Our IP includes
48 patent families, including key patents that relate primarily to our radiotherapeutic candidates. Our patent portfolio includes 20 issued
patents and 51 pending patent applications in the U.S., and 173 that are issued or pending internationally. The effective lives of the
issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio, ranges from expirations between
2026 and 2046.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our Iomab-B product candidate,
we have four issued patents in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent
terms of these patents expire in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally.
In addition, we own both U.S. and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment
of cancers and non-malignant conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents also cover
key areas of our business such as manufacturing key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron.
We have expertise in utilizing the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150
patients with our alpha-emitter-based therapies, &#8220;gold standard&#8221; linker technology and 5 issued patents in the U.S. and
33 issued patents internationally related to the manufacturing of Ac-225 in a cyclotron, which we believe has the potential to
produce higher quantities of Ac-225 than currently utilized methods. In addition, we also own U.S. and international patents and
pending patent applications that relate to the manufacturing of Actimab-A and its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 8, 2025, we had 27 full-time employees, 12 of whom have
Ph.D. or M.D. degrees and 20 of whom are engaged in research and development and clinical development activities. In the second quarter
of 2025, we conducted a workforce optimization aligned with our strategic pipeline prioritization that reduced our headcount by approximately
fourteen percent. Also in the second quarter of 2025, Dr. Avinash Desai resigned from his position as Chief Medical Officer. There were
no disagreements with the Company that contributed to Dr. Desai&#8217;s resignation. <span style="background-color: white">We do not expect
the aforementioned workforce optimization or departures to have a material impact on our operations or ability to execute our operating
plan. </span>We believe that we have been successful to date in attracting skilled and experienced personnel despite the competitive hiring
marketing in the industry. Our employees are not covered by a collective bargaining agreement, and we believe that our relationship with
our employees is excellent. We continue to engage external consultants on an as-needed basis to temporarily supplement existing staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Option Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors approved the cancellation of certain stock options to purchase an aggregate of 4.9 million shares of common stock held by
certain current employees and directors that were initially granted under our Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock option expense for the
three months ended March 31, 2025 and March 31, 2024, respectively and stock option expense for the three months and six months ended
June 30,2025 and June 30,2024, respectively, is presented below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left"/><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
months ended March 31</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
months ended June 30</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6
months ended June 30&#160;&#160;</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>$ in thousands</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2025</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Research &amp; Development</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">2,070</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">340</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">16</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">337</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">2,086</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 9%; text-align: right">677</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General &amp; Administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6,657</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">887</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">885</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6,690</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,772</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">8,727</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,227</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">8,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">2,449</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the <br/> Three&#160;Months&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Research and development, net of reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,879</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,825</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,624</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,593</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,418</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,878</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,353</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended June 30, 2025 and June 30, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of
Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan
Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve
lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. There was no other revenue recognized
for the three months ended June 30, 2025 and 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, on April 7,
2022, we entered into a License Agreement with Immedica, pursuant to which Immedica licensed the exclusive product rights for commercialization
of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable payment of $35 million
from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive certain regulatory
and commercial milestone payments and royalties on net sales of the product in certain countries that may result from the License Agreement.
We continue to retain commercialization rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at June 30, 2025 and December 31, 2024. Long-term
license revenue deferred was $35 million at June 30, 2025 and December 31, 2024, resulting from the receipt from Immedica; this deferred
revenue will be recognized upon the European Union&#8217;s regulatory approval of Iomab-B or provision of definitive feedback that Iomab-B
will not receive approval in the European Union.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock-Based Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the cancellation of stock options in March 2025 resulted in a significant decrease in non-cash stock compensation expense
for the three months ended June 30, 2025. During the three months ended June 30, 2025 and June 30, 2024, total non-cash stock-based compensation
expense, including stock option compensation expense, was $0.2 million and $1.4 million, respectively.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $4.9 million for the three months ended June 30, 2025 decreased by $3.9 million from $8.8 million for the three months ended June 30,
2024. The decrease was primarily a result of lower compensation of $1.6 million due to lower headcount and lower non-cash stock-based
compensation expense of $0.3 million due to the cancellation of stock options in March 2025. In the second quarter of 2025, we conducted
a workforce optimization that reduced our headcount by approximately fourteen percent. In addition, there was a decline in Chemistry,
manufacturing and controls, or CMC, expenses and clinical expenses of $1.4 million due to lower activity related to Iomab-B and preclinical
expenses decreased $0.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expense of $2.6 million for the three months ended June 30, 2025 decreased by $1.0 million from $3.6 million for the three months ended
June 30, 2024. The cancellation of stock options in March 2025 described above resulted in lower non-cash stock-based compensation expense
of $0.9 million for the three months ended June 30, 2025 compared with the three months ended June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended June 30, 2025 of $0.6 million decreased from $1.1
million for the three months ended June 30, 2024 primarily due to a lower average cash balance during the respective time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $6.9 million for
the three months ended June 30, 2025 decreased by $4.5 million from $11.4 million for the three months ended June 30, 2024 primarily due
to lower research and development expenses and lower general administrative expenses, partially offset by lower other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Six Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the <br/> Six&#160;Months&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Research and development, net of reimbursements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12,579</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,460</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,562</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,555</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,015</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(22,816</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(20,023</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no other revenue
recognized for the six months ended June 30, 2025 and 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-Based Compensation Expense</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cancellation of stock options on March 31, 2025, described above,
resulted in a significant increase in non-cash stock-based compensation for the six months ended June 30, 2025 compared to its prior-year
period due to recognition of previously unrecognized stock-based compensation cost at the cancellation. During the six months ended June
30, 2025 and June 30, 2024, total non-cash stock-based compensation expense, including stock option compensation expense, was $9.1 million
and $2.8 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $12.6 million for the six months ended June 30, 2025 decreased by $2.9 million from $15.5 million for the six months ended June 30,
2024. The decrease was primarily a result of lower compensation of $2.3 million due to lower headcount. In the second quarter of 2025,
we conducted a workforce optimization that reduced our headcount by approximately fourteen percent. In addition, there was a decline
in clinical expenses of $1.2 million due to lower activity related to Iomab-B and preclinical expenses decreased $0.4 million. These decreases
were partially offset by higher non-cash stock-based compensation of $1.4 million, due to the cancellation of stock options described
above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses of $11.6 million for the six months
ended June 30, 2025 increased by $5.0 million from $6.6 million for the six months ended June 30, 2024, as a result of higher non-cash
stock-based compensation expense of $4.9 million, due to the cancellation of stock options described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the six months ended June 30, 2025 of $1.3 million decreased from $2.0
million for the six months ended June 30, 2024 primarily due to a lower average cash balance during the respective time periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $22.8 million for the six months ended June 30, 2025 increased
by $2.8 million from $20.0 million for the six months ended June 30, 2024 primarily due to higher research and development expenses and
higher general administrative expenses as a result of non-cash stock-based compensation expense of $9.1 million for the six months ended
June 30, 2025 compared to $2.8 million in the prior-year period due to the cancellation of stock options described above, along with lower
other income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
selected cash flow information for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the<br/> Six Months&#160;Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12,966</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,346</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash used in/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,971</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in
operating activities for the six months ended June 30, 2025 was $13.0 million, a decrease of $2.3 million from $15.3 million in the
prior-year period. In the six months ended June 30, 2025, our net loss of $22.8 million excluding non-cash stock-based compensation
expense of $9.1 million was $13.7 million. In the prior-year period, net loss of $20.0 million excluding non-cash stock-based
compensation expense of $2.8 million was $17.2 million. This decrease in net cash used in operating activities of $3.5 million was
offset by an increase in net operating assets and liabilities of $1.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no cash used in
investing activities for the six months ended June 30, 2025. Cash used in investing activities was $11 thousand for the six months ended
June 30, 2024 due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used in financing activities
for the six months ended June 30, 2025 was not material. Net cash provided by financing activities of $24.7 million for the six months
ended June 30, 2024 was primarily from the sale of shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
August 2020, we entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which we are able to sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common
stock. On June 28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement,
with JonesTrading and B. Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement
to include B. Riley as an additional sales agent thereunder. Shares of common stock are offered pursuant to a shelf registration statement
on Form S-3 (File No. 333-273911), which was declared effective February 5, 2024, including a base prospectus covering the offering, issuance
and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus
covering the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued
and sold under the Amended Sales Agreement. During the six months ended June 30, 2025, there were no sales of shares of common stock.
For the six months ended June 30, 2024, we sold 2.9 million shares of common stock, resulting in gross proceeds of $25.2 million and net
proceeds of $24.7 million.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 31, 2025, upon filing of our Annual Report on Form 10-K for the year ended December 31, 2024, we became subject to General Instruction
I.B.6 of Form S-3, pursuant to which in no event will we sell our common stock in a registered primary offering using Form S-3 with a
value exceeding more than one-third of our public float in any 12 calendar month period so long as our public float remains below $75
million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing
this report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following
the date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion and analysis of financial condition
and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles
generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of these financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities
in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts
and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience,
known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes
in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these
estimates under different assumptions or conditions. The Company does not have any critical accounting estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness
of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income
taxes paid information included in income tax disclosures. We would be required to disclose additional information regarding reconciling
items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax
rate. Similarly, we would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of
total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. We adopted this standard effective January
1, 2025 and will report on it in our Annual Report on Form 10-K for the year ended December 31, 2025. We will update all required disclosures
pursuant to ASU 2023-09 at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and nonemployees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminate the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and nonemployees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permit a grantor to apply the new guidance on either a modified
retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting periods,
including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual reporting
period. We are evaluating the impact of ASU 2024-03 on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. We are evaluating the impact of ASU 2024-03 on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Known Trends, Events and
Uncertainties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to
risks and uncertainties common to companies in the biopharmaceutical industry, including but not limited to, risks associated with completing
preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical
products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to
secure additional capital to fund operations. In addition, the consequences of the ongoing geopolitical conflicts, such as the ongoing
conflict between Russia and Ukraine and the ongoing conflict between Israel and Hamas, including related sanctions and countermeasures,
and the effects of rising global inflation, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions,
the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. Additionally,
recent changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may
in the future impact, among other things, the U.S. and global economy, tariffs, international trade relations, unemployment, immigration,
healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these
changes to our business, they could adversely affect our business. For a further discussion of factors that may affect future operating
results see the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statement Notice.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as discussed above
and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>
</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Evaluation of Disclosure
Controls and Procedures</i>. Under the supervision and with the participation of our management, including our principal executive officer
and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of June 30, 2025, of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange
Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as
of June 30, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required
to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i) is recorded, processed, summarized
and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management,
including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding
required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Changes in Internal Control
over Financial Reporting</i>. There were no changes in our internal controls over financial reporting during the period covered by this
Quarterly Report on Form 10-Q that has materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160;On June 24, 2025, the court in the
securities action appointed lead plaintiffs who intend to file an amended Securities Complaint on or before August 25, 2025. The Defendants
have not yet responded to the Securities Complaint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court has not yet entered that stipulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly Report
on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; and in our Annual Report on Form 10-K for the year ended December 31, 2024. Each of the following risk factors, either
alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the
value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additional risks not
currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our
business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are providing the following
summary of the risk factors contained in this Quarterly Report on Form 10-Q to enhance the readability and accessibility of our risk factor
disclosures. We encourage you to carefully review the full risk factors contained in this Quarterly Report on Form 10-Q in their entirety
for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks
and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are highly dependent on the clinical, regulatory
    and commercial success of Iomab-B, Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We continuously evaluate our business strategy and may modify our strategy
as necessary to respond to developments in our business and other factors, and any such modification such as a divestiture, spin-off,
spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business, financial condition, and results
of operations;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may expand our business through the acquisition
    of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
    ownership interests in our company;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business could be adversely affected by the effects of future health epidemics;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our business is subject to cybersecurity risk;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have not demonstrated that any of our products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Healthcare legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in the healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may rely on third parties to conduct certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Disruptions at the FDA and other government agencies caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively impact our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not profitable and
have incurred losses in each period since our inception. As of June 30, 2025 and December 31, 2024, we had an accumulated deficit of $398.6
million and $375.8 million, respectively. We reported a net loss of $22.8 million and $20.0 million for the six months ended June 30,
2025 and 2024, respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the
products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no assurance that
if such products are approved, they will be successfully commercialized, which would have an adverse effect on our business prospects,
financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies, or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited access to
the capital markets to raise funds. The capital markets have been unpredictable in the recent past for development stage radiopharmaceutical
and other biotechnology companies and unprofitable companies such as ours. In addition, it is generally difficult for development-stage
companies to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends
on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If
we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds
are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations, financial condition
and our continued viability will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the clinical,
regulatory and commercial success of Actimab-A, Iomab-ACT, ATNM-400 and other pipeline candidates which we may never achieve</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the drug candidates
we are developing, or have developed, have received regulatory approval. Based on the current status of our pipeline candidates, it will
likely take several years or additional clinical studies before we can seek approval for any drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A drug candidate was studied in a Phase 2 clinical trial
as a monotherapy and we are now studying it in combination with other therapies. We believe we have aligned with the FDA on a Phase 2/3
trial that is intended to support a BLA filing. There can be no assurance that the Phase 2 portion of the trial will be successful and
support advancing to the Phase 3 portion of the trial. In addition, our Iomab-ACT drug candidate has only been studied in a limited number
of human subjects in a Phase 1 trial with a novel CAR-T therapy. While we believe the initial results from this trial were encouraging,
there can be no assurance that future results with Iomab-ACT from the commercial CAR-T trial at UTSW or sickle cell conditioning trial
at Columbia will be positive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for Iomab-B in particular,
as previously disclosed, we completed the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML) and presented
the trial results in February 2023, which were expected to support a BLA filing. The SIERRA trial met the primary endpoint of dCR with
statistical significance (p-value&lt;0.0001) but did not meet the secondary endpoint in achieving a statistically significant improvement
in overall survival in the intent to treat population. On August 5, 2024, we announced that the FDA determined that the SIERRA trial alone
is not adequate to support a BLA filing and is requiring an additional randomized head-to-head clinical trial to demonstrate an overall
survival benefit in an intent to treat population. Further, the FDA is also requiring an additional dose optimization trial to calculate
the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver
as was done in the SIERRA trial based on several interactions with the FDA prior to the start of the SIERRA trial. Based on this revised
approach now required by the FDA, the safety and efficacy data generated from all Iomab-B studies, including the SIERRA trial, are inadequate
to seek regulatory approval for Iomab-B, as dosing based on maximum tolerable dose of 24 Gy to the liver will lead to variable doses to
the bone marrow (the target organ), result in underdosing or overdosing of patients and translate to a global patient safety risk. We
are seeking a strategic partner for the U.S. in order to conduct the additional studies required by the FDA; however, we may not be successful
in our efforts to find such a partner, or the trials and studies may not be successful. Further, there are no assurances that we can satisfy
all of the FDA&#8217;s requests, and there could be additional regulatory hurdles that may result in either non-acceptance or non-approval
of a future BLA filing. The U.S. commercial opportunity for Iomab-B may thus never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trial results in the context of global regulatory submissions
for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization of Iomab-B
in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions at the FDA and other government
agencies caused by leadership changes, changes to regulatory approach, layoffs, funding shortages or global health concerns could negatively
impact our business</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
ability of the FDA to review proposed clinical trials or approve new products can be affected by a variety of factors, including government
budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept
the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition,
government funding of other government agencies that fund research and development activities is subject to the political process, including
executive and congressional priorities, the impacts of which are inherently fluid and unpredictable. Disruptions at the FDA and other
agencies may slow the time necessary for new product candidates to be reviewed and/or approved, which would adversely affect our business.
For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several
times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition,
the current administration has proposed substantial reductions in force at various government agencies including the FDA, which could
significantly reduce the FDA&#8217;s capacity to perform its functions in a manner consistent with its past practices and could delay
reviews and negatively impact our business. There has been significant turnover and recent changes in senior leadership at the FDA and
other government agencies including the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;), which is the division of the
FDA that would oversee and review biologics-based targeted radiotherapies like those we currently develop and plan to continue to develop.
We believe these changes could result in changes in the FDA&#8217;s perception of the approvability of therapies, the perceived value
of certain therapies or therapeutic modalities, which could create material challenges for our development efforts. At this time, there
is significant uncertainty and risks associated with future FDA regulatory policies and actions that could have a material negative impact
on our business. Any or all of these factors could cause us to amend, suspend or terminate the development of certain of our preclinical
or clinical programs, which could have material adverse impacts on our business, our product candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates ultimately become approved and we
do not secure a commercial partner, we would have to build and establish these capabilities in order to commercialize our approved product
candidates. The process of establishing commercial capabilities will be expensive and time consuming. Even if we are successful in building
sales and marketing capabilities, we may not be successful in commercializing any of our product candidates. Any delays in commercialization
or failure to successfully commercialize any product candidate may have material adverse impacts on our business and ability to continue
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of future health epidemics.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be adversely
impacted by the effects of future pandemics, epidemics or infectious disease outbreaks. The full impact of such an event cannot be predicted
at this time, and could depend on numerous factors, including vaccination rates among the population and the response by governmental
bodies and regulators. Given the ongoing and dynamic nature of the circumstances, it is difficult to predict the impact of a future pandemic
on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A future pandemic could adversely
affect our clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to a future pandemic if their geography
is impacted by the pandemic. Further, future pandemics could result in delays in our clinical trials due to prioritization of hospital
resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials, or the inability of patients
to comply with clinical trial protocols if quarantines or travel restrictions are implemented that impede patient movement or interrupt
healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party
service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and a future
pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us,
which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a future pandemic
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">theft or misappropriation of
funds;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">loss, corruption, or misappropriation
of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data
or employee data);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">disruption or impairment of
our and our business operations and safety procedures;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">damage to our reputation with
our potential partners, patients and the market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">exposure to litigation; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased costs to prevent,
respond to or mitigate cybersecurity events.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA, EMA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
rigorous regulation by the FDA, EMA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the regulators, we
may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and
efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical trial results
may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business,
results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product
candidates for fewer or more limited indications than we request, may not obtain the price we intend to charge for our products, may grant
approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, as for Iomab-B,
despite the Phase SIERRA 3 trial meeting the primary endpoint of durable Complete Remission (dCR) with statistical significance (p-value&lt;0.0001),
the FDA has determined that demonstrating an overall survival benefit in a randomized head-to-head trial is required for a BLA filing.
In addition, the FDA is also requiring that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate
the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver
as was done in the SIERRA trial based on several interactions we had with the FDA before starting the SIERRA trial. The head-to-head Phase
3 trial will evaluate allogeneic bone marrow transplant (BMT) using Iomab-B plus a reduced intensity conditioning regimen of fludarabine
and total body irradiation (Flu/TBI) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI.
This is different from the SIERRA trial, which allowed physician&#8217;s choice of salvage therapies and heterogenous conditioning regimens
in the control arm. However, there are no assurances that the additional trials will be completed or successful or that we can satisfy
all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in either non-acceptance or non-approval
of a future BLA filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously disclosed and
noted above, Actinium has licensed to Immedica the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We
are evaluating the impact of the FDA&#8217;s 2024 determination of the SIERRA trials results referred to above in the context of global
regulatory submission for Iomab-B. At this time, filings for regulatory approval, obtaining regulatory approvals, and successful commercialization
of Iomab-B in the EUMENA region and on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also evaluating Iomab-ACT,
which uses a lower dose I-131 for conditioning prior to cellular therapies such as CAR-T and gene therapies. We are currently studying
Iomab-ACT in three clinical trials including two investigator sponsored studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A (lintuzumab-Ac-225)
product candidate has also been studied in several Phase 1 and 2 trials under our sponsorship and investigator-initiated trials in patients
with r/r AML and we plan to continue to study Actimab-A in clinical trials. Actimab-A is also being developed under a cooperative research
and development agreement (CRADA) with the National Cancer Institute (NCI) and we expect clinical trials to be initiated that will study
Actimab-A as a single agent or in combination with other therapies. Product candidates utilizing the lintuzumab antibody would require
BLA approval before they can be marketed in the United States. We are in the early stages of evaluating other product candidates consisting
of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA
may not approve these products for the indications that are necessary or desirable for successful commercialization. The FDA may fail
to approve any BLA we submit for new product candidates or for new intended uses or indications for approved products or future product
candidates. Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA, EMA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA,
EMA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and
cash flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally,
even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that
we request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Disruptions
at the FDA and other agencies may slow the time necessary for new product candidates to be reviewed and/or approved, which would adversely
affect our business and may cause us to amend our business strategy or. For example, over the last several years, including for 35 days
beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have
had to furlough critical FDA employees and stop critical activities. In addition, the current administration has proposed substantial
reductions in force at various government agencies including the FDA, which could significantly reduce the FDA&#8217;s capacity to perform
its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business. There has been
significant turnover and changes in senior leadership at the FDA and other government agencies including the Center for Biologics Evaluation
and Research (&#8220;CBER&#8221;), which is the division of the FDA that would oversee and review biologics based targeted radiotherapies
like those we currently develop and plan to continue to develop. We believe these changes could result in changes in the FDA&#8217;s perception
of the approvability of therapies, the perceived value of certain therapies or therapeutic modalities, which could create material challenges
for our development efforts. At this time, there is significant uncertainty and risks associated with future FDA regulatory policies and
actions that could have a material negative impact on our business. Any or all of these factors could cause us to amend, suspend or terminate
the development of certain of our preclinical or clinical programs, which could have material adverse impacts on our business, our product
candidates or our ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe or effective for any indication and will continue to expend substantial time and resources on clinical development before
any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have three product candidates in clinical development and have not-yet submitted a BLA for
any of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are
numerous developmental steps that must be completed before we can prepare and submit a BLA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical and biological product candidates under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and
the Public Health Service Act (&#8220;PHSA&#8221;), as well as their respective implementing regulations. Such products and product candidates
are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. The process required by the FDA before a drug or biological product may be marketed in the United States generally
involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">completion of preclinical laboratory
tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for
the humane use of laboratory animals or other applicable regulations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">submission to the FDA of an
Investigational New Drug (&#8220;IND&#8221;) application, which must become effective before human clinical trials in the United States
may begin;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, good clinical practices (&#8220;GCPs&#8221;), and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND application. Some preclinical testing may continue even
after the IND application is submitted. The IND application automatically becomes effective 30 days after receipt by the FDA, unless the
FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time
period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA
may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or
non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized
by the FDA. Accordingly, we cannot be sure that submission of an IND application will result in the FDA allowing clinical trials to begin
or that, for those that have already commenced under an active IND application, that issues will not arise that suspend or terminate such
trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND application. Clinical trials
must be conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement
that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Phase 1. The biological product
is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening
diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing
is often conducted in subjects.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time, effort and expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that the clinical
trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development will take, at least,
several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. Also, the results of early preclinical and clinical testing may not be predictive of the results of subsequent
clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies, and preclinical and clinical
data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed
satisfactorily in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval of their products. Success
in preclinical testing and early clinical trials does not ensure that later clinical trials, which involve many more subjects, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing. Any failure or substantial
delay in our product development plans may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">conditions imposed on us by
the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delays in receiving, or the
inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical
trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Funding cuts to the NCI, which could delays and/or pauses or termination
of our ongoing and planned clinical trials under our CRADA;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">failure to conduct the clinical
trial in accordance with regulatory requirements or our clinical protocols;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">inspection of the clinical trial
operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">varying interpretation of data
by the FDA or similar foreign regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">failure to achieve primary or
secondary endpoints or other failure to demonstrate efficacy;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">unforeseen safety issues; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">lack of adequate funding to
continue the clinical trial.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initiating and completing
clinical trials necessary to support FDA approval of a BLA for Iomab-B, Actimab-A, Iomab-ACT, ATNM-400 and other product candidates, is
a time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not
necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable results in
later clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For instance, we worked with
the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with r/r AML who are aged 55 and above
prior to a BMT. Even though the SIERRA trial met the primary endpoint of dCR with statistical significance (p-value&lt;0.0001), the FDA
has determined that the analyses from the SIERRA trial do not support a BLA filing for Iomab-B. The FDA now requires an additional head-to-head
Phase 3 clinical study. We have further discussed the specifics of this additional clinical trial with the FDA. Based on these discussions,
Actinium believes it has aligned with the FDA on the patient population for this additional clinical trial, which can include all adult
patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader patient population
than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA is also requiring that
an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed
dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based
on several interactions we had with the FDA before starting the SIERRA trial. We are seeking a strategic partner for Iomab-B in the U.S.
to advance these additional trials. Even if we are able to secure a partner, there are no assurances that the additional trials will be
successful or that we can satisfy all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in
either non-acceptance or non-approval of a future BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. We may also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data. Our clinical trials may be open label studies and certain of our clinical development and/or operations staff may review interim
or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time. Interim or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line, interim or preliminary data
we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from preclinical studies are not necessarily
predictive of future success in clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one
or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse
differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by
us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our preclinical studies or early
clinical trials are favorable, later clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates,
which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our preclinical studies
are favorable and our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate
claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early
clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate
the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are
safe and effective for the proposed indicated uses. If the FDA concludes that any current or future clinical trials for Actimab-A, Iomab-ACT,
Iomab-B, ATNM-400 or any other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness,
we would not receive FDA approval to market that product candidate in the United States for the indications sought. In addition, such
an outcome could cause us to abandon the product candidate and might delay the development of others. Any delay or termination of our
clinical trials will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product
candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that
are not currently part of a product candidate&#8217;s profile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The key patents related to the humanized antibody lintuzumab, which
we use in our Actimab-A product candidate, have expired. It is generally possible that others may be eventually able to use an antibody
with the same sequence, and we will then need to rely on additional patent protection covering alpha particle drug products comprising
Ac-225. Our final drug construct, Actimab-A, consists of the lintuzumab antibody labeled with the isotope Ac-225. We currently own issued
and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using Actimab-A and production of the Ac-225
isotope. In addition, we possess trade secrets and know how related to the manufacturing and use of isotopes. Any competing product based
on the lintuzumab antibody is likely to require several years of development before achieving our product candidate&#8217;s current status
and may be subject to significant regulatory hurdles, but such development by others is nevertheless a possibility that could negatively
impact our business in the future. We own 4 issued U.S. patents, 2 issued Canadian patents, 2 issued European patent (validated as a national
patent in several countries) and 1 issued Japanese patent that relate to the composition of our Iomab-B product candidate. Patent applications
relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue to file patents related to Iomab-B that
can provide barriers to entry but there is no certainty that these patents will be granted or such granting thereof will adequately prevent
others from seeking to replicate and use the apamistamab antibody or the construct. Our patent portfolio includes pending applications
related to radioimmunoconjugate composition, formulation administration, and methods of use in treating solid or liquid cancers. This
subject matter includes composition, administration, and methods of treatment for our product candidates Actimab-A and Iomab-B. Any competing
product based on the antibody used in Iomab-B is likely to require several years of development before achieving our product candidate&#8217;s
current status and may be subject to significant regulatory hurdles. Further, if approved, Iomab-B would be entitled to 12 years of market
exclusivity in the U.S. and 10 years in Europe, during which time no generic biologic or biosimilar product referencing Iomab-B can be
granted marketing approval.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Actimab-A program clinical trials are
testing the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A program is comprised
of several clinical trials conducted under the CRADA with NCI, Actinium sponsored trials, investigator-initiated trials in AML and other
myeloid indications and solid tumors that will study the same drug construct consisting of lintuzumab-Ac-225. Negative results from any
of these trials could adversely impact our ability to enroll or complete our other trials studying lintzumab-Ac-225, including future
studies conducted under our CRADA with the NCI. Additionally, negative outcomes including safety concerns, may result in the FDA requiring
amendment to certain clinical trials, placing a clinical hold on certain or all clinical trials or discontinuing other trials utilizing
lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are currently developing, and in the
future may develop, product candidates in combination with other therapies and that may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing,
and may develop future product candidates, for use in combination with one or more currently approved therapies. For example, Actimab-A
is expected to be tested in combination with KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> for treating HNSCC and NSCLC. If any
of the approved therapies we currently or may, in the future, use in combination with a current or future product candidate is found defective,
removed from the market, or otherwise becomes unavailable, our clinical trials may face significant delays, be suspended, or terminated.
Any such events would likely have a material impact on our operations and the development of the affected product candidate(s) and may
ultimately prevent the approval of such product candidate or render continued development efforts too costly to proceed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a current or future
product candidate were to receive FDA approval to be commercialized in the U.S. for use in combination with one or more existing therapies,
we would continue to be subject to the risk that the FDA or similar foreign regulatory authorities could revoke approval of the therapy
used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with any such existing
therapies. This could result in our own products being removed from the market or cause material delays in, or the suspension or discontinuation,
of our production and/or distribution of the applicable product, as our ability to market any such product will be limited to the extent
specified in the FDA&#8217;s approval, if granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iodine-131 is a key component
of our Iomab-B drug candidate. We source medical grade I-131 from multiple suppliers, including two leading global manufacturers. Currently,
we believe there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for future commercialization
of potential I-131 based products. We continually evaluate I-131 manufacturers and suppliers. While we consider I-131 to be commoditized
and obtainable through several suppliers, there can be no guarantee that we will be able to secure I-131 or obtain I-131 on terms that
are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs including ATNM-400 and other drug candidates that
we might consider for development with the Ac-225 payload. We have secured multiple suppliers that are expected to provide cGMP Ac-225
for our planned clinical trials. There are adequate quantities of Ac-225 available today to meet our current needs via our present supplier,
the Department of Energy (&#8220;DOE&#8221;), who has been our primary supplier of Ac-225 historically. The Ac-225 currently supplied
for our clinical trials from the DOE is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is
able to produce sufficient quantities that are several multiples of the amount of Ac-225 we require to supply our clinical programs through
to the early commercialization phase. The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production
via a linear accelerator that is currently being evaluated by us. Initial preclinical and modelling results have indicated that the linear
accelerator sourced Ac-225 does not impact labelling efficiency and expected distribution. In accordance with representations made by
the DOE, the capacity of Ac-225 from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial
Ac-225 needs and support new program expansion by not just Actinium but also other companies that are developing Ac-225 based products.
Additional routes of Ac-225 production are being pursued by the DOE including the generation of new thorium cows and production via a
cyclotron. The cyclotron production method for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents
an additional path towards production of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we
are aware of at least ten other government and non-government entities globally including the U.S., Canada, Russia, Belgium, France and
Japan that have, or expect to have, ability to supply Ac-225 or equipment for its production within the timeframes relevant to the potential
first commercial approval of our Ac-225-based drug candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2025. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. There can be no assurance that the DOE or our other suppliers
will be able to supply all of the quantities of Ac-225 we request in the future. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons, and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in the future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the size and nature of the patient
population;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the patient eligibility criteria
defined in the protocol;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the size of the study population
required for analysis of the trial&#8217;s primary endpoints;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the proximity of patients to
trial sites;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the design of the trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to recruit clinical
trial investigators with the appropriate competencies and expertise;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">competing clinical trials for
similar or alternate therapeutic treatments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">clinician&#8217;s and patients&#8217;
perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain
patient consents; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the risk that patients enrolled
in clinical trials will not complete a clinical trial.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, refractory patients,
which several of our trials have or are expected to enroll, participating in clinical trials are seriously and often terminally ill and
therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related
or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical
trials, delays in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely
affect our ability to advance the development of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that the data generated in our clinical trials will be acceptable to the FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to the FDA. Certain modifications to a clinical trial protocol made during the course of
the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, the FDA could take the position that some or all
of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require
the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product
candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial
while it evaluates additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in obtaining regulatory approval for Iomab-B or completion of our ongoing or planned clinical trials would adversely affect our business
and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from the FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the
future, but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have
received or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Actimab-A and Iomab-B for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products, and, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">restrictions on the marketing
or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fines, warning letters or holds
on clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refusal by the FDA to approve
pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">product seizure or detention,
or refusal to permit the import or export of our product candidates; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injunctions or the imposition
of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and
reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly
approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products
are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the
product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as
a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally
does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to
obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower
than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain
or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues
particularly susceptible to any cost containment or reduction efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect on our business, future revenue, if any, and results of operations.</i>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever. The Affordable Care Act may also affect our operations in ways we cannot currently predict.
Affordable Care Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs,
reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion
of state Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and
abuse enforcement. Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may
result in the development of new programs, including Medicare payment for performance initiatives, health technology assessments, and
improvements to the physician quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, during his first term, former President Trump issued several Executive Orders and other directives designed to
delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health
insurance mandated by the Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part
of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation
the Affordable Care Act have been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision
requiring individuals to purchase and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty
to zero, beginning in 2019. In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that
the rest of the Affordable Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the
individual mandate but remanded the case back to the lower court to reassess whether and how such holding affects the validity of the
rest of the Affordable Care Act. The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court.
On June 17, 2021, the Supreme Court held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain
individuals) did not have standing to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly,
vacated the Fifth Circuit&#8217;s decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act
remained in effect in its then-current form; however, we cannot predict what additional challenges may arise in the future, the outcome
thereof, or the impact any such actions may have on our business. This uncertainty has become even greater given the new Trump administration
and its proposed agenda.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Affordable
Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, former President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, which began on January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS
released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets
out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to
advance these principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More recently, on August 16,
2022, former President Biden signed into law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among
other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. Specifically,
the IRA authorizes and directs the Department of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain
high-cost Medicare Part B and Part D qualified drugs, with the initial list of drugs announced on August 29, 2023, and the first year
of maximum price applicability to begin in 2026. The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase
the price of certain Medicare Part B and Part D drugs faster than the rate of inflation. Finally, the IRA creates significant changes
to the Medicare Part D benefit design by capping Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 15, 2025, the Trump
Administration released an executive order entitled, &#8220;Lower Drug Prices by Once Again Putting Americans First,&#8221; which among
other things, included multiple directives to various agencies aimed at lowering prescription drug prices. These directives included reports
and proposals for new regulations related to reforming the IRA&#8217;s Medicare Drug Price Negotiation Program, reducing the prices of
high-cost drugs, and enhancing price transparency. On May 12, 2025, President Trump issued an executive order implementing the concept
of most-favored nation pricing. Under this order, DHHS, in coordination with other federal agencies, is directed to take actions to ensure
that the price of prescription drugs paid by federal health insurers, including Medicare and Medicaid, is in line with the prices paid
in comparable nations. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction
in payments from private payors. Further, on July 4, 2025, President Trump signed the One Big Beautiful Bill Act into law which, among
other things, is expected to reduce funding to federal healthcare programs, imposes additional requirements to be eligible for healthcare,
and clarifies exclusions for orphan drugs under IRA&#8217;s Drug Price Negotiation Program. Current and future legislative and regulatory
changes to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for healthcare products and
treatments that could significantly impact pharmaceutical companies and the success of our product candidates. At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in the
healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition
and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and research
efforts rely, in part, on funding and support from U.S. government agencies such as the National Institutes of Health (&#8220;NIH&#8221;),
National Cancer Institute (&#8220;NCI&#8221;) and the Department of Health and Human Services (&#8220;HHS&#8221;). Government funding
for these programs is subject to annual budgetary decisions, which can be unpredictable and influenced by shifting political and economic
priorities. Reductions in government support for cancer research or other healthcare initiatives could limit grants, contracts, or other
financial resources that we or our research collaborators depend on, potentially delaying our clinical programs and increasing our reliance
on alternative funding sources. For instance, we have a CRADA with the NCI for the development of Actimab-A. While we have been informed
that the funding for our CRADA is not expected to be impacted, there can be no assurances that this will remain the case and any reduction
or elimination of funding can have a material adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, with the change
in presidential administration that recently occurred in the United States, government spending programs have become even more difficult
to predict and may be subject to greater risk. Considerable uncertainty exists regarding how future budget and program decisions will
unfold, including the spending priorities of the new U.S. presidential administration and Congress and what challenges budget reductions
may present for our industry generally or for our company. In particular, President Trump recently attempted to place a widespread freeze
on most federal grants and loans. Any freeze on government support for our products, programs, or studies could significantly impair our
research and development activities, business, and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disruptions at
the FDA, the SEC and other government agencies or comparable regulatory authorities caused by funding shortages or global health concerns,
in addition to substantial uncertainty regarding the new Administration&#8217;s initiatives and how these might impact the FDA, its implementation
of laws, regulations, policies and guidance, and its personnel, could hinder government agencies&#8217; ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner,
or otherwise prevent those agencies from performing normal business functions on which our business operations rely, including timely
reviews, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA or
comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and
policy changes that may otherwise affect the FDA&#8217;s or comparable foreign regulatory authorities&#8217; ability to perform routine
functions. In addition, government funding of the SEC and other government agencies or comparable foreign regulatory authorities on which
our operations may rely, including those that fund research and development activities, is subject to the political process, which is
inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies, including substantial leadership, personnel, and policy changes, may also slow the time necessary for new drugs to be
reviewed and/or approved by necessary government agencies, which would harm our business. Changes in FDA staffing could result in delays
in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement
or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant
shutdown of the federal government. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government
shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular
inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could materially adversely affect our business, financial condition, results of operations and prospects.
Such changes could significantly impact the ability of the FDA to timely review and take action on our regulatory submissions, which could
have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or substantial
leadership, personnel, and policy changes could impact our ability to access the public markets and obtain necessary capital in order
to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the change in the U.S.
Presidential Administration in 2025, there is substantial uncertainty as to whether and how the new administration will seek to modify
or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty
could present new challenges and/or opportunities as we navigate development of our product candidates. Some of these efforts have manifested
to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and/or retain key personnel, which could result
in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite
regulatory approvals in the future. Moreover, the new Administration has proposed action to freeze or reduce the budget of the National
Institutes of Health, or NIH, as related to its funding for medical research, which could decrease the ability of facilities that rely
on NIH funding to enroll and conduct clinical trials or increase the costs to us of conducting clinical trials. There remains general
uncertainty regarding future activities. The new Administration&#160;could issue or promulgate executive orders, regulations, policies
or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products.
Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory
frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations,
policies or guidance as a result of the new Administration, there could be a material adverse effect on us and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our relationships with
customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties,
including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare
programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits
and earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback Statute,
which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration,
directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order
or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs
such as Medicare and Medicaid;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal false claims laws,
including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties against
individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims
for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the
federal government;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare
benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual
terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective
business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the covered
entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable
health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Civil Monetary Penalties
Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary
if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner,
or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Physician Payments
Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs,
devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to
physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in 2022, applicable
manufacturers also will be required to report such information regarding payments and other transfers of value to physician assistants,
nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse
midwives during the previous year; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">analogous state laws and regulations,
including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited
to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party
payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise
restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require
drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration
and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical
sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which
differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote, and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S. and some jurisdictions
outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system
that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to
drug pricing, including specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically,
there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency
to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare,
and reform government program reimbursement methodologies for drugs and biologics. In addition, the concept of most-favored nation pricing
has been raised that would seek to establish drug prices in the U.S. to the lowest level paid by comparable countries. Such policy action
could cause us to amend, suspend or terminate the development of any or all of our product candidates if a viable commercial market did
not exist, which could have a material adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If future legislation were
to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial
results. Managed care organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state
level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility
in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory,
payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material
adverse impact on our business and ability to operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may rely on third parties to conduct
our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply
with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The protection against generic competition
for our biologic drug candidates and reimbursement by CMS may be subject to future change</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our ARC product candidates are regulated by the FDA as biologic products, and we intend to seek approval for these products
pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for
the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the
FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based
on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA
until 12 years after the original branded product was approved under a BLA and in Europe a biosimilar product cannot be approved until
10 years after the original branded product was approved. The law is complex and as a result, its ultimate impact, implementation, and
meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the antibodies that we use, the final constructs of
our drug candidates consist of an antibody, radioisotope and in some cases a linker and we are not aware of any regulations that would
require us to provide the final constructs or components to third parties or potential competitors. Therefore, based on the current regulations,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA for
at least 12 years in the U.S. and 10 years in the EU. We are aware that generic versions of certain radiopharmaceuticals utilizing peptides
have been submitted to the FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;) pathway, however, those products are not
covered under the BPCIA and therefore that generic pathway is not applicable to Iomab-B or Actimab-A. We expect this would also apply
to other biologic drug candidates we may seek to develop in the future based on the current provisions of the BPCIA. Additionally, the
Inflation Reduction Act (&#8220;IRA&#8221;) that was enacted in August 2022, states that reimbursement by the Centers for Medicare&amp;
Medicaid Services (&#8220;CMS&#8221;) for high-expenditure single-source biologic drugs, which we expect Iomab-B and Actimab-A to be,
can only be negotiated after at least 11 years following approval compared to 7 years for non-biologic drugs with negotiated prices taking
effect two years after selection. Therefore, we currently believe that our ARCs are less likely than small molecules to face pricing pressure
and negotiation from IRA. Further, a drug or biological product that has an orphan drug designation, which Iomab-B and Actimab-A both
have, for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiations requirements &#160;until such time
the biological products has designations for more than one rare disease or condition, or if is approved for an indication that is not
within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn
by the time CMS evaluates the drug for selection for negotiation. In August 2023, 10 initial drugs were identified with negotiated prices
expected to take effect starting in 2026. In 2027 and 2028, it is expected that CMS will establish negotiated prices for 15 additional
drugs in each respective year. We do not believe there is a high likelihood that Iomab-B or Actimab-A would be identified by CMS for negotiated
pricing under IRA but there is potential that IRA and other additional state and federal healthcare reform measures will be adopted in
the future and the implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or successfully commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A, Iomab-ACT, ATNM-400,
Iomab-B and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical
community. The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived
effectiveness and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability,
relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product
are approved for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the
level of education and awareness among physicians and hospitals concerning the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage,
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Actimab-A, Iomab-ACT,
ATNM-400, Iomab-B or any of our other product candidates to significantly penetrate current or new markets would negatively impact our
business financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently plan to build
out a manufacturing facility in the future to operate for the purposes of manufacturing our own products. We have never built, owned or
operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing so we
may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build out our
planned manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on vendors with
specialized operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary, or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, pertaining to the global patient safety
profile or efficacy results of our products, the achievement of milestones, the interpretation of contractual obligations, payments for
services, development obligations or the ownership of intellectual property developed during our collaboration. We may seek to amend,
modify or terminate agreements with partners, suppliers or service providers related to Iomab-B, Actimab-A or Iomab-ACT but there can
be no assurance that we can do so successfully or negotiate terms that are favorable to us. Failure of which can increase the risk of
or result in litigation or alternative dispute resolution options taken against us. Further, we may exercise our decision-making authority
under certain circumstances pertaining to global patient safety related to our products, which our partners may disagree with and may
result in potential conflicts and public disclosure of our rationale and position. If any conflicts arise with any of our partners, such
partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following,
each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating
revenues: unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty
regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into
additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including providing
us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress of its development
and commercialization activities or to permit public disclosure of the results of those activities; initiating litigation or alternative
dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.&#160;Litigation
or alternative dispute resolution options can be lengthy and expensive, require significant time and attention from our management and
are highly uncertain. There can be no assurance that if we pursue, or a partner pursues litigation or alternative dispute resolution options,
that we will prevail. Monetary and equitable damages awarded against us could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. If we are unable to enter into or maintain such arrangements when
needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory
approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates,
either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw
their approval of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require
the addition of labeling statements, such as warnings or contraindications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be required to change
the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may elect, or we may be required,
to recall or withdraw product from the market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we could be sued and held liable
for harm caused to patients; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our reputation may suffer.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or
prevent sales of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, the issuance
of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may not provide us
with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able
to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods.
We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, vendors,
former employees and current employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent rights are territorial,
and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending patents on our products
and product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual
property rights in some countries outside the United States could be less extensive than those in the United States. Many countries, however,
do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes differ. Competitors may
successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for patent protection. Changes
in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result of these and other factors,
the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indeed, several companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems
of some countries do not favor the enforcement of patents and other intellectual property rights, which could make it difficult for us
to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings to enforce our
intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk
of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that are initiated, and
the damages or other remedies awarded, if any, may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of pharmaceutical
companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and
enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed
unenforceable, invalidated, or circumvented. A third-party may submit prior art, or we may become involved in opposition, derivation,
reexamination, inter partes review, post-grant review, supplemental examination, or interference proceedings challenging our patent rights
or the patent rights of our licensors or development partners. The costs of defending or enforcing our proprietary rights in these proceedings
can be substantial, and the outcome can be uncertain. An adverse determination in any such submission or proceeding could reduce the scope
of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, or
reduce our ability to manufacture or commercialize products. Furthermore, if the scope or strength of protection provided by our patents
and patent applications is threatened, it could discourage companies from collaborating with us to license, develop or commercialize current
or future products. The ownership of our proprietary rights could also be challenged.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors have applied
for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any patents,
and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible
that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because
of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our
patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent
related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents issued or licensed
to us may be infringed by the products or processes of others. Our ability to enforce our patent rights depends on our ability to detect
infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may
be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product, particularly
in litigation in countries other than the U.S. that do not provide an extensive discovery procedure. Any litigation to enforce or defend
our patent rights, if any, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management
and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded if we were to prevail may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of enforcing our
patent rights against infringers, if such enforcement is required, could be significant, and we may not have the financial resources to
fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations. There
has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry.
We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because
of their substantially greater financial resources. Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although
we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of
confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access
to, the same or similar information. In addition, we cannot guarantee that we have executed these agreements with each party that may
have or have had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements breach
or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade
secrets through such breaches or violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not have identified
all patents, published applications or published literature that affect our business either by blocking our ability to commercialize our
products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering the same or similar
technologies that may affect our ability to market our products. For example, we (or our licensors) may not have conducted a patent clearance
search sufficient to identify potentially obstructing third party patent rights. Moreover, patent applications in the United States are
maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the
U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries
outside of the United States are not typically published until at least 18 months from their first filing date. Similarly, publication
of discoveries in the scientific or patent literature often lags behind actual discoveries. We cannot be certain that we or our licensors
were the first to invent, or the first to file, patent applications covering our products and candidates. We also may not know if our
competitors filed patent applications for technology covered by our pending applications or if we were the first to invent the technology
that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional
patents and proprietary rights that block or compete with our patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our potential products and respective patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making, using and/or selling
its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize an invention covered
by the patent where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the
appropriate authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if
patented itself, cannot be commercialized if it infringes the valid patent rights of another party.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to damages resulting from
claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees may have been
previously employed at other companies in the industry, including our competitors or potential competitors. Although we are not aware
of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently or otherwise used
or disclosed trade secrets or other proprietary information of the former employers of our employees. Litigation may be necessary to defend
against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be
a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual
property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product(s),
which would materially adversely affect our commercial development efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case
of non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant patent agencies
in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance with a number
of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent lapse
can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which
the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our
technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results of operation.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future operations and
successes depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon
to manage our business. If any member of our current senior management terminates his or her employment with us and we are unable to find
a suitable replacement quickly, the departure could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the third quarter of 2024,
our overall headcount was reduced by approximately twenty percent, with a majority of departures coming from our clinical and CMC groups.
As a result of these departures, we expect our personnel expenses to be reduced by approximately $3.7 million in 2025, which may be offset
by additional hires or consultants. We do not expect these departures to have a material impact on our operations or ability to execute
our operating plan and are actively seeking a strategic partner for Iomab-B in the U.S. to advance the additional studies and trials required
by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An overall tightening and
increasingly competitive labor market has been observed in the U.S. employment market generally. Specific to the biotechnology industry
in which we operate, there is significant demand and competition for highly specialized talent that we require. A sustained labor shortage
or increased turnover rates within our employee base as a result of general macroeconomic factors of <i>force majeure </i>events, or due
to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract and retain employees, and could
negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development and potential regulatory
and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level, or if mitigation measures
we may take to respond to a decrease in labor availability, have unintended negative effects, our business could be adversely affected.
An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, general macroeconomic factors or as a result
of biotechnology industry dynamics could have a material adverse impact on our operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success also depends
on our ability to identify, attract, hire, or engage, retain, and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to need to grow
rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well
as potential commercial operations in the future, which will place a significant strain on our financial, managerial and operational resources.
In order to achieve and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities.
Moreover, we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our
expenses and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials, and we could be held liable for any damages that result, which could exceed our
financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future
claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the
costs of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of
waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our
research, development, production and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience growth
in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing, and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may
divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans
or disrupt our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We continuously evaluate our business strategy
and may modify our strategy as necessary to respond to developments in our business and other factors, and any such modification such
as a divestiture, spin-off, spin-out, merger or acquisition, if not successful, could have a material adverse effect on our business,
financial condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continuously evaluate our
business strategy and modify our plans as necessary to achieve our objectives in response to changing circumstances. As part of such a
process, we may delay, modify or discontinue the development of certain of our drug candidates and choose alternative approaches if we
believe such changes would be in our best interest. We may also expand or alter our research and development activities from time to time
and redirect allocation of our resources. We have implemented such changes in our business strategy and may continue to do so in the future.
There can be no assurances that any product development or other changes that we implement will be successful or that, after implementation
of any such changes, that we will not refocus our efforts on new or different objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired
product, company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated
with some of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products,
businesses or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business
or companies may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute
each current stockholder&#8217;s ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Our common stock is subject to price volatility which could
lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading volume of our
common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate
substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating
results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and
the financial markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market
price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The trading price of our common stock may
be highly volatile and could fluctuate in response to factors such as:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated variations
in our operating results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements of developments
by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the timing of IND and/or BLA
approval, the completion and/or results of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory actions regarding
our products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors
of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">adoption of new accounting standards
affecting our industry;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">additions or departures of key
personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">introduction of new products
by us or our competitors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">sales of our common stock or
other securities in the open market;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">inaccurate or unfavorable reports
from securities or industry analysts; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">other events or factors, many
of which are beyond our control.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, such as the Securities
Claims further described under &#8220;Legal Proceedings&#8221;, whether or not successful, could result in substantial costs and diversion
of our management&#8217;s attention and our resources, which could harm our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain provisions of our Certificate of
Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to
complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">provide that the authorized
number of directors may be changed by resolution of the board of directors;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">provide that all vacancies,
including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors
then in office, even if less than a quorum;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">divide the board of directors
into three classes;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">provide that stockholders seeking
to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders
must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s
notice;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks associated with litigation
and claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
legal proceedings, as further described under &#8220;Legal Proceedings.&#8221; In addition, from time to time, we may become involved
in various claims, disputes and legal or regulatory proceedings that arise in the ordinary course of business and relate to contractual
and other obligations. Due to the uncertainties of litigation, we can give no assurance that we will prevail on any claims made against
us in any such lawsuit. Also, we can give no assurance that any other lawsuits or claims brought in the future will not have an adverse
effect on our financial condition, liquidity, or operating results. Adverse outcomes in some or all of these claims may result in significant
monetary damages that could adversely affect our ability to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect to any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2024 and 2023 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tariff policies and potential countermeasures
could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">President Trump has increased,
and has indicated his willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain U.S. policy goals. Such
tariffs and any countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our global
supply chain and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty
about policy changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to
the U.S.&#8217;s or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other
countries on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition,
results of operations and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-8374"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-8375"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-8376"><ix:nonNumeric contextRef="c12" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-8377">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-size: 10pt">Amended and Restated Bylaws, dated August 9, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>16.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1388320/000121390025041582/ea024160001ex16-1_actinium.htm">Letter from Marcum dated May 8, 2025 (incorporated by reference to Exhibit 16.1 to Form 8-K filed on May 9, 2025).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><p style="margin-top: 0; margin-bottom: 0">&#160;</p></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024943901ex31-1_actinium.htm">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024943901ex31-2_actinium.htm">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024943901ex32-1_actinium.htm">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024943901ex32-2_actinium.htm">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: August 8, 2025</span></td>
    <td><span style="font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-7" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-8" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-9" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-10" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-11" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-13" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-14" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-15" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-22" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-23" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-40" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-41" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-43" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-45" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-47" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-48" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-53" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-60" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-62" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-64" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-65" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-66" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-8448">0001388320</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-8449">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-8450">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate" id="ixv-8451">--12-31</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20250630.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-08-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][Jh90VW2guslo+qNwtbRN4sFmCUllZisnUgh4a0U/7nvWwhqsW69cZnY6hXwLMm6Vb2GQuLtfIJF4u67EcbfAEeq31d6sglYawtnMLz8BhCWVANVxR8BxWzRUQb97sRuAm8QaNCOG6s9tgl/Xq0xqtS+9+b0A2bRxjnYL3937pOh0Yxy5gH7tVRuZCfSHeqq4C6Jeia0P7FSEshCfSv4HqnKJqQ21kFxiVDtsVA9vk4G4r4P8Uv7YCK40WiynjqLr2fI/caAxFoLeytEecwgnb9tNG7drNh71XixfLcBas6kQtI+sEzlb5lhOlbkCtDzgoRt5X1N7VLNV1rJMVJQviVPw9XPJY23eBa23M5Gz8Eix3WKT3KeXQc8=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-06-15</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:OperatingLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:FinanceLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-11</xbrli:startDate>
    <xbrli:endDate>2023-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea024943901ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION 302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: August 8, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea024943901ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 31.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION 302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form 10-Q of Actinium Pharmaceuticals,
Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: August 8, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ea024943901ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: August 8, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ea024943901ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2025 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">The information contained in the Quarterly Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: August 8, 2025</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> G # 2(  A$! Q$!_\0
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M-DMN&&X,QY! )Z<]*TA#FOKL3*5CUBBN#C\>:E-;>='HT/\ I.H-IUB&N?\
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M,O&,)(5%397W*;E:]M2Q15/^SD_Y^+K_ +_-1_9R?\_%U_W^:JM'O^!/-/\
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M1?6_,'O;<OX_\ CO/"&@WT=JDVFQ[+6/RHA&6C"Q\'9\I&5R!P>*N?V+IO\
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M_P _4G_?(HYJ?<.2OV1DIJ<<>H23K'B(1&*)%4# .!S[XSS[TZ[U&V:W=+=
M96^42&(+A"2=H'L,#/UK9M_!UO-,$-Y*."<A1V&:B_X1.#_GZD_[Y%/GIW%[
M*M;8S8-82WEM0D2B**)49L'<V/F(ZXP6]NE0B[MY]1CFN&D1!"%D,:X+MCG.
M.QSCZ5L?\(G!_P _4G_?(H_X1.#_ )^I/^^11STQ>RK;-&*UZDDDK22.&EF5
MF>-<$*HXP/KC\JBOK@75U&80<)&J+@8R0.2!VR>:W_\ A$X/^?J3_OD5/;^&
M[>V)83.S^I XI^T@M4+V-5Z,IJ)@JBX(,N!N(^E+6W=Z-&EP5$S=%[#T%0_V
M2G_/9OR%9*:9T.E).QE45J_V2G_/9OR%']DI_P ]F_(4<Z#V<C*KM_"/VC^S
MG\S'E;_DSU__ %5S\>EQ)(&9RX'8BNNT/_CR;_?-85Y)PLCKPD&JEV:=%%%<
M)ZP4444 9NO_ /($N?H/YBO)M;T>\U'Q!I5Q;W$]M#;PW"R3P,H=2P7:,,#D
M'![5ZSK_ /R!+GZ#^8KAJ[*"O \O%R<:B:['G^E^'_$EG<:0C231V]O'&I$<
MR[8R'8R;QN ;<".Q_"EA\.^(DABD:>]^T+!"Y!O21YPG._(SC'E8]OQKOZ;(
MZQQO(Y 5%+$GL!6OLT<_MI=CSR\T#Q%?'4Q-;S^3,-ZP_:\JSK,&&TECCY,^
M@[8XJS<Z)XAN7U!-L_[Z.Y5FDN@T<L;IB*,)GY6!QD^QY.:ZK0]:MM>TX7=O
MQ@E70GE#6E3=-(/;/L<1_97B..^WQR31,@!6Y^T9A2$0X\ORN[;^<X]\]JP+
M34[Z&QN;ZWN+K?:K:^5')<M,MQ.=P=/^!9SM[8'2O5J./0>O2DX=F-5>Z(?#
M]K+96VFVUQ,\TZ&,2R.V2S9!//U)KK)M0NUGD42G 8@# ]:Y^T_X_;?_ *ZK
M_,4WQ4]XZ"QL!,+B[G*[X6"M&@RS,&/ / 'XU,TKETF[.SZF_P#VC=_\]C^0
MH_M&[_Y['_OD5PK:_JEQ92+D6=TMOM$1MV=Y)=K!RI!P K+[CGW%-BUG63&_
MV9HV5,.7DA9O-R8UXYX^\QX]/K4>[V-O?[G>?VC=_P#/8_\ ?(H_M&[_ .>Q
M_P"^17"S>(M5AN(;=D5V$OE2D6Y7S 963>.>. #P"!W/(J?0-9OVL(Q<1M?1
MQ6\32SHOEF,E3O5@Q^8C /'//2CW>P>_;<[/^T;O_GL?^^11_:-X/^6Q_P"^
M17(^';K4S=S1:G%.@O(_M<!D8$)DX:,8^Z "AP>>M1017=C<7OV2:<R-J4=K
M&URSRJD3(A)"D\X.>:++L%Y=SL_[1N_^>Q_[Y%']HW?_ #V/_?(KSX:_J9AN
M+967S4B $ B8R'<KDON)XVX! _\ K4RXU_6VM;F%0(#%$/F\LF1 NP^9[[LM
M_3H:7N]A^_W/1/[1O/\ GL?^^11_:-W_ ,]C^0KE-;FC750E]=W5O8?92T#V
MS,N^7=S]WJP&, ^IZU3N=?U6 R+"@>1<H()8#YB*$!65R#@Y)P0/7V-/W>PD
MYOJ=O_:-W_SV/_?(H_M&[_Y['\A7!W^J:W%$T<MQ&JB<H)H[9EVB.:,;B,G(
M96.1[=:L0Z_J<ES&C+'@R(D:B!@;M#(5,BG/R * V.?R(H]WL'O]SM/[1N_^
M>Q_(4?VC=_\ /8_D*JT57*NQ'/+N6O[1N_\ GL?R%']HW?\ SV/Y"JM%'*NP
M<\NY:_M&[_Y['\A1_:-W_P ]C^0JK11RKL'/+N6O[1N_^>Q_(4?VC=_\]C^0
MJK11RKL'/+N6O[1N_P#GL?\ OD5:O[VXBDB"2$ Q*3P.M9?:D\6-*FCW3P%A
M,MB2A3J&VG&/>H:5UH7&4G%Z]BW_ &C>#_EL?^^11_:-W_SV/Y"N,5M8TRUM
M4BC1II8Y9I%,DD^[9&"J@L1M+$D5'_;FKRAEMI()56-Y/M(M6VN5C#; N>#D
MXS_44_=[!>7<[?\ M&[_ .>Q_P"^11_:-W_SV/Y"O/AJNJ?;#(SRRXE?]UL9
M0@WJ5!QUX/Y5)<>(=<MH8P\<!,B)*9_(*K'NC+;",_WAC/Z9H]WL'O\ <[W^
MT;O_ )['_OD4?VC>?\]C_P!\BN1URXU:YM;&WTZ&5;R2/[5+Y3!0NT#"DMC@
MN0".N :Q;O5-5N$U9K9KM$U"+_1B%.;5DB#OCTR"1]10^7L"YGU/2/[1N_\
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M!.+]/\*YGQK_ ,AN+_KUC_E7.UO3H1<4SCK8RI&HXKH>D?\ "50?]!.+]/\
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M2*KD9"]R,@9QZ9(_.@"7-&:7!]*3!H **** "BBB@ HHHH **** #M5W4O\
M70_]<5JEVK3O98$:$26_F-Y2\[R*E[HTBKQ9F49JUY]I_P ^?_D0T>?:?\^?
M_D0T7?8GE7<JYHS5KS[3_GS_ /(AH\^T_P"?/_R(:+OL'*NY5HR:M>?:?\^?
M_D0T>?:?\^?_ )$-%WV#E7<JT5:\^T_Y\_\ R(://M/^?/\ \B&B[[!RKN5:
M*M>?:?\ /G_Y$-'GVG_/G_Y$-%WV#E7<JT5:\^T_Y\__ "(://M/^?/_ ,B&
MB[[!RKN5:*M>?:?\^?\ Y$-'GVG_ #Y_^1#1=]@Y5W*M%6O/M/\ GS_\B&CS
M[3_GS_\ (AHN^P<J[E6BK7GVG_/G_P"1#1Y]I_SY_P#D0T7?8.5=RK1VJUY]
MI_SY_P#D0T>?:?\ /G_Y$-%WV#E7<YKQ5H][?:K%-!&K)]FC&2P'.*Q/^$;U
M/_GBG_?P5Z1=RVX:+=:[LQ*1\Y&!Z57\ZU_Y\C_W\-:0KR44DC&IA:<IN3?]
M?<>?_P#"-ZG_ ,\4_P"_@H_X1O4_^>*?]_!7H'G6O_/D?^_AH\ZU_P"?(_\
M?PU?UB?8S^IT^_\ 7W'G_P#PC>I_\\4_[^"G#POJIB,GDQ[0P4GS!UKOO/M?
M^?+_ ,B&IEFMOL3G[)\OF+E?,/7!I/$3[#6"I]_Z^X\Y_P"$;U/_ )XI_P!_
M!1_PC>I_\\4_[^"O0//M/^?/_P B&CS[3_GS_P#(AI_6)]A?4Z??^ON//_\
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M/H?[K?R-5^U6+'_CZ'^ZW\C5?M2ZE/X4%%%%,D*#T-%!Z&@"Q??\?;?[J_\
MH(JO5B^_X^V_W5_]!%5Z4=BI?$PHHHIDA6_H?_'F_P#OFL"M_0_^/-_]\UE5
M^$WP_P 9IT445RGH!1110!1UE8WTJ=99#&A RP7=CGTKD/LVG_\ 00;_ +\'
M_&NLU[_D"W'T'\Q7#UZ>#I*<&V^IX695W3JI)+8N?9M/_P"@@W_?@_XT?9M/
M_P"@@W_?@_XU3HKL^KQ[O^OD>;];E_*OQ_S+GV;3_P#H(-_WX/\ C1]FT_\
MZ"#?]^#_ (U3HH^KQ[O^OD'UN7\J_'_,N?9M/_Z"#?\ ?@_XT?9M/_Z"#?\
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MQ'<Z>DDY8W(7@<;">PJ+^S$_Y^Q_W[-79O\ 6GZ#^51TE>VY4K7>A6_LQ/\
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M;=3<HHHJB0HHHH *DO'2("21U1%C!9F. !ZDU'VJOXCM9;[1+VT@ ,T]HT:
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M"YCBSXCU^WB::6WM9]H4>7% ZDEH/-!SN/"GY3Z^QXJ]I>M:E?ZRMF'M9;1
M[M=QPL%G "<)EN,%B">?NUTU'08 HL%UV"BBBJ)"BBB@ HHHH **** "BBB@
M HHHH *.U%':@#@?''_(PC_KWCKFZ[;Q7H.HZCK"W%K"KQ^2BY+@<CZUB?\
M")ZS_P ^R_\ ?U?\:^APU>FJ,4Y+8^.QV%KRQ,Y1@VK]C$HK;_X1/6?^?9?^
M_J_XT?\ ")ZS_P ^R_\ ?U?\:Z/K%+^9?><?U/$?R/[C)MKB:TN$G@<I*AR&
M%>GZ%JAU?1OM#1-&XD"MQ\I..H]JY'3?!UY)=K_:"B*W7DA7!+>W'2N]AC2&
MR\J) D:, JJ. ,5Y685J4[*.K[GOY/AZ]-RE/2/9_GY?J)1117EGO!1110!)
M#_K1]#_*HZDA_P!:/H?Y5'2ZE= HHHIDA1VHH[4 23?ZT_0?RJ.I)O\ 6GZ#
M^51TEL5+=A1113)"K]C_ *D_[U4*OV/^I/\ O5G4^$VH?&6:***YCN"BBB@"
MEJ[Q1Z7,TT1EC &4#8SSZURGVS2O^@9)_P!_S73:]_R!;CZ#^8KAJ[\,O<>H
MUAJ576<4V:?VS2O^@9)_W_-'VS2O^@9)_P!_S691759]W][#ZCAOY%]QI_;-
M*_Z!DG_?\T?;-*_Z!DG_ '_-9E%%GW?WL/J.&_D7W&G]LTK_ *!DG_?\T?;-
M*_Z!DG_?\UF446?=_>P^HX;^1?<:]O=Z8;J$+ISJQD4 ^<>#FMV2ZA$K@P,2
M&/.^N1M/^/VW_P"NJ_S%:>MZK'I4\+S >3+.ZR.3]Q0CN3[_ ':YJRU5V'U:
MC#2,4C9^UP?\^[?]]T?:X/\ GW;_ +[KEIO%NGVZMYT%\DB*7DB,'SQH &+,
M,],,#^=.D\5:="B/,EU$#*87#Q &-@0/F&?]H'C/!K+0/94^QT_VN#_GW;_O
MNC[7!_S[M_WW7,Z9XDM;V-1<@V4S E1/A5<!RF4)Z\C]:J?\)A!YNJHL2.;3
M'V<+*,S_ #^6<_W<.0/H<TM ]E3['8_:X/\ GW;_ +[H^UP?\^[?]]URNHZE
MK6FZ=<W$UG8%X"OW9V*NK$#CC(()[\'M3]8UFXTB+3EF^QI+=2M&[R.XB3"%
MN,#)SC'2GH'LH=CI_M<'_/NW_?='VN#_ )]V_P"^ZY"#Q= ]O$]S;S6SC89R
MZ'RXPP8C!ZDD+D<=.M7(O$EG-=06JP7@N9FPL+0X95VAMYYX7!SFEH'LJ?8Z
M/[7!_P ^[?\ ?='VN#_GW;_ONN8D\36\%Y>VTMK=;K:1E_=IOW(J*[/UX4;A
M[U->:G<F\M[/3(H)I9;<W.^9RJ! 0!C )))/X4[(/90['0_:X/\ GW;_ +[H
M^UP?\^[?]]US,OB:SM4<WD4\1B&V9D7?&DFS>8PPZMCVJ,^+=/7S!+!?1%"R
MD/!@EEVDJ.>3AE/T-&@>RI]CJOM<'_/NW_?='VN#_GW;_ONN5/B_355S+'=P
ME25"RQ;2[!]A4<XR&('I[TZ+Q9ILY401W<I(0 )#_$Q(5.OWB5;VXSFC3N'L
MJ?8ZC[7!_P ^[?\ ?='VN#_GW;_ONN6G\56-I'++<I<)'&X4CRL,@VACN!(Y
M^;H,U(VN2'3$N(K=&GFO6LX49R%+!V4,3C@84G]*+(/90['2_:X/^?=O^^Z/
MM<'_ #[M_P!]UR6J>(Y]$LHGO[:W%PTS*5CG^4Q*-S2#/.0/X3WJ"7Q8ZZ\^
MGQ16\H%RD"(K/YDBLH8N/EVX .<$] :6@>RI]CM/M<'_ #[M_P!]T?:X/^?=
MO^^ZYF]U:Z%]81Z;]@N;>[D:(2F5CM959C]T$=%Q]:VJ=D'LH=BY]K@_Y]V_
M[[J:YN(D= T+-E ?O8K-[4>(+LV&GSW@3>;>U,NTG&[ SBDUJ'LH=BY]K@_Y
M]V_[[H^UP?\ /NW_ 'W7('QC8)<LCK*(_)B=3Y;*S.Y(" ,!V!.>E2_\)?IK
M[/)AO9PX&UHH,@DJ6"\D<X4^W'6GIW#V5/L=5]K@_P"?=O\ ONC[7!_S[M_W
MW7(WGC'3[:&1HHIYI!;FXB0* )0$#X'.1P>XQUJ6Y\46L*GRXIMWFB-6E3:C
MXD5'VGOMW<_2C0/94^QU/VN#_GW;_ONC[7!_S[M_WW7,KXHL'**D-XTD@#PQ
M"'YY4()WJ,\KA3Z?3D4EKXGL[MPL$=Q,7 =5BA)98R%.YAV^^.F:- ]E3['3
M_:X/^?=O^^Z/M<'_ #[M_P!]URZ>*+2?48K*WCD,K3K&XD&W"G=\PP3W4C!P
M:I7_ (O:R&N*;(-+8.JVZ;_^/@$ D^V,G\J- ]E3[':_:X/^?=O^^Z/M<'_/
MNW_?=<I=>*[2&=K:..0W*N@*N,*09%1B#G/&\=0,T+XNTX6R32"XV%3NECA)
MCW!-Y4'KD+[4:![*GV.K^UP?\^[?]]T?:X/^?=O^^ZY>7Q7IT$/F3QW<6)#&
MZO$ 8SQUY]&!XR:<OBG3W?8L=V79ML*^3S.=Y0A.>?F!ZX]:- ]E3['3?:X/
M^?=O^^Z/M<'_ #[M_P!]URDWB[3K5W6Y\Y&!XC\HAU4*I8L#C&-PZ9_&KVGZ
MU9ZG=7-O;>86MSARRX!YQQSGMW ]:+(/94^QN_:X/^?=O^^Z/M<'_/NW_?=4
MZ*=A^RAV+GVN#_GW;_ONC[7!_P ^[?\ ?=4Z*+![*'8N?:X/^?=O^^Z/M<'_
M #[M_P!]U3HHL'LH=C1GN85*9@8Y0'[U1?:H/^?9O^^Z\J^(VLZG8^*$AM-0
MN8(OLL1V1R%1G!KDO^$DUS_H,7O_ '^-=5/!N4%*^_J;1PL9*Y]!?:H/^?9O
M^^Z/M4'_ #[-_P!]U\^_\))KG_08O?\ O\:/^$DUS_H,7O\ W^-7]1E_-^8_
MJ<?(^@OM4'_/LW_?=2"XA-LS>0V X&-WL:^>?^$DUS_H,7O_ '^-'_"3:]MV
M_P!LWV,YQYQH^HR_F_,/J<?(^@OM4'_/NW_?='VJ#_GW;_ONOGW_ (237/\
MH,7O_?XT?\))KG_08O?^_P :/J,OYOS#ZG'LCZ"^U0?\^[?]]T?:H/\ GW;_
M +[KY]_X237/^@Q>_P#?XTG_  DFN?\ 07O?^_QH^HR_F_,/J<?(^AX+F%I0
M!"P.#SN]JC^U0?\ /NW_ 'W7D6@>++ZZ=8)[Z9;@ [6WGY^/YUJ_VE??\_D_
M_?9K%X9Q=FR'AHK2QZ1]J@_Y]V_[[H^U0?\ /NW_ 'W7F_\ :5]_S^3_ /?9
MH_M*^_Y_)_\ OLTOJ[[B^K0['I'VJ#_GW;_ON@W<'_/NW_?=>;_VE??\_D__
M 'V:NZ;KL]M-MNI'EA;J6.2ON*'0:ZA]6AV._GN85E(,!)P.=WM4?VN#_GW;
M_ONJ\\B2R>9&P9&52&!X/ J.L%'0CV4.Q<^UP?\ /NW_ 'W1]K@_Y]V_[[JG
M11RA[*'8N?:X/^?=O^^ZT+&1)(2R(4&[H3FL.M?2O^/9O]XU%1>Z)TXQU2+U
M%%%<X@HHHH S=>_Y MQ]!_,5XO/J4CZ_J NM>?3?LEU##;VH56$RL <E<;FW
M$D9'3%>T:]_R!;CZ#^8K@6MK=[A+AX(FG0821D!91['J*[L.KP^9O36AQ\WC
MJXA%U*+.V=%2X:.)9CYL9B8+^]&/E#9XIUSXNU"(RV;P6,-VL\D)F>9A" L(
MD&"1G<<X ]JZW[);%Y7^S0[I1B1O+&7'OZT26EM*I62WA<%@Y#1@Y8=#]:Z.
M67<TL^YP>G^)M5?^S@+I#YLUG'.]PW!$D+.<8'&2/SQ5BS\:7*VMIF&*0"&%
MY1/+^^F\R0J/+ &&(QS7:&SM67:;:$KD'!C&,CI^7;TH^R6V^)_LT.Z+_5MY
M8RGT]/PI*$EU"S[G&7?C"_-G.S6\4,<D<[0/#*?,!BE"'.1CG-3S^,[RU:XE
MDT^&2V1[N*,1R'S&: 9R1C&#76FUMR,&WB(YXV#N<G\S39;.WFA>-HE4.&!9
M!M8;N"01R"?6GRR[A9]RAX3UR;5]3GAF%H6M)H!YEK(71]X#=3Z=*[;4K"UU
M"7;=1"18Y&95)XY!4Y_!B*Y7P]HMGHMRB6@D)EF1I'D;<S8P!^0KNY+>,RN3
M=1C+'CTYK&II;F(EYG/#PYI@216BDD,D;1.\DK,S*P ()^B@#TI+KPSI5Y.\
MTT#EY&+.5D(W$D'^:@UT'V:+_G[B_6C[-%_S]Q?K65T1H8MIH6GV3L\<)<L"
MH\UB^P%BV%ST&3FF-X=TEK>& V:>7%&T2XX)5ASN/4] <GN,UN_9HO\ G[B_
M6C[-%_S]Q?K1= 8B:'8K;7$#":87&WS7FE9W;:<J-Q["KLMM%-<V]PZDRV[,
MT3 XVDJ5/Z$U>^S1?\_<7ZT?9HO^?N+]:+H+F3<:18W<DKW$/F&9T>3).&*J
M5'Z$U'::)8V5PEQ$DC3H"%DDD+M@J%QD]@  *VOLT7_/W%^M'V:+_G[B_6BZ
M PKGP_I]U<33R+,))CF0I*RYRH4CCL0!D=\"IKS2+2]\DN)8GA4I&\$AC8(<
M97([<#CVK7^S1?\ /W%^M'V:+_G[B_6BZ Y]_#.DN"IMV$17;Y0D(3.W9NQ_
M>V\9J:;0M.G8M) 23(TI^8_>8*"?R1?RK:^S1?\ /W%^M'V:+_G[B_6BZ#0P
MY_#^FW _>0$G<SA@Y!5F<.2/0[@#0N@:>D+1)'(NXH=XD.\,A)5@W8@L>?>M
MS[-%_P _<7ZT?9HO^?N+]:+H#G)?">CSJ0]O(<J58^:V6! !!/OM%7&T>R?3
MS8F)O(\PRC#D,K[MVX-U!R<UK_9HO^?N+]:/LT7_ #]Q?K1=!H8D&@:;!(9?
M(\Z1E96>X8R%MQ!8G=W.!^ Q21>']-ALQ:I"PB$J3+^\)970 *0>HP !]*W/
MLT7_ #]Q?K1]FB_Y^XOUHN@,Y[&V>6WD\E5:W=I(@@VA6*E2<#V)JQ5G[-%_
MS]Q?K1]FB_Y^XOUHN@N5NU2ZO;Q7<)MIEW12P;'7.,@C!J3[-%_S]Q?K4]U
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M>1?[BP.<#ICZTFL5YBM5+'_"K]%_Y];_ /[_ !_PH_X5?HO_ #ZW_P#W^/\
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MN*T[VS8QZ(;^PGO+*&U*3VZ1F0K-L4*S(/O8PP]B:Z:BBPSCV?7H$\NRMKV
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MO"228DR?:I:*5WW"[(OLT'_/)/RH^S0?\\D_*I:*+L+D7V:#_GDGY4?9H/\
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IY4?9H/\ GDGY5+11=CN1?9H/^>2?E3TC2,810H] *=11=B"BBBD!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $^ [L# 2(  A$! Q$!_\0
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M^H-6* "BH)[RVMI(8YYTC>=]D2LV"[8S@>IJ>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\:N9;X>+M0M++4+FQ%[XHCAFDMVVLR&VR1^@KV6B@#C
M_AW<WMQI&J6]]>SWC6>ISVL<T[9D*+MQD]SR>:Y!-1\2/K&K:'<7EXJ:%#=W
M+W!?_CZ21?W ;UP"3_P$5Z_10!XW%J_B&*/P_ID5Y=M_PD.G630SAO\ CW=
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M(O\ A%O$VO0:QJ<]S!?RVL4(;>D$/FJ&=4QRRKN(]*]CHH \3N=>U,Z#KO\
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ME(,*\HY8;>/8U:M;?6(O$?B*UL-6U%X]"L81860D^2601'&X?Q9(''K7JE%
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MM?$J6D%L),PF%V48(QR,-QZ5[;10!X#9ZKKVH/';)KM_:H(M5G8P/M+&*3Y
M?I4T/BW7]/L9[FXU;4KH77AJ+4&"%<Q2M(%)3Y2%&#SP?6O>** /G_P[K6JZ
MGJNF0:C?O=_9-=0VSN[2L$:!SPS %AT[?2NB^&?B#5KOQA>:=?ZI=:F/)=Y'
M$C&.%@^ &C= 8VP>@..*]>HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !H_M73O^?\ M?\ O\O^- %NBJG]JZ=_S_VO_?Y?\:/[5T[_ )_[7_O\O^-
M%NBJG]JZ=_S_ -K_ -_E_P :/[5T[_G_ +7_ +_+_C0!;HJI_:NG?\_]K_W^
M7_&C^U=._P"?^U_[_+_C0!;HJI_:NG?\_P#:_P#?Y?\ &C^U=._Y_P"U_P"_
MR_XT 6Z*J?VKIW_/_:_]_E_QH_M73O\ G_M?^_R_XT 6Z*J?VKIW_/\ VO\
MW^7_ !H_M73O^?\ M?\ O\O^- %NBJG]JZ=_S_VO_?Y?\:?%?V=Q)Y<-U!(Y
MYVI("?R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^2_CI(Z_%*^"NP'DQ=#_LUYOYLG_/1_^^C7HWQU
M_P"2IWW_ %QB_P#0:\VH ?YLG_/1_P#OHT>;)_ST?_OHTRB@!_FR?\]'_P"^
MC1YLG_/1_P#OHTRMW2_#DU[ \DR21@INC..M &+YLG_/1_\ OHT>;)_ST?\
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MPUI>FRW6HVT#"Z> HTC.6SQC/)ZD 9/?%;5O_P >T7^X/Y4R]_X\9_\ </\
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M,X>9_4XKC#PQK<U%6NM5N3; SAG)4H,Y%8CJRR,K*58'D$4@$%(>M*.M(>M
M!7IWP#_Y*E;?]>TW_H->8UZ=\ _^2I6W_7M-_P"@T ?6-%%% !1110 4444
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M1MYGE5&8*#D;?>O(])^*/B^35K>)M5)2:X3S!Y:\Y(![>E>C_'7_ )$G3/\
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MG <TT]32 2O3O@'_ ,E2MO\ KVF_]!KS&O3O@'_R5*V_Z]IO_0: /K&BBB@
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MW\0^U!T%% Z"BORH[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/.M6L+OQ1KNJK96>C1+I[B(RW,3^=*^W/WT92HYQWKJ?!UXE_P"$]/N$1T#1
MX*O(9""#@_,>3R.]<?XG\'7%QK5]J2Z1I!@D(9KB?4)H2W&,L%X%:NI:-<_\
M*JET_2U$%PEJ3#'ITQ968<A58\D&@#L+W_CQG_W#_*GV_P#Q[1?[@_E7GVGZ
M?K<7BS4[B>*Y2-HGS+*V8GCV)L51GJ"'KT&W_P"/:+_<'\J )**** "BBB@
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MOXA]J#H**!T%%?E1W!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>;^(9+W6/$5UH5G]J(8ARER 82R@,"K8)4>Y!&>U=GX<L1IVA6UK]F>V* [H
MG<.0<\\C@UJT4 07O_'C/_N'^5/M_P#CVB_W!_*J%SJUA+-=Z9'=Q->Q0EW@
M#?,H(ZD5<2:.&TB:614&T %F [4)7V GHK/@UFSGE:,2!2IP2S*!G\ZT.M5*
M$HZ25@"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC1O^0W8?]?$?_H0KW?XZ_P#(DZ9_U\+_ .@UX1HW_(;L/^OB/_T(5^J\-_\
M(J^<CAK?Q#[4'044#H*\/^)'Q0\0^'?%MWI%@;=;>-4*LT>6&5SUK\ZR_+ZV
M/J^RHVO:^IUSFHJ[/<**\B^%/Q$UOQ;KEQ8:E]G,44'F*8TP<Y YKUVHQV"J
MX*LZ-6UUV\QQDI*Z"BBBN(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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MGSETN\6X>  RA48 9Z=1[5O5G5I3I2<*BLUT8)IZH**,CUHK,84444 %%%%
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MI%4_(V<K_=SW'L:XBZCV/(F.5)%>.U:Z/9*:'!!IC?>-.7J*:WWC68"5Z=\
M_P#DJ5M_U[3?^@UYC7IWP#_Y*E;?]>TW_H- 'UC1110 4444 %%%% !1110
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MMQ =SYSP=X&?K7OX+/\ $X/#_5Z:5M=T[Z_,RE2C)W9VGVML?\>L_P#WR/\
M&O"/B3X!\3^(?&UWJ.G:5));2*@5BRC.% /&:^@*\VU6#Q1/=>(VTN&^MTDC
M\B!6DR7/):5"3@'HH ^M<.79C5P%5U:23;5M2IP4U9G-_"3P;XA\+>(KJ[U7
M3)8H9+?8K!E;G(/8U[%)>NL;,MG<.P!(4*.3Z=:Y3PLGB2#4A]O%Q]EF8[TF
M(;R\1)@@^[;JZC6#?#2+G^S4#WA3$0)Q@GC/X=?PJ,?CJF.K^WJI7TV\AQBH
MJR.:D\5^)Q-B+P1>&+U:YC#?EFNAL-4N;JT66YTJ[M)3G,+[6(_$'%>9Q6'C
M4V]AO741*E@8Y,R\E\/R3G&<[??I7HOALZH+"2+5=S212;8W8 %TP.3CWS6-
M2K":M&"CZ7_5L:3[EFYU.2W0,NG7LQ/\,:#/ZD54AU^YD<*^@:I&#_$R)C]&
MJ+7]/GO]4TD1?:4BCE:2>2&4K\JC(4@'G)P*Y&TM_%7FS7MLM_;#?/)%:3'?
MM "A0Q)YW<GVK)2BE9QO\V!Z+]K/_/K/_P!\C_&HI]1>%05T^[ER>B(,C\S4
MY62:RVEFBE>/!9>JDCM7GD5OXSMK?05CBN9UMGE,WF3 -,Q9]OF'^[C;^=2M
M]1G?0W[RQAS8W49/\+J,_P Z?]K/_/K/_P!\C_&O.;.'QM:O!<.MVTT1E,B.
MP99=UPG&,\#86Q["NE\9IJ,YTV#38KOS'N!ON86(6! 022 ?F)Z =.:3 UY-
M7DCG\L:5?N,XWJB[?_0JM"[)/_'M/_WR/\:\]U?3O%<5Q=?97O;B ZF90"^"
MT?DC:!@C"[^*VO"@\16^L7D.IK,;&1[B5#*0=A\WY #UP5)/X4VUT0'8T444
M@"BBB@ HHHH YY_%%A=ZC?Z/&LPFA1U,K+B-F5064'U 8?G7"?'1T;P'IH5U
M)^UIT/\ L-7>P^$=.BURZU-C)(;@LQ@<@QAF #$#W"BDURS\/Z3H]Q?7NFV;
MQ0KD*\2G<W0 9[DX%=F Q7U7$PKVORN]B91YDT?(5J1]L@_ZZ+_.OM2TFB%E
M!^\3_5K_ !#TKSO0=;\/:I=V4%SX7L8OM<$#I+%;HZ)))N^1CCU7%=[_ &'I
M?_/A;_\ ? KU,ZSE9ER6AR\M^M]R*=/DOJ>!?'UU;QK8%6!']GKT/_322N?^
M$S ?$G2B2 -S=3_LFO<-5N])TW7;J'4O#VG?8(+9IA<,JN_&,9!'RAB=HYR2
M#6=HOB+P_=ZAI\,_AFTMOML4926&!&$<CE@%8@<?=KMI<1JGE_U+V?V7&]^]
M];6\R71O/FN>E^=%_P ]$_[Z%?('CD@^.]<(((^V2?SKZQ?1M)C1G>RME11D
MDH, 5YO<^*]!>,7-IX8TVXC?4/LZLR(2T> ?,Z'KGOQZUYV39LLMJ2FX<W,K
M;VZW*J4^=6,']GQT6XUO<RCY(NI]VKV#Q)="+PSJ<D,^R5+:1E9'PP(4X((K
MGO"][H&LWES9+H-O:746Y_E@4)(@<H&!'7D5J>([&VTW0KF\LM*TZ66%=Q2Y
M&U"O?D"N?'X]8O&/%<MKVTWVM_D5"/+'E/E=O%.OO-YS:U?F7^^;AL_GFOIO
MX8ZA-??#S2KF^O'GN9%<O)-)N9OG8<D^PK N[^#3HXVNO!6E<Z<UVXC16*,!
MG!&WA>< GG-=9H$>A:UI[36VD16_E2-#)"\(4HXZC X[UZ&;9U3Q]%4X4E"S
MO?3[M$B*=-Q=[E7X@>,G\'>'UU*W@BNG:98MC/CJ#SQ]*\QM/C[J;W21R:1;
M,KL%_P!81C/X5Z!J6IZ+8ZOJEC?Z#:B"RM8YXWD53Y[NQ4* >!SQDUBGQ-X<
M:WM##X<TI[B33I+V9 B8B8)N6/IR3@UQX/&8*E1Y*U#GEKK>Q4HR;T9ZC'<1
MM&K&1 2 ?O"N,\6_%'1?"&H"PNXKB:X:,2#R@"N#[YJ_H<VBZ]I$M[:Z0BRP
ML8Y()(PK"0 ';^HY]ZY^+4K2:UM9KSPE8.TNHBR:955XPI/WE8C+>G'&0:\_
M#SHPJ7K1<H]D[?CJ6[VT+/A?XN:'XHU:+3(+>ZAN902OF ;>!GDYKOE=7^ZP
M;Z'->46GB[0B)+D>%;5(DN61?)@7S3$ WSXP/[AZ'%>F:6EB;&.YT^%(X;A%
MD&U<9!'&:>)G0G.]"#BNS=_T0HII:EVBBBN8H**** "BBB@ HHHH **** "B
MBB@ HHHH **** /DGXZ_\E3OO^N,7_H->;5Z3\=?^2IWW_7&+_T&O-J .B\+
M@F]&&5 .=Q->E6MVENACM%5IF!)D/0?3->5Z$X2Z!(R.]=S!.67"C:/YU>/H
M.IAX\O0^?QTN6NI,V[8K''<2LPGF9,;#R,D]_6N\T$W']CVWFA7E+'[F""/3
MVKS+S?+CVI]X]6]/I7?^%_-_L"T974N';9N!P!Z5\[/GC3TT.>/+*IJ9&NVJ
MG5[AV13\Y E0_,A_VA6!J<!> K)B554A)EZY]#_]>MG7[HIXCNP,J=PW ]SC
MFLR8I*I(X)[ \5QX?&U</54SU986G.'-3>J/';Z VUY)%SPW&:A1MCJPZ@YK
MI_%MB$D6X4=>#7+5]=)QE:<=GJ=F'J^TIJ74]J/CKPA<>*YM4EU*Z2'5]&;3
M[M/LK9M&\L(#_MYYZ5'8>-O".CGP9:6FHW4UKHTMUYTTMLRL0^[# #/4GIUQ
MUKRV'1)9/#5SK;2K'#%<);HA',KD$G'T&#^-9=0;G?2>++ _#ZXTI;N;[<^M
MB\5=K?ZK!YS]<<5U&H^/?#>K>)/%5O)>7$&F:W:P1I?QP,S1/&.Z<$J<G\A7
MC-31_>'^[0![)8^/?#]MK=C!#=7#V.G:-/817LD+!YY'&0=HR5&>F:X5+A4M
M3"6+AOF9 >7/^T?Z5@VZG>.]:$<OD\QC#G^(C./I3 U\"5/,OYC"BC]W"IY_
M+M74^&)H1;.4B*IN^4<DGWYK@T<0[II 992> W0>Y_PKK/"EPTMK<RL2\ID
M('88XKKIUDK(AQN=;+>![FW9H=\2Y+9'*^]<WXE<LCNA%S9.<E3]Z,_TJ[J,
M\]J+6X0E%)/!'/\ ^JN>U;40V9;4[),8DCZ@BO0^S=GD>SMBO=,Z)XPBYE9E
M7F.4=4_V6K)U2$F8S;<;CS4LLBX,D)VAOO)_GM54R':4S\A[5Y=1>\>RC**E
M92!TJ-QAR/>K4J?O ?6KNH:#)8:!8ZM/.BM?R.(;?'S&->-Y]B>*P&8U>G?
M/_DJ5M_U[3?^@UYC7IWP#_Y*E;?]>TW_ *#2 ^L:*** "BBB@ HHHH ****
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MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\D_'7_ )*G??\
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MB)959EX.,#KSVH L44FX<\CCK1D9QD9H 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^2?CK_R5.^_ZXQ?^@UPFGW"PD@C.
M?2N[^.O_ "5.^_ZXQ?\ H->;JQ4@@\UK2J>SE<F<5)69U#REMJ/&D8V@@+SD
M>YJ6UG".$7I6'9S&12')^6NBL;-I( ^T#N,\%AZBO8A)25T>17IJ"=RY"'-[
M&P)Q7LN@2(^DVNQ488.25P0W>O(;.)I+A80,D_=)KUW1<R:%9LV$D/"@KR"/
M3UKRLSJ04HQ>[V/'FG)W70\^UP/<ZM<R7* ,SDA1Q@=JK$P6L*O+_%T XK2E
MM+B]\5"TN&*RSR_-ZJ#_ /6K1^(^@V]A8V%S:+M5%$;J!U_VC[UX..E6]RFW
M:+['M9%A:6(K\LU>R.0OM-M=8M2L4A!QT!Y%8.D>)=8\ #5[33R$FOX1$+CN
M@!SE??M[5O:7M65"#]:R_&UHHMUF Y5NOL:O 8J<I_5ZCNK:?+H>OB\-'"55
M[+X9/;LSAW=Y9&DD8L['+,QR2?6FT45Z8!5J%L,O^[56K,0^89_NT 7X6!QG
MM5@$,<"JEO\ , !U-6%1B^P#+#M6U.:3U$RTC1@#H#_.O1?!5ZEAI3RL1B1^
M".:\Q/!PW!ZUW7AE&CT5,GAF)!KH^M6V1E.C&:M(L^,M8::YB)#;%3&2?O9K
M@9V$TI/ %;GBF266_P#F5A'"H4$]R:P%(/;K3J5W+1"IT(T_A)B@M)E.4D52
M#P>":T_#7A;4_&NLR6UCM9UVO,7;!5"V"PSUQZ5E$F7&XYVC %:_A[Q1J/A.
M6]GTK:EQ=0>3YK#)C&<Y ]:RJP]U2-4RKXYO$N/$$MM!!)!9V"BSM89%*LL:
M< D'H2<D_6N0?AV^M:VH3SW=Q)<7,K33RMN>1VR6)[DUDR?ZQOK7,4-KT[X!
M_P#)4K;_ *]IO_0:\QKT[X!_\E2MO^O:;_T&D!]8T444 %%%% !1110 4444
M %%%% !1110 45'/*(())65F"*6(09)^@KBQ\1X6@T>7^S9XTU"61&:4[1 %
M?9\Q[$GM0!UFG?ZNX_Z^)/YU<JEIC*\4[*P8?:).0<_Q5=H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $95="K %6&"#W%48]$T
MJ*,1QZ=:J@<2!1"N PZ'IUJ_10!0T_\ X^;_ /Z[_P!!5^J&G_\ 'S?_ /7?
M^@J_0 5GZOH>FZ]:K;:I9QW4*N'5)!P&'?\ 6M"B@#G?^$#\+^3%"=$M62+=
ML#+G&[K^>!3M4\'Z9?Z%?Z5!&+-+TAI7B4$EAC!(.0>@%=!10!QVC_#?0].T
M:73KV(:BLL_VAFG0+AMH4;0N,<"ND;2+![.WM&M8S;VSH\,>.$9#E2/I5VB@
M#,7P]I*B$"PAQ TCQC;]TR9WD?7)S]:J+X*\-I]DVZ/:C[)_J,+]SG/\ZWJ*
M ,:+PGH,%S-<1Z7;K+,KJYV]0_WN.V>^*2U\(Z!91B.VTNWC161@ O0H<K^6
M:VJ* ,:\\)Z#J$317>F6\J-,UP0R_P#+1OO-]32_\(KH7V^.^_LRW^T1[=K[
M>FT84XZ9 Z&MBB@ HHHH **** "BBB@ HHHH *Q-?_X_-%_Z_A_Z U&J>(ET
MS6]/TTVDTGVP2-YP'R)M4MC/<G'2N>LO$S>)#IDDUI]CFBU,)Y#,2X'EL02"
M!C(YH [RBBB@ HHHH **** .+^),5TVE:5<6ME<WAM=4@GDBMHR[[%))( K+
MU![OQGJMHT6F:K8VK6=W _VJ%HBKE5*'\^A]C7I%% 'AFI:1XNU#PLFI7=G?
M>=/?JMW:1JS/Y$:;$.P$$@D;C@]ZWO!7AO4O^$CTV?6EU"6.TTH&%[E63;)Y
MIP&&2-P4XP23BO5:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^2?CK_R5.^_ZXQ?^@TGPP\%1Z\\U_>QAK=#L0,.">YI
M?CK_ ,E3OO\ KC%_Z#72^%_$EM8_#9VAB56B@8&->,MW_2M:<6T^7?I_7D<F
M+E4C3_=K5G(_$#P;!X4NDELG=K6<]&ZJ?3Z5FZ/,S;<L751C!/;TK3L]=/B+
M[1I&L2^8[<P.W<=0/J*P[BU?1[E[8[LCD-V8>HKT,/4NK-[&%2C/V*C)W9W5
MM9I=:>+F! KQ.>AZ=Z]#T6Y%UH]I),/))RJJ_KZBO)O!6J,#?B9AY*!7(;H.
MM=9I'B9;RREC@E*FV^;+#Y6!'05SUL)&L[N6J/+E@:L?F.T:&\F\97%S=H%,
M<IQ@YP1[UU'CA?MG@F65#DHP5L'IS7G_ (>\32S7%XC1>7)]X[CD]<5TNBZF
MFN^$M3TZ1L2B2103['((K@S>@JE-5*6\.GEU/5P*E@L1&HU:.S_S//\ 3IL7
M*J>/2H?'$H%C&F>6(JY#I4\%ZF>5!Y8=,5S/C*]^T:H(5/RQC]:\? 14L3[2
M.R3_ !T1[V;2A.=.,'>^OW'-T445[1Q!5N(_,,^E5*LQ=1]* )H)"OX&K\2M
M,X6)69V_A R36?;KEF^M=IX/L%<SW3#E?D4_SJDFW9 <\D3&1$9=ISMYXKO]
M"1H=,6)QC8Q SWK-UW2S,!/"OSH<D5M:=(TVGQ-*FQ]O1NM*P')^))9KJ_)$
M;+#&=@S_ !-ZUDK#D\@@CL>U=3-%/J6K,[PM%% "J[NY]:Y62Y?SI"3DECR:
MWH)<UV3*]M"4Q(J'C+'&#GI4$RF%?F%7X;>2:*,[2"Q!4$=:[K_A%[:?3UMI
M$4S.F3(P^Z?:O0E34D<OMN5V9Y-*V<$]STK/E_US_6M+4T^S7\ENW6-RIX]#
M69(09&(Z9KRIQY9-'6G=7&UZ=\ _^2I6W_7M-_Z#7F->G? /_DJ5M_U[3?\
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M'(ELY5E."#CM5#P)XVB\<:7<7L-F]LL$OE%78$DX!SQ]:N>-O^1)UG_KU?\
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MP/#O@G2_#NGW%FF^[CGD$C_: I^Z %& ,<8Z]:Z2B@ K$U__ (_-%_Z_A_Z
MU:]Q(8K:61<95"PSTX%><:+KFI:E<6%OJLPN;F+4U_>VX5H54Q,P 90.>>_-
M '$?M _\C'I/_7JW_H5<'\/O^2@:'_U]I7>?M _\C'I/_7JW_H5<'\/O^2@:
M'_U]I7ZUEG_(D7^"7_MQP3_BGU]3)9HH%W2R*B^K'%/KYX^*GC3Q'I7CF]T^
MQU:X@M%1,1*1@97FOSC+,MGF%;V,&E97U.R<U!79]"1RQS)NC=77U4Y%/KY_
M^$WC3Q%K7CJWL=1U:>XM3#(3$Y&,A>*^@*69Y=/+Z_L9M-VOIYA":FKH**\$
M\2_&;4K77KNQ73HPMI<-&&2XD3>%/< ]Z[3X8?$.[\:SWMM<V45NMK&K*RR,
MY;)QR373B,BQE##_ %F:7+:^ZZVM^8E5BW9'H]%1W%Q%:V\EQ.X2*)2[L>@
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M (JOL*BJ!GQK>?"7QMI]LUS<Z%<>6O7RBLC?]\J2:R1X*\2]] U;_P  I/\
M"ON"B@1\1KX&\1G_ )@>J#ZV<G_Q-6QX+\1M:+;G1]1"ALY^QR__ !-?:-4K
MG5;2TOX+*9I!-.K.H6)F 5>I9@,*.1UQ3NNPK/N?'8\!:^2,Z5J  [?8Y?\
MXFID\#^(1\B:9?J#QC['+C_T&OK"'Q9HTT,TPN9$2*,2DR0.FY"<!ER!N!/&
M1FGIXFTZ6V>:-;U_+D\MXDLI3(A(R-R;=P&.Y&*3%9]SY'_X5YKF3G3M0S_U
MYR__ !-.'PZUH];"_'_;G+_\37U_I>LV6L6 O;.1S S,@,D31DE3@_*P!ZU)
MIVI6VJV[3VID*)(T3"2)HV#*<$88 U-GW*1\?_\ "OM;$7E_8=0VYS@64O\
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M9?YFOBX_>/UK[1MO^/*]_P"NLO\ ,U\7'[Q^M?H'!FU;_MW]3DQ'0^A?V?\
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MO_#SKMW;%1U./7K760RW3,HD@0*>K!\UY=JGA?Q,^OW<T%H)H+BR6-78I^Z
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MFW\7!3[X'T.!0!TM%86@>*M/UV"U$<A2[FMUG\EHW4$$#.QF #@$@$KG%;M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MILMY?K<+IMJ;:V5(MG#!06;DY.$%=+110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K!!X# 2(  A$! Q$!_\0
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MN6?RK"1$64QKC,ARV O/'.>M+>?%C1(=-TBZL;6]U&355D:"WMT7> G#[MQ
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M]0\P+,'7:2"N3D#.,^WTKJ-+\%:+H^N3:S:)="\FWER]W(Z_,<G"EB!S[<4
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M*ZM(86^U2$A79"V23\QXZG)KIM7N-&N?&GB63QAXAO\ 2I[%X/[*\B=HV6/
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M,Z;XXB(U8R$XR!@'OBG^'+6YU+XI>)M;O;:6..S2/3K$RH0"GWG92>H+8Y%
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MK3R7-_\ .+9K$DD@-G;@YZ#DG->CZOITB?&#PS/;63K:I9W7F21Q$(K-ZD#
M)_6@!-4^(>MZ1K-I87?@JY2.\O/LMM,+^)C+S]X(,MC'/M7H-<%96MSJWQDU
M"_NK:9;32+%+>S=T(1GD^9V4D8/&!QZ5WM !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(Z+(C(ZAE88*D9!'I2T4 58=-L;>2)X+*VB>*/RHV
M2)5*)UVC X'M4EO:V]G&8[:WB@0L7*Q(%!8]3@=S4U% $4EK;RSQSR01/-%G
MRY&0%DSUP>HI$L[:.::9+>%99\>:ZH TF!@;CWX]:FHH B@M;>VMQ;P0110
M$".- JC\!Q4=IIUEIX<65G;VP<Y80Q*FX^IP.:LT4 17%M;WD#07,$4\+?>C
ME0,I^H-1?V;8?9HK;[%;>1"P:*+REVH1T*C& ?I5JB@"I)I>GS"<2V%JXG(:
M8-"I\PCH6XYQ[TL^FV-U<17%Q96\TT7^KDDB5F3Z$C(JU10!4FTS3[F9YI[&
MVEE=/+=Y(59F3^Z21R/:B;2M.N?)\^PM9?(_U.^%6\O_ '<CCH.E6Z* .:OO
M!T.I^+K/7;W4+N:.R.^VL&V^3')C&_IDG\:WWM;=[F.Y>")KB,%4E* LH/4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !12$@ DG '4UFVOB'2KV2X2W
MO8W:W!,G/0#^= &G16/!XHT>YM)KJ.\4P0_?<@@?AZU+-XATJ"PAOI+V-;>8
M@(^>M &G138Y$EC62-@R,,@CH13J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[ L:[C3--\1V.JZA+9VQ8O&@=B1CK0M0->BBB@ HHHH **** "BBB@ HHHH
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MYTZ=:,XJ2ZCIUXU(*:V?D7ZSUT+2DG:9=/MQ*^=SB,9.>N:O@Y )&*Y(M?\
M_">R6T]\S6DML=L*\!/?ZUKU.A*Z-V+0])@5Q%I]LBR## 1C!%6;>QM+546W
MMXHP@PNU0,5PFGZ5;R-J]\^HZC_9T.413<'DCDD']*-*CN=,CTB1KZY*WMP7
M*S2[L)V&:?\ P"7H=U<Z=97B,EQ:PRJQRP= <U(UM T"PM"AB7&$*\#'2N:U
MCQ1+I]SJ$:>21;P+)'N;[Q)K*\3^(TO=!CC@:Z6<M&95M\JQ!ZA326UT4]%=
MG=3V\%U"8IXDDC/56&144&FV-O (8;2%(@=P54&,^M<%#:ZN^GSQVDMU:6CR
M*$BO9<2OZ@-VK,UN\O(-/@L]*O;V"ZMKH/*DLF[*CDC=W%,$KGJ TRQ"D"T@
M +;L;!U]:G:&-V1F12R?=)'3Z5Y=!XLFN?%CZR+U_P"R%M"B0J?E:0=3CUS6
MMX0\5I]GOH[^YGE:,^<&D0AL-_"![46)N=K/86EU-'-/;1221\HS*"5^E2M#
M$T@D:-2X& Q'(%><WNLW.HZY)>9N(["VD0(Z2[."?[O\5;$#7K^-[NWNM0=[
M2:SWI$OR^6/7ZT)77WE-'70PQ0IMA147.<*,#-25QO@RP_TV_P!0BO+N2T+F
M*&.:7>..IKLJ&+J%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0
MD $G@"EJ*Y_X]9O]P_RH SE\2Z0^[9>*P4[25!(S3O\ A(M+_P"?D?\ ?)K$
M\ 6\#>&LM$A/GOR1[UU/V2W_ .>,?_?(H H_\)%I?_/R/^^31_PD6E_\_(_[
MY-7OLEO_ ,\8_P#OD4?9+?\ YXQ_]\B@#$O]1T74419KH@*21@&J&G0^'M,U
M9]1@O'\QXQ'M(.,5U7V2W_YXQ_\ ?(H^R6__ #QC_P"^10M-@*/_  D6E_\
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M>'CGPYIO_7M'_P"@BM*IY$:^WJ=_P7^1G#3[C_G^EKQWQ'XVUNQ\3O"LZ/\
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MON-TQ^%6386INS=&%?/*>67[[?2K%% $-K:6]E (;:)8XP<[5J:BB@ HHHH
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MX PC!&%&<YK9JJNG6B3^>L*B7^]WI25[%4IJ*E>^J'7UE#J-E+:7"EHI5VL
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M)%']Q% 'TKBP_M%.<96LGH>?A'552I&:5D]"2BBBNT] **** "BBB@ HHHH
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MW1]*;=]0/GK]I'_C\T?_ '6KP:O>?VD?^/S1_P#=:O!J0!77?##_ )*+H_\
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M6KP:O>?VD?\ C\T?_=:O!J0!77?##_DHNC_]=OZ5R-==\,/^2BZ/_P!=OZ4
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M8V,\'BW4)6N;Q+<ACT#=Z /;:*\Y7X=:VR*W_"9ZER >M+_PKG6_^ASU+\Z
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ML/4G4I*4X\K?0I#[D?\ N+_*BLI=?@,<9^P:G]Q?^78^E+_;T/\ T#]3_P#
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MFVY*V[_1B* %  P .E0_8[;=N^SQ9SG.P5/16UCC4FMF%%%% @HHHH ****
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MLA!*MI,;:5VW"1$'%=1803VUE%#<3^?*BX:3;C=^%(##F_Y*+;# _P"/!_\
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M*_B#_P C]HO_ %PDKOCXDTL''V@_]\&O-_'.H077C32;F 2R01PN'=8S@$T
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M*P-3\2Z-INJKI=PH\YXFD.$X50.YKHJYOQ!X5&N7\%QYJ1+'&Z-A?F;(XYH
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MW?PKTEONGZ5QWP])-IJN3_R_24 =E1110 4444 %%%% !1110 4444 %%%%
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MO//%>K7>F^*]/>TU:0AIECEL@.%4]\=37H8.0#1TN-[V"BBBD 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4F1G&1GTH?A&/M7C]FTT/AJ^U^._N6U&&_94#395AO
MQMV_2A;_ -=[!T/8:*\VOO'FHQ:W91VHBEMKAQ;NF/\ 5R%<]?K4L7C36;MG
M@L[:*6ZLHI#>1GCYQT ^M.P(]$HKBO _BRZUZ*\BOF5;R ;FB*;63/8BL:S\
M<ZTD*ZG=B"2S:]>U^SQCY\#HU%M; M5<].HKSH>-=7CC@O\ RH9X+_>MM:KP
M\;+TR:R)/&NMZAX9U%!=I9:I!(A*M'AD4MC'N/>BS ]<HKD]>U^\T7P[IS1E
M);R[:.$2L/E#-C+&N0T?Q!K-MXAU31C>K-?7-T%CN'YCB 7)P/Z46UL'2YZW
M1D9QGFO+M1\?ZS!80/'; +%,T5U=(NY05/7'H:9J_CB]M+F>[L?)D+6T3(Q;
MY26Z\46 ]4HKS(^.M8@OYM&E$+WK3QQQW 7Y4#C/(]JZ+P;KFHZK/JUMJ)A:
M2RN3"KQ=&'K0E<5SJZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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@ZA1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $T!!8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Y[Q'XW\/^%)[>#5[[R9;CE$5&
M<A>FXX' K>AFCN(8YH75XI%#(ZG(8'D$5P7C'X3:-XMU&"^$\EA.O$QA0$2K
MG/.>AY//Z5V>E:38Z)81V5A L,$:@ #J<#&3ZGBO0KPP:P]-T9-U->9-:+T_
MI_(A<UW?8P;/QLFI>,+WP]9Z?/NMK-KA9YP8EE8/LVJ",E<_Q=..,U2TSQ?X
MCO\ 7-3T@^'+47-A;"1WCU#=&)6QLB9M@P2,GO@8]:UQX?N!\0F\1>=']G.F
M"R\KG?N\S?GTQBD\,>'[K0M,U%9IXI=0OKR>[DF4'!9V^3/?A0H_"O/+.:'Q
M*U.#3M:O+S0(DCTRZ@M"\-YYB2RO(JLH;:/N;AGCKQ7=:EJUCI$,,U_<"!)I
MD@C)!.Z1CA5X]37&W/@&^;X5Q>%X+NV_M%7CFDN) VR243"5F..>2#4FM^'?
M%OB31_LU_<:+!<VUU!=VC6ZRE"\;9(?=S@CTH ZZSU:QO[V]L[6X$EQ8NL=P
M@!'EL1D#GV]*X35/B?>:==:ZXT:UDL-&N##.[:@L<SX )*1E>>&Z9YJ[I/@;
M43/KD^M:JT<VIW4=SOTF5[<IM3;MSG./QYQ4^B?#W3K/6-7U'5+*QU":ZO?M
M%M+-"))(E"* "S#KE2>/6@"#7OB+)IFO)I5CHS7LHLTO75KA8I'1B1MB0_ZQ
MQC.!4H^(<*?$*;PO<6+0Q):B<7;OCDQ^9L*XX.T,>O\ ":K^.?!.K^*+B5+>
MXTF2SF@$:K?VQ:2S?O)"ZX()'8G&0*S-=^%=]JLFIO%JRI+/'9)!<-GS!Y*-
M'(6(_OJ[=* +NB_%2+5?!6M^(YM,:V33I?*C@,N3.2JF/G'&XNH[]:Z;PEXC
M/B;2)+F6T-G>6]Q);75JS[C%(AP1G SQ@_C7(R_#"ZG6XT\WT<.DW.L+?R+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 445BZUXGL="GBANH+^1I5++]ELI)QC..2BG%
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M+NE"GAG&21W)]ZY?P-XAFU#Q7;6[_%*'7E97/V!=*$!DPI.=^.,=?PKJ?BC
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MQ)X1N8;2".>36?GE2,!F_P!'F)R0,FNVKD?&?_(<\&_]AG_VWFKKJ "BBB@
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M:Y_QY_R3SQ+_ -@JZ_\ 134 :&@_\B]IG_7I%_Z *T*S]!_Y%[3/^O2+_P!
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M7:3=IH&H6-O=Q3MHUS-J!F615!#AD_A.WD4 >ZT444 %%%% !1110!R/C/\
MY#G@W_L,_P#MO-775R/C/_D.>#?^PS_[;S5UU !1110 4444 %%%% !1110
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M)K#2=1M+K54E>_%M!*T<3#]Q$V2/F9B689!). .@H ])1@Z*XZ, 13J0
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M *%6O61X?_U>H?\ 7_/_ .A5KUOB/XC_ *Z(2V"BBBL!A1110 4444 %%%%
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MG_'IXA_[&"__ /1IKL*X_P"'G_'IXA_[&"__ /1IKL* "BBB@ HHHH ****
M"BBB@#(\/_ZO4/\ K_G_ /0JUZR/#_\ J]0_Z_Y__0JUZWQ'\1_UT0EL%%%%
M8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH Q_$OAO3?%6D-IVJ6PGA#>8BEBN' (!X^IK"^'/P_L_
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M* "BBB@ HHHH Y'QG_R'/!O_ &&?_;>:NNKD?&?_ "'/!O\ V&?_ &WFKKJ
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M110 4444 %%%% !1110 5S?CF:2V\,2W$6K#2Y(IHG6X-N9R2'&$" Y8L<#
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MY .:6BM$K.YR2J.45&VQY9\4/"[7MS97-E]B@"JRR!Y!&6)88('?W-=-X/\
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M\%:S/X>T!(UFDEM[=EDA8%O+)(X&%_G7M%%<LL'!N3[GNTN(L33A2@DG[/\
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M4GA*Z.M7-];V.Z/?)8EA*#N&,;03UQGVKS?P2="F^(VF-X9OO$E[;K!.;O\
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M  H_X6IX&_Z&6Q_[Z/\ A756MU;7UK'=6DT4\$@W)+$P96'J"*FP/2@#C_\
MA:G@;_H9;'_OH_X4?\+4\#?]#+8_]]'_  KL,#THP/2@#C_^%J>!O^AEL?\
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M8;8NU@1\O8YQ7K?AVRN-.\-:7971!N+>UCBDP<_,J@'GO6G10 4444 %%%%
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M6*MSM(VGY3E1G/2M_P $ZAJB:#XG,^HRZIJ-EJ%XJ131X*E6;8..S8! '0'
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MRQQG(XY]Z /2:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC6-D\IQC*D,2<C/7O6M5>QL+33;86UE;QP0@DA(UP,GJ?K5B@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% ''>-?$]]HLD=I9"&)Y(A*)Y2<L?-1-
MB#&"V&)Y[?F*-W\0+^"*^:+387>#<0AE(,.)O*Q+G !89<#(R!C/>N_(!ZC-
M)@<\#GK0!YP?B!J3W)^S6",)HXY$$Q8*@-H]P0/E!ZKMY]:U-'\;SZKXCM].
M:U@ACF,@V&0F9 L:.&(QC!W\?3\NSVC.<#-4HM&TV'4WU*.RA6]<$-,%^8Y
M!_/ _*@#@[[QW<I>:@]S<BQM+6"?,=N@DG#I<+&@(88#..G8!L]LUHZ7KFJ/
MK/A^VN]1AFFNK;-[:PJK"-O+W!P1U!((+ XR,8YX[@JIZ@'\*  .@ H 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ KH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKJ&(5NIZ@ \$CTH V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-JUQ92,RHY1U="C(PYP58 C@@_C5/PO_ ,@J;_K^N_\ T>] &U1110 4444
M%%%% !1110 4V2-)HFCD4.C@AE(R"*=45Q<16EM+<3N$BB0N['H !DFFKWT
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MKG@#H:BU/Q?=6":G"EM$][9; R<[,F%I6YSDCY2,X'44 =ABC%</:_$FSNM
MM=2BL;B<W"S-''$5!<0INE89/ !R #R>*UM:\76VB:'8ZM+:7$MO>%%01 %E
M9UR@(SW.%SV)':@#HJ*XO5_%^H:9J]Y8QP6<\D&GRWYA0L6A1 I'F-T^8[P
M/3/-:>J>+8-/ATZ2*RN+O[?!)/&L6T$(B!R3DCL>/>@#H:*Y>W\=:==3)Y%O
M=/;2,8HYU3(>40^<4"YSG9WQC(Q5.P^(,6K2:.;&Q)@OKF2"5Y)E!@V1[\D
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M'6-,O()+2]ACMI$D.QH@QRJY'/N<4^*U-OH]M9,X66Z7,KO_  QCYG)^I/\
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MFH7<,"P0B>SECOGD8,JHC;U0 ?-G.#R/?-=]%+'/$DL,BR1N RNAR&'J#3Z
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ME]W8Z&BFHZR(KHP9&&593D$4ZM#C"BBB@ HHHH **** "BBB@ HHHH ****
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MKRTLLB*>1T5I?]H@X/#=..U=O5+1[:VL](M+:T),$485"002!WYJU*S)$[J
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M[49Y"2A._DYX&2?[M,\">-H?"WAITU!9;EY+C";00=H51U->M66C166B1Z9
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M(T%V/NW-NQCD'XCJ/8Y%5/\ A-_"7_0T:+_X,(O_ (JC_A-_">,_\)1HN/\
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M"%V^UG^*;_0Z^BN3TGXC^&=2LO/N-5LM.?<5\B]NHXY,#O@MT-7O^$W\)?\
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M&U=HQ@=!V^E6*BMEV6L2^4(L(!Y:G(3CH/I4M "%0PPP!'H:,#.<#/3-+10
M@ 48  'H*QO"_P#R"IO^OZ[_ /1[UK3SQ6MO)//(L<4:EG=C@*!W-<QX5U_2
M9-)NQ%J%O(T=U<R,J."0K3.5/X@@TFTE=ATN=755]2LHY_(>ZB64'&PL,UY)
MH?Q>^U>(9+:YF(MQOP7"XXZ= ,_G7%:QXEFU/XCF.&:5!<7B(L@&-N2 "%K6
M&"S&L^6E0DFM7S*WN]_ZU\C6E0E-/VLE3MW]Z_2RY&]?7;J;WQCU74IO%=K'
MI#22110*&\N,-A]S=>/3%=]I&@^)M6T>SFU/7S&DD"'R+="F 5'!Q@Y]>:Z2
M'POI]O;001-<H(FW[DG92[]W8@\L<GFME5VJ%R3@8R3DUO5Q$94X4HTXIQ^T
ME[TO7]-R>2C&*:U;WNM%Z:]3Q+QE\(M3U+6XI]+6"2 1J&9VVDD9SG)R?K7L
MVGP-;:;:P/C?%"B-CID "K%%95,16J0C"I)M1V3Z7-*E93BHJ*5NRM?IJ%%%
M%8F 4444 %%%% !1110 4444 %%%% !U&#35C1#E453[#%.HH"X4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!DZEX=T_5;^WO+E9/-AVC"OA7"NLBAAW =5/X>E9/BKP9::VNG
MO:V&G)-%JEO=W$DD(!DC1]SC(4DDCL>#WKK*YKQ?H=SK']C2VIF9[+4[:X:-
M9=B%%D4LS#^+"@X'OTS0!I?\(WH7_0%T[_P%3_"C_A&]"_Z NG?^ J?X5IT4
M 9G_  C>A?\ 0%T[_P !4_PH_P"$;T+_ * NG?\ @*G^%:=% '/WG@GP]>WE
MA<OI=JC6<K2HL<"!7)0KAQMY&&SCU -7?^$;T+_H"Z=_X"I_A6G10!F?\(WH
M7_0%T[_P%3_"J3^"?#SZU#JATNU$D4#P"(0)Y9#,K$E=O+#:,'T)]:Z"B@#,
M_P"$;T+_ * NG?\ @*G^%9<GP_\ #DGB6'7#IT(FBMC;B 1)Y)!).XIMY;GK
M73T4 93^&=">-D_L>P7<",K;(",^AQ5'1? V@:)I,&GI817:Q;L37D:2RMEB
M>6QSUQ] *Z.BE97N4IR4>6^G;H<Q:_#_ ,.6FOZAK":="\MZD:O#)$AB38,
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M=7\#>'M8LC;2:=#;<@B6TC6-UP<\$#OTYK:L;&VTVRBL[.%8;>(81%Z#G/\
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M>617RJDY( 8?D:Z"N9MO#5U9^(=3U&.2PDCO[E)SYML3+&!&B$*V[_9R..]
M&H/$.C-#),NJ6;1Q %V$RD*#T)].A_*D_P"$ATET!AU"VF9XC-&D<JDR+@G*
M\\\ UQLWPUO!IGV.TUF.#S-.33YG%N<O&)6=\8;C<&*^V35EOA_<OK%M>G4+
M9(8&4QP1V[!8E$#1;$^? 7YMW3/;.* .CLO%.DW>E6VH/>0VZSQQ/Y<L@#(9
M$WJI'J1SCO3K#Q3HFIVMI<6VI6Y2[7= &<*SC.. >>QKDD^&<\<UB!JT9@@E
ML9I%-N=S-;1&/@[N P.>0<5''\,KU1I*/K,4D>G?9=BFW; \EV;@;\ L&Y)!
M(QQP: .UB\1Z)/(D<6K63NY5459U)8MTQSWK-O/&VFV.BQ:C<$*\LFQ+82HT
MC?O?+R,'!&>?_KUAQ_#0QV\$:ZC&#%:VEON$&,F";S2W7^+I[=>:C'PRGBMW
MAAU6'$Z1I,9+8L<)<O.NSYOE/SE3UZ T =Y;ZC975Q-!;W<,LT)Q(B."4^H'
M2L^R\3Z9>6LURUQ';Q1O* TSA=R1OL:0?[.[C-9GAKP4OA_59+PW0N,)+'"2
MKAPLDOF$-EBO7'0#U[UR1\$:Y?HND?)9VXL;NSEN98O,#*UR'0KAA@E>>?>@
M#=O?BMHUC9:U<26UTS:5>K9R1J!NE))^9>?N_*W_ 'R:ZO1M9@UJWGEA1XV@
MG>"6-QRK*?Y$$$>QK@[_ .$:WUQ=S'50K7 N\CR>-TI.PGYN=@:3Z[NU=7X3
MTNXT_P#M>>Y1HVO+]Y$5CSL55C4^V0F[\10!T5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4M8TY-7T6]TV1RB74#PEAU4,",_K5#PUHD^
MC0W37=Q'-<7,BNQC4JJA45 !GGHN?QK5OKN+3["XO)V"Q01M(Y) X R>M4O#
MFN0>(_#]EJUN J7,88IG.P]U)]0>*T]E-P]I;W;VOY[BOK8U****S&%%%% !
M7+)X>L5^($FI@S_:OLPEW>:<9)*XQZ8 XKJ:HBUE&NM=X'E&V$6<\[@Q/\C4
M3BI6NNIU8>M*ES\KM>+7KMH8_B7P]?Z[JNEN+F'^S+.3SY;-]P\Z0'Y"Q'4+
MUQW./2F>'/"<NB:I)<R7:31)"\%NJH00CRF4ECW.3CCTKJ:*LY0HHHH CGFC
MMH))Y6VQQJ79O0 9-.1UDC61&#(P!!'<5B^,;*6_\):E!%<FW/DLS,%SE5&2
MOXXQ3_"<$MOX3TR.:;SF%NA#X(.",@=3T!Q6?,^?EMT.KV$/JWMN;7FM;RM>
MYLT5RI\:JFHW,,FGNMI;ZBNG/<"0'$C*I5MO]W+ 5:B\;:#+(Z"\*LDAC;?&
MR[2$+\Y'&54D?2M#E,_7? BZSXDBU<:C-&?+>&5" W[MHV3:G'R_>)/K5[PI
MX<GT"&X^TW,<\LJQ1@QH54)$@1>O<@9/UJQ9>*M(U#4H]/MIW>Y>)9=GEM\J
MLNY<G'&5YYIA\8:(E_/9R79CD@D>.1GC8('1-[+NQC(7F@#=HKG)/'6@10QR
M274BM)((UB,+B0DKO'RXS@KS4]IXIL;FXUM'62WBTA@L\THPA!0/D>P!H W*
M*Y:T\>:7<&[+I<1+#<""(&)B\Q,8DR$ R %.?PJQ)XUT,/-'#=B:2*U^U'8K
M%=FPN"6Q@949H Z&BN<MO'&A7$AB-WY;JK,^Y&"C;&)&&[&#A6!J_I/B'3]:
MBN)+223%N0)1+&T97*AAPP'&"#0!RVI?#@W]_J<HO4BAO/.D!6,[R\@3ASG!
M12F0/>NHT#2IM*M+@7,R2W%S<R7,IC7"AG/09YP !UI?#^NV_B'2Q?6V OF.
MA7=G!!(_48/XUJ4DU)71I4ISI3<)JS6X4444S,**** "BBB@#SZU^'5S:--,
MNH0F<7$-S$3&<2/'*T@:3GC.\KA<#O77Z!I9T70[73VE\UH5.Z3;C<Q)8X'8
M9)K2HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM+N01W$MNTKR_>1(O[NT#YBI()/7)S7?44S$P7\)6#^)K?72T@N+==L:KM
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MO\J$&(RGYRH!( !P<'!S@5N:?JEIJD3O:NY\MMKK)&T;J<9&58 C(((XY!H
MN4444 %%%% !1110 4444 %9&I>(;?3=6M-.>)FEN4+J=Z*  0#]XC)YZ#-:
M]<UXB;3XM1CN)H;N2ZM[5Y?]'<*!%N7.[) QGG\#0!<B\5Z%/#'-%J4+QR3"
M!&&>9",A>G4U))XCTF/3)-1-ZAMDD,189SO'5<=<\=*Y;3K3PO=R,T<%W9Q6
M$*78>65H\IY6W=MSD@*2,^N:EM?^$&CT.6PM;Y$M(Y_/;9*X=9&R,@]<GD?G
M0!NP^,-"EM/M#:A%&!&DCJYY4-@ 'WRP&!W-.'BO11=FUEOHHIO,:-49NI7K
M]/QKF(/^$+:]FTI R1SVK;9&D)1D&TOMR>#PI)]JLV>D^$-3N3:6*-(9D=PZ
MNQ7*,NX<]P2AP?6@#K-.U6QU>%YK"Y2>-&V,RYX. <?D0?QJY6+X:\/+X=L9
MK?[7)=/+)YC2.,=%50/R45M4 %%%% !5("V&MD[V^U&W VY&-@8_KDU=K&&F
MK_PE+7@GF#^2"5R-I&<8^G&:RJU)PY>1;M)^AA6J5(<OLU>[2?IU-FBBBM3<
M**** ,?Q59K?^%]1@>62-?(9R8R 3M&<?3BG>&+?[-X8TV/S9)?]'0AI"">1
MG'X9JWJL,EQH][!$NZ22!T1<]25(%)I$$EMHUE!,NV2.!$=<YP0H!KIY_P#9
M^2_VK_@;\_[CEOU_0N4445S& 4444 %%%% !6=KT=]-H5Y#IH'VR6,QQ$MM"
MD\;L^P)/X5HU1UE+^31[E-+=4O2O[IFQUSSUXSC- '&P^%=96'2XKC]XUBMW
M#YJW+?.A4^23DY)!/?IBLN+PGXSAV_Z8TLD(\N*1KG&]#$J$L/[PRQ]RH/>M
M?3]*\96RQQ"Y$4160DM*LA0L9#SQ\S9,>#P!@U$VF>.W*2I<002_9U#[9%.^
M15?&21T)*$_C0!++HGBL:+H%C#)'MLS'YS?:")"57&6/.X<D\=2!5?1O#/B2
MUU'3)9Y9!##)N8-<EO+'&_(S\V\Y(ZXSVJUHUSXLO6U^.3SHIDCV6KW$85/-
MWO\ =X^[MV>M6=.L_&*:M;37=TILU<!H2ZD^6=^=Q Y8?N^1[T =E17GNH:9
MXX&HZC=6+1O+(OE0.]R%55$C,"%V],;00>>O-='X8?5IO[0?4W<HEP8;;>FT
MLB_QXP.I)'T4'O0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %17-K!>0-!<PQS0M]Y)%#*?P-2T4#3:=T9
M7_",Z#_T!M/_ / =/\*Y_2_ACH6F:J;[]Y<@AOW%PJM&,^V.U=K16;I0;3:V
M.RGF&*IQE&-1VEOJ_P#@_A8RQX:T)2"-&L 1R"+=/\*LZGI\>J:;-82NR0SK
MLDVX^9,_,OT(R#[&K=%6HI;(YIU9S^.3?JV_S;.<G\%Z6]MJ=K:+]AM]1M?L
M\T5LBJN1G#@8^]@X^@%.UKPA8:[!JL5U+,O]H11QEHR T13=M9#C@_,:Z&BF
M9G+W/@73KJ[DN7GN [_:. 1C,H )QCJHSC_>-/U7P+HFJV,EN87M7D!#2VLC
M1,V2I)8*0&)VCJ#72T4 <Y-X.LYYKII+FX,4PD\N+(Q"[[2SJ<9)RH/.<'/K
M4\GABWFT*;3)[B67[1.+B>8A=TC[P_(QC'R@8QTK<HH QM4\.P:@L'D3/8R0
MK(BO;JH^20 .,$8YP.>Q%9=SX!L;AYBMW/$KPB)!&J J 5*Y.,O@H,;LXYKK
M:* ,"Y\+0_;[>]TRX_LVXB$NXP0(1*9-NXL".OR#FH)_!ZW"R.=4NTNGN1=?
M:(U0,)!"8L@8P.#GZUTU% ''7OP_@U'2X-/NM2G:&"*2% L48 5\<XQ@,"N=
MW7EO6I'\!6I+^7J%U&LLWFSJ A\S%P9U&2. &8CCM76T4 <</AY9>9:,U_<L
MMJRF-65#MVRM(H!QD<M@XZ@#/2K">!K)+1+<7=SM2WM+<'Y<XMW+J>G4EN:Z
MFB@#D?\ A7]B;1+%KVZ:PVXDM_EQ(WD^26)QD97' XR*U] T"WT"VEB@*,TK
MAG98$BS@8'" #H.M:]% !1110 4444 %%%% !1110 5RGBN'0I+H)J\\W[ZT
MD#6T2L3*B%7SE1Q@CIWS75US'BF;0EO=/35()+FY$@\F-"^%WL$W-CC^+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 E(# 2(  A$! Q$!_\0
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MO/M1SGFL.2RUL+*1?I([12(O&P!B1M;&.PR*TM,BNH-.MXKV42W*H!(XZ$T
M6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#&X1\GTP/YT 5O\ A%=._P">E]_X'2__ !5'_"*Z=_STOO\ P.E_^*J>SO\
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M&Z,,C;E20R<E>,@'/2@#HJ*** "BBB@ HHHH **** "D'WC2T@^\: %HHHH
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M^[Y>7VB_#?[PO7YU/V3OMHG:W;;Y?\$S[E42[F6.7SD#L%D_OC/7\:U/"?\
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M .WQ,@*W65/FCURH _*K55R1[$\\NY=COIFE13MP6 /%(U_.'8#;P?2JT/\
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M#Z4IZ4B]!]* %HHHH S="_Y!@_Z[2_\ HQJTJS="_P"08/\ KM+_ .C&K2H
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MG:.YK;BECFB66)U>-QE64Y!'J#398UE3$D:.!SAAFLSPP"/#.GA0 !$./Q-
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M_.BZ"S(ZDA_URT>1)Z#\Z?%$ZR D#%)M6!)W+%%%%9&HU_X?J*=37_A^HIU
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MX K_ /%4 ;5%8O\ 9NO?]# G_@"O_P 51_9NO?\ 0P)_X K_ /%4 ;5%8O\
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M@?N@?-MQ^M:-9]M# NM7TJ3[IWCB$D6/N ;L'\<G\J -"BBB@ HHHH ****
M"BBB@ /2D7H/I2GI2+T'TH 6BJ]_=&RL9KD1/-Y2%O+3JU4M#UI=:AFE2 QK
M&P4,&W*_&>#QT[T /T+_ )!@_P"NTO\ Z,:GW.LV%DSBYG$6QU0EAQEAD?I3
M-!S_ &6,C_EM+_Z,:I;C2-/NYFFGLX9)6 !=D!)QTH JOXIT2.))7U&((_0\
M\<XYXXY(ZT1^*-(E69H[L,(5W/A3P,XSC'3-20>'M*M[".R6QA:"/[JR#>>N
M>2>3S5DZ;9?/_HD/SKM;Y!\P]#2U&48/%.BW4L<=O?QRLZEAL!(P 3DG'^R?
MRJ0>(M*8PA;M6,T3S1@*<LB_>/3M4D>A:7"#Y6GV\9VE,I& 0#GCCZG\ZLPV
M5M;P)!%;QI&B[54*, >E,1DR^+=*MX(YYWDBC=&?+I]W'8^_!Q6E8:C#J*2/
M"L@"/L.\8SQG(]N::FD:<FW;8VX"*47]V.%/45-:V5M8HR6L$<*,Q<JBX!)Z
MF@">BBB@ HHHH **** "L^]@FDU73944F.)I#(<],H0/UK0K/O5G.JZ:8Q)Y
M0:3S=O3&PXS^- &A1110 4@^\:6D'WC0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_X?J*=37_A^
MHIU '/>+/L)M;;[;'<-^]/EM"0 IP?O%OEQCUJN;.*Y\%P_9!>)&D>Z.(,P9
MANS\P[]/\*ZFB@#*_MZP,OE;[CS-N[;Y#YQTSTIW]LV9_P"?K_P'?_"H4U.%
MO%3V/V4B58<"?=UZ,5QZ<CFMF@#,.LV8_P"?K_OP_P#A1_;-G_T]?]^)/\*T
MZ* ,S^V;/_IZ_P"_#_X4O]LV?_3S_P!^'_PK2HH RO[>T_S?*WW'F;=VSR'S
MC.,]*=_;-G_T]?\ ?B3_  K-G\01P:R(VTYQ*)OLS2M( ?+^4A@._+CCK72T
M!8S/[9L_^GG_ +\/_A2_VQ9_]//_ 'X?_"M*B@#,_MFS_P"GK_OP_P#A427^
MFQW4MRB7(FE"J[>1)R%SCM[FMBB@#*_MVP\WRM]QYFW=M\A\XZ9Z4[^V;/\
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MDX&=V>G3/]*TU88'- #JR+CPWI=X)3/;!GFD,KR9P^<8^]UQCC%:NX>M('7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "P 7(# 2(  A$! Q$!_\0
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MY-9N-'@M+73MNKZQI\-M:VFI1:H;9;?3KZTA:WOIX8H=5B9"FJ6$:Z=?">R
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M^(D-EX+TC?J_C<W7CZ"ZU87=QX4LM/30X)M2#38OC7]H']O[X:>%M3\2^(_
M6A:A#H7P'G^(FM7L?P[DL_#.G:S)\+O%/B[7?M>JP^/KJ^BU_P  ?$&R\,>
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M-.ZE5JU9QITX.?+.-*+DVYU9KDA&-W=RA&7]*%%?Q??L2?\ !</XV_ C^Q_
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MM7BNK^&+2PM6EN-2CN'221V@MV6XD(QM R#Y83;\K9?;AOF)X-?K+XH_9O\
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M7S9MPW7:U=-Y;BJSJ8*,W=.668O"<B=XX=V43 \'?%+P;XWL8;[0]:L+R&8
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MN["QU!(H[^RM+V."XANX$N[>&Y2&[MVWV]U$LR.([B!B6AF0+)$W*,IYJO\
MV+H^-07^R=,VZL&&JC[!:XU,,K(PU >5B\#*S*PN?,!5F!X)!\>^&WQ\^'_Q
M#C$.EZ_:+J$8"W&F7I:QU6U<#YH[K3KL17<+*>&+Q% <_O#QGW)9$9/,5U9"
M-P<,"NW&<[@<8QSG.*^'S++,TR;$SP6983&8#$4WK1Q%.O0>ZDI14U",HR<8
MSC.#G&349QG*T9GZ;DV?93G^"I9ADN9X3,L'55X5L%BJ6(@G=-QE[&K/DG&2
M7-"<:=2$U:<(3BU&,1V\%N(@D,-K#"(Q&%2.WBMXTVB,( (TA2,;0@ 14&
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M9)%+0O(H\EEE\Q@(")&7'[9X:?VWQ%B*>59LXYQD-*2IPR[-L-+'>^E3J<N
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M$L=8MDD?1]4,>\0S, ?(N57YY+.9E7S%4[HV DC!(*M[#179@,?B\KQF&S#
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M17'R)#^R5\7?AI%&O[._[5OQ)\-:;9JB6/@;XQVEE\:?!D,"@*;2"ZUEM/\
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MB^'9XBKEV:XS*,O5&ABL=2JXW&6A6Q;P?L*\<-/"5Z5&"F4445^9G[F%%%%
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MX88;>&*WMXHX(((TA@@A18H888E"1Q11H%2..-%5$1%"HH"J  !7#?"[X8>
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M\M%*A4DDU[\:=I1<E[LI)2U2E:Z:E^".FK>1W*J5D.6[!CQQ@#@<D9.*^GO
M.@W[1QW<EO-YEP4M].M1'(;BZN)CA6CB +;%R!N"DL2$4%B ?OZ/]ECX=P7
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M>S=O+D2[L;W3;VUN%4&2UO+#4(+:[MKB(G;)'+$,,#M+#D]+2  $D  MC<0
M"<# R>IP.!GH.*6OFJCIN<W2C*%-R;A"<U4G&+VC*HH4U-K;FY(7LFXIW/O:
M,:T:-..(J4ZM>,(JK5I4G0IU*B5I3A1=6LZ49/54_:U.6[2G)),****@U"BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Q WH# 2(  A$! Q$!_\0
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M?:P\872ZC<VETMMH[Q^4Q7R6D(W[1VSGD5KW.K:KX.\1Z]9W/B?4[NT'A_\
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M65<#@$\D"K%EI]GIL+0V-K#;1,[2,D*!068Y+8'<^M6:* *SZ=92ZC%J$EI
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MN>;1K"2:\79<N]NI:9>.&..1P.OI6K10!CCPGX=6)XET/3A&ZQJZBV0!@G*
MC'\/;TJQ-H.D7+7C3Z9:2->JJ71>%3YZK]T/Q\P';-:%% &>-"T@?:\:99_Z
M8JI<_N5_?*HPH?CY@!P,U'9^&M#TXL;+1["W+0^0WE6ZKF/.=AP.F><5J44
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MATT7):64HJR*A,>YUW(I;H&91D"@#<HHHH *S;CP_HUY)<R7.E6<SW10SM)
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M[17F&F^-M=G^(2Z,(K7^S8YEM3&[J)2/*#^8!G<>3Z8QWKT^@ HHHH ****
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MO]W?M.3R%48Y]10!ZK15/2=2AUC2+34H%D2*ZB655D7:R@C.".QJY0 4444
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M8(SJ S('QM+ $$@'(% %1_ VANC#R9E<O!(LBS,'C:%-D;*<\$+Q[Y.:CC\
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M!0[L\ &GV?C#6;W5;>^-R4@^W65FUH$&QEFAW,V>N=QXYZ"@#;^+7_(@3_\
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M %%%% !1110 4444 %-==\;+_>!'3-.HH X&VT7QIH5Q.FC6_A1X9B,SO%-
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MU&:<H2C\2L9N,H[H6BBBI)/%?B+X8UO4_&5S=6.EW,\#1Q@21ID$A0#7*_\
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MYB<VEY*T\G+-&^'MB1GY, %3TY.:Z?X>(\G@SQ!/!I,?E7>H74MO9_=CD4@
M*"0/E)!&<8H Z_6?$NG:+:":5I+AV=8T@M5\V1V894!1Z@$_2F:/XJTO7988
M[*1V,UJ+N/>A7<FXJ>O<,,$=JX/1_#/BWPQX0O-)M+"&>]GN48WD%PJOY3(
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M]\/J\>G'4[Z,S:=%8M;"X0&XMX3T(VY_BY*X//&,UK)X+TN/4%O4>X5UOSJ
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MJL #C P*Y/P?XBEU_P 77@.GO$D8=R6;/E,<*<^YVX_.O1:O%1=!^Q<;;/\
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MV0!]!@?A6Q0 4444 %%%% !39$62-D;[K @X..#3JCG#FWD$1(DVG:1ZXXH
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M@@]"#6'X/_Y +_\ 7_>_^E4M8&DZ3XTLO!WA^STR\TVRF@LE2YBOH&E8-@8
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M )*KX?\ ^N[?^@-7T?XU^*>A^#;]M+NY)5U!H5FCS 7CP21R0<]C7SA\(O\
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M:NUOGG@A\#[F>.N>M,\0:KJ>B> KV]N5C?5%@*1+;Y(:5OE3&>^2*Z>C&>M
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MEXATR"YNH?[.MIEW>7&^9'7MSQM!_.L_QA/9ZA;RV5W*!;PE3MY_>29' QV
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MC4(B@*JJ,  = *=10 4444 %8/@__D O_P!?][_Z52UO5@^#_P#D O\ ]?\
M>_\ I5+0!\I^+/\ D<M<_P"PA<?^C&K-M/\ C\@_ZZ+_ #K2\6?\CEKG_80N
M/_1C5FVG_'Y!_P!=%_G7[O1_W>/^%?\ I*/+>Y]$_&?_ %.C?[TW_LE>2UZU
M\9_]3HW^]-_[)7DM?"Y/_N</G^9^B99_NL?G^9[!\,?^1 UC_KM+_P"BEKR
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M_P#12UY >II8'_><1_B7Y"PG\>MZK\CH? G_ ".^E?\ 7;^AK=^+W_(WP?\
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MC.*Z;_A6'@?_ *%C3O\ OU7+FF/>/I*FX\OSN:_VN_;4ZO)\#OON?.WG1_\
M/1/^^A7J'P9O+:&\U<RW,* QQ8W.!GEJZ6[^&/A4>)-+$7ABS^Q&&X\_;%\N
M[]WLS[_>Q^-:G_"L/ __ $+&G?\ ?JOG*."5.:GS;'IYAQ/+&8:6'=*W-UOY
MI]CP;79XCXAU(B5"#=2X(8?WS5:RFB%_;$R)_K5_B'J*]\N_AAX+%E.8O#&G
M^9Y;;,1<YQQ5?1/ACX1.@Z<;WPQ8_:S:Q>=YD7S;]HW9]\YJ'EZO?F_ ZH\7
MR5-0]BMK?%Y6['-_&>\M9ET7RKF%\&?.V0''^KKRCSH_^>B?]]"OHG_A6'@?
M_H6-._[]5F0?#'PI_P )1?A_#%E]A^Q6WE9B^3S-\^_'OCR\_A6E;!*K-SYC
MDR[B:6"PT<.J5[7UO;=W[&#X#O+5/A7X@1[F%78W.%,@!/[E:^7J^TO^%8>!
M_P#H6-._[]5E^(_ACX571)3IWA>S-SYD6WRHOFQYB[O_ !W/X5UTH>S@H]CY
MS'8GZUB)UVK<SO;[O\CYT^$TB1?%+07D=403MEF. /D;O71?M!313_$:%X94
MD7^SXAN1@1]Y_2O??^%8>!_^A8T[_OU1_P *P\#_ /0L:=_WZK0Y#XMKZ%N;
MJW_X946#[1%YWD)^[WC=_P ?0/2NYT?X8^%#<ZO]K\+V807Q%MOBX\KRX_N^
MV[=^.:U/^%8>!_\ H6-._P"_5 'Q;7K7[/$\-O\ $&]>:5(U_LR09=@HSYD7
MK7J6N_#+0!XT\*"Q\+V_]FF2Z_M#RX?DQY/[O?\ \"Z>]=-_PK#P/_T+&G?]
M^J .GAO+6X<I#<PR,!DA'#''X5-6'HW@[PYX>O'N](T>TLKAXS&TD*8)4D$C
MZ9 _*MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *:T:.RLR*64Y4D<CZ4ZB@ HHHH **** "N.N?&TD'B=K!;.-K"*]BL)9O,
M/F":12RD#&-HQ@]^:[&N2N/!*S>)6U%;[9:27D5]+;>5\S31J57#YX7G)&.W
M6@#AOC+X3M]3ECU_^U((A ([:2(\M\S[01^+"K\/POTZS\-?8XM<DDNU0C:+
MA1$[9S]T]*O^.?A;HVJZ1<RZ1H5H=7FN8Y6E+;2P\U3(<DXY7=5C6/@]X3OX
M;9;'2[6Q>.YCED=$+>9&#\T?WN WK775QM:KAXX:<KPC>R]?Z?WF]/$3I24Z
M>DM-5OIM_77J<9X#\*^(M/U2YOKR#1HO++PQI=3E@V"!N '8]C6-XWT?77\;
M0K#8VSQW[@;[8YC0@#..1GCGM7I>J?![PI>S:>]GIEK9K;W2RSJL9;[1& 08
MS\W )(.?:EO_ (/>$[G4M.N+;2[6VM[:1FN(%0D7 *X )W<8/->;]7I<O+;0
M[EG&.59UU4?,U:^FWW6_ H^+M'UK7_ TFD2SZ6Y$:");>0B0,O0Y9@![UE?"
MO0=?\):%-YL>G)=7#AYEN[GYR!T4%20,>_K7177P=\*3:YI]Y#IEK#9VZ2K/
M9B,E;@L!M).[C;@_G2R?![PFWB"&^73+5;%+=HWLMAVNY((?.[J!QT[UO8\M
MR;U9KS:].\134-"25.@-O<Q3_CABM?/6@ZS GQ"MK&XMI/+CO,,VT-D _P!T
M>OI7MJ_!WPH/$4E^=,M38-:K"MCY9VK(&),F=W4@@8QVHM_@[X2BUZ\OI-*M
M)+.:*-(K0QD"%ESN8'/.<C\JRJ485&G);'?A,RQ.$C*%&5E+?KW^[<XSXN^*
MIK>UTZXTC2T,46Y9#=6@*J"1C'/'-=%X0O\ 6[SP!':S:;ID33Q2>9ON?)#!
ML_*$49!QWS6S'\)/!RZA<3R:):202(@C@*G$9&<G.>^1^5);_"/P=%=W<LNB
M6DL4K*8HBA B &"!SSD\U?*D[V.1UJDH\CD[=KNWW'EW@[X?Z]8:AK4FH2-'
M$T$EO &N0X96'.WYP<XX!I/!O@77H(M<75KBX5987MHA+*KETR.5_>##'C!]
MC7IFF_"CPJD^H&]\.6;(UR3;9).(]JX'7CG/%&F?![PG9S7[WFF6MXD]R98$
M9"/L\> !&/FY ()_&J,CC?A5X3U_P]-?W5W>):W4G[M#>%9%,8/;#\$]>G:N
MJ\<Z?K^M^$[NRCU6R>5L-&MF3')N!R.=W2I]'^#OA.PMYX[[3+6_D>XDD21T
M*E$8Y5/O=%'%-TCX.>%;'1S:WVG6M]=;I#]J>,J<,Q*C&X_=! _"@#S'1? 7
MB#4?AYJ5IJ,SM>73I(D%W,NY2N[:59FXZG/'>NR^%OA76?"7AV2(WEA975PX
MEF28K(6., 95N,#]2:V['X-^%K?PXMA<Z?;7-^(60W[1D,7.</C=VR._:FCX
M,^%QX5&FFQMCJ0M1"=1\L[C)MQYFW=USSC- '0&]\0K@"ZT"0=\R.I/ZFO&?
M#\7C]?B#):76JWTME;DRD3SXC=6SM!^;CO\ E7H^H?!KPO=>&I-/M;"VM=0:
M!8UU!8R65QC+XW=\'OWJU>_"+P?<:9);V^C6EO<,@5;A4)*GUQF@#S+P7HGC
M*S\?237%W=?9+5B8?MUP?);<#C=ASG ^O..E>L:JVNWVD7EJ][HVV:%D/D.X
M?D?PG=U]*K7WPD\&W%IY5OHEI;R[T;S I)P&!8=>X!'XUF>+?A+H$^AE- \/
M6<=]Y\1W!BGR!QOY)_NYH XSX7^&/%.E^(K^ZO\ 49K;R@T$+W<@EC89!)QO
MZ],?C7I&NZ3?ZOH-Y8WFNVM]'/&4-ND4<6_/^T2<>N?:JNL?!WPI?QVBV.F6
MMBT5U'-*R(6\V-3\T9^;@-TS1J?P=\)WD^GO::9:V:6]R)9T6,G[1'@@QGYN
M!D@Y]J .9^&'@"\\*PWOVO4%L+F=O]=;W,4F] >%P5R/7K6;XE^%UUJOQ @U
MF.>VGM=P:X>6ZC#2LO0[0,<]_I7<7WP=\)W.J:;<V^F6MM;6SNUQ;+&2+D%<
M*"=W&#S1<_!WPG-KEC>1:9:PV<"2+/9B,E9RP&TD[N-N#^= &;\1/#VKZYX2
MEM(-;CNY8V$D,42)$P8 X^8,.,9&,=ZK_##1-?\ #7ADQRW-C#=3OYLJ7LI=
MB<<#(;C [5M/\'?";>(8KY=,M5L5MFB:QV':TA8$29W=0.,8[T)\'?"@\12W
M[:9:M8-:K"MCY9VK(&),F=W4@@8QVH V9+SQ$5*BZ\/L",$^9(I_G7D/A&S\
M<6_Q#E%WJ%Y)96C%T%U<$0ON!V[N3QU]>E>BV_P=\)Q:Y>WDNEVLMG/'&L-F
M4(6%ESN8'=SNR/RJS%\)/!J7]S.^B6CP2(@CA*G$9&[<<Y[Y'Y4 <'\6;+QA
MJ1L;S39\2I^Z:/3;EMI#-P6R1SGVKM?"P\2Z7X:L+(W>DNT4>&:]F<S$Y));
M!(Z^_3%2VWPC\'17EW++HMI+%,RF*(J0(@% ('/.3S^-1:=\*/"B3:@;SPY9
M%&NB;;))Q%L7 Z\?-NXH \_^)OAOQ3K/B>PN[2Y=DE*PSG3YRL:KUW8+=<9]
MNE>I:K=ZCIO@J*V\,+!<:BD"11"]ND!C 7&YCG#,/3/)K,TOX/>$[*6^:[TR
MUO%GN&EA5D(\A"!B,?-R!S^=)H_P=\*6%O<1WVF6M_))<R2QR/&5\N-CE8_O
M'A1QF@#PZR\'^.M+\86^NZA97-P_V@/<S6]VC.ZDX?!5L\@FOIK3;/0M,7=9
M+:1.PY?<"Y^K$YKE=(^#OA6QTDVU[IUM>W6YS]I:,J<$DJ,;NP('X4S3_@UX
M6M?#2:?=6%M=:@L+1M?M&0S.<X?&[MD=^U '??;K3_GZ@_[^"HYKJTE@DC%Y
M"I=2N1(.,CZUPA^#/AC_ (17^S?L-M_:7V7RO[1\L[O,QCS-N[KGG&:=J'P;
M\+77AQ]/MM/MK6_,*H+]8R6#C&7QN[X/?O0!S\?@K5W\)S>'I3X?C6UPUM=I
M)F2[(EW@2?W0<8/6I)?!NHZI'J-Y>KHMK<7UY9LUC;3CR1%"?F)..6(SQBNE
MO/A%X/GTQ[>#1K2"X*@"X"$D$8R<9[_UIU]\(_!MQ:>5;Z):6\N]#YBJ2<!@
M2.O< C\: ,"_\"FX/B VJZ4LM[JUM=6K"105BCV9' X/!X'K65IGAG5]?\1Z
MQ%#9V$>GQ>*&NI;V3(N%\M@=JC'(/KGUKI/$WPKT3^S8'\-Z#:0:C'=P2"1&
MV$(L@+<D^@->D  = !0!XYJ7PR\0S6%E);R0FXM=0O9C MR8PT<SY4A]IP0.
MHQ6M8^!M6TM?"<]G86+2:;YT=U!<3F3:LC9W*^WYB.H&!7IU% 'C^@?#/6=(
M\96]U=*EU8V]_)=QW(O2I&[)R8]O)YP?FKH]2\+ZTGCRZU>RM-*O;34(X(Y6
MO<[[41DY*#!SG.>W(KO:* /)M.\#>*K;4=(MIUTXZ9I=_<W$<R2MYLJRA\97
M&!C=BFW?PQU.3X<:+I=M]FAU33[K[3,L<FQ9SENK@=<-D$@UZW10!XY+\-]<
M'A2WM;;3[1=06\FN"TM^SF)G4#>K;,$''*D<UZOI-O<6FD6=M=R1R7$4*I(\
M:[59@,$@=A5RB@ HHHH **** "BBB@ HHHH ***Y3Q;XND\.7%HD5HMS"Y)O
M94?+649( F90"=@R?RH /%WB+4-&OM.ATFV-_<MOFGL%3YY;=<!F1B0 P)&!
MSNZ5NZ/J]EKVDV^IZ?-YMK<+N1L8/N"#T(Z8KS#PIX7U#Q#=F;Q!YUU;)O87
MJ7[,K2<+OMW1\A7 ;>O 'R@#@UZG:K962QZ;:^3%Y,0V6Z$ J@X!QZ<8S0!E
M>)/%6FZ!Y5G<:A;6NH7B.+,7&0C.!_$>PR1U(K&\ >.)O$-LECK,*6^L*C,?
M+YCG"G:Q0^H/!7MP>A%<[XOOE\3ZY#HD]K,MS'/Y)T]HU%Q#R2EY!)T9<<,"
M<$<'FNW\+^&-/\(Z8ZJ((Y96\VYDC!2(R8 +*I)" X' XH W;N[@L+.:[NI5
MBMX4,DDC=%4#))KSR7XGK;^*48?9;OPM<6JR1WMJQ:2)@<.SCT7(R.H!#=,X
MZ#QOK7]E:6(I':TMKI6C.IM$LL-L_&WS5/\  W()Z#VS7)^!/ MG=O:^(+G3
MUM%!\VV@4LIC;D, <_/ P.55QD XZ4 >IQR)+&LD;!D8!E8'((/>N.\:^-5T
M>SOK+1KJQDU^VC2?['<,<F/.6( ZG;DX'.*ZN2<1VT_V6-9Y8%.((V )8#A?
M09XZUY!=VZ>/O%NV&)))=A:07%MM>PVX#VUP!C<K<E&!W Y(..: /2?"OBFV
M\3Z>940P7D.T7-JQR8R1D$'^)2.58<$5LW,WV>UEF$4DIC0OY<8RSX&< =R:
MR+#3].\(Z%'8:?"S^3"PMX#)NFF"Y8(I8Y.,D $\"N)\1^*Y_$5ZFG:?%.=.
M2..[EBAD:&ZOH2#EK=@1G8<;E/)*X^H!V]CXNT2_T.+5TOHXK62183YQV,DI
M.WRV4\A\G&*VZXK0? 5G::BFM:L5O-2C)*3LI0.,8662/[OG!?E+5-XD\<PZ
M-:7)M[=YI$CCECG WP^4YP9CM.3&A^]CGD>N: -@>([ >)FT";S(+TQ":'S5
MVK<+W\L_Q%>XZBKUEJ%GJ,<DEE<QSI'(T3M&V0'4X(SZ@UYCI?A&[\4,QU>X
MG9/.:2Y<3.T<C'+1W%G+DF/@A2O3'!&1SWDUSI7A+1E@MH%CM;1$+008W11%
MMID(SDJ.23UX/4T 6M<UF#0-*EU*YAN)+>(CS/(CWLBDX+$>@ZGV%/36M,D:
MQ6.^@<WZEK4*X/G #<2OJ,5YOJ&L:EXMU]K>,W=I:V<[6XCM'9;FVE;;Y=Q*
MF=LL) .!C&'.<]NK\->$-*\*1R:C,EM%?2(!-*K$0Q9.66(,?W:%B3M'<^PH
M ZNL;3_$^FZA?:E9;WMKK3G(N(;E?+8)VD&>J$<AJYGQ3XUN50:5ID0M+V>X
MELFN;W*Q02!<HI93E6D!4HW3G/;%4]'\!VVNQ6]SK$5Y]DC'[JUO7;[3 VXB
M2%Y,_O8"1D Y_*@#T2SO+?4+.&\M)EFMYD#QR(<AE/0BJ&M^(K'P\UFVH^;'
M;W,OD_:=N8XF/W=[?P@G@'UIFI:]9Z,(85A:52_D;;?:?+DV;DC(SP6X ]R/
M6O.8)-6\=WK71;8EQ$4@C&][:':3YMK>0D_>((^8#J!C&.0#U9=1LWU!M/2Y
MB:[6(3-"&RP0G 8CT)J>1_+B=]K/M4G:HR3[#WK"T+P[H_@ZQ:"Q0B2=OOS2
M[I9F ^5-S')P!@#L!]37'^(O&%UKK0:5IEI*D4\ N)87D:"XNU5\2P0.I&V1
M,$,#UZ#UH ['3_&&BW^@MK!NUMK>-O+G6Y^1X),X*.O9L\8[]JWJX7P]X#LA
M?0ZWJ6^\N5P]L\ZE'9,?(9TZ-*@)7=UQ[UW5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F/
MQ'OKN/6Y8?M,MO;V^@W-[;M'*4S<JZ!3QU(!Z>]>B:;++/I=I+/Q,\*-)D8^
M8J">/K3;ZQT^]> 7UO;S,CYB\U02&Z\9^GZ5<H **** "BBB@ HHKD'\<B);
MNZFTR5=.M=0-A+<+("5;(7>5Z[<L* .OKCOB+J5AIFBQ270N9KN5S#8V<$I0
MSS,,*#@C@=?:M^3Q!H\4DZ2:E;*T )E!D'R@'!)^A.*K:M+X<N'W:J]E(]HX
M&9B"8F89 'H2* /-I;O6K.\5-0OY3JE@NEQQ!9B0YD?$ORCA\Y()]J]DK'DC
M\/V]I;:M*MBL$"KY%TVW:@)P,-]3Q]:G.O:2+,WAU&V^SA_+,GF#&_\ N_7V
MH T:*SY==TJ$6YDU&V47 !A)D&'!. 1[9XJ/2O$.FZS=:A;6,_F2:?,8+@%2
M-K@9_&@#4HKG%\9Z7)XF71X9HY1]DDNI+E904C",%(/Y]?:M%=?TAK)KQ=1M
MC;JVQI!(,!O3ZT :5%8K^);&.^6-IH!9M:?:OM9F7;C<%''ISUZ58/B#2!:_
M:CJ5KY'F>5O\P8W_ -WZ^U &E7B.L>+-7EU[Q)>075Q 3HLQL;;:RF)4DV^8
M0?XB,M],5[/9WEMJ%JEU:3QSP2#*21ME6^AH>RM9+@W#V\33&,Q%V4$E#U7Z
M>U '(^ IY/MNO62SR36-M-#]G+N7QNB5F 8]>3G\:ZV^NTL;"XNWY6&,N1ZX
M'2BSL;33X/(L[>*"+.=D:A1FII!F-L^AI/8J-N97V./^'?B2;7])N#=LWVF.
M9CAEQ\A.1CUQR*[*N:\!@?\ ")6IP,[Y/_0VKI:SHW]FKNYVYER?6ZGLX\JN
M] HHHK4X HHHH X7X@7=U'J&B6BHSV4QG:=1<& .4C)4%QT[GZBN5EUV>\OX
M[^UGNX?*_LO[!#),2QCE.'R,_.2,@GGI7KE[86FHP>3>VT5Q%G.V10PS3&TN
MP>Y@N6LH#- -L4AC&4'H#VH MT444 %%%% !1110 4444 >#-K>K6T.L7UO?
MW!::TOVA<3%I&V3 ;G0\1E%R%Q7H_@::07^OV23/+8VL\(MBSE\;H59P&/7Y
MCG\:Z6/2-.BN)YX[&W66<$2N(QEP>H/KFI;.QM=/@\BSMXH(LD[(U"C/K0!8
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **1F5%+,0J@9))P *Y/QAXF
MM[72Y=/LC=W-Y=VCR(=.(:6&'&#..1D#(( Y/:@"3QGXRM_"UB2AA>[)7Y92
MP2)&)&]]H)"YX]R17(Z+H%SXIUZW\0Q;+'9,6O)(9R\BS8Q)$I*[)(V&P9.0
M-K #/-2^#M(U'4=2CU":=+VWDAV7&J#;)!K%N2=@:,G*2IT/&!C'/;TZWMX;
M2!(+>&.&%!A8XU"JH]@* $M[:"SMTM[:&.&%!A(XU"JH]@*\^\4>%]6M=6U#
M6-&OM4-S?;/)BM"N8YU! ,C-UAX'R=,LQQZ>C44 9DNBVM]<Z;J%_ C:E8C=
M'-&2I5BN&&1U4YZ'C@>E<)XJU=_$.HS>')K)+>>WO5DTTWF?LNIE%^>%R0,'
MYC@<\@$9Q7IU5;_3+'58%@O[6*YB219561<@.IR"/<&@#EO!.EWJ:+J.G:I8
M3Q:6\NVTL[YUE>.,J-\9()R@;.W/.*FUO4+KP?I-C8:%I7VJ.*&1LSSL$BBB
M3<07PQR>BY_I76U#=6T=Y9SVLPS%-&T;CV(P?YT >2^'=)U*WU^QN=)MR[-,
ML\E]%.O[VUE^=HKM"<^8N[*L!S@5ZDFCV,6M2:O' $O98A#)(I(\Q0<C<.A(
M[$\BL""W\._"[PH57S%A!R6/[R>ZE(_-FP/P [ 4WQD=1U#P_9W6F+-/IQ99
MKVWMG:.XF@(SB-@1@C(..IQ@'U .<CU9]<\-3ZOJ^KRI--=K:06=E$D<VF3&
M78 &/SLPX+ \$9P,5U?AOPS+91B?6%M)[U9WGC,4?RQ.V0[QYY7?]XKT!)]:
MB\.^$+6TE74=3@M;[4HV_P!'U"2 +<-%@;?-]9 ,@MW ^M;-GKEAJEYJ-A8W
M<;7M@_E3QL.8V(R"1QD<]: ,/Q+JE_\ \)1I6@VVIII,-W$\INVA60S,I \E
M-_R@D$DYR<=*R])T@ZIXADN],N"ND6=Y)$8I<,8G7"R)%C(,,BG!4_=*@CIB
MJVD^%]2U6_FB\0H;ADG8:E!> R6MT#N,4UMG_5LO"X&.,YYY/5W^M:#X-AT_
M3=B6ZSR+%;VMM']T%@"Y Z*"1ECZ^IH MZBR^'/"MY)I5@A%C:N\%I$N 2JD
MA0![^E</(TNI:;HLB^(5O]:U5V>SNX8$6$*L;.T,B+RT/WE.<D%AT-:_C;2=
M4U'5-/.Z[?22#&182-'/:SL1LN.#AU7I@\#).#6EHWA_2O"]D^J7L&FPWZQ$
MWNH10"%7'5FQ_#G )QQF@"UX>T"+2;.W>:.)KZ.'R?. RR1YW"(/U95Z#/H*
MPKO5)=2\7:OIE[J,-KIVF0I(^GM$A:]C9-QD+MT4-\HV]"IR:TUUJ;Q5X0O+
MOPO,(;IO,B@:[B*X=3CD=1GL>V0<5@>&_",&J11W&LZ>T]FJG9::LAEN+2<-
MB0+(22T3$9Y/TX- $GA3P\VJ0+J%]*;W2+RUC\A+Q-TTL).]$G!X+1G[KYR0
MQSZUO>-=9N= \-M=VC1PL98H6N)$+I;(S!3*R]PH.?3UK0FUO3+'6;/19KA(
M;RZB9[>(C =5P"!VSSTKCM:\/ZWJ'B^8RS2A94!TZ\C!:WB4 ^9;W$).&#Y^
M]WXZ8% $.I:5+J.IP:5::JU[J36?GWTSA(X;R%G"AB(_N2KA2C@?P=Z[O3M,
M@T]&=4C:[F"&ZN%C"-<.J@;VQWXK,%MX<\":1<7<5G;6$+$;Q;Q8:5SPJJ!R
MQ). OO6?XCFOO$?@VRU+0D:YLYUCN9[(,8I;F @,45P04?V[XQD4 8=SK0U+
M2?$6IZWJ4@MK">6V72[.-4N+5E?8DBN?G,C Y&."&P :Z+P]X6N+5I)M<:UO
M;A;D3Q.L8QYBC:)P"/DD9<;@.,C(ZU%X>\&V$?DZAJ%M'>W$>U[*XO( +J&+
M *I*W\3+T!/(Q784 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLEP(?*MK:VC)_B8("S<D 9R6.> 30 _Q+KG]@Z)<WT<'VB6()B(-C&Y@NYL
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M5\?P2K-/#>O-8W*M)#"I*72) "<<=';G'K6_HE]XMM?!E^EU!>76HM-,$N6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M84N?4XZU8HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1E### $>A%+10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 55ETZSFU"WU"6VC:[MU9
M(9B/F0-]X ^^!5JB@#E)/$%_%X\CTN18AITA$410!G:3RRYW?-E1QUQC\ZRI
M_B,8]=\E=/;[$(Y54%U\R259EC'?Y%R3][%=S]CMA=F[%O%]I*[?-VC=CTS4
M1TG3FDED:QMR\P(D8QC+@]<^O2@#E_\ A8U@CVYN+"XAAE20F9BI7S$+ QK@
M_,?EXQQR*9!\2;6;3[2^?2[J&WGN!"TLC*$C! (8MGD'...]=:-,L5:%A9P
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>atnm-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.actiniumpharma.com/20250630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:atnm="http://www.actiniumpharma.com/20250630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20250630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>995307 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Leases" id="atnm_r_Leases">
        <link:definition>995308 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>995309 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Equity" id="atnm_r_Equity">
        <link:definition>995310 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>996002 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>996003 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" id="atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable">
        <link:definition>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" id="atnm_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][K37ZeeTpOBmQ5Vx+/fLOjBW4+qWORKCpfRvX4VuVMGEGWnOVLY9xUXz/PCTWLxp6iElPfKdzggjTmEfSVI7twNwGfq33MNiz+tpitkha3Lx6XgbtKED9N2TwE4EVKCwbdDAqWRqZZ5RPv0ZbTL/1pekwKv9Cg7bngyBtfcSFHJ6jxZanyhipGMG4X31pi53E24NAfTHzPiBlj6tJIbJhh0eNqyEZNjY0pGOxjyFhC+LwCTbHPeiVpODi1wvtyD3Vxk4zEDGFrpjKQlAyCmEr4UsKoXJp4R7ZJAMlfq3c7ohUFrGAXzE1Vw/RfPITr3iObwHMEzD1rw5Xqf2rQJX2XBlCu32k8CcXIHmPEr72zG3Z+b3AhpOoj/8=] CSR-->
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>996006 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>996007 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" id="atnm_r_ScheduleofComponentsofLeaseExpenseTable">
        <link:definition>996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" id="atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable">
        <link:definition>996009 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" id="atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable">
        <link:definition>996010 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>996011 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>996012 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" id="atnm_r_ScheduleofStockOptionActivityTable">
        <link:definition>996013 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" id="atnm_r_ScheduleofRestrictedStockUnitActivityTable">
        <link:definition>996014 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" id="atnm_r_ScheduleofWarrantActivityTable">
        <link:definition>996015 - Disclosure - Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="LeasesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesTextBlock"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
  <xs:element name="LicenseRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenuePolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
  <xs:element name="LesseeLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
  <xs:element name="EquityScheduleofRestrictedStockUnitActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="NetSalesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetSalesPercentage"/>
  <xs:element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonRefundablePaymentReceived"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="AggregateMarketValueOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateMarketValueOfCommonStock"/>
  <xs:element name="NetProceedFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceedFromIssuanceOfCommonStock"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="FinanceLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeasesMember"/>
  <xs:element name="OperatingLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeasesMember"/>
  <xs:element name="OtherRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueMember"/>
  <xs:element name="RevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueMember"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>atnm-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
<!-- [WMV6][zazP7wqE/BxQqA+139RZlNPKedOwzEMbNvHiQCX4XMiWfCIToVf012XflyUb574fRelt3i1bPI//53B9w8cSiHHF07vdZW7nHwBBmc+XMC5BdRbuoZPvZshrHdEMq84+2dGF9YU36Z4OCXWKFH7lsCM2vfp4wQqlXvhOkr0oc156WCYJTYO/tIZ4nuGB43oi50kTXLYXOvCoF822Y4eHqXVIvf5n5Xw09UtTYho1PoqDvI/vzy/XQekWfVOwGdjdPSZ0+v635GCv16o12q5i+AFZRkmE80V0P8R91MvruAdzofv91vJmbv4I85PeZ1YXCrhYncHCPUG6CNrjfkm4LGr20FOrgvyavoZ6LZTTGd4D/8hfshln6N4eSw==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>atnm-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250630.xsd#atnm_RevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_RevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_OtherRevenueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20250630.xsd#atnm_LeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenuePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
<!-- [WMV6][f8EHHJ1sPAqfq3ZKcoPObGv8hqBVj2PnE59pVbJEzNCHzyeWVmsQ94BsH1xRNUwKbffRziu+1bCfhXamHQjZRSJNX2bbgB1OY7ODxN6osVMXHR440IvqrfOe7OjZ98J2OxsfwNtmt2utLiO/bybmBEXa5TmbmMzYxdgQWfZx/wGB3kXmdFYCIxSNYpuKrIR3VaP3S6Fa/62/aYGtINYQPAmPN9m/U2mAsVC8hX5DMgRBfum3brwkOIkwoE4vtY69xBeSCLR3VBPXiHIjMpitKbEMlESdecIT0z6QsOm4vZNMH1nhjNqaMC0rT3xqDgB3CyB7iPS5ujbEkrL9SN8gXxyK/ZQFKGzRthUYjUbPQNOwQE0hRRX8g6Y=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250630.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeasesMember" xlink:href="atnm-20250630.xsd#atnm_OperatingLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="atnm_OperatingLeasesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeasesMember" xlink:href="atnm-20250630.xsd#atnm_FinanceLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="atnm_FinanceLeasesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250630.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250630.xsd#atnm_NetSalesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_NetSalesPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250630.xsd#atnm_NonRefundablePaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_NonRefundablePaymentReceived" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateMarketValueOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_AggregateMarketValueOfCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="23" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>atnm-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Components of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating Leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Number of Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $985 and $891</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in/provided by financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20250630.xsd#atnm_RevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueMember_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueMember_lbl" xml:lang="en-US">Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesTextBlock" xlink:href="atnm-20250630.xsd#atnm_LeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250630.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20250630.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="atnm-20250630.xsd#atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20250630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20250630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Operating Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Finance Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Issuance of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Stock option grant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Finance Leases, Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Cancellation of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeasesMember" xlink:href="atnm-20250630.xsd#atnm_OperatingLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeasesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeasesMember" xlink:to="atnm_OperatingLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeasesMember" xlink:href="atnm-20250630.xsd#atnm_FinanceLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeasesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesMember" xlink:to="atnm_FinanceLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20250630.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetSalesPercentage" xlink:href="atnm-20250630.xsd#atnm_NetSalesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetSalesPercentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Current annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20250630.xsd#atnm_NonRefundablePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonRefundablePaymentReceived_lbl" xml:lang="en-US">Non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Base prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateMarketValueOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl" xml:lang="en-US">Public float subject to market conditions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price minimum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price maximum (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
<!-- [WMV6][3nvSGys7bz5OxhWv1NlQHLHDjVhjM0Gq4WOPcI/vXrN6+56JxBaEZL7nsHRAo4d+rbJ8Fk8H0bkJwh3gx/OFfppoqOEi7CjN2FndJktL29Uw67nN59cIeVWEkRQIM49it9QQAKgOxHpwmtjhNt6oZWBfE7nLhy5dngK1zhU4QEHbG5hl1bMOAep17eD7JxhwbX4Jg6jlI5H/Nz/FRcEltAo9pFqw9SdlWOLetqjVujNmIpTrssoUt0uBp2fPkVp/beF7S5Z4uuqLFMK3y712JuC1I+OD3YWnHyT4tDJpMO0M6phXvbhkZ65huRDgTlr5PrJv7oZkamWI02hLFDj7U5zcugv+rFFycGEuuZ1uGTHRBny8Ybe4Vh0=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Stock options fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Cancellation of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250630.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable_lbl" xml:lang="en-US">Leases - Schedule of Maturities of Lease Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl0" xml:lang="en-US">Amount of aggregate market value of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LeasesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for leases liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of lessee lease liability maturity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for nature of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Net proceeds from issuance of common stock..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetSalesPercentage_lbl0" xml:lang="en-US">Net sales percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NonRefundablePaymentReceived_lbl0" xml:lang="en-US">Represents the amount of non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">The entire disclosure for other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure weighted average remaining lease terms and discount rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeasesMember_lbl0" xml:lang="en-US">Finance Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeasesMember" xlink:to="atnm_FinanceLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl1" xml:lang="en-US">License Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl1" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Finance Lease, Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetSalesPercentage_lbl1" xml:lang="en-US">Net Sales Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetSalesPercentage" xlink:to="atnm_NetSalesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl2" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl1" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueMember_lbl0" xml:lang="en-US">Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueMember_lbl0" xml:lang="en-US">Other Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesTextBlock_lbl1" xml:lang="en-US">Leases Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesTextBlock" xlink:to="atnm_LeasesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl0" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceedFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceed From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateMarketValueOfCommonStock_lbl1" xml:lang="en-US">Aggregate Market Value Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateMarketValueOfCommonStock" xlink:to="atnm_AggregateMarketValueOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonRefundablePaymentReceived_lbl1" xml:lang="en-US">Non Refundable Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">Lessee Lease Liability Maturity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_LesseeLeaseLiabilityMaturityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeasesMember_lbl0" xml:lang="en-US">Operating Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeasesMember" xlink:to="atnm_OperatingLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivityAbstract" xlink:to="atnm_ScheduleOfWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>atnm-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Aug 08 18:33:33 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20250630.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevenueMember" xlink:href="atnm-20250630.xsd#atnm_RevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="RevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueMember" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRevenueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTextBlock" xlink:href="atnm-20250630.xsd#atnm_LeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20250630.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenuePolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenuePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20250630.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20250630.xsd#atnm_LesseeLeaseLiabilityMaturityTableTextBlock"/>
<!-- [WMV6][9Tuj3qqN2Ll5GJ4behoetAqZBcv0YUvlzyJCbinSrFMsfP2wduvJseDJsKc1NcATWVNLnP/dyJ6YjDTzegM9P9mdX7VtcMhD76+7WBdZVCcUTNy+sjZXIiObMuSnD34tJlVJaAvnaA62YL2rV2MGjGwqZ6HsuvPLm8y7mGTZEeyaa2dk6pELQ5kEbPvPjsHLkAPfJGfuHkC8dUDp2dGWkYjVQ26J+hwm1ulW9/eysIilXb6HtYjqRV/VqarVNAYY1cIJPWEudMQPsmcJI1H2U5Aco4fGFvNsSjBN1jssOod8oiUp8AAhrdLfFNcL0YBvF1p1zwd53DP1s6+3msDNo6IP8irbxd9WtAjfVxtQua46VP6vBKX+n+Y=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LesseeLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:href="atnm-20250630.xsd#atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesMember" xlink:href="atnm-20250630.xsd#atnm_OperatingLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="OperatingLeasesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeasesMember" xlink:href="atnm-20250630.xsd#atnm_FinanceLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="FinanceLeasesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable" xlink:to="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20250630.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_0" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_0" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20250630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20250630.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetSalesPercentage" xlink:href="atnm-20250630.xsd#atnm_NetSalesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="NetSalesPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="NonRefundablePaymentReceived" xlink:href="atnm-20250630.xsd#atnm_NonRefundablePaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="NonRefundablePaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20250630.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20250630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateMarketValueOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_AggregateMarketValueOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AggregateMarketValueOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedFromIssuanceOfCommonStock" xlink:href="atnm-20250630.xsd#atnm_NetProceedFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NetProceedFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Park Ave., 23rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,928<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">61,029<span></span>
</td>
<td class="nump">74,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $985 and $891</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">63,017<span></span>
</td>
<td class="nump">76,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,714<span></span>
</td>
<td class="nump">7,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">8,314<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease obligations</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">44,004<span></span>
</td>
<td class="nump">44,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">417,624<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(398,642)<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">19,013<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 63,017<span></span>
</td>
<td class="nump">$ 76,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">8,825<span></span>
</td>
<td class="nump">12,579<span></span>
</td>
<td class="nump">15,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
<td class="nump">11,562<span></span>
</td>
<td class="nump">6,555<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">12,418<span></span>
</td>
<td class="nump">24,141<span></span>
</td>
<td class="nump">22,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,503)<span></span>
</td>
<td class="num">(12,418)<span></span>
</td>
<td class="num">(24,141)<span></span>
</td>
<td class="num">(22,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income - net</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,878)<span></span>
</td>
<td class="num">$ (11,353)<span></span>
</td>
<td class="num">$ (22,816)<span></span>
</td>
<td class="num">$ (20,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic (in Dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">30,103,063<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">28,994,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">30,103,063<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">28,994,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 373,934<span></span>
</td>
<td class="num">$ (337,583)<span></span>
</td>
<td class="nump">$ 36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,752,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">10,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
<td class="num">(8,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">390,081<span></span>
</td>
<td class="num">(346,253)<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">29,396,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">373,934<span></span>
</td>
<td class="num">(337,583)<span></span>
</td>
<td class="nump">36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,023)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">401,410<span></span>
</td>
<td class="num">(357,606)<span></span>
</td>
<td class="nump">43,835<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">30,550,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">390,081<span></span>
</td>
<td class="num">(346,253)<span></span>
</td>
<td class="nump">43,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">29,396,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,154,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,353)<span></span>
</td>
<td class="num">(11,353)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">401,410<span></span>
</td>
<td class="num">(357,606)<span></span>
</td>
<td class="nump">43,835<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">30,550,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
<td class="nump">32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
<td class="num">(15,938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,427<span></span>
</td>
<td class="num">(391,764)<span></span>
</td>
<td class="nump">25,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">408,553<span></span>
</td>
<td class="num">(375,826)<span></span>
</td>
<td class="nump">$ 32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,816)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,624<span></span>
</td>
<td class="num">(398,642)<span></span>
</td>
<td class="nump">19,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">417,427<span></span>
</td>
<td class="num">(391,764)<span></span>
</td>
<td class="nump">25,694<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,878)<span></span>
</td>
<td class="num">(6,878)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 417,624<span></span>
</td>
<td class="num">$ (398,642)<span></span>
</td>
<td class="nump">$ 19,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,816)<span></span>
</td>
<td class="num">$ (20,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,071<span></span>
</td>
<td class="nump">2,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,966)<span></span>
</td>
<td class="num">(15,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in/provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sales of shares of common stock, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in/provided by financing activities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">24,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(12,971)<span></span>
</td>
<td class="nump">9,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">73,228<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">60,257<span></span>
</td>
<td class="nump">86,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;,
or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production,
final drug product manufacturing, preclinical research and development (&#8220;R&amp;D&#8221;) and clinical development. We are deploying
our technologies, capabilities and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation
radiotherapies. We are focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline
of clinical and preclinical stage targeted radiotherapy product candidates are directed against validated cancer targets for indications
in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed
by currently available treatment options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,928</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. There
was no revenue for the three and six months ended June 30, 2025 and June 30, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the six months ended June 30, 2025 and June
30, 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and six months ended
June 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">547</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,734</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740):
Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments
in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income
tax disclosures. The Company is required to disclose additional information regarding reconciling items equal to or greater than five
percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required
to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds
received). <span style="background-color: white">The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. The Company adopted this standard effective
January 1, 2025 and will report on it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company
will update all required disclosures pursuant to ASU 2023-09 at that time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting
periods, including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual
reporting period. The Company is evaluating the impact of ASU 2024-03 on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On March 27, 2025, a putative class action complaint (the &#8220;Securities
Complaint&#8221;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#8220;Defendants&#8221;), styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who intend to file an amended Securities Complaint on or before August 25, 2025. The Defendants
have not yet responded to the Securities Complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On May 5, 2025, a derivative shareholder complaint (the &#8220;<i>Georges</i>
Complaint&#8221;) was filed against the Company and certain of the Company&#8217;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#8220;<i>Robinson
</i>Complaint&#8221; and, together with the <i>Georges </i>Complaint, the &#8220;Derivative Complaints&#8221;) was filed against the Company
and certain of the Company&#8217;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#8220;Derivative Action&#8221;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court has not yet entered that stipulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">346</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">346</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Supplemental cash flow information related to leases
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Weighted average remaining lease term:</span></td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-size: 10pt">Operating leases</span></td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: center"><span style="font-size: 10pt">2.1 years</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Finance Leases</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">1.5 years</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding six months ended June 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(67</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the six months ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#8217;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $35 million at
June 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#8217;s regulatory approval of Iomab-B
or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales
Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock
are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#8220;Prior
Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911),
which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration
Statement, including a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock,
warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum
aggregate offering price of $200 million of common stock that may be issued and sold under the Amended Sales Agreement. On March 31, 2025,
upon filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, the Company became subject to General
Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock in a registered primary offering using
Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month period so long as its public float remains
below $75 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company did not sell any
shares of common stock during the six months ended June 30, 2025. During the six months ended June 30, 2024, the Company sold 2.9 million
shares of common stock, resulting in gross proceeds of $25.2 million and net proceeds of $24.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,923</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">240</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, June 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.36</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2025, the Company granted newly hired employees options to purchase 26 thousand shares of common stock with an exercise price
ranging from $1.06 to $1.43 per share, a term of 10 years, and a vesting period of 4 years. The stock options had an aggregated fair value
of $29 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from 90.1% to 90.7%, and
(4) <span style="-sec-ix-hidden: hidden-fact-67">zero</span> expected dividends. During the six months ended June 30, 2024, the Company granted options to purchase 1,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $8.8 million in stock option compensation expense for the six months
ended June 30, 2025. During the six months ended June 30, 2024, the Company recorded stock option compensation expense of $2.4 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2025
was $0.3 million related to unvested stock options, which is expected to be expensed over a weighted average of 2.2 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at June 30, 2025 of $0.1
million is expected to be expensed over 0.1 years. During the six months ended June 30, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $0.3 million and $0.3 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (6,878)<span></span>
</td>
<td class="num">$ (15,938)<span></span>
</td>
<td class="num">$ (11,353)<span></span>
</td>
<td class="num">$ (8,670)<span></span>
</td>
<td class="num">$ (22,816)<span></span>
</td>
<td class="num">$ (20,023)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;,
or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production,
final drug product manufacturing, preclinical research and development (&#8220;R&amp;D&#8221;) and clinical development. We are deploying
our technologies, capabilities and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation
radiotherapies. We are focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline
of clinical and preclinical stage targeted radiotherapy product candidates are directed against validated cancer targets for indications
in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed
by currently available treatment options.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Segment Information - </b>The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,928</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers
</i>(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. There
was no revenue for the three and six months ended June 30, 2025 and June 30, 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements
</b>- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i> There was no revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue</b> <i>&#8211;
</i>The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.<b>&#160;</b>There
was no grant revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenuePolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional. There was no revenue for the six months ended June 30, 2025 and June
30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -
</b>The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share
</b>- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and six months ended
June 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">547</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,734</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the Financial Accounting Standards Board, (the &#8220;FASB&#8221;), issued ASU 2023-09, <i>Income Taxes (Topic 740):
Improvements to Income Tax Disclosures</i>, to enhance the transparency and decision usefulness of income tax disclosures. The amendments
in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income
tax disclosures. The Company is required to disclose additional information regarding reconciling items equal to or greater than five
percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required
to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds
received). <span style="background-color: white">The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. The Company adopted this standard effective
January 1, 2025 and will report on it in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company
will update all required disclosures pursuant to ASU 2023-09 at that time.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, FASB issued ASU
2025-04, <i>Compensation&#8212;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer</i>, which revises the Master Glossary definition of the term &#8220;performance condition&#8221;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#8217;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#8217;s goods or services from the grantor&#8217;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#8217;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#8217;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting
periods, including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual
reporting period. The Company is evaluating the impact of ASU 2024-03 on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, FASB issued
ASU 2024-03,&#160;<i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i>&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,928</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">329</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text">For the three and six months ended
June 30, 2025 and 2024, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,420</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">547</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,734</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">173</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">346</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">346</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flow information:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">306</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Weighted average remaining lease term:</span></td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-size: 10pt">Operating leases</span></td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: center"><span style="font-size: 10pt">2.1 years</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Finance Leases</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">1.5 years</span></td></tr> </table>Below is information on the weighted average discount rates used at the time that the leases were evaluated:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LesseeLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands) <br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2025 (excluding six months ended June 30, 2025)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">318</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(67</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LesseeLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee lease liability maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LesseeLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure weighted average remaining lease terms and discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.43</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,923</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">240</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, June 30, 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">166</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.36</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit (&#8220;RSU&#8221;) activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the six months ended June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding, January 1, 2025</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Outstanding, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable, June 30, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,928<span></span>
</td>
<td class="nump">$ 72,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 60,257<span></span>
</td>
<td class="nump">$ 73,228<span></span>
</td>
<td class="nump">$ 86,355<span></span>
</td>
<td class="nump">$ 76,990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">5,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">5,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Current annual rent</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term operating leases</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term finance Leases</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates finance Leases</a></td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems', window );"><strong>Schedule of Maturities of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Operating Leases, 2025</a></td>
<td class="nump">$ 318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Leases payments</a></td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, Less imputed interest</a></td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems', window );"><strong>Schedule of Maturities of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Finance Leases, 2025</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Leases, 2026</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Leases, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Leases payments</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Leases, Less imputed interest</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of finance lease liabilities</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=atnm_OperatingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=atnm_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NonRefundablePaymentReceived', window );">Non-refundable payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-refundable payment received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Stock options fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Stock option grant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Cancellation of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Stock options fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AggregateMarketValueOfCommonStock', window );">Public float subject to market conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Base prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetProceedFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise price minimum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price maximum (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation of stock options (in Shares)</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceedFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of common stock..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceedFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Schedule of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending balance</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Restricted Stock Unit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs Outstanding, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Outstanding, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs Outstanding, Cancelled | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Cancelled | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</a></td>
<td class="text">4 years 5 months 15 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Exercisable</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Leases</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Equity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable</Role>
      <ShortName>Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/OtherRevenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/EquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable</Role>
      <ShortName>Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0249439-10q_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable</Role>
      <ShortName>Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20250630.xsd</File>
    <File>atnm-20250630_cal.xml</File>
    <File>atnm-20250630_def.xml</File>
    <File>atnm-20250630_lab.xml</File>
    <File>atnm-20250630_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ea0249439-10q_actinium.htm">ea0249439-10q_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="376">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0249439-10q_actinium.htm": {
   "nsprefix": "atnm",
   "nsuri": "http://www.actiniumpharma.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "atnm-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "atnm-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0249439-10q_actinium.htm"
     ]
    }
   },
   "keyStandard": 192,
   "keyCustom": 18,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 5,
   "hidden": {
    "total": 72,
    "http://fasb.org/us-gaap/2025": 63,
    "http://www.actiniumpharma.com/20250630": 5,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 82,
   "entityCount": 1,
   "segmentCount": 16,
   "elementCount": 510,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 376,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c32",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingencies",
     "longName": "995307 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.actiniumpharma.com/role/Leases",
     "longName": "995308 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:LeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:LeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenue",
     "longName": "995309 - Disclosure - Other Revenue",
     "shortName": "Other Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.actiniumpharma.com/role/Equity",
     "longName": "995310 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.actiniumpharma.com/role/LeasesTables",
     "longName": "996002 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.actiniumpharma.com/role/EquityTables",
     "longName": "996003 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable",
     "longName": "996004 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996005 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996006 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c57",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c57",
      "name": "atnm:MilestonePayment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.actiniumpharma.com/role/LeasesDetails",
     "longName": "996007 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable",
     "longName": "996008 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "atnm:LeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable",
     "longName": "996009 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "shortName": "Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable",
     "longName": "996010 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:LesseeLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:LesseeLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenueDetails",
     "longName": "996011 - Disclosure - Other Revenue (Details)",
     "shortName": "Other Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c60",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c60",
      "name": "atnm:NonRefundablePaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.actiniumpharma.com/role/EquityDetails",
     "longName": "996012 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c14",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996013 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
     "longName": "996014 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c77",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c77",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable",
     "longName": "996015 - Disclosure - Equity - Schedule of Warrant Activity (Details)",
     "shortName": "Equity - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c78",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0249439-10q_actinium.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r70",
      "r350"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r487",
      "r806"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r694",
      "r695",
      "r696",
      "r697",
      "r749",
      "r808"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r716"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_AggregateMarketValueOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "AggregateMarketValueOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public float subject to market conditions",
        "documentation": "Amount of aggregate market value of common stock.",
        "label": "Aggregate Market Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r529",
      "r540",
      "r556",
      "r591"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r583",
      "r592",
      "r596",
      "r604"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r238",
      "r247"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r57",
      "r71",
      "r91",
      "r92",
      "r93",
      "r121",
      "r128",
      "r141",
      "r142",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r263",
      "r265",
      "r306",
      "r340",
      "r341",
      "r344",
      "r402",
      "r466",
      "r467",
      "r470",
      "r487",
      "r492",
      "r493",
      "r505",
      "r709",
      "r710",
      "r766"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r75",
      "r91",
      "r92",
      "r93",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r263",
      "r265",
      "r306",
      "r487",
      "r709",
      "r710",
      "r766"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation - Unaudited Interim Financial Information",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r521",
      "r533"
     ]
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital on Demand Sales Agreement [Member]",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r449"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r90"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r39"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r123",
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r291",
      "r371",
      "r372",
      "r373",
      "r374",
      "r471",
      "r627",
      "r688",
      "r690"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r345",
      "r389"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r152",
      "r153",
      "r443",
      "r704",
      "r706"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r694",
      "r695",
      "r697",
      "r749",
      "r805",
      "r808"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r390"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r390",
      "r408",
      "r808",
      "r809"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 31,195,891 shares issued and outstanding, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r170",
      "r176",
      "r347",
      "r487"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r459"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term license revenue deferred",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r198"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r560"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expenses",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r84",
      "r121",
      "r132",
      "r142",
      "r453",
      "r466",
      "r467"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r379",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422",
      "r423",
      "r433",
      "r434",
      "r435",
      "r436",
      "r450",
      "r451",
      "r452",
      "r480",
      "r481",
      "r495",
      "r497",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r745",
      "r746",
      "r747",
      "r748",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r379",
      "r381",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422",
      "r423",
      "r433",
      "r434",
      "r435",
      "r436",
      "r450",
      "r451",
      "r452",
      "r480",
      "r481",
      "r495",
      "r497",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r745",
      "r746",
      "r747",
      "r748",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r760",
      "r761"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r560"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533",
      "r584"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533",
      "r584"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r82",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r113",
      "r115",
      "r116",
      "r117",
      "r120",
      "r168",
      "r237",
      "r258",
      "r261",
      "r303",
      "r304",
      "r339",
      "r354",
      "r460"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r82",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r115",
      "r116",
      "r117",
      "r120",
      "r168",
      "r237",
      "r258",
      "r261",
      "r303",
      "r304",
      "r339",
      "r354",
      "r460"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r119"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average term",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r63",
      "r64",
      "r65",
      "r78",
      "r79",
      "r80",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r122",
      "r149",
      "r150",
      "r151",
      "r167",
      "r186",
      "r237",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r334",
      "r353",
      "r364",
      "r365",
      "r366",
      "r376",
      "r426"
     ]
    },
    "atnm_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options fair value",
        "label": "Equity, Fair Value Disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r751",
      "r759"
     ]
    },
    "atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "EquityScheduleofRestrictedStockUnitActivityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r526",
      "r537",
      "r553",
      "r588"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r523",
      "r534",
      "r550",
      "r585"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r326",
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r327"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of finance lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r331"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases current liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance Leases payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2026",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2027",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2025",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance Leases, Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r327"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-to-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r326",
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates finance Leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term finance Leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r486"
     ]
    },
    "atnm_FinanceLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "FinanceLeasesMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases [Member]",
        "label": "Finance Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r592"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r520",
      "r544"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r411"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r518",
      "r521",
      "r533"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r89",
      "r251",
      "r252"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r684"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r583",
      "r592",
      "r596",
      "r604"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r608"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r608"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r522",
      "r608"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r88"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income - net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r131",
      "r142",
      "r466",
      "r642"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r629"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r486"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "LeasesScheduleofMaturitiesofLeaseLiabilitiesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases - Schedule of Maturities of Lease Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "LeasesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for leases liability.",
        "label": "Leases Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "atnm_LesseeLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "LesseeLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "documentation": "Tabular disclosure of lessee lease liability maturity.",
        "label": "Lessee Lease Liability Maturity Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Leases payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r689",
      "r693",
      "r775"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating Leases, Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r91",
      "r92",
      "r93",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r264",
      "r265",
      "r266",
      "r306",
      "r388",
      "r462",
      "r470",
      "r505",
      "r709",
      "r766",
      "r767"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r52",
      "r349",
      "r487",
      "r492",
      "r493",
      "r688",
      "r692",
      "r703",
      "r762"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r68",
      "r91",
      "r92",
      "r93",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r264",
      "r265",
      "r266",
      "r306",
      "r487",
      "r709",
      "r766",
      "r767"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LicenseRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "LicenseRevenuePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Revenue",
        "documentation": "Disclosure of accounting policy for license revenue.",
        "label": "License Revenue Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r155",
      "r156",
      "r157",
      "r200",
      "r230",
      "r231",
      "r232",
      "r248",
      "r305",
      "r337",
      "r362",
      "r363",
      "r369",
      "r380",
      "r381",
      "r429",
      "r430",
      "r431",
      "r432",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r469",
      "r471",
      "r474",
      "r476",
      "r477",
      "r478",
      "r482",
      "r483",
      "r484",
      "r485",
      "r489",
      "r711",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "atnm_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r155",
      "r156",
      "r157",
      "r200",
      "r230",
      "r231",
      "r232",
      "r248",
      "r305",
      "r337",
      "r362",
      "r363",
      "r369",
      "r380",
      "r381",
      "r429",
      "r430",
      "r431",
      "r432",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r469",
      "r471",
      "r474",
      "r476",
      "r477",
      "r478",
      "r482",
      "r483",
      "r484",
      "r489",
      "r711",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "atnm_NatureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "documentation": "Disclosure of accounting policy for nature of business.",
        "label": "Nature Of Business Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in/provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in/provided by financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r41",
      "r53",
      "r65",
      "r66",
      "r76",
      "r77",
      "r80",
      "r91",
      "r92",
      "r93",
      "r94",
      "r98",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r114",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r171",
      "r173",
      "r177",
      "r237",
      "r258",
      "r261",
      "r304",
      "r306",
      "r352",
      "r409",
      "r424",
      "r425",
      "r455",
      "r457",
      "r458",
      "r503",
      "r709"
     ]
    },
    "atnm_NetProceedFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "NetProceedFromIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock.",
        "documentation": "Net proceeds from issuance of common stock..",
        "label": "Net Proceed From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_NetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "NetSalesPercentage",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales percentage",
        "documentation": "Net sales percentage.",
        "label": "Net Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r546",
      "r547",
      "r548",
      "r549"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r530",
      "r541",
      "r557",
      "r583",
      "r592"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "atnm_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payment received",
        "documentation": "Represents the amount of non-refundable payment received",
        "label": "Non Refundable Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r455",
      "r458",
      "r463",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease obligations",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r327"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r486"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r486"
     ]
    },
    "atnm_OperatingLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "OperatingLeasesMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases [Member]",
        "label": "Operating Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "atnm_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Other Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_OtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "OtherRevenueTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "documentation": "The entire disclosure for other revenue.",
        "label": "Other Revenue Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r528",
      "r539",
      "r555",
      "r590"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r531",
      "r542",
      "r558",
      "r593"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r531",
      "r542",
      "r558",
      "r593"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current annual rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r178"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r390"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r178"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r390",
      "r408",
      "r808",
      "r809"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r170",
      "r175",
      "r346",
      "r487"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of shares of common stock, net of costs",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r448",
      "r454",
      "r457",
      "r458",
      "r472",
      "r473",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r628",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r707",
      "r708",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r338",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r448",
      "r454",
      "r457",
      "r458",
      "r472",
      "r473",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r628",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r707",
      "r708",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation of $985 and $891",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r332",
      "r343",
      "r351",
      "r487"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r155",
      "r156",
      "r157",
      "r199",
      "r200",
      "r230",
      "r231",
      "r232",
      "r236",
      "r248",
      "r305",
      "r335",
      "r336",
      "r337",
      "r362",
      "r363",
      "r369",
      "r380",
      "r381",
      "r429",
      "r430",
      "r431",
      "r432",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r469",
      "r471",
      "r474",
      "r476",
      "r477",
      "r478",
      "r482",
      "r483",
      "r484",
      "r485",
      "r489",
      "r497",
      "r705",
      "r711",
      "r752",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r154",
      "r155",
      "r156",
      "r157",
      "r199",
      "r200",
      "r230",
      "r231",
      "r232",
      "r236",
      "r248",
      "r305",
      "r335",
      "r336",
      "r337",
      "r362",
      "r363",
      "r369",
      "r380",
      "r381",
      "r429",
      "r430",
      "r431",
      "r432",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r445",
      "r469",
      "r471",
      "r474",
      "r476",
      "r477",
      "r478",
      "r482",
      "r483",
      "r484",
      "r485",
      "r489",
      "r497",
      "r705",
      "r711",
      "r752",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r523",
      "r534",
      "r550",
      "r585"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, net of reimbursements",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r446",
      "r455",
      "r456",
      "r466",
      "r774"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r524",
      "r535",
      "r551",
      "r586"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r525",
      "r536",
      "r552",
      "r587"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r532",
      "r543",
      "r559",
      "r594"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash \u2013 long term",
        "verboseLabel": "Restricted cash \u2013 long-term",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r631",
      "r685"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "netLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r44",
      "r348",
      "r367",
      "r368",
      "r375",
      "r391",
      "r487"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r149",
      "r150",
      "r151",
      "r167",
      "r237",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r292",
      "r294",
      "r295",
      "r297",
      "r302",
      "r315",
      "r316",
      "r364",
      "r366",
      "r376",
      "r808"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r447"
     ]
    },
    "atnm_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r81",
      "r91",
      "r92",
      "r93",
      "r121",
      "r129",
      "r130",
      "r140",
      "r142",
      "r144",
      "r145",
      "r146",
      "r148",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r306",
      "r340",
      "r342",
      "r466",
      "r479",
      "r492",
      "r493",
      "r709"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r486"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r486"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of shares (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "atnm_ScheduleOfWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rates",
        "documentation": "Tabular disclosure weighted average remaining lease terms and discount rates.",
        "label": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rates Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r145",
      "r464",
      "r465",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "RSUs Outstanding, Beginning balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Unit Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "verboseLabel": "Stock option grant (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "terseLabel": "Aggregate Intrinsic Value Exercisable",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Outstanding, Ending balance",
        "terseLabel": "Number of Warrants Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance",
        "documentation": "Weighted average remaining contractual term for portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Cancelled",
        "terseLabel": "Cancellation of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "verboseLabel": "Issuance of stock options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r208",
      "r227",
      "r228",
      "r229",
      "r230",
      "r233",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20250630",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "terseLabel": "Weighted Average Exercise Price Exercisable",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r715"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r32",
      "r33",
      "r63",
      "r64",
      "r65",
      "r78",
      "r79",
      "r80",
      "r95",
      "r96",
      "r97",
      "r99",
      "r106",
      "r108",
      "r110",
      "r122",
      "r149",
      "r150",
      "r151",
      "r167",
      "r186",
      "r237",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r334",
      "r353",
      "r364",
      "r365",
      "r366",
      "r376",
      "r426"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r169",
      "r170",
      "r172",
      "r174",
      "r316",
      "r338",
      "r370",
      "r377",
      "r378",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r457",
      "r458",
      "r498",
      "r807"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r147",
      "r169",
      "r170",
      "r172",
      "r174",
      "r316",
      "r338",
      "r370",
      "r377",
      "r378",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r457",
      "r458",
      "r498",
      "r807"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r538",
      "r554",
      "r589"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base prospectus",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r371",
      "r426",
      "r438"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)",
        "verboseLabel": "Number of Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r214"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28",
      "r29",
      "r44",
      "r376",
      "r426",
      "r438",
      "r504"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of stock options",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29",
      "r32",
      "r33",
      "r44"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price minimum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price maximum (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r744"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r42",
      "r392",
      "r408",
      "r427",
      "r428",
      "r487",
      "r505",
      "r688",
      "r691",
      "r692",
      "r703",
      "r762",
      "r808"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r124",
      "r125",
      "r126",
      "r127",
      "r340",
      "r342",
      "r461"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r117"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001213900-25-073743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-073743-xbrl.zip
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M;*-C,#47GXTI!,<'![NE?$%,16UA:6JB$,]B,!T1)B:OV6&!-RY0 S/PX9I
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M%C*AZ$'Z2K4=1$T9.B4N,MMH0>ZM0&/,8-71DK<SA77,U7 CK<,G#SSZ8,*
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M&=S$Y"S"BNM[TFUB&)^;<99?8ZZMWI.ST+()",3Z:C!V\:J9CNZEB+2ABIY
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M#(S#[50#_[ECZ5L+'!=Z@'S#+G]Z%HZG2W<B?T")R^Q/-2[%M*^MQ%G> +H
MBQP6);:R/UT!9F!3EJV"X%<2NV)1K^<AMY9-U8<%)W<M-#,"Q]_IQ632W"['
ML%U_C_YD+_[.WN;/8_R >?78/J;,:O1K6&#G= AL!E.TNR1<CM^\ 5*N(0C
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M0E,.1K-3ZJ$;SA=DZ,X3K,!(,^?8JKZ>#@F 9?#FQI'K5 <%!AI)S=:E!2J
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M#3B@SLBT#6C1FO@8[DZ=L^)K;&^MN++ )0J[M5EC?QTK7G9>6RL.J#,P+TC
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MUYNWRPA=9T&2K])LC3XMUD_0(;HKBLUW3Y]^^/#ALR7Y)E]&&<[3;;;$.?P
M'1Z2"<LI3S(,$WZ'7F81.M[>HJ-OT;-OO_OB"_(_].[Z!'U^]/E7;,A__#6.
MDE]O@APC G>2_^V3VDH/-UG\69K=/OW\Z.B+I^6'G[ OOWN 'S2^__ %_?K9
M\^?/G]+?5I_FD>A#,NVSI__[YO7;Y1U>!X=1DA=!LH0%\NB[G/[P=;H,"DK)
M7KB0] OXUV'YV2'\Z/#9YX=?//OL(0\_871#Z*]9&N,KO$(4\N^*QPW^VR=Y
MM-[$ !#]V5V&5V) XBQ["N.?)O@62 ^+/(=%GGT-B_R)__AU<(/C3Q!\^>[J
M7(K3\\9<;-#3L>$LNC 6IO 5.]@ LAC^]9I P.& KQ2,HY-P,:GA@A\*G(1X
MQQF8.5TVOHE!+-*L'$@7_MLGV_SP-@@V_S[.<USD)]LLPTG1)4I.H*&0K(+\
MAH+#!SZ%??$4QT5>_N00?D*I(YZ;<:4$$J!H@%GNT4\,"%*D11!S1O1C]^_X
M)J:[C'P%!PQ.#M^]_>3OUS )XM\@-N*O3^E$?V_">YPU*1MDRW)=\M<>@/D7
M3Y<IV;:;XC"N@[W*TG4/3XI4A=;3OP_B_R2,!Z \<%O)YOFP5\[7'4.M./HZ
M"FZB."HB/-&V%BS@8V]WP=#:X+5A?L5 SJ>Z2$BPM-[OM?FF$POG.[^VME((
MYLC\'JX// W>%NGRU[LT#HF6??;;-BH>1V:[8 $?IT$7#*4@U#__KS]]^_FS
M;_Z"V+":7'B1##G#Z@(B0??IWT>F^P9G41J^+8*L,*?^D8#\+X(8WBT[*N\9
MB8^:>W%$(I\EH3F)G^F0>/\$^=DX^L]Q$DY^_O4N-_J>-+D-A2#I7I$H2,(9
MGY2ZC)9<K'+2[+07+<'+L^+?EUD:;I?%(GN+L_MHB8\?(BW]BHRM"1GYUT[
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M.<38Z\R\JS;HNDWF-[7?RNVUWWDN_6)DH]6PRMI&H7&-E*XP1:BM: 7G^KP
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MTZE.TKR8]'4F6\6'QUH"BX;^6%7%YP7AR4MK'41P"2 Z*;K&V9J=*K#7X#I
M5T'A.="@A\/UPT-%FN'=2^GLTW0$%*_A^GX20J&9>SV/ C]*7@G;E790M7]Y
MUV,GJB3MB;(BU&LY5^"5X$@DZ&4]3H8FX<TFGDG*/5FHC!CG 6IT??(K.+47
MJW<YIN&A$Q:,TEW5JWPI ),Y@.IEHJ ++LQP6*2'$+/5CC?V+GP:[):)81]I
M1A+(,EMCFKM0M9)[0Y\"FKZFDT38Y'5)/ N9A(4RP1)A;A,'2)/G@RA\F6;,
MW)"?)\P\<9Y<W^$W9"WRO(/7WV+5.%BEA1LD#[51%G(>L#8&U%I)0 &;'9*!
MZ/10C 1R8=>[%>"@[(BOE_IEHTM.]0X=C=ZV+L>F&CI1%+QD$?=GJ1B0W@>&
M(,8Z;;X^_#Y0U4R4OSK:L>]C7<M\WD4R544QS45]A_/+0;,1.4E8_TSN<3G/
M^ZYT"76,S27T0+U($^KB9F5P)(]?R94M&^O\%I8 (NOMFR:'5%QXI:-'3YGZ
M.O2O+CX5BE99 JV71[ZX8:%KY\G9PY+61R5W+)6[Q4T<W=(GB9E&-VP%5Z:T
MX:#*DDWHFS5=U=ZL*.7S@O:&^<Q4O6-Z6[J;W)_>-HI@['):!E/6V@S<6EJX
MLIN"GD,@<6ZY&0"LGN79N\]S!,%H!/T.)-B0&'*-I8563P\"+H;#0R2Z+:P]
M5O'7WM7,P=)@*M5R,MF8FG;!8JTVV)73DRY$79['25@Z/*F_4^5+EJ@G(R[G
M[(P>&7 W'F@/6O7XHE0I-"-3WS(4IG=M(TU=?S:G6KDV6!(YKF0WX+*;5;++
M]&VR_-J?HFW,PTH&S0@S4AQ%[Z+/)K6":BSOPWQE"N0049VS$55?.N3F54WJ
M6<MS75UQ+LV&B[N.)#(#;Y 4K\0*LW<WOIT(6Q!NG#N_H5D,N>[%$_F\Z840
MZ<I<6*JA&8SVUIS!F&6RVUU.C&DN]OIZEYBP>?2<%^/E9W>Q"X"T$T_YE3ZW
M&UTA%MHWNHQL4]SHTXNQX>(SNM''$U_973ZOJUQ3=BTH9IW)DN>X93=[$Q20
M /9H8<HRF,Z=O=40,@U;%!\8L<X@S/ST6A"IYR%[QI2=M<0:(P(-\!6PE22.
MB#*RA:FL(<X6JY=$Y(/X)QR,79-F "!^LG=LP>UUA[%3\P !B7P[Q8:+1S.O
M9Q#11E$(O BW!0 >2N.80ZGE_)J')-O+0&^RB)[D3G8ZGV[Q!;D.KC_@^!Z_
M29/B;NS(4VLP7&NWMH":G,E?^[5-#14)X_-81JZ1$^S<2;/Q\KX#8 =(L. D
M]BR_MLS7/H65\CKE(0RG_?6'U-/96Z[N/G3&$$*3L_8;S_E\EJRW.6/KU!DA
MB<"=@.JN.H]D9FUY%)R<OJ71D+\F)V9+^FQO=C>!LZJ@6+\.@;ZH0%X,$]T'
M\98:KUJ&?F&*J7^COS(DL#>(=;2CS,7!Y=4@;RP^C60FL?#,YJ#2/I:&F-#K
M;17,K.7BD4[]W4(0E*TNLE:K"Y^-+N36;#E>]CULH=+=71J'A*!0@;5XA-K"
M\,,71)3"J@765+5/39?W<369 BF1-#;4L^ICR^]&V5$;>MA+:!41O%L"ZC;B
M)*?I3/7&SF7^GJ/*U-8 ^:M6;0NRAO^0M3%ALZ!R%M_B/IKPB.ON#B+G@)K6
ML.Q->]GC+(/,$=A\+QYWG_#]>/PAR$(.U&);Y$60A$39E 750:5)"(7:!C&$
MUGT^Q<'O& ,/GB /:/:%FG0S36HST'P3]&F4H$?RD,V?H!H !^B,_HEN@AB4
M3:_O*H\[H',5>N"O=4L'X7G5A?>%!-Y7Y$,H"G.)LR@-7V5I/K9380H(O2F-
MX^(A*[BPA2XX] :&"?,#1,?BT._;=4)1Z^S ">@\NOE?HW'<1+B(6L^=Y_F6
M6CR(V.14<4O9'/3P9X+TY \!&D+T@>J="J3<"*;6S7+V@+-E1-O9+L>N5>@2
M<@]-3MQAIZO%E8,0'24X^N>X<<<77Z,-/3*7+)V,@\$L(=G+?6X&O*^7FS,,
M;;=[^>\]W_!6HCSJGC?GUF1/L#Y07Z;9"D?%-MO/G6\*_AY>\X8HVF[^$U#@
MX[CQT-O+[6\IT:,> #8\F^KFUSNKP*#,WOXS,\%TX7/N[Q@; VW32VVD[T#]
MR<1LS->SF-(3/IWUX9G3I3H2U/MH"-7$;: &W=RP^[U;1[\[1^30L$"5 9X6
M.9 R3\O8)6I\8+"'+D\+-$=U><[L2/ C\F/Z.&T9.NB!/0Z\YP2L*,FCY8\0
M*#KC Z$-Z'[O^Q8VLBY6M[<9O@T*C*KO$1T@T\+W>PM+9'&BG2IB@?6&[ F7
MNL(Y66Q)S@4:./4NB8J<@C6+<#Y3Z)RGYXR,@$:DWVY&'O0'<W9#_F88[V<I
M:B;!?S;D'I I9*V\L\C=\X1 NZ4&,AI=?GT7)$(WV%Q>O*9@N]^.CC"3]<5X
M^RYO1NUUHX'VZGUK*:>C/'!M6+('>[FEAM-?GA)%ZF409?2^W]/-WH_7#)U)
MKG#7?233D2@$O1K&,I4:D468C?O_VGFBO5=\'#AZ3'?MINI%XD>B(D&OBSW3
M+%I@?T2:11,S;<V"#9O!"]NAE+K9Y@*&S%*O:,+Y\>@5IGA]3'J%(>ZCZ17_
METZ3F6D5-BR?G5;!(WCV4+'H0OXQG2<=[+3UB[T)<!M?9MWL>S%KYKJS(3;O
MXU$QC)#ZB-X:)GB/IEN(3I*/\2 QVB).SQA]?@]YZ.Q\,^![:=0HN4@+_#[(
MJ/UDD='^F].5M;&&P\/%;PNK3GM+-E98#<2S>]!./B2.0 O"6;5PM=VD%RG?
MC=W=:ER H+E59-U?9P&IRW#7^: ]60$06?T/Y^UGYT#E^HDP'ZC\% >18\!]
M17-1ROL!G6.FJ34VO5DKY16U)WGC@^5O%(U7C^QCO]BF+!^BA9&HBLC;6N40
M=$M5O?TO'S)#:3HRSYN8ZD[B4.DG1[G3$'5 ^QA40@T\1RL?XG;OSD!HI]3G
M=!DW(P6N*C Q?Q5N!^H>>4\TT#'0XLX>-E&VO^X2 S&<^.YM$G\FMIH*J#E>
MOGK .7Q>>474/ANYM8$_@LO72&RGO'[U.3>O#6^0.>EY]YM ^C%HXN9HCVN<
M%>4Y?CPGAH7<.S@^3)D]2<O2=TG9*1Z'9P]+\NGQ&OXULI9N!\.8._LYV]D)
M3?0-52JX%:S:/?1@=A2M-UO8I!&9AF!1S+FI7I^$:+?64Y)NW+Y4CJ3:;.T1
M559]838"4;/QWAQ%V$H,>AM?]8JLC\I2@@)S<[&I*"#T<Y9/@(EV!3=!J-@^
MV5#ZI6W,TD\R0N^1!4Z-B<CKQ26$+J!;/_\/(;(@O7T9P+/U)DX?,:YU8GJ#
M)RB5*5]G?$N7A@=8"HXL5J_6LBM'/[-O_^59)^CE75WVU!C;WO6B&AY7;]]-
M(D+JM9P'?BO!D65NB.K!B.7)AT!I<;,N5/TTF,!XI;&]>^$2W582YGP*Z39/
M/F(>'8U6=;C26XM!S'DFRWGJ\."CH/\SVSPB[LZ<Y+!MSNVC'&X# IDUF#MT
M9[,[A2RI2T,7*Q_]LSI0B,[#,B>A2]N](*R-5LR:1S?,>[EH>\DZ>@M'NNWH
M+0)!TW@KVD7.^WNKB+_K[RW%TB[\KVX<,V&X:)PS150&@9:5T_<;IH_L%:ME
M"-H_>:_)-XM5[=5]_!"-W9Q3O,;()T&L..&% $@DXR2-R>@4=M0]1K4Q*$C"
MQK]IRB(J[H($-0?]#-/[?@\K&5N_*^3$,9>J/"O^?07SZ$H1&5"3(/*OG?0T
MYW(@+8T%I:8/PN*\B)9!C-Z07;C-F"QT6>Z2YT*R X^[*-G:-DYQ%MU3\=[Y
MMJ^B_-<)C@OE4A,HWZJ30P6+1$1V0]!N3%M /!P(.ARLGPN]J-MI%V^BF+P!
MTP1SDZZ6:M$9Y%2-;*\N87SU&=JP[[S&P\OH7.D20JSL>'J!B[<!F>T2$[HG
M17"K%T\J&.8\O*L+@\SEAPN4PY=H4WWJE<%RHE<LEB W9FS1*<Z7640MZ ZB
MB.JKN>X.U@./1&SH9XA,OO9Y]FMRKB^ZIXVN_;.#3D?#EJG7#\IYC-TG0[B$
MAT1=$1P28=E]1:O2^+;?J9C4%!4)AK8'#;^1P,5[U5$1!@M&>W8/,M$"0?84
MW689>W@F$,:;M50*#Q(A84Q=&$2HF<H!N[R@*<)JFX00.LMGO<)+3!324$^]
M4$W@7M%00"-3.=+D,*O&E%HED0,VREOLM@YG=CI('][6D75!543G)$WR*,09
M[Z3!)E\DUUF0Y,%R MW$;&T?U2%, .SME!30.$BO'5ILF-V(-C(FB+5<PAK'
M25BZX\[S?(O#TVU&M"@6ID2+EET22<3D? _;WX\MJD/!<5]$<"#$$G&&.#*T
MR=)\@Y?%-O>=[3J2E#1D? S"6=31H^=\=5J\";)?<4%76JQ.TO4Z3>A"6G=V
M_RS.+^Y>D"3R=KF]B:,E6L5I4*!\>_,+$3M4I&A-IT%$1L*(1M!YN\>U659=
MYGJT&.%&9P'6O%D6%^1S-Q=Z_]+N3T0#Z&2.BX#55LSIN%F%&UMP77*SZQ''
M]H2[P,5EEBXQ#E\2!&!V\,6:GW$Z\[C.>-> 26$7W;"A.0+.HHB/!G%;TO$L
MUOTSW^927>[5[:=:5+$M?;V+/FXDDY_B908FE2DT0=5R'M(O>D"2VLEX_8,-
M?(S641*MMRS%^10\\1DUTK.S[HG?A!Q-%G?4N#ZBC"QRYXE3D:N6FX_(E2!I
MBESPL&\BUV:QCL@UB.*ZP#_DPN>+%?W[V'(Y"DS[4UZ_#K8T_I'Z'1J>*E\:
MX9@2,TK*68=^/MIJT?] SYWJ.3]):_FQ0'/MGQT3>,D>X1_!24^^VMMMHA"D
M47:+C*#\4?/7_W=XB'Y^_^;'K__U\Q?)_=M7C_DW-[]_M7BX>W__["+^Q_>O
MOS_]Y<>[7]X<O?KMR_>+R^7YT_O_S2Z^_O-77__P\"(X^^?K;Y+\^ZOC],OP
MS]G-#]^^_/7;[X]N?OWAP]T7MP]/%R]7FTWZV^(L^N;DEXO/7R;A#[\6KS]_
M_N[#U]\D%U\]7Y[C']^?_7KUC_,W7SZ/BN?_^,?Q_]PN'K[??%@7O]Q=%%^G
M_WS_8G7V3?+Z[O&K,+G]GV>_W[W[\A]GW]^\^NHN?G;S9G&,-\^^P:??_/!P
M]^'F?[_\X?;K7^+SK[Y_>O'[TY=7R[.X.$Z?;U[^]N'YVS!^OWB-B]]^^7'[
MR\7Z?'.=Y7GZKCC:OMA\OKK\]<?-TQO\\INW7_WSR^WVM]<OW_S/%X_?//O\
MA^W)L_,_+TZ_^.E]\OWC]9?%Z0^;-XNC-U]O[O[W_N;NUW]^_=7=]NKT]CK.
MOKK,?KC_)OWGK\'Z_?G1YW>O7Y[^\LV[KWY?;F_O_YR]?/FX?'6VW?[SV?;5
M]?=7+Y+';W^ZP5_^>'?TMW^AD[=7AX>6AAI6Y*;JOW$:Y<LXA5C(D<\C^3H>
M7"I28)19LF5^]PH:S-S#0-]YLGV\:^3)*G%V7A.C N28/,77C+*GO&;'RS2[
M3//BGAT[99X9?#&72](2^KVY1^WPDT71\H$H:P7"[--%.TQ>1[F+!S#%/KJ+
M@G+3#^V-#K1G#^"PPU0'GT3AG0907RTA)L%&'J]&OT%QM,)^\N3<B5QG.TY'
MZ5E<K"58/Z90LP8*9%V!XX_96N=\IZH!W^OK5(E:WR:]KP:5%O,9;%FGTCK9
MC=K/EX&7Z<2 ,FOV'FYJ#OC'N*D9:B:;FHWX^#=U4UI=;^H:7V:VJ4^C^RC$
M20A@[L->;L"[1[7_=''JV[LA_S;?6TNRJ31.OE<[Y!_B)Y?$3XH!KYJB3^%"
MMX3$3^BN';"R'!A5U4S/5]UP&>GXX ?0;H!+\CBFO\>A>!W87,GHL2&:B_JH
MMJ4'FK2 R.Y+A-FG?@75C+UUF30@A'5-]ZH6)\[NHZ5$U"_2!,R4F/D6\^NT
M".+Z[T_2O+A(BY\PY!:EMTGT.P]OYU5*QW9,.8'9]:O&"5:27?,NR:K/(6I4
MM86\EI=U(:7"4K63,V6$NLECP\BN0)I*2G\$WXWM W ,O _/M5,,^WH5!;Q7
MD>^:"'Z$ULG6EO/%UK,PW2E4S<0&T:)JUW=!LF\7=Q\>'\]EWH.IZ07_49X!
MNF+MYJ;7X9AE?=B+ #HP+%8OMGF4X#R_3.-H^<C^>XT?BA>Q=EJ4UDSNS(3Z
M0,DRH^A8,%J4H_TUZ#1BTR[_21O[ <8'(I@1Q%8O:4P*V#WZ16CP/:"YJ _C
M@QYH\B3W* >1NR2P0<DO^H0Z1.^28!N"J0B=0PNO:(U8*=DHB,E/5FFV]GX6
MF\E!_> TH)BUE0**1I#Y0DJF:653N90/B50!)$M^SR(B7!LHET>$L3&!;V>'
M#B?KTM6+O;5,O<O)V7J6%Q'9?'AL3;<UN7-70'-]F5*8T_NQ^LRW;(@Y4I<&
M 5I#<H'P+:N'M$DS5U>?WIH>W+$Z<,EB[=G8N5QE1FQM^("T:6#IUSP)\KOC
M)(0_(+;_/HBA5MNN*XOX]PR L:^Y(:!XL*(-@5?JW,SOH'5D?H=J0VBA^5K_
M)?B]UXSB,82F<:,.I>2P K:L>\*TAZQJ)?='JP(:5=E:S_YU#6YU"];*D;0\
M,:MHDUJY?Q?7M/ZZKBV+VI#)>J] *AR=H-Y"P:^L&7.YT4W:B"#V;K8K?(^3
M+89:-.114F3!LG@?%7<GV[Q(USB;5AX-%W<ME&;@23M2TDE0S6WB^T5BQ_-F
MRSUCRMB+:*,13KVG3,LV,[K)1'-9'WJC)FRF_8B\U VTY7/3H&) $%M5[U5Z
MC[.$3IOG45Y &.&T!Z3.BA[$3P,LB>2]H@T/^?'A]WHVX&9=TG1QMZI/_CI:
M0EP2IX^-QTL]@]O6>4I89(\$-J8C(JZ=6UJ<J)Q:_9@.T=!R3*"&U^LIF3].
M-R!\/$QRDIM/9T4/IXX&6/*NX'0DM8+4QB+P;'LW$!LPN-7V6(L<XR;^,O<^
M6?,\@?8_Y+:])*2>QIIG \$\LO:4,,KLS3#3(9T*E0TOO!J<[?G?GY+33Z !
MD:-!EA"%#SI4T<6G5='Z5G,>HZ6&1U%Q]W6:YX@,0ZP4+:OE[#622H^1C7@G
M#>SM)>L"?Z@]*+(T(7]=LH>3"_.=\?(^'/NF0$JO;#@7XD=T'*8;\%CL)D7-
M67U?W[9"41=;*Z+9]54L"<NRPM2KFCT][&9VWGO!"LP^*663:0BIZW?,('97
M[QM[FED]@T^"350$\2(YQ6NBLM-^D\>W&:;+&'2/UYG'=55\#9BDGETZ$I&K
MF8U%=#"J1L^BY;P![RKQTJ6)H;L-.E7ST@HBH1'?QSW=PYOS.12>SN*RCL&\
MBKA(%EP*@Y3X90_Q+C)#@IYVB6?ZK#9YBG;F]UIE7BD!K$@HC\/W?2;T,DA2
M,G[@KF=5DL;;]8WY7._Z^N+2/N')?':]B/C5KN\@8['K82*B>H3;99$?D_N"
M);?DI^DZB+2Z./6P6S[WZ+L^EC!="H(T.)I^3RV<? #ZF8WPM?6UN%3*A1K?
M 461BJ"@:L0U] H=_59H3#ZV=T4D&^*EI3<!_PC]3#_[EU=[HI 3S>._@],@
ME8#/]CI*\#GYZ_A=,#L+3/"8U1*""H)^08!/$?W6VR71SR&A5#21M*\-0NN/
M@S$Z3<BL^I>&B5%8N,;(IF"59 @!D-4.H]^BZN/NO>&MI+R$2]UR\B),[2^-
MXZ2(PBC>@E_B+5YNLZB(<'X1K/$DTM*[G!.M0Q<:66?GVC"T&W> 8*10%?%2
MMDB3LXV"13H$L:T)M[S#X1::38I7.7M8QMN0]0H$&=^R[,O%JNWHF$2]&1<X
MUY?CJ- ;2/WC 2KG1F>7;]%)$"^WO-I<6P_S<^].(G2-.WM\VEO?]P,AF$I[
M' VL&5P.YE#+]%0N-Y# >0K+D"W4<$W3661*[&SN$WOAZK]W+&EM>3_1U)<R
MQ'L;Q-!/8!(=2+&00[59#H4JIPG51B 8(E!WO.0Z]?&NF>JD1-VRE M+G2JW
M=;IZ ]4_J!RG*_J[UU%P W6PR4].<1%$<2[09&2QKK:3.Y"H00 J$^C0(:H?
MD[LYX5],'FO3HD_YQ$_\ZAZC2,,NWG8(8>WB)G8JS6ZQ16<QB;8@$6#3.9U<
M]3:0:5SG?7(Z!\/4$$97LFE#NBE;O^;*EIK79(GC)(3HR\GL&Y. Z-38/@$"
ML@<E#$ P0F0SF4T8\#CR952ZWY;&%GN+[F-F6-S=,;M: M1-_2Z)BN,ET<W)
M1\::B^W<XWN>I3> )8AJ&W-3=:G5HV Q"S I*F=5:"ZNKX2!HE!=#4-H:FM@
MM.V(,9G7;#A #A^$PZ'54(UZ]H%0,YKC3: M2J.T;!%I4%;IY7&0$P7M?0!+
M%HOL"FI*3Z('J59R:L53 "*+/841(*M\#$HS1$?-PEFHP<)&LG@/^K9UL$33
M3N&742SD\&B40V$N0QW+Q&RD2.KBZ$%_Y/-HJMNX9S$W^J8>,!H7:2E8L[LZ
M]7C:*U[=*\\T:O(*;M71PF+KLSGR[K:65<0[17D1+8.X7@]J#A&1 @Z4,9!M
MO"SOH?J;F3R)+](DV/WDFOPM#UA']DDBY4U7=^N^- /.M'P.C;ZM_YM6Q4?%
M79"@YJ!9.(@L!:7AH[0@J*58G^(LNJ?4*[U48/.91%%7+N4XC$4%BT0^=T,J
MS^0LU'0=#M:%JQ=U.T\.L\)8VNP$YCB7]CA]4YO*[^?)@*9A&Q,ZZP9HT=2>
M,K'RW%K#_1.L"8!:+.;@9M/BD4 9%N Y_@,E3)?;==GE0K01CV]O,WQ+NW9G
MO^*"%NE<K%C-# HA '8D<NVL(6L:WBE!.05:TSG0/:U<2GZS9*4W:$?:SSQZ
MZGN1[.Q?3;*,KN[U\HO%"C2RTD7<N;[#""K19!B%4;Z,4W@TH%6:H9B%7<3<
M>?OXF<^3M(6-)#*BA>W8OE(-FE=UDTN?]R/WAC_2L[V?'<'--@ZR.B_(]HCI
MO(PC.X:07<2F_LR+.FV(L8!E9L0:^8+I9V9?<3L1_TX;? MV=3$V=#S;6+S6
M7\9F]LF]<:O]'4VA&?;RZ4U$MD>1)IA[250G75#=1>MR%-JP85Z/MS8.'=J+
MD?2@!FCW,;/='4G5ZNV&+^%3(9BXV9O[4^T"%Y=9NL0LDAH*VT E5RU%#B+2
M-VQLCH!&*.+#.RK<9UY#V31P[+),ER[.E0H"&:T,<XDSJ$84W&(5@W):&V=3
M?>N=$RW81807HN=>8[Y(DRN\VB8A*!_\G(4*4-$]#F4DO\(;UATP1T7C?DG2
MY#"K9BLO&7+GL_G\<D6!:)<_O51QSREJ7^9ZR( 73DK-U/[5,"$Z'48HD/:@
M!UB71K/1"\AQ5@01I/F@(D4)_M#XIK$B>!T*\C)Z1-%Z Q;@@K._>/RO8)/F
M?R%75]6N,RN;@WV&SA.:7Y0?$+6C(!<;V< %T=37M-%GD1Z@W\B%4$2K:,DR
M&@F<=.:'#:813$2<>"8,6_<S;U%[GDO?^3@/=K'G[S$XC G ]S@C5\D57C.Y
MH<],R.T!=PV(&Z!S!7T'K=_E'_A2*&!K$6GBB_&'>@'+4=]8R!=$&:SH\:09
MCU =@1F;!SZ>DM9!>1=E:6=F;CY/\B*C2^5G#T2OB7) 4$:75O:93 3?R^5M
M64O$ ZFCMQOK;8[H"0<5T9A2@E)>("W=%M#%(833SV_BR1R(WA7G.4#E[3R=
M#'D<ME O?WZ914OIPZ;F0E@2T*&J (93=;7"&8;WYPTN/F"<H!7T0ZN\"D1I
MQ5G\"#LD!W!SJ"$:PH$#O\5\97I"5__8 !SP77VOE+\-T:=D8]&YR.01T3:(
M<!,\"#1/4)00W82MX]-BX8MW#G>0CA Y?Z9/@"[M&F2W8^#1TU%0;F&^0]@
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M)SX(\5&H8R7T>AF/7!OGF6O_$Q6=FW[INI$\J\RSU;2LA4-?R36P#E#GXJ]
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M*O:9?YH_J!N"*.SM/-VS!_[:+HMQ0EK<V6J%U>_Y@[89KF.K.Z#&NK8!KSZ
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M9&2S>.I%+H9&(RN&C]Q9#[NY,/XR87I8)6H#KB"$R]=/TX!Q!4K28O4NQ_1
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M4B/Q"F*:;;B8C*N TYTE2@9XBL5:2JI?*[<<-;BX&,8#*_>\/9->B7F5B9L
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M;!MW3^RW0%_'>^B^V^^%B0 982SO3^S"=$X7Y@ N#-"HQDQX%6?: .PL69N
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MWCU3YYNTE26/[PBL"=A-!D//=4D,I3M8;"MR)0=?L?3(VUIW;Z \Z\KN-$R
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M.R$X1S?;2M@L C0*F@B28^A,?GETOWB.$)5YT=FN[]RG?K<';,LR_#&[&VG
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MXJN1OV[YVA&6BUZY*;Z:^:N8KQU?^:B7FR*LE;^F>4B-]TY*YFDS;T3)5-5
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MY;(KU0(X'B?\,K=JSP5^F$[82-4RX]!EVG%UU\TDT_)#_X5$?](8[-=C5B!
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ML)ZJ6:PW=D(3I]96K][UL_56IHE^O_F4"L-ZYNXIDG@LIM":M>QWOC,8:6+
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M@@7F.<8 F\7@ T?KE$ ^@/^["@]X'QP-/^A9>OP/D2=%Z_79?+RK'P/31Q3
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M "*=)X(24'V?>")Q3A->(&!NP/=I>T^:8;D>>]:4W!5T*)=SI=VGPXLH/;,
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MC%0XQT4,410/)['P#"@GD3U1:G7X[#O)](#@BHIH4'A(512N(G!R?!++B0;
MZ$ 7Q6,6-#;4#"?<EP(98,4W)9<6(!0G%"%EE"]T"[E>#NZ=^HIBJ>I%!NHK
MDM$_\P4O**!>PZ:@ 1!LW8S09>[(]DU *[Y((S*'[_S7MT3D+Z!S]8J5OA^B
M2.DX DG#47\"M@<R+KRE$6VPVO[HLIYEH3)QSR>VXZ%,5_3]CP"L>& F5+S/
M *YQ'P1DO2HFB+\> 1.:WP#\)6*E6MVY6+D+V2].!(QNM!"*C+X2/H/H ZA'
M T41N]/#.J=(3&L!8=Q$'9 K?1,%EPNJQ2X97G:RFN%=Z_ LQ5N3#J6IIL%X
M4[R1[097??;)EY&-0LY^P;OC^GW7T U@$WRO*E6M'4_RRDCRWUTPBZ_@16@U
MN#$B;^Z<R+\+7 3;84C8I0+2@=!2-.6S\')@O8+7HL0UE 45BE8I<-V(2"J@
M<:O]SAD/]D?]IL'&&@M56ZKJE-@JA0?2/J<I&KZ<YID\ @"SH>A2HJDKZ7')
M\0KI=+Y%>PB:UNMDX$:>(U6/9">J+F1D*@DX($DEK#O%1>#V% )P'( @F/,<
M9KH<#_P)87FO(+/2WJA5=GYGY![C-@1='+@V!<G29+=4)#-T\KBHCO)H"U52
MH/&49$.Z<DW%IB>^,[%='I"OZTHRH5>B0DX7P01PB/6 9&S?&7"A@!9F&>M@
M9/!AY/68K80*.%TO!\45RH]+>NKJ!^B1I)#=#H<&&.9H-^,,KV>#OZ!PPO0,
M>:>D&(O=C;YFT@Y!@X5'2*T.IGZ184&4/9[8EF(*<TNXL6F\<MOPP,?%OB!U
MP8K*6!(0TL>@ZKJ>0QIF(7Q(.78P_4 &F8N)T < D98]!SI<),!,R \B."HN
M1E*A9P8PU$)U(&8_'>7ECL<"9(+;J@2XV9(&NNYI8P%9WA'C)+N7OB)WEQ(>
M(ENC&Q/N7WP>:IR*P9 )J'/T@0$M24^@:< Z>JAQD8RU'>.)'*YC='@+X4<"
MS^&<C<7H7J!\DXNQ?& 98;I5(9).7(Z]&90TL//&MDLV(5WGF?1C<A[@TF!\
M WQ^A^LOMT0WWS'(E3EDWQ_8(]:K^&!SD@E59C\+[N&R$4<K;5J(Z(ET5;SI
M!%V09#K"K4=+$I?ZPG6Z]9^!J;H&<F=8E?C0I0VW62HR!OZ5HQX *DCR#9O[
M?8OAMY0FUMZV,/_R);D'G5/N@<P]:)]R#[9!^' OI7C1@BSMG./.-2$1\@IB
MKXJ<+U6%!R.N^R9VE$F48(^H.";JQ-CI?06P<A',"E@Y2?F=TAC*LZ$-JMD+
M*F84B'7#0'QR'?"BFAHUZQZ=*$UZ:,ZU\B&0-%&D[-EGMVWZJ.=)'S6@#V$K
M871/)I/^]:P2#"J7<F, 2-4F+O!-]5,P"KQ:J?PD4M'3P5FNZ$XT;)& \/[Q
M\6S#N?$K$N #O*V6?N=D*]B^"X3FYMPL(V'^^XJ-*UFZ>M_!+?G4=]YWZ:YL
MVBQB.VUHMWEXQ1#$>X$K!$!HY .$[:9TRPO4;OV42+8R:9MB\3,\<_9TNQ\
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M*@J,.-"YT$SA&?0M:.@8  41R$6+LF6U,@@. 8XH<\#B:3BQ!8JZ%U8:X28
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MM%*EIY"#,^AF)\N9@S235B3-Q'?U6(Y)\ZQ;G<LOP7V;N#,*$*'\\LDV$?A
M++/OY0<LDK1%N?%G+/3O19J$H^-*T<KG7D I0=\ZU=77<%Q/M GP/<,T_E 3
MG>:HH<R^3PA403=$[">EUL$5BD%#J* 5$7RZ!JQKZ4%]PSWJ+G8G(J+:$P^
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MB:*P [V&V@"V# 5%P7?0NR!BFH+&0'=$MWMBYZ>M>-86NW1V\KKU<@#KIQQ
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M>%4A?)54 \RP=3;>9=LIJ^YL!$SQK /"\P6#Q&'#2LG9]<@@P! -Y\2?Z/?
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M 0KBN1;4<F$?DV;FJ&>C(3.EHYRR<SK[5H<+Y<63U:U9QYB^2.K(<$+4E@7
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MVB;3Q#[#(8J1AG3N3/>@@C;30BVO8.4Z8;GTKXA%Z99$\Y+#<ILQ.-F&GE3
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M,<[@G*3J*<M QH43M[[AD:J<HQ@FH+:C7/\1IH)J>C2CG:;C$(ZO\<SS^D]
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M>IZ+89J+E L5/Q8$\G6-<S&9I[@LO&9YNY.T$VSJE\$%-HDI+;B>=R^XWFU
MW._IX/VN6MNMP U[K;CAP$Y@4,*7$'L6I +6G8[""H"Q#FBH[0"=)ZX</#O^
M*,P'-A=\$7AX2(0#2*..<=Q:,KM,,H!#EL_9F.7 X*=S\ADYM,BG!?'"ASNJ
MMQ^ZOV/LS)"3LXBBK<D6NMYOV0U.7^$6=<]'PW#D,-1/2%&IKS<X$$Z/?^L)
MS2C\N,N.*%$B=&4-;6P&T@+FXP3^@8EXD6+];';@A=E6A;];T>T*,R81E3K%
M+\)6"I6*=R$MHB>)"A>QIV'N8?1L*G"IC[&P\Q94 S/.*C3IT59&%"\85Y2,
MY)5AWYU7,<:@CC3(L* C&;5!#>-<*Z;YAMEE=\EE][:Y;)7+?K7-96]F+AO-
M_]9JA;CP&-@,:KPTG,O8J4U, PO5[O86LO$T=^HC9$?,C>WR!VC0-%IZ+H&R
M1K\'U'\3PR<O<A,ZH=Y"(=UNI$F*B/":;,R%(PQJT%V'GJSV[FN)^39[S3/U
M'T&-F;76R V;TGVTL^Z-)D4M#$%V/G_#--T#NU^QY0;\'U6R\CZ^SDHGIG&%
M00=T ;XS.TV  ?!9RB^9*(Y'37ZMP-^BL68<!^+&"EA.ZK>L-/Q5?J+L[\IB
MH2[XN^*F:$N>2:D*SQY68,6(.$'.)3!T\"*[Q$G'E6[($G"1)Q@NY*\CUG<!
MOZ8YMKD\//PN5I_P4\S':\]##'/$=-;"1\U=>4U9.;]24>\+1%1%<FMUZ%1T
MHC(16#H"CDLUBCR,&RIR3NE+H7OJVG6].G^MUH. E_(NSL84W0T0P@T8PM5,
M89NP$&#,6!;>!D^MF+5_(#+GA.=(_$NIJ.[Z)]?PQ,X;S&RI7^I(\LD;W6K.
M<A,U[G<>A465U_I_A!,L+A)N>^*Q%B#(V'2KJS.=&W^[$45NZ75@-8&PXJ[?
MIOZK702FNHOT?O&(BG]C#\$I(:[W6N(DGA4GP96S6N&Z81#7OFJ89FZ4Q$[,
M-PL;\3UTV(HHOU9D\![XJ542DB$F3#9,A)\N&P@JL(&8.5_[S\,E1Z;(Y>1N
M/K7"/GZUFFU"2,1K1%^KJCV$:K,%N*0\4A+E*INQ,C[$]UZC9KFM9-DI1FY4
M,%MK1PED&[==V$,7Y6[N-TSH4@GDTHYS&6V@AZ-2*=J2;,6-EA$W",)K54%2
M\;F4*Z'0270=1XQ[D-6G7@4JO53H#!$!*52.A?/U9/,:&> 9R3ZP?U_QUL&6
M)'91)G5L@C^+A(XH^$)-?1S)@#LY&E4ZXNA$"N&V3HO6IL-J*4-J1](AU<W9
M1-7V!"04ZS 1-B$UQ]RWH,&X).)#\0ET-^$3%.L!JV<8)NQ4S**HM-: 0THJ
M#V!U<Q&\E6D!<G6B.494N;T,H*@59&&76E#[4F(7:HPG/UBB6"))@=@M(RRR
M\=]&6'O$R5;NW:A+TLZMMJ9,\H'?*#Q#X=,+P!*!?VD3Q#TLPNC9JB4PC/P$
M$=5-5MCGX)0.896P5";09UOC0[B)+\;<R"L^ZU\-?M.@ @2)9"3'W&!D$:7<
MP(33Y(P?89RX\9ZI28J=T#\S#Z8(*:K)29;$F=W+Q5.H5A"YB+EG1S%%=.>*
M=5)?&WS&P[&A"4"!@%\AV87BY"C87\&!)*S9*1R*O9=BT[Q+H]FS?!JFDK0M
M:OY^/TEB.G3$SJ]4Q95"(?FFZ)RF#)_5YY$_\VN>58O /QF<_]KI#RY.W]4Y
M_M4G<+27OY__*G\WK7W>127Y].TZ6>VJH1VH#5)]W; /7+TS;84&5M<8%I&F
M+'CLI] &L1SPDT%X9E4ZSB-5ATOSXGY*<>G&56J2T82XL4#ALA\$.SL[N*5<
MK:AL!%38'H/4/I4:,KV$-8+;[8/;!LA9FEK:3#7P:9^K5L##2(',R.^3OD8U
MD?V.E(QK(@<6R8/D$12;@T_60>\7[XU-%('2B!ZXX>\86/?)=QE>(=P>'G"%
MW/-LY)XNC[!\?HEEN 8+%R0;D%6M(Q;58@].V5RPO%1=8B'1!]P<I]3/ 6"U
M;WR-Q$. B\3D\1L6NC<X.OQU'!V><'105PZ'940K@:[]]C:#&5Y;^,_@0QWX
MJ5FAZCH<:71#T"$*@V*\YNPM@8]->SL=2C(MK'@V5,IDA;.L8=ECDAW":]9N
M@E*OU8"[UD//O@.FC-3)4VTL?\7TSF(,7(/*7;A>G!63'37#9QVN(&^H:_UJ
M@?_8/]++ B9AQATD:RNC+UH-[L64Q.$!V_!#LN 9=^7K.M1)QG&ZE !3MB>S
M4A8]U8^;XF48%D^*IK?$S<'Q,S;N^#M2Q2O@+*O0?MK.=ME?[):5U9 8 ] B
M9(X;TU#/KQ\($4>^UFND#-)_L8F L+UY*?MNJ\53R8R"I!%9@2SN&D-TTTQI
M-#NILIUHQ;P47K(6Z'J0,N7/S-CN;C.VDK'=W=EF;!\Q8TO&W3%F$R_7)0Z;
M\,3W?. ?QG3;"+5Z92'7&BO2AD:S2Z-)U4EP$/ULABQ9024*IY(B-@:<G<SE
MM"\[OA2-=-%YK@DDF;!:6-#XLS4.-EB;-V^O.GO.;TZ/?W/^#:^.4[_641L[
MJ!C$$)--6A<\S-Q36*OPSW $:S%6K2,(" U7/AHJA5W BUU8++S3]WZ;G^NF
M?F!9Z]*>A:(A]FR:86I;%'*OC;GTVFA0E8QA>U+N(ZT: ]Y>,JQXMC3-EA8N
M-@;5;AL98WG!G4:@F2TXBE<+/0-;*IA0B+ULNW=V>]<BB0 RUHN%B$9*L#:O
MK;6/)50U'F(::(P5D*KGGU6V;4:"W?\4H3!;+-,\NREG%G-0@)8/FJ;LNGGC
M*M=+"O/#$*MTNU"Y/R+SD;)Y*[->.VX8*J_P=\/ HJEA6TLM@Z^@KVT],R@M
M[FR$/XV1M"7&2/Z0'EK;$++X5&8Z4R)GEWJ0/-T/8>(UU**&=QH++2Q5F*6@
MZ#G17%,\1LK*0$>2M8E->FV +YV-1@M[ @_E]@OJ <>ZJZQ26('#_-BQ> KX
M>YAET%]5 ?19O/CZLZ-<D* X.B1_\#.2N6&/U#>J1^H >Z0&5#M/3%Y7&GS.
MR$_/J>28,-\BLQIQ=/-A:@TV0G/;_& J)*+*U#S"YH.0_E%AHVT3JJ:<:4+8
M7X.,%PRLR^;&9]*EB&)MB.D[O0\AE>\RCYVT;^T@N%CJ!LM(FI@Z!&RZIH&I
M7R3DWC&,4?(DC+<28)IXH^H&!]TMF@O&9&ACZ15%#]<#+;,,-"]S8JN5,Q1O
M7/R.E;4.S9M%I\'8[\!H5ES1$!5BT-*CMG_A\+T1Q[)Y&WF.XV2Y>F4"9UDT
M[&\%TUDHW7V5AI^$!3%R66UT,149\K6<.1ADI!A99*"_<HI\8P9.3Q$![H:L
M4;YO,WO5QZ-B__/!Q?O!MA+7X-M,9*/&['<'<E+?(B?UGH"<]*ZDI-YK/(0Z
MRV.=/7R*=;KE5&6+*K'",:*7#(!(L^*A=C)U$ X)GKN>,\%GN/1WHQE]=!Q%
M"]!18#%A\$992T43"DC+'8W].M$<D@EQX7PM&C6W:^<8+4AA]O9!YI$*/#EA
M([<O^ K.5EN/@Z!%MJ7'+%4&GFQ9EIZ!*M.9QM/Y'9U*,C;>6X[*;ZJ7Z=/3
M,L/(U%H\\4C S@7/)\^4^PQ2E6ET!(4.= D5>@5UNE1N^^+9!8K:F2*N%E)T
MULW3L7J;ZV/P\_<CE2OEH:44]V>4#L-2;&M9\,/&A>P9EQT2APQLX*R"<:VP
MX4Q A"PB,4W$8,-+8UR-+$T\6I99F7V*1[B;6/E4T\FFK-^MR-(,)B%1]<1P
M<1&K!VI@+I[J</%4-/:L\BECN6E7F#S0,2CDV7>DN%:*R*5F=$;S3;=JXJ7B
MADT_^R@S5[:YJTDL=,)//<7^HJ3K=GLO_1GXG0H?'RYBY(>+PIQA*KCAS.OD
ME7%15%$KJ:S2(QSXZ.JN4=+[ 2Z]N7I]O>.4AK]A:7"2C3XJZ[9*DQ"N5L*9
M)]C,B6?U '+Q^"WA5<+#V?<.MREKZQ._+LNSM\WRJ"Q/;YOE^4(B^ 4/Q.>+
M0#R?(B7TWW_XP2_RT=]_H#YT_[NSL]O]8S'5#0MG$9IX2+:,[0155\*7^"]L
M!O@ Z=B[= E][(M"FDJ7F><&4:Y44)UL"XQR<@S$)035R%M]B9CX/CQDBBZ2
M4O-@.WJ.H6 ;DBL"VDZI$,'BVRC(P:( NT+_JN6>L=,0<M=X5NQ(W24)T3.Y
MA(8XBFI!(!KE[]$UTW"7RWI#PG6]"(6KB5]%P&/;ZZ]U9%C=D,'(SP.?^L<R
M>C[[T/LK3_U>ZZGO';:=>G_ML;]U</=IIOJX!_V"NVYRTZ$!\_L&WJEJN7EI
M1PFT4CA1I5]]8O"OB^&%]M581V@)SJH2GH 4A/#HVQMW6N>$CTC@IKU:.H-R
M9<98-1,E/!JK$#M#=WLGC*Y_BNPP<SYL3AL-TC:QY?1ZKK$J+(DCJ6FL+XYQ
M9 /FXT"QH_28YI80CJ1&6-M4:S^D87GWV$*;V-_W];==V</5M_:^<W[5@3W@
M _N0P9'/6:L',;;N:]GO;RU[9=GO;BW[>PO;9MQ8^A9R[BP*>)%^?X^6D=TA
MJ'8)M6OU6E>&SVN.U*+1B4JH7+*]UK^@OE4W6#^GC<9)&"=5'JW3Z7_=EO@K
M%LHJ_7NP3O\^Z&P>1<Y.%*9&6SN7"EGLE(;4Z0UKXN;X/?=MFM6_Z%@I<TY?
M*^1:K;]2TR[1/I1M[JC O.4+>8Z8_]7>7'TL^=_?^:FMP1;'ZX91F'.>';%-
M!=EKBO_"&R&3P :>A96GX.@;/@5"U""@)6F^S47GIK>-$R@>6\@LXM"=5#D5
MPE8+HDI%@A2'CE^UU8L07PI?228H. @HE!8LBH?/.D?-))*3N"756I<]KB7E
M7HG--F/(C4ML=702#5.=.FM_T:=O]D,K,]4!QM/T^,S_])@YUL?/I][+7#W8
MFJO*7-W;FJM/+=(N]/",BWC.K?J?.'T<%.$F'.45T$*'HF&OMQ<<'NT@9G@%
MLWX>.65_P\B4]'FM?6JYK29VEQD13;GJL.)R0^RQ]4&D$/P]]=B"H6DI?3\?
MRXU&MOP<ICXRU?&7V0C;HW>]]_4A$)!Q$C(0DAA931VB&>;J23/TCBX]..7X
MH5[O",?;.SHPY.M=_QQK:K'.</V:!+7)'W0.?X)5I4 Y88PT#D]%D9!30?I7
MR:.1ZX\N]'E&V'M\JSP"ERC)1L*R7S,9Z^_>W>G@VBONF6DNG0J:@P [$:3L
MCRR71ATMO9UUB%Z!K+!)+EZXLRR?6[R[NI2#W#'-/A,6*R ,.8Z4Z5.X^:X\
MCTM'.-- Z&U%"U"?Y?X.$@!(%?E+^@=?VYX>*A<[)$NS"MSKU!TBYQ:(3)C!
M6RUMJ%6FA+HA_]C;J7>8M7!Z*P!VWK/_FI:_V-UIG_LG.7)-A,WVT_S97>NS
M+!GOJF'TGY6?[W4/K<\[/G"X D^F(;I&N$0TQC:%L&G#HWEPR4.@O5HC-+([
M=3)B0].!+#=%@ITSN'&$!KS"FBL9_=X!([^KJ@^N46<>#).=JH,,5]J_WK-$
M.L"#(>UC/^_KF.@8R1+6'/:_.!;USW6C^[GTCRI*\(D_A=C[! \==1-0- 6[
MAG6JXXP-#']/#/\0MQLY#E.F7<S2*#6$&ZM%RD1LD)AP'$_G:]K.!U+EB[G.
M)!N2+K":S@>>.>JW-)IG3:!.N^:D,E\XVCTX4U<-$S"X7E2-QH'VCY@PK9ID
MSZI)7MV;'M'FJG<,H[#HVJYIQWU2B"XT%B-A6H@4DE1THIL^]6P5*>76T@V+
M=[WK7U9##D244B3U3VQ-QK-3"UQO,K5Z4CEV1=0-9%P214^659$HHB@JSGYV
M@UVDN[J9#!'[2J#[;Y<&Z&[YS71=4HDZJ'ML1D.E[Z29O'6N<C\UZWM#;;]@
M=^L[LQL<H)-N"J7T)HD1M*)*?>7B;36DTI UJGO109ZC@^;4(0]A<K*3MVL8
MDHSK"$1R D-ODAE@16ZQJH=&4+M\;:Z"Z%-<E+K##RG5U4=$THY=?Z!NXX![
M ^SNU"ILK/G&8N!C$%)8,V"RTXA*$9Q1PK_9$L(Y9CA%'#@<<HS.$.6="I92
MP D?XL _5HNG?Q%U:N@,:[P(8I68*L:%D!QD"1(OC!.*3,4:2.*V*U$L4^E8
M.NT-D1,$S#B36""KS2YZTEM(J6FT/L=5A+:(B6 13ZXJSJ3JM:+*)^$HLH$G
M%M4J&( YV4V"E='='2+<Z$F6@)7#Y9=L\[L[IBA/OO>37*OM*JP"-5E7M6%,
M2E?4*K[$9O3<FJ\9RE!.O=(H(NIZ+G8Y59L3(R6U5&.E$0XJ7&B:H#D9!J=F
M1-, U#2'J2@S16142I-7TVG(Y#A*;!H#HB6Q%9M#P:+7$7UI0Q(I>"9'(='1
MBHSI13:!XN\S53Z"IYCRLN)\Q8]%,B"UW-++G:]&T[B61D_UL+12F&E(,T]7
M/&/!5%Y[!EN=/D&%T<!I/RYFGKK[*EV@3E,0WZV,5 X?%O+!FDBU$>L(?BO[
M6F,N#^8OZ1 WR1*E#T')I--R%HC6X?ITXJ2*;K :;S+I**0:*:*"FM&9A%06
ML;*3/6&<VZ<(+R.PBT-<DG&.UU6%+U% _)3Y0^W]^P_XN.*_)_$$"<2+*FKK
M'K7:J&:?'C7Q^HND8+%S)#8CXQ@.!0QVFL#*(=$G+0G.;FAB2_6Z^E*Z-=)I
M5F\$ZUPMD=<XW:'.VRJ.1JK5M*K31I&Q:]7L?S$'(+"9H<@$)YV"UXPBF)#.
M4%R\0?)B"C= Y!=)N"RX@>PBXH)Z4S^&:\Y]J98J<0AR3_L>BH XY6_URC<W
M@:*JP498A8\)\6FX:$7IF[N5@AAV!ZXF83 .4>+68Z<;EU7Y,\_&X??8Y<%J
MLN=?$O44@QMT@;MIGO<^3#W[(RK_#*L]J*>/WQ]W>OY@%HT^,B?\J6&[.-5A
MHW^=_,_5Q8?C?M/N0V5T_O[X]-_GS;_!<3FF_M%X=E4WO^,(VT,14)#$&N$9
M%'/[ALOI?X49IXW"R;2:#TD76SX61?+&ULZ<#DX+%>PBS:;(Z(C 0FQSQ2T!
MQP(OM8I"6::G-G^JB"P*0GRVA\_F2\]E"M&02771ZB<)&:HB+EW!@!;X,]7H
M"[4L\6*K&=+K!'F9Y5ZC9+;KGV'W79":%8?>IGPS_;8;J B]>*2:X8:=+THK
MHZH&I#.K@3^L2O(N;,IQ?AD[46C_@#+6M-C:QA^"*3&)2VU!T-B4GZ<Z(/I6
M!T2'>-&S%U%GO-L[(]:C:<P5K+LFK%\(9BQDFR<4;D-%Q^2MHF/B9X"7@%IX
MM1: 1ZU2 I@+46U/V*$%BZ>0PN6Q40_'EP-%AJS'@ARV:L/PN]K)8W,0\QY@
MC3[$/; 1:H/7A!QD9,V/.MH4N(X\3E0P8B%*%BQ !0K#6'V>6K6,- \\AC2S
MTMC&EAM"LK'D&'B=-L)8(O,8CG^47L=YELX9T. I56"<5DN>V?&M,TB@MV*Y
M*/1F8G>&^V*N#K^V6PHZF)1#RZ,DNA8T!HFU8682(GCUF(]11#U KSJ\3!(T
MCF7!>&&Q]3(.6'V(R@[!V,Q %_ZI2#Y =82CCQ;C-GWV2TK<6BC 4X(L6XNU
M#/;-F!MG5N?32[8PO28/EU)$REOYPO?])BSC9XQA)6;LD#!C:^%A7^,2?0;,
M\EYXH)=;/)#" ^UO\4!?N^Q?VA096%F?6A>8UWI=NV$5:0'<]=^0B:Z*BD))
M3<%5^1HIM\&T0CN]&S2?\.YR\'9@8C!L4QN3DUH694R7+%8'WZ99VG ?!#$1
M"PUH(/?PC>I=1^:N]1 ,_I4@XX0HA<G3L.&9!44<D);+IEH4*\-PB)+-HAP+
MMG[140I39N7&$<L 0KNKG:",>MU7/XF]HA$;PTPQ[O 3V/XF7 :W/H8'2?(.
M:6 Z^'A)X%'O'OVD8<2P@KL\Z6UV8S^HL8BT:NI#MJ,U)LR(."EJ'0)>G#2S
M6(JR(?&;D?CH<5O3QDXUF,HY8LQ4RT= /H64K1Z!K7$<JG%ZM7&NW%?CCHK%
M:9NMG0GVHBOJO>C>6[WH8+Q'F"V?@Y3/"B<G!#N\[\GO5\_\_))P5P?=WD';
M0_:Z.WO^NH<\"#?WO0RUQ^, NF4@L/F^DF2*5_>U9\!2>>E(P:5UND]=&8 =
MELW96I%KK<B76RM2][_D"-H(=%X,MAV%G>R*+HNO-<).;!*NQXO)BJNY80NY
M0'1J-T0"(]6VG7M IZ*_5#,F'4O#S"VZ1$R-@-K7:8WGZ1@:!_],: ETM[Q%
M:W?5HBU2$0']802*8H)Z- *5B:WHJ >!$Y"2#JF^"3<PB([I9U'5$H\3Q:%4
M2D1GJ2R&)]OE4\]4W?8HB4"=/@VH:5$IPB_F\#+_;A _X^W/?%*8N=1^)6:<
M;+XJWI=(9H+ *"L6L6T$VR2,E#,!TIK!ZEHGP(0)+8YD-PGD-N*@ZAM>?1(4
MBQ5=Y KQ2'RHW!"L[Q:WF,BT2G>O##OR:J[)0'3]<Z?'S8I0:PU?;C<-TO&M
M$9>0)@@]=5A,ZE /$M%F=Z+U'.6W3!%YS:K"NVTAL LGIX=KCU^Q//;#UW^&
M'LTFM$!$/ GPZ68Z;,$:'EWXU6^7[P8#A@:3$\%)>M.UF3N[H!PAOL[*(&Q8
M8N\N<8?#;=Q!Q1T.MG&'S<PGX/%M8F<\:6M<1$J%Z4ZP5H=*4,MO>PZZ#!M3
M9FRI:\YM"\7Q&YSY 2:&)(  G\^XI3S:%9Q0LCK;J@["-<T%VD(Q]XU,CEK'
M_5DE9<,_!$N'/1A1E4A?+F66X1MM9:PZCZ?8R!:[E0FLPD+,&7"3 OK:74C.
M+RX"RPGI^F^XA)5Q(^:[PS@CC&S.9HP>T(@[5D;C6J?.!68J<RXP8!N3KPN\
M4O^/=9%RRL+EJP'96,SHKAHF66:U4*?-D3>83;;J<!7J#Z[$C/#"TFS+R3$3
M;-RS$,4O-TQ+/SC\XC0CP1Q<M4$N/J1(,%U@RU(%[!UD*8<]"")'%< 303M(
MN\E?P18V9&DHIN+G@CKE8]HGNYW%3,RD[ZU@D$YX$Y:,?<J'U*:9V@[IA58L
M TINX0B$)-.P[*#Q%)8(UWL8+3/A(D<<I[9=[#Y_'4Y>ZZ=J>X>JP'7I$?5<
MQ%]C!I*X#Q 0AEU>.Q;2T+S!'K%8HH&O!2S0K>:)&A4T+):<4820CKW@%S7D
MDG'X6,_F*?WU^NS*?0L^$6>I^DN73C\[NW^=LKLO!\??T1%?RVZ@VU89'=#>
MR?@,)(?NGLLD ^?T7R2@Z+E*R>B K"\=J3R[_-= EWCPKM=$0^I:!OV+SI7>
M[R9\,H^2<$$N"X:\=4^'U^J>J.#F2Y;SQ2P;)B$ULY&V1*$>R^M._^U;N[4Y
MIO0K[&&)4JL>Q0^9FZ\=OWT]>&MZ,5]9D>D)-I@AU&3HOSO]#80X1"R_1 WX
M0N$\!"8/8"IP<L@\P+<.CO</5L!>G"6BZ3O+T_7[W!>*JJ&ND %Z#AM# 9O"
M___\*Q@&0B53Z>]#NM@;*/V@P'+Z&^BN75[!EE/KYU,X61=N(RM!3Q:&J1J\
MZ0P')XV"^<[M^N\RLVW/=E[L/[?:RYY2WL,[(3BN7!,=$R %T:YR0W]YN<3*
MU'FDM^%TT'_G1+W#%+5&.*9L#Y71*K-G'H4%0<084RV;!0>>GH';HQ("6$ZT
M>_"3[F-M0]58[%[D/LD-K0V)@HMA4V4=L$'*:-$E*=1M-9JJ7JM@"4G4#;7U
MLLP^<F>MA##S17W"@XM+(W4N=M<<4A?VCOM.MZIC6]4-)Q%Q&(%48B-DE?[5
M]=XCP7A1JE&:617";'T$@A$)R_@\YL9<J'5M72N;Z&+9= X& RDP7+)LBTB+
M%H)W%M0:F<I255^H<%7#5-D@O11;32XA5-,(*TS=%EG2! L[R)(*;U'Z8;'R
M#A=%7:M$9Q@15>GIRB\DDHGR$;["5>M@67RXNOQ=008]"S)("3];<9K&V<*U
M<Q==R30TXEBM&D;7-W!5:;S@!F/)!!(KC)/,[4\B;M^;UE;4".RSR7J:D46S
MYFTT.)2.5+UJ;'.MW1;4=.]RF\,1%7Q^#IH@Y$Y%/D7IQY&=I27S,F0;7-W"
M78^J99>FHV&MCM3LD7*V;XB*B\.';)>JE= CHX"AW=)Z;\>"ZUY9A:?:VZ4J
M.9,)YJF1B@=Y<=S:=*RADUTX1[A&[I-J 4NMBNGR TU+C^#KP?*1:=>,1O3$
MI40M*VXK20/I1S519E="@&P-%:A!QZ:2+VTBD+O^Z<3*9C3EBVY<KS=\L:L;
M1Z//K1J8ACX5E2LMJ4M7E&-N:0?8LC!/*"CPG7F[*WJX&--74CD<\K50V'6-
M2GT4G&O)NUV#AN2[-$U<<$=6&-V#+*GF0S!EQ0FG=O+T<2IM";&T9AS180A+
M 79Z6(W4*6=DK-  ^/(?QP6%8*5WJ)6"MOH<L1/(A5.U NK>#I-]+*)LD>@$
M(E*$*)^^4(\>?4P8QJL1N71!A:;S)+U'^IL@WH"'*,C?3!F/J,O!3!C1.<D5
M;(2?+R:27\Q"TS$%/@R;,1)-E60W:.?QLZ\11R31(>I5Y6>?EE2"RAVTEJH,
M'+MBZ#R^-.D([,HG2IR@,I56JED^!?$8AW,JS0U)%5Z'1=;)1J.D(D@SP7$+
M;>']^_RDL/T1]]-8>83K8CX]*&PW!$TGOB%&D<&+RRO0S^*OCP@.%)+=51<)
M#_;%:?CY@E(5.64:L5N,WR=9C9UN6_#7$;5.1954:_/5(M:\3[XM!X'/U8'H
MCB"#M0W)FF6F3)$($1MN.R;S/N)FL->'2>%2S9:\0UP5.G&X-?('J2>$18IS
M ]U142CX3E[%-!$5+79=&U+K9 :8UHOFML<U=NXV<,MJW _H%<=SMB\4#: I
MS4.=S[X+ME.T;'KNN<AOJ27RXA0YQ&T(E+:8]#WG&';A"L7$1I-63T[@!1>#
MSI1G2&3*F\S8>E([?L=M'X3%-+I>ME#H_#O*02?CHN=SL%<JPLA@J^MTU&5N
MB+?+";PK5OP[1_M'NYI:Y752@?K+Q_[K.)/O;-AU=I<4V]$VQ:92;"^W*;;-
M3+&!EXF1)>8+-6V<U4UM%(ZNB>+[!+8//#[J7>6)RQ_X6 LC9H6N"4;51:4[
MJJ<G V\5PDBU60U-WD [3:X2@HN$;!D=%T=B,Z/;L+S6L[ B,*?V(+SKJ=FW
MH$+Z.%84U=Q4H.MB#/G1U:#\+LD 4J2I7EQ7>!CA%-4.%@N&4B\N ^;28,?D
M66I'R)[#W["7>>ZW]C%'K@8B(7-:T_*BT9B;&8.EHN%00R*KHNW*V##=^B6Y
M+7FS7W_#M;I_*Q:(*A,]"7?#- ?G?MP!OR/+?\;;OHRPH:7W)AKF%;K1X!WN
M!0;IUA(-N#P]N;CHJ]A'5+8228E=8""PUKDAS#[XH;L_.3'89[V]%X<OGWM2
M6BF; U;(7'6F'>NFM -AS_8O(B&+TJ;S>'"A[6P;V[Q3>]O.B\/#YZJ.4P!1
M]#+66*B[F >APUH*OOQ?2?G+3A<<HA[;Y*TK4>B(A%X+^.H)FNJ=-XCPOJPC
MO$\LA+>$LPZ/?C*T.(H'"U3+T.),0#N42OZ>_1;^&8(]=(&:X>\[722%6YBQ
MDEXCKO0%M[HNLU'&>;?3*]+=<0%.Q@D" $J_=[0#ANNRT$D[:Q\\#/WLPM"<
M=>W"/JH/6^NH&27M50K,J+E.8<*]&0O6EQ,7<? STU"0U4ZUUR0&E("Z>#&X
M6+#GDS$P+R-XJ?UQ$[0$OR:PGL7Y)2%U%^>GL9_CF&@UK/+O>53?8D]O,8J*
M&MW:RHX:_O_\4GG51/Q=&CIOG0NYNM+287 NH)7Q:#]E(UPP/E<IE"?7?&O&
M=IYZ_6J*%?L' 2755FL[O-(S@K1@N"(36C^#4\8,V@P54)EC_4^85I-P5%:Y
M*K>53AW&K1^<&0H\\A*Y!W;A:8L(8^MY- USC:)Y_;:ON5B,A?+:K4-W)%=,
M+B)#P;)@S%FAEQ\7(VSK-J8X(_6,8G[9L;141_)Z,*)PY4SRSQT00JUA$C"@
MT4>T>^T!X8RI^HG":5C[0PVX0YH!TT-T_=_485*UV#/TY/X#5T_)[!&T(YYZ
MLUA38]84S#"HQ]A^(S'X*F;&GW ,W@3%Y#,K:HH#FL2) A+(!#"L5BQ 1OQG
MX7,J!:OI]\C@ANNW'4*<!A?K+SW_F5PE1C6SL\NL,&H/6BZ0P@)6T47BWWZ1
MX(-5_!Q_?C9\3KLG>5YM1"I(L)5["^$_2XRC:"'@A? DN6H&@T9I!TO-1&=W
MJH45T6!5"-J,\N W($*%"8P;.]5J9*9+%7!@Z@^*D<**'/%Y08NWD\?%1__J
M_<&>#C0BPXC9;=E<'=V# <"A(T:1V@CX#D"I$_R(4@.U&>EO>FU##&UPH(.M
MUH&=-$++'#>8F[<5B&HCB'95B*^%-[^N:[2#//!:9KH;4;"NHL;4Z@0NDHKI
MCYC@@VX4C!^WYI%PC2>PCR&ZY2DGC9@FE3H?Q[GI6:WDZTU2O;AZ?:IE3,#6
M9DR>'M-M@[!AZ?YH"8II,<N*Q8R;1=!$Y&V"PF G47>4(4'EY6&RAJ:T.CD1
M'"-V<E[,E@6X5&&J!6(TRV*1N#"YIGBN2<%)J-10#&+Z?RU"R[& G$R^)S8<
M3R.%"X_'3]DJH9;);AR*4B:HH?R@GIWU KOQLYI@W'(A,&%C.LD(PD+C:#E^
M>.AC/0\T#9OP6C+<4_;R7]8L:AJLG.S6X3Y]S<I7:K)H^T1%8<:.]> [UH,B
M3D9:76E%@S=_)85/"H%<*&O;.D]K2D% SJ6]XW"I7F7?!&4K&EL)J!H;&AW2
M; GDD/.4_ S2;(S1)AQ._^QM+6-,J .T+&0D"KTHL?M=?XPD_IB9 -TK&2<V
MY!WU;=#2.C?K29E,$DE(!F:-Z0I)Y?-S)TW#*QP663Y$XP0_(>LR1.L#)"#/
M;@(,OLP4E3U16X6?XCGLHR2T$_/PW7WO5_+JC-:5W!1EJBA1C0X3V38M1UP/
M2MWGKH"PO>?("<=+T5HQ]5"VYM3^FW!,NC;:@64URWU%J1*V992M9+^PZ[\V
M%BLR0O)G K>J3I%3AU.P<"A%XPR:@*BRX2_VZC+J^+8F-U^5LRRG^QCV")]"
M"15.C5O9GUV?2L/8+-*9&(4\]T)5EZ< %Z&JBT261UB;%-6>90_;V5(".464
MPK)>V)B!NNL2<$2BL7T_D(C*,A-D"O:-"@Q;Q)XMJ34&@__9!H/<R7+S>ZT/
M_Z(WOR#Z7'94*>A0"L/J0C&%Q_:.F.N(^ VD-2T9UJA3Z-^$&BVX]0@!8VY0
M3@ZX@S9FNW-,>LAF4#YTF&?AV+3FL(>C#K<9A0;'M#AG2B,2SX'^H#N!@P-K
M N15Z4&K,0MJ:02N4.2,>3,OL,_*D+W:9LA4ANQPFR';S/CZ>>KW09LE_F$@
MW3C@JB5Q(+PQ 8#>@GN!69J^NM($S#IGHDM)@_O]UR;D)W\R6/I%!?I6R.)8
M@>BO)_QXKOP E2" $@$F^SGVI2D\!N,K9*.Z*2RK!M$345X2BD*U9%)7V,F'
MLY-W% 8B=KT/"[0S,+*!US=,F*(^F"DK58.,U*\6$^3B"0@PG$>(GJ>^&XMP
MR1"2B?_CWD%WQY]+YP_R&-2L;,]&1ZEBC53<Q68Z8Z;2]3'^H*W9QF('"B<9
M*6@V 27ID9Z:,<P,U7DF+KD% 871P56+5I<,G/W!/%N&"0%I8.1I5)KV1>+D
MT=JWKBFI;H2,"HTUSMMK'7K7;')<J&Q?/!2V2VO,IF5&^Y8%$IMSLKAY) .K
M"87'$N.8+S1E1-[(!&^R/!E_PXG!"ZJB.&;V=UAD M]<1:-9BJCWY3><,$2*
M 37[4;@P@#'J;>HBFT&(EJCB:VTZN!^69,W:<=Q2)%;4XVL1A2@1^ 1'!6\X
MH>C51)KPT'A,%#N*D%LU+Z F<V#^+R+5H +=)K+;J&J.#N<D S^82*H8G4"O
M:^LDTC(&7?2P-"V7/-NR#1R"CD J0MR:.9?EW70T(&\-7?#6M6?N\(KXOR+J
M;"2@43S\]$E0K%@M3"X&M[YHZ8K,<S)*C$I(V(KEK $]6Y?:6L5_RJFTJ4ST
M'@I["KOQ7IHA YA-X9*97?/=70ML_#5_4>TG$T\8Q 8QIL4(R2OJX'IK39E>
MV;P<FQE:(V:\&>VA;@NMU[9-4NEYU"":T8B_G5S %2_<,6/\X2BPZ>R8>J2>
MXR.!\+C/GJKVEEY7JJ+(7EBAIZ7>U-^FCKT?!,ETQ#/8^!"YKMOWC LU2":E
M4P46KG.QTCQ+X(0DA"?-I7<-]N1#'B%TXXHY.I7Z4Q1#PX(*,/%&#.N&;V"U
MF51[9:5P].EPYVDZ$;_P0G>UZ8]*B9KL&A/OHF^LNZF4J(#(UT= ->]HQ14?
M&?(D([%>S@SFJ;^$XPLN.;48TZVQ[$P]$@ZKSS$H0-9%3H%Z)G$6Q5@O48:D
M ;BK!F%!^<O\$B$K0I-0,P:$1&+M60\/=9&<8G,J*(>2+W#%\=.8=\,J7CMB
MZ+"*,U9!Q2R4WJ&$+!X^+C4ECQH--83(Z^XT=@VJCAR0E8R.L]DVW@YNK8US
M=Q=80HZL.K$+:\(JH:0V-[.H9;+<8LF:&=O@A <C6:L/U;>'&E [B0D%'Q3Z
MEMJ^IE9QLZ\:\V#R '<P5D($FX:Q17DYG8\5:Q+ =.@8L(HSL6!KY-3( O\,
M#Z .*!,J)%,RQD**[Q_G(2A!"832V@S.+G4HBDML:,.QW%U+#Q=SF^6ND2Q:
M=NXPS.%.%N&E6Q7.-!?TJA-CSCI'1-<UZIK#G#R!S=&6$(F\<P#Y:Z"GL-F*
MO@:X7VQ%'HAM-*B^O-=H!*7@Q&/]YIJ.B6\Q8XE#:OZ-RH_^.YO$T[8N7[_*
MW*D^! 64 '[BR^"(%RZT6C0AJ;!H@5THM8Z4=O?$(H<A1U?_!)[5H "]C%)"
MY"H@>QV']'-_.$2D@13WWOC'N,W]A4;T:\77?W?<-W@6QC6TMA6@[J5\M(H8
MW+ PUQ<[1KMPKJ2@5^P_4QUXM6W'1H-CV;F]@]ZSC\]M?(6JM- "9^,N0GLD
M&+]&86!X)T8THYFTLM#!?NO+G@BK6(5QJ?NOT<J2R,C9-2]1W>1 U2(C^32B
MA($.A\<I6$PX3*VX5IV$UN9\M5,F3C*E(6]"KH[&HFM9#!(RMLFD!1,I1$E8
M*\RK4=@VDK:6)HIS:D<E'#?S_A K;6"6U9\5?$'Z?88(J@GAWP&'$Y8"%,$X
M.[7:,28@M0<JF3_G6  <E-?"\*F>&$^*9F A<SWEL,,1'\6JI*0VXW ".SAF
M\$2\ !,DI79 XY@+.Z1M).8>(DFWH'?/6Z;Y9JI2F0WU,2 O&P,S^))T'KWD
M%N&%[@-(.0S20_R"K8'(%;#"[\@0\=QQGTB5ELIYCTWC%]MG,"U92!J1Y,C]
MBN5'B1/#%CJ?Z&$5PZFXCHM8\)GE+,^JZ<R!V\!(2O]C1/D0\I='\F#BBE25
M3_"6/V **:IM$$^\GP2TP@2 RD.,4"Q+5A(C"3FJC(-06*E &[[3N&O8<S94
M76M$*T]";#*<==@)475V2M]*M&T!*D<YS?:UIQ^-9 OLOX?$E;$(2TZ6Y.4$
M3EA&2L4N,/1V]W>XB9KZL"Q(E(ZYJ(L>$"ZLRC"*/=V NGDLT5]-.WR'+,;>
MSC:+H;(81]LLQE,'_4B648N\SS/P<Z(246C<?,\?8"X6 Q@NDM7[+N*>OZLP
M$,C.&$SD66# C9X5#%S1>=CT,!2_H\T*%]PM-3!51#E43$J@F\B^I99XJBM3
M9$NV ;>VHI=H3]KAA*&7(GI-PY/I-VD%0QXC2@$V%,M.<>8<:LHT[\0T2\8=
M[*@PQE*">00^SKA0> 12PY$]/D_#*X@ZC(U S/NK92 HY$B+E')5[8[JSC@D
M$LSM],@O#^'E\*A7JO2*W-]QLX$C5S'!QZF2JC/*BC*PTAJ(V(!WD/',SEZ'
MHM;:A:4+[G2.MU3(K9[)H>%IX#VEL"4,:P#[2\PU?8!XM3 8S%Y)FK'P)#$S
MI,"OYS&RE$DI.A%PH)N *.#>3QH! V\\-(X2#N#0%(%_*!1*1Z]J1P]*B879
M'[0=&5"( L2N@977PB71B2K3&JW@&CT<-&=[IEF&CF^F@5K</ JL;&Q3_8DN
M:C1MI3IO$2FN97H"QSQ"%9 PX@#:1>PDVCL57R[I<'-+:7QVS:'*!:AI(H+A
M=1CSUM;VZ[NWB\_)$%/]%=&Q[F (W2H\+ 56JR3 4C[(PJ+Z@7L@\ =U(ZV>
M'-S;:WZ",AH*_6IR,L7/3\[W6#+??)0D"_2 T^G??]CYX?Y# ".TG.%'=WY:
MB7W1EALQ?2P*,%S43_I/!1CW5.VTL_CTRP]H@/RMS-5P8,5(1ZK)@:7S@]@H
MY5A]2$8B,)RU:U&.5W][=_77G4)"7*).$?\9\3KAPU^]/'SUBZY):GG)9SSU
MQ%R,^C8T2@@D=Z0:"5-Z&K4+N2<3_P*N/5*G+PV^46D&>Y#PG_QSUON^*_RE
M/_^DXWX*47AOU!1L+_-NP+GSYX/8,KVDOE%]$@4BVF[W5[C='RA<K3%*(;6Z
MJN9^Q V_M1VQW=RO<'-/%*\-V9B]'>+0V5&V'[$AD,G79N5ME?A7O/$7CGLJ
MSNA_3<M?_%>O?MKNZ->ZHPR[,N&%5Z^Z1])L\!9'6!7"D@N,WFZK$+P@<UU,
M^"_K,&R>VZ;C4+0@.ISD0B'Z5^_..OO(RR>1=TYQ6 SK8"8CYHV0(E1YW0A0
MF:!]:@>R:AR4#,*B_#ZQ'0M-CS#7,(Y.<:&:V$,S&H1)O/$XY\!'9 C@[5)Z
M)Z6GXA3C"!;W6X::-ED#+L'SABT<S,(X_88CKD[9ERYG0@B"8<OPYHW5*7AU
M1K@ZC&@L8V2;DZ:=PNRHRE /X)!@@11#1GI'#5YI$/#] Q4>X[P>5B-A>$LJ
M?Q'WFJ*D^XBQ)D(#?.*W*9*?VWI-Z HY2.X)'J! >( P(A8,*M<-)S 2FRR)
M$/U:ZAI0,51I_)\*S;SZMH^19",><A# @6-)S:2#V.SZQ\QN1?6+,^0!P%XO
M'>3$U%]0<.& ]"W22Y#X$4#)T+ICB>0L7F"L7@*SLZS4"5(D1L<T*O470HKT
M@O.P@L9"(IVNMU+21PH]$B'EL%5P(;$-'*J[%"W8U%&6(3='Z!9<*B$V9>Y8
MPUA&V)F#UI//"7Y'IH6;W<%4&DB'FA\=G:VD&QH\4W:),I/=I#4-Y<"V&3-0
M,OV%)A1E4!/B!3I95;)[J\/AL5-R:_4G.B!8MG,QB\:#+9ME51'51D)81P7,
MB=(9M[22:OS GR31I]ABU.84B8[)$WT_(RDD/T0WM-2E-I0H_$U@"9Z&)1AD
MMP77%AB,='IZO S^!DC1*:L;=8%A\U8PEZE9JV+/<G>P3;'I2AY*(T;IE"!!
M*GU2P(:-(D/=A6JDRC4,)$P6L]!_%G6GW4 ,,^:)&4:E^KUWVNGM]9B#M>KT
MD"(M(M1?SM4*5(%/+]<U&;$[,5VYS7+!@%&DU+Z&@X!-%I''A6CJA:6%%D,J
M-PC(6^52;+U.Z B_=D;%$*NHZTTI'A[#C&5 #-+Z8%ESGHP^@CTA_:S^WSB:
M)E$>>*%F@B;R!)A/0;A^&75'Y510DX-MK"AR,>T:A3G%KD:*8<4J[Y?6N#99
M#1TX!TUHF>86"9#.NSA9EL82?>^*V[EX+:?"B*@GE.N@%9$5Z-C*Z./RNL;Y
M.9)^2UC2XO0Z/CLO7/X^F^_-Q0[,^XQP!&L#2V[P>'= [X(5-/8<PX.Q7JU&
MB4]OY *&C&F*ZNDXU@[.FQ7%G)$6.0*NFE%,J5S4@DEBMA6&1'Z:,!36U5/6
M56)ZV!(J30?P;-2X@9CS//!63:FH(L=39H?[G"7Q*RP[-;U'Q&MDJ*>^N,"E
M76!^0#G"\"NB[6MQ*1^SE_P7YX\&';W%E0FN[-465[:9+K[2([;/$Z:^8E)!
MBY7L%PL!Y;CWS'*14@U3@4Z\-C70T&$X#,-L25$H#TQJ+84<4!/TC0@!;HA8
M[-I/3QD5!)M8,1QA!*4X@,4F2@0L\&=&CUD:-O!W]SL%XM&% 81I7^JD+Q8^
MWMO?L16DH0*CUAFW\6M9E>VJ6LKQ&FYT3PXDQ*%UHTH(0GTI1UNJ/DV[)E7S
M'6/]^B@D-U630:%ZU9=!Y'KJ4:/:]4IVRZFZM:XIJ\G7:[?S=^"U0.=@0F&"
MX=*)@\8R(Z>KA;$>VDD&P5"$+Q;MYYC89! G#8OQ,9IE":Z+V9@ /#8BE?6H
MCPC/W+1!*\KB19:.U,^XHY.*6(E9^RGXN":@S;(Y?&JEA2AEQC,0-K@("_/[
MCD *$:?NN?:D$%OA18?V.M4XSK$:E7:@V.3[[N&;W<(F4(]BL$,(^@I6_@.A
M63?7 3VOH1:M@/U"<1S8P"]$.IZ^#PQV3&K&QQ2?R'65-E?:4UA?%[H';DY!
MX*2$W2A8S&VU85'/UPNVQ,2+5;6IY62QLCY]+[ R74M=>QE:W<I5E0K(PBY)
M,O64 :MR[*=4( E9E=#)MS"TH*+"'-GQ C4P74 "XQJ*@MDZ7GWN,\HTR^R>
M$V:V7@\2%RX=V)<K#K&:Y*GK#ZL<R[BLJ!,FM9Z@JV&(K&747@)NUU(+E? 9
M%-[^D7K3))R#G^%*#Y76R.#H-' P0!B"8_9 B+JASE)@ZKSXG<W%D1$@.(*7
MP;.7X:"W=B4LEY"%M7>X9\+OLJP(+9=GU/":7 K)A=]H3R346(]- :\)!J7=
M52.GXF5G41",3%\R=HMZ;WW0M2?E6.0FW*Y@*<2Y?%+N< ^;V0EOV_ZVJ]T;
M#I_9M?)N3:&QHR9DKJY']3;_/ "+?1P&_DF%ERA]Z)_A(DP=V9>\"VEJSA>S
M-&&G@9$\S;-9FXI(OX/V.&(2TSVULWN'7?]"@FQMLAXJTG$3<3!B79M23<R]
M>A4LTG@0L\"*&-NZ,]>R")7+'>ITF%$4Z*JMFD=."N8@I9VPT^!<E^P_Q/7R
MF4&(W6T00H(0>SO;(,1F!B',W2J-/LE<]/#BUKQ0J NU':!8'MPH)]?MZ@"_
M?*FI8"V?U3(36HNB3*!5XQCP$X:K@6*;E+2A' SI,XF Z ?JFIP6?QH5#"H7
M7>ID&GL>[!B^4DV!1._J2+ZG(P0:AE1' MY8*>:K2C&5*:[73'-6\;:Z$>_V
MNA&G8*4E1=:ZLBW67Z-L#)[H*922D(#\!RD6.7=KGES#H@JGD%4BU^!10"'#
M:V35#6*,..^>MTG+[&U<&'8G$9?'N5A\<[%\5R;22C[:OPW_\5L%#P5[AE 2
MCQH2V5P*^IKC=A28U"K2A^\>^I,J20@A AIID61+"C/U=O%+-[-LSFBI][/N
M<1=-G3/\WW&$V;9"D2NK3Q(EI^2OB8%3F.T8G.*FX5HK;@5$0('%5J9R3S.5
MWUCDV1@VS/*/<,V.ZK39"3>LT>K0HO=6O!_4.!5>J@CF^8AR#29^!6,#1/6)
MP1/7FT6#NR2V%T4OW4=%$;<-W9"L'^?PN>LX#8L9LIN$,:X4CY-\(JKA4\T3
M0<4-9G$T\<^(-33QSY'A'MON7%%#5^1I]=*,"$5,EEYCAK"I&E.M4%0GE3 N
MZ=YC9E<)8PTHR@U!5->_6Y^YWY'OGD+HW-N6^"1#M'AP)(PK7;$YU*@+V5^H
MUK3,='=I59]K]75!9(XJ1"5*%RL_: ?_Y4/I%.-?. E&']=Q-LIC$A(DU:V=
M.F%R?WD_+"E_3!"!CS%1>DO[>+F*Q]1:/DO3*-%=AI2/A.0UZ&+/8BJW9SX9
MRW>!(UIAARE)3JASI_EZR)[A<%U(Q87BL@]!!X2Q=/W5;+B"'W%FR-220GHS
MBQ?,$9(Y;R.$'Y9,DNC^[G+)\D&F>M.<:W]3Y+8EH#<1TH-H=E(F*Z=^<W2A
M15ASS4$2RK-$PKR)S9.H%7LXF7R;]Q7=0)=E!F[..;?2QK,7I04+^PG5/D??
M,/CW7&%W]GJ!%2!\G8%)B7K[.,Y!BA$MI.GOZ+B@$9,DNC!,<9X5M)3<E9P9
MJ2KDS*)@+@C_%!N8<1O4_>XKS3A=S,*<33U,FF3J,3.DM!TN-3FT0L!9)X_2
M7&J$HB0H:A&K;K%Y2(0)S#1&>'X0[K'HA0M,B)9$W-_;\UD.WB/"D._(WBO[
MTY[^M/E@U[\D"BAK.0H>0E$-_R"N1A6#20LQ $G7LGU)5 B2XI*_."OXM(=N
M<Q)5E]:B""%!I,!U<'=A#S80FW*&+1]PMUR1%@21]:O]P#?49U(37ZQYA^^\
M@SX=?W)>Z?VS JMD;R?0+[1^47M=X%.]/_%1H1X&2^KFL6KQ/VNGUY;IKRFK
M=^KR[SZ+SZG&YTA,2T$^&CST*!A9FMV "^VN2Q)-RA]>_..VK\C$3<0'@V*-
MA;.+N6 9T(KY^P\O?UC[Y-MB;FWQL[9R,$J*+'^^;7$;I6,PA3VO]?3PG*Q"
ML"^U1MO%-HLM:F*[U@^QUB];UYHG9D_O(=;]]A+453KK?@M'"@P'\"/[*5E5
M($=NFP#\A;W>K>O[^V[K\!]X,_ZE46W23/:_F9EL]V3S9K+=DWLJT;9@;CX=
M/MO=V0]V]XZ"W8.#YRO9FG:/?FI3J1<J$LI5*%9)PIWF8\S?G]9R"-SVY;:A
M_7B_$;RJ/80:"_WPC]U@YW"G<>N9]ZYX:',X-O/"5[\J>_O;-:FO2>_E=DGJ
M8K)WN%V3ID(YVDI*?55>'GYQ2?DKU^+OG ):1SK#+Z3>%F$BUU_?JNFXCNYX
MH]]_/_ZB++0M?_#RH+$!#_'VS9CNT=%W--F]O>]GKD='!]_/9.'0OFJ88=_N
M='O!X>'N%YGNPSI,S7=?983:>;25ONN5W': @L/=KT@W_H69]H+=[V2F^Z^^
MBVGBAGX9_;#I,X5#>MAP(;[)F>X&^U](>EOY&;\EE,[],MD7U,Z; !7G!GU&
M<+G>+]X59?+/."UT8J>%!"PPL!IUWO;A)P=&;,"*8T'1),,&%X24)ZA $3'U
M3CD+-*<2(O"P&E3*/+$SXS@L0[?5"*,]X:^:4LX "'_>@,E^5B.#S49(M,7N
MV_4H95AO(E1?^+ADO#(=VJ9:6]+&+0]LJQ6ZO2KI#39?Q%>BH/UMF+_X!Q]=
M_B6?7_Z9#C%_0IWD.^K@QF _S_!N;D#+*MP^XV=VKO?Y ^W4[I??*=::7V+!
MOY+9[C^5>,$]>!VE5?2S&L!MLZ^M[II_WO?;#^N4J@5%PP@5=6^75+5,?^WX
M5[JU#;NNQ8#KK/M,FSWZY$-X@+!QZ^(W#=:5)_(<R]K\W-VKSS?</P<ZTZY4
M[O>D5?OQZ)[+-[$ 3Z O[B&R%/+:BNQ69!](M?ZE6Z-]85JF??L'__H5]J"#
M>>Q(][DJ4E/% <5ZRVJ[18]H;X@???AR/9*K5M,:^&E$)3EY%,^'55YPV&%E
MMGZM&EN+)&A?O?6X@?W@Z+ 1(/S\MSSV\(^"HZ:K=^>W;+8)H* 1Q%?XA8$1
M3WP=[@8O[^RS?K,VP5YP\.K+0 LVT.5B^S5K7&=?_:X=!@<[3P\(>>)%Z.T&
M^[VC)Y?=U3IX<\V5C1K,HT#\./H2(['S+7'"[8YLN$ER2@TVJ!\&[J;*=Z*%
M^]7KM)=WSAE\NVH]V'GY919A<RT22QE]]?NU%=D-$=FM(;+YADA3,>RC:+^+
M2C_)BEL=D_W/.0?P)7^<5<,DNA.NZU[/D-5^]C(X.KS5%-]==0(:6?VO9MZ]
M7K!W<*LG=MO$VV%MFX/Y>4Q46^/EZ\B ][9DP(H,N+<E ]Y$T1><IF10MQC*
MW['GV@C/&Y*-6SW2/$DSMQ-112WP59MZJH7JZD$HRQ^8*,QZ00TN\E22LU\_
MRT\)OGVG^(Q/35N-;.+]QCV9PIN0Q*K"7AN7<^RN]%H1;%\9DNBK/$R+281=
M+XM2Y\,(U4H4>G9SS-#PP!*2%2X*)@(D M.S:)X1$>AEDH6I]Z\(.:PQSCS@
MKMX#4OK4FN+L\E_<=;.LQDO#Q\\4A(/C_8,.=Z/!;_?3,AYF\+$+:K\TR-(_
MJBGQ?-/1D*XUAIR?P,B9'XYF2*_I)<OY8I:-HT42T5")/Y8^X/8JHR[ @^/>
MJXY^Y*!_X5]U$-NK6H7:O:]*G(7F=0T+/+^9+:5TLJ<I4E5[]SK%CW)XORX]
MV<?E)>[@878-6P\;UH>=3/S# !N0[ ;U5K.PF6_C$5'Y]=T.LZ=S:O85!DA1
M650BXLQ6KO[F)_Q=YKR,/HV2BGK!*K+YG'NIXZX:E2U$N9[5; *Y*Q6')7(2
MYU:'\9,/9R?O^K#-4^+O_8"]-:EM*78\NF&J8)Q27"9<DQ"F?K68Y!FEK[.T
MDT<3\+CHI"["I6(9_W'O0-%K>H2L-_,51O:P4#WJB/?Y+%RBQ.W"$(@JD\34
M:@W27$?F6,?1P<[%^'ZK[9V:+\RK2L(RRY?4)<WJ_@FCBXHR2_6PI;M:M@2]
M1<SO*:7GBS#1#6_TRK>NJ.YPDU,%B&EQTQ@Z$?[;O+EY),^J[:+:XGKW$HJT
MRIBHU=%W?S3/J6.RM.]-8JOY>AYYVKC!HP=KZ5SCH$WAXL$3JV+6BNA5/6:)
ME\7;#'Q'E$AU*IO?EZY%> ?PL4765715B+5U&"9X WG%+,+R%+@+A/,_$^;O
M&5QN_ 9X7:)?EX:Z-]K,$E:0FJ&MW)D5NG4)3 \J'%!,HN.%XVMN!:^?2/(J
MD^,NC=:=TKYDG>92P1EHWB7'<"SG0WB (D#MFO7T5JXGOMI2)'=\="#G#Y=6
M'T'2"PLYDTH7@20A;;IZGS9V;^!][N)RSV'2E]3P")3@AQ2&9)&@*SUCNA*[
M[7[PEW$A=SR\DCB"L?]2%(TQ<L7J0[[@T1"0U%LI-/W4N&T<W^;Q-^S8G=?4
M@^0[(\>NFQMMS-<NXW6LZ+3I>/ Y8,44.LW(Q]BW,>0.(7B)C["M #]J9*^Q
M8#/N;#AV_6-N2?*YOF))J1AW2-* QAZ8)P.S6^LX!,IMLPA8H>QT=XU&@1'\
MV.ONJU_4[=V'=2SO5U?ZZ".Y;]QO?QOW4W&_W6W<[QY=>9]"LH<N*M=B5U07
MRTIT[C9>N K0K+%\Z'W^:+=8N'/D0=U,U,;DQSW[$6BZ_7C4/;K/0STV-C%.
MI>\\O 6,21PJ=PV&G&0W%(*R[@Z<2*_[4K]SS X;?])T^<&%X-^UW5U>VW5$
MC][I[M4??<];?D73([^UZ9&WLNG1/3H8^<T.1D[KLU+[#5A=/Z)^2=@R=!;-
M,="U##RW?1D[YM2]OJ"XW.!L$&A1<AL_Z=_RONRW[XNTA'*:QMGMY!=YI)[H
MZ2<:R8-=.50/_J9;8- +5H/)U6KCRY]2ZVQ,N'OU4GGVH=ZU],5G*KY>=Z>F
M^/;N]%#/L:=9\=W'91A'Q2B/A\KG<%R(U?JMW6E@_?89=\!(4:#HCF2W?&7_
ML4[I _NZ-AYVFUUREL-I$8^BA<997 .=QM*R.8\P481WB["^\$$(YW2?W5D.
M68"MNU\?43Z2O6[/NZ=P[UN6AUQ9H;JTKD&W3/&XPN&28"%\1KO3QC/UJ?&B
MFMH&&*,/>B@,#&MK>*NU(-%\Z>I6[S.NF?WN0>V:Z=E&U><)M:?ML)7-/!WC
MCC\[57=KJPD"2X=-'[FI6C:9%!'9I?Q5&[F["<?AGLW3#[9Q$Q4WV=O&31X?
MW_(EZ>TNXT]W);=;_]$GG^H&:/LMM=V6VFX#J>W@X/*OML1V&T7UMB6VVQ+;
M;8GMML1V6V*[;Z^8\>E9PK;$=EN1_<I$=DMLMWD\$\UW;XGM-J$F^CLBMNOM
M!@=?,[-=[R#8?[FN2>C7; 1\P]1VO5YP\/+IV^@\-3-)<'#P]+0<6VZ[>](R
M[@>]_=[W+KN[N\%.[^F%=\LILWGV4XM=NR6WVQ2G8TMNMXXF:V_+%=8+7KUZ
M^@:H6WJ[K=!^=4*[-48VWQCY5@GNP!X_ZMW:KO4;9+C;W0EV=K<,=UN:KP>B
M^2KB3]\CR=>6WFNMP#B\4I[%CG$/L?FN6:6>D-!B<XH.[PF 75^]EJGJ-6%_
M.0CJ)6R!MYH& [RA%308;75M=Y3RD85QCLN"J=XZRRC,/0;JJL(?.4!J8@LX
M6'%6%<G2KU+K<*T<#U'EA66C8-@AX6@=K/<%*#C\OT#!\:K;T^Q@1,&Q:ZJZ
MOV_EL"4E>&!2@EY;<>XM)]JMF=IM<!+T#NPRJMN>^44H"7:;O $U2H+;> $\
MFQ? ?R)>  ])[U;4]N_^Y=I^O[VV7]>WT2849AL*C]@.VPK-9N!XW:GXN<9+
M$-R=U4'?6Q[=6UOB@2WQP!V(!VJGIK=6NWEMVDT90:S=#AK$ R_OJS#!AJ S
M;I18[?1XM]D4?HT^YG-.D?^HI^CQ;85[47.]W):8JA+3_6V)Z5.+]);KHJGA
M'YCKXA8+EZV6O95,%[O=G0;3Q?H[8,MSL>6Y^$(\%[N[+9QOMPBT-FH\=MF.
M:D;-[HYMYWRF1(M9<R>6"T\^? O-1=URNG,8AE;*BJNLG)2W.EKEK)/P#)OH
ME>]&K^YMBH%5B*363.I$JL![8.*.QW%CWL;_J>(Q45_#_@_"18SQLXNH &]X
M%#WA<=Z8NVT]CX%71$E$00@2] E\#$0"_C1WPZX-EH.?-U)+?H5\!5\U*8'F
M)/ ;= 3^EH]@RT?PC?(1?!X0=GTYUP#U;U5()PM=Q" 1U[A9QO %"J :>)CU
MM4_/>KO!JY<-R,_:5S1.S5,,^R#8V_^L83\*5MW9^3B]!C^S?><?"#?WP)0/
M=Q['LUZCQN5!-N;^=;(K59V]=2^HR<B80[F3. 7S?/T!_NHPK\\^'_5[*]IO
MXR>_NQ\<[CX]XG=;5K]Y%2YW1_SRF$:S,)U2$!&=KH!=KP@<V>LP,;W0X!K(
M8^V:?;5H6;09#F\M7OSV8,*O@KV7M^K+E=-N$]YO%2E\S]#DR+ISO39#^:YA
M2D)#]?9,+#)@; 2C0NI #XTVV:M%Z;Q&E,Z@/]8.@%N=IBNCK=1SDJ!==V[)
MU A$JCF:E@IJ;(U1![6AV$':]4-9W6'#G@X/Y=! 2S!7$A=N.ZS:_K8Z0MSB
MTD+]P),]@Q8)4Q=:B) M\Y2"8E_$?&PUZ:N!7C8AW?'404/3?= Y<&W^R1T/
M7->_U=,1(>GIJ,O=(NG[=EQ\4>5PP;( XJ5*Z8 '"7!OP$8Y*]KF='CW4(;8
M\A#19-C!N>MK77N;7\,G?=_HF+N!7_9KP#O=+A*;OE)"8Q;F_'0LEL#6N*AR
MOO.SV6:AWK!/<)IZ_6H*7\75W6FV0\:U51D26,WC" 8U_J__YVC_:/<7_Y(Z
M[=;Z)/\S2Z/B*@])\ZL.X]QO'"9Q'8_@*V_?#JAOD/W9P&OV599^P:'T"BZB
M) EDSS'1C..#_T6@(LQM.O.Y0[?S5+]:2!/D< H#Q0[@<E69FPJIE:M<)(:Q
M3EW_/&7)VSTBR6MK%9WZ?9CWF.:.>N<B(K[F\9U7C!8!EYB> U^L_]UK+BF^
MZ'77OXB3: DK.JIR.E !K/6(D00K'@:G:AQ/N.\QK &8G#%NREW'BDT"&#@>
MF?=C\M,@1N$IW'PYG.+["#Y:87/HKG_9>BYI=^$6IC6UMS^$@QPE$^IRK5NM
M:S)L#_[Q)LOG_F5GSW_V!D;BO\NZ_M[>7F?W<.]5K_?<;EJ-R%5*F$;P(H8I
MO(F&>17F2_] X=\,)#[TT3Y!!4:HA@J1'=>1!CO0:$FPX@*'.XH($*_T#TO;
MCP>N=-ES#A#P*OURY1<W89[#Q&$/JS1F2^,%"$91#3$?N[#Z2O_"@$*]S&IK
MS6B]6T;K-T<;@EKY%,^KN7-$^(NH:T>M)\;91]U)>QC1FQ 3B^_)DK%?Z?;@
M*P3S]O('R_P53#+^!\P,W>M[A=[WWMP1_PAGFP9K8\7;GVEW*X;[$[1J@3=2
M-HJBL5QK![6&I6!.>NXGK(NON\G7PR:/[3SUZI5$U/1Y @8Z-NEFI=Y/TXJR
M^PBZ\I7BZ.UT_J4M#O)G6"I:>E.#9 RC40C7#9S'/^",X9%1\%Z\W_)J1.[4
M:?=U]R6^5JFFP&_>:%2WY&-!7LE=JU'PX%JS+B Y4E3[Q/J/U2,9/4MS,JL"
M_ZOU(-T4H7<=)A6B4U#8\._S+,=V,*"EX1+IE+,X'ZNE653#)!YA_CXLZ77I
MTN_M@OV6P&+ DM!Y42"2(J,.YZCQ&]_-X=Z(TP+6":$ /QX>>%N?2#>$EC;P
M8S$\6#H]ZF/.2$ V+#XM2+10C^+Z1I]B]G-R!4O13<Z+:C*)1W'$8C6!@\$[
MDH1IBB4?IL<'"KC9?]A:T8 :VN'9([.&]-WOV_W VH=;L+8":Q]LP=J;*/J$
M>QN@IX!55OT1U8.A>CF!P:#[O@6Q(J0;U"@\#H0 S5+B##O\!1R(N!A51:&L
M.?A LBSB@K4YA39@3;$RCYP@3Q(QJN>2I8_A.QR&10N:[ON4#C;YC.91INF/
M<F-FX35:(5BH!PHZS*4T>H25_F34\^5OMA6,!7C6 HQC3_"K6*4X&D4+*:M&
MQ?\!G VTQO%UA?\,Y[N[\\NO_?Y[^K'WRW/V)_F=&C-:4@E>VW!AVO^I8K29
MP6N"NVD>?H2;34D8+<P?U7C*GZ6K+B273%#D>/,@]I2 \+1V''D-G+ K/L7I
M1D=W&&Q1DA45N9/4FQA6@=SRUM@M5C'>:0-<F'L;;A\#QO#A@EQ9N%_C,L/M
MT8+R)\? *KZ-.8M'/5RQG3*OR2C.1]4<7@H["9/%7ZF(FOT%7G>]G##X"AR6
M;#2J<K6CDZJ$)>CZOT?LQ)(EH;\ VP=7/(Q/EUKF,6KGP/N89C?PA!SL/EG@
M:Q8__!F^=AWF6.@N?!(X\BR7'23S.(GA"[0"&$+/4@K8&+^O-D&I&5 'A$4<
MX:-DCL# 8S%=PH^XVD9DPF%6J>KY/%_B']G<U:+2"-*SE)&SB'9J.*9RW06>
M(2RVH#Y;-"FQLKK^@%<<1<0L'4]M(K!7^).65C41%_2*'^%YP>_0*Z8*$%KF
M+JC?LJ*^"?Q-=)O',5KU>MNMR&81>688O*3\89'N:JZ(%7*C@Z2DA)JW@5$_
MSB(.U)(>P=^,U%5@Z0S]FN_(^I,2?K2+8,W[XXSTHW4_OL^S%'X>/7K5_D9<
MB*>I\8C!&][CL_M&*TIKH> 60:<1],?K#/Y'7R=O^I>OU77B<6C([U]^H,=U
M=EY1V!+/QE7X"2^AJVP!;N7A_L[SG_W3.6811!%CT;C^I'^L]3WJ$W"HTQG=
M@]3[- _3@@[X:"D5'J.8;N^JB"95DD8%,0M(658)CS/7AR[&DK@N:5YKO"JQ
MX<?VX$Q"PJIQ)S6'OA52@\!Z@5HJE0W![_9*FO0BC,<.@%["K)+Q:A\EJ/@;
MN@"&D;IVZ:WRH<@.RMK/QOA>/F;/4H8%?B!?8? 8^#0\!'3)%)1E2?H[Q)#*
M=:0X I1#*_5JF,:M2K[DYA@66R1+MD B'+,,_QFFB)_C9^BKBT4"VH>J"N"J
MK> V6>(,/5RNKG\9S^,DS),E><;K9VF61RWD,\VW@:XQVB2C")LJ/K_S]#PF
M5+G'HV\3&KP^3/3YGV%*P>>>2G&>X&1APX2'!:X_&,P\+F%9*147<@RKU4"A
M"X[T.BKX)::ST4Z4DT:W*$AK>!W"DN*"X_-4+)BD*!2E1^Y_(:>X.5JO9Q'0
M4"@BUR&UF,)'?SW:=L!BC0^O%A26".D]LN^6_#NY(F>E)8:">:''*R5_"@(F
M]^HZ%<VZ$3?7YO!1G2+;U%*BPW@5^>8*0EJ7@\[.?N#_+?Z'S>M%CM_N+T3[
MY1)^J>NI=_1<$G["PH?&V@!FDZ-1S][8 ,8%^B/7E]K+G9=PJ0U LQ&;%5MM
M9>91:DS3BZ4%W"[B;+T/ERKU&>KG_>U%_ _E%R(!52$)O;,0 \7^KZAI4;N,
M(] 7L>6TP0+!691K&10,W0EX:6JS4>YITCF4_-"H(7M4"WM4(QF5;V4'C1D:
M^$6%99:%KV ;]M^T;:Z=8ASE=994<\Q/>N!-P1T"4Y&K!JU\_4+MG2OH!EG
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MI?\F\G\K8X8Y.XOMO&(J#9)\#E&>:30W[G/LDMDC+@8/>H6['T\;9)(U_<.
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MP*73"$/ZWA]FRL++?4]QRR??ORJ9.Y[UQVG:5D5=EU:;&@<44EC0MGUXHLY
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M(^Z+MM?3S%XQ"8,PUY>40''*V #O("1!Y>7]Y7D"A L8N57E" 93:^SDP-%
M1J_C&HJ(:3W#/E2>,:=@*((BH>3#I'UL9T$^!F.'+'T8J0]-AAU_P>Z1$?M?
M:S8,7PA)3#/SK%+OA_:"DDKM15'?UZP.S1Y2>/(X5&&[C/]:$"-"A8HF.HVI
M,7(E2[%0&@SYB(XR]9:0XX74% V'[C[HWZUF6FP(T'8P@M*V0V&,I<)#OLQ
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M,TFBM4#>2S?\LB#(6W3&BV#5?I(,W&=T VD(N<'&R0?)>'=TA_Z0WXAS^N:
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M$DYFLP5'521II]I"E#$CAZ9E?_;YT<-'#U6;,3HH@:F:D"BH[D371LG.6$V
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MQ6Q24ZUY_(I,X,HRE"G_.]]RT)EW/10OD/S0J0H_N7?,^@BH*7=X!-:T<O1
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M,O<IHI#:D(2]>L(00MV#1-Q9R[VDQK<+Q+E(^M8]MQ/!^.FBNC=,3"-0H2Z
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M[33CVZX'&6'-,[KG"9&@B.Z*9A?7YD#0*N"&KAQ./O3&3!+4DG$E1'MT@ O
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M0+S$&TC.BO)NWBL1M$(*'(M< '2*^.&MY]CO^^!+C.&H)#C!U?:1?$3 )[;
MM4\HJT?.6\R8'300[/Y*SS&>Q3]GZ5OW$6ETB(&<'+T00&:_DF;+28X4P$C^
M1#[E,8 P>GVNN3E.C$LCB%_^&TUT!S ALYAKLM#T%A!]^2?,E]S"??2ZJ0B1
MFW;LR7SL(UD6AW(\%S4+'C;)C=3%B9/D72"JS;TO:)LQJ0,?5F=!=*Q'0PB=
MD)*F'-[MOY[]W[>O__'T]#^Z[89&^F_?$(^1_QDV\/+5T^?_\W+\-V2?U1/^
MZ9<W9V?XN/_AYS-D]>,&.O'D*'7$M 1 3'D:6^9[AZ>8* M,Y,PI0[X%F82D
MXW,?&:SQ' 'HRMY6GF)O&,9'TD<!R9?O)79?%+,R\529NR)/6(SSE,;XV)W6
MC"GFU%4GSJKXW$,>:SUF:DMUHF?B1#(>0ZZTZ*.!N2?1,J%%8]X\%%$-M O]
M/GC*2=A66^(8THAUGCQ&I &G%'S7<RB! A,RK)]H!=^^)*I65B>,UHV'%;)]
MB+FFRT3<"!@+&O,D9/G8/:5\7P5_F=>CJ5+9#,3Y->A:4WC]..[,@#&];-ZE
M-@;(.1Z%$*I[MJG)@#*4@=F5R;,H=I'F Y'+($5:H==37XX\7]E5PI*4T7%F
MGT77Z1 CB]5X5<=$+T/K]VPRK-U TQ,6=J"Y"2((U_+_YP,V%"&1^0M_,FCK
M9G'752&#H)1;=$-O53FE].UUB#499)1( -,@^&/OI(DYVI]M38SU4F_W$M=^
M/@?M"WH,-\6-/3K@QA0W]O" &_LZ#%SC$4G7>1])*FZ*:?7;R$*DO9ULN:8(
M8QF()KO3*#+LS2&7=?X3Y?$7>MU;X$ \;WRL7AX]?/20:0^H(HL<<HV4>UJ[
MX-Q'+%SXB>K\W_U*6E-#CA_."Q34GN-Z.*'6Y 3Z^('/QVJ >^ZOFFQ5%OCY
M8M6<0Z(CZ+!3LOM,W7CX$$:,BXL.T1JR: U\>\OW-6Z09Q-#JJ.G%LX0_<NW
MT3%C<$%3W0>;ADXKLB+^#F>_];SFXJ@<L$D+)G\Z>5%.0.D0^:\NJ3IS58:N
MP?A2XJ0U]$J_2JF55P>O%:'/U%R;&7<>-<X((ZV\+7!\E@'!KL?R@(R [TU1
M#*]"^7>-H,.@3(R4&(KD=P@\,OT(FK2D)-(UZ^M:X$+0?MM1ZJNGBE*>H"A?
M_YN/T+]_JEE7FX*;(%-+U[!,7D"D!7.#&)W9.$,2D#-B_@S<K9IB'DN,;"KS
MB04O>#M$!C%KH%7%V8\O7FF]/I2AIM6"E8P"IJ;,Q?[_J0)3<=^T/%UL!>^;
M><&>:%ER+E4#)8)B=-EE52@LM0N[B'_J'+C'IR6!+C3R?5:7K9^%>\+%\/3E
M,Z%AN)^#WXAP/^C1Y0LR0Y%>T#R=]_9)Q&?&-=JW<5!CSD*^-0]#,@(FJOOO
MGX(LR\]9E80%/KC9MCC]9H6(;?E[PA2_DQIJ<T2/4#*YQ,._?J^?F#57G;C;
MG/[KG*[IC9!<FGW73$"8:-U\U!@"R*184U'=C,55X''5#7NU&XF_L%G+SN8T
M5F!2ON'&3*R_7<G#*F/#-7,\.8-'<&?.PR,6MIDV @:LI(Q.6?MF*]A--?P0
M'3FR'5*TK_VC8.\C5IM>8\:J,_,I<HW:J)U!:8IP*57/T-BXG+GYTP=O*T,X
MRVLLHELC<A=W=_;N?"3/]8$#<E@2/<#TX-JES*' XL/JM.$>8V=&NCVR7$(O
M.\$#=D[LD5OH9@71JS/.W@XY^)]X6,>)1&-7T1R$HT8WTPA1K#8EFK)2]+W
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MO0(SC(C-U;+4Y%=(OLV,,;G4F C-$FR'#"1V--'RI?*\>>S.:$]@H^&O,NT
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M]0/W;K X]9!6.M7HN@GGG PZE;X$JJ%Y"TB38!>P#H3QEW(WQN'[8PGG)',
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MQJ@=>QS'T:*KVICX#- \? QI8XPJUT ++FCZB\69SIWI^TKRV&U)\\NC&E+
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M.G/D>_@[-Z21EU:6"7&!NA<-YVR)H!2:CO _E)7%*T:^"Q "POEXCM)YG Z
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M)YG?QQSP\+<)Z29=(LF\[&I3)*?QX0]B?B9)N"K3BI&IMNG;NRO@5UW4?2O
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M4#;(XJ"+M=T(J55F -,=F)WI+HN VMR/C8#%#DL7SDK;?+ )CL&UPT?CK/_
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MU+\@'1G2["T3SJSA0Z8;?U^YUV ^Y14L&:Y%4R^]SX!ZT@A  [IP:8CJ+2F
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M@,%":;EKDMC%C #[>5F?H4X(=_>FB]S[X4C?46(C0@X.''!96Z"SH2)(F%T
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M_AQ_\REEF9  8O([L72WKG1.MH?&/7?]79T!"27RWC#J0G +B::3K RN*GS
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MIHOR=PAUC;8< KM2-H8;9L%;'^P4O'J1F(]2>V0ATG)N(T0RL&T/$S.!88;
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M7TRY<2^.Q X. 1M#@ VB1WA?6/EN.\*KPN?ZG7[_+%D 'JZ- W3A<]*1-.0
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M^0-DXN,&<B-03%#ND3E@19E0.!I_$R2=<"S2!9EK=,G1)MI5T A[LA[(S,
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M@SG'R (<J6_2TM#NFQ_%JW&UUZVTNE:G>&7U/CHOC_V2"#MF95)\E%K5]K4
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M    96$P,C0Y-#,Y,#%E>#,Q+3%?86-T:6YI=6TN:'1M[5I1;]LX$GX/D/]
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M'L)C5>1?=F&'4@44KL0%'0"B;Y_KV'AYM+")+,J]@$,=TKZ'[2O -MR1O$M
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M [">_(CP-07TE+ \1_2U"_2B1 ,B*4144 1]"&H;R@Z3!C8F!6W1/$+K,M+
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M[[S6&U2:; ?G92I/]_R>)"3X$SK-/@:<BX2%A\!Z=VBFE;>>.=5V%-2[]ZH
M#YMS[-OYR4OA/G-:_WS@&[O 6C0+%0O)_L(ZK9"-GP^]E R#S3#:KW'K2C:#
M0!0<;VJ;O3.W)\X<2O?'%^Z/-JB[C7Z9[Y[J^D7_-U!+ P04    "  4B A;
MH1Z:]N)J  !^?0  #0   &EM86=E7S P,2YJ<&>\NP585&OW-SPT2HF -$-*
M@Y2 Q(!*B8*T--(AW2",@" ]A'0IW2%=$M((2'=W]Y S\XWGZ-'G?WS>ZWV_
M[[V^X=K[&O:^5_[6O=:Z][X',8%8 -QZ(BTG#4!!00$8(/\ B&G (P V)B86
M)@8V%A;6C1O8-W&)\7!Q<'#);Q,1$%-3 &FH*:BH:!FYF&GI.1BHJ%@$63GN
M\?#S\P.9A<6$>$6Y^/AYOS-!P;YQ Q<'EPP/CXR7CHJ.]__X@V@&$&*CT*#:
MH:'0 U )4= (41!M "  @(*!\M<'\..#@HJ&CH&)A7WC)@YR0.4M "H*&AHJ
M.AH&!CHZ\JX7\CX G1#C-AV/)":1TDLL>GMB7I_(C]@,#\M:2)0'#QCY#!U\
M;]R\0TI&3L%TEYF%E8U?X+Z@D/"#1X^EI&5DY9ZHJ*JI:[S0U#(R-C$U,[>P
M='1R=G%U<_?P>^L?\"XP*#@J^GU,;%Q\0F)Z1F96=DYN7OZG\HK*JNJ:VKK6
M+VWM'9U=W3U#PR.C8^,3DU.+2\LKJVOK&YM;AT?')Z?0L_.+R^]VH0#04'Y^
M_F@7(=(N5'1T-'2L[W:AH+I^'T"(CD''@WE;4@GKI3T1/:\/-O'#R(]E+3<8
M^)0/2 P=!F_>8>1?9#K\;MI?EOWO&>;[_\JR?PS[9=<4 !<-!0D>&B$ !#B[
M9$E_<_._'B7,52/7BNY+(@,[VREZ%G1C4Z@!C/?E;<AL<#LC))ASQ-AE'R5>
M[CS-,AIC*<8'T5BJ:+L/;GQ# #*W\')>!-0B )KTY0%F%]YJ*#?VY)9B04!]
M747;'&T+0FKM@9K@-58NE[94:4$2KZ;[KKCVG1[>/8;K,JY2=HFV$%MGS9/3
MZJ$/LNO#"$ %%V/LMGD #P,=M;"H\X*:[.>[NE[A<#G^>+T7=Z9DW_)5=:M;
MH!NMF5#?V$+!JJ3I>#E -)A;?&>X4RO$TFYJSOR@'0C].)0=)9(R\3[[E.U^
M:#%/\EGQ5OIS^YDL1BC2V,R74L3/4?Z7AYV@-_L(?PF156FAZ2G&;EA69;TL
MH1%O9W<_@;>EK*AS[JR<;<ZC3 EG"VXN:[W[M6WR*P!-/^ONKI<^P>.3\@["
M@[-*>DKIYVM[O?+5(P+,M77.0XRUYM?M4_O0# J_3CV)V62C2J?Q.=8QIUE1
MK^IGPTLC- M2Q \/ZKIN[G7=S.K>#?4\R=[H%D%--#.2<G]WS:SU.2\IUWIL
M7C'ZR]'\)\8/\I0![!$NI^@&7HZ[&@.0O2+KE13^>9#B<$:5]E40<UM]EIJP
M6F=?V!<QOBF(T3UHX,E-]N"03E)($5.]A5)1B.61A9Y;&G>C)%W5<@[5L6Z1
M&4O-GK+%#K&2E&QK,,L'U'\.]H'7MEY%+45\FGIZ(3B>(-['PS1W$V_P@MT9
M;7NSL20W+!=IS R-=XH]2$C6[=S&572?7-KR]J_+^\E6UP5K@&EECYR,(ESV
MA)>3#8P81ZK2;MF6J%,*.<6'YW%>3>;S?XU\R7";M)?E9<L"86*3$9UC1E-Z
MPR*<1>'5+@4UE<!(GCU_Z45A,Z,RV4&6ZFH0E3'*ON[]RB6-X9/&^U;R? )S
M.1QVTX_8W0WXPN:%6SH H)ZLH:A!WT2S1U+N1>O! D5FZM]><2[?YX3E"&1_
MB-0Q<FQ+"E2?<JA9SU94>#"67948GK-\?I+D97.F4*7+,8, 9%BO7O?5BO@L
M$\.BM4O7=UQ&-.)>7"M\AL@.QVJC>+E#S5)7QQTN C^1M4CDNUMG'OOL]SD!
M#U* NY"=M%)"#YO1.[SG?660K\>7+N1D\#/RCX.)&$+E9>D-=>M+ GM%BV'J
MGO*"GXR,Q]5=632KWBR\_/0!LV4 '=)3I=^I<6].!&Q:L*E^%FEQ/)-0QIV\
MZ&T0ORII\&"]45#:7"Q382EX8>'<QV5(BN/RJ?VDHJ.C&7&(?>W7,MNMFD6%
MU@>'J@-M89JO$C<KL%'QA 4DQ"<'(K0ML%:OX'Y9?TV7(99B>N[ N\MMG8KO
MGKF6:\=46O@8;JVZVG3,UDM+7$WNAZJA'.*HU0ZKFY_$<_:M^L^V)R6%G9OC
M4]I-?SLE;@S]DLJ<H:2I1U'?T'30D>#J?4OWV:LHN=*5V]*.WYRWPR>+M/H*
M1.Y4(N=:! :QDL1?!PG50= W5G<B+&%I-O"3$EARVO&A,P( 3LQC&HV8B1[T
M9NIA2X,Z@ ?:QV%P2U!Y--R;JVG_6*7"$XZZEG8$!QW@O%<#[:P@ &DA)5?7
M(V SYNMK7?#\6OK@_CD6/P(0=X@ O-%)ST, ?M[)N!(&K2]MPQ$ @3L0<+-P
MSG43Y!IUE43QUW7@9#<" "+5/[O(10I"Z0.M7H,72%GRP;^NP_L5+\[K$("F
M/JF,^0-\"P2 >QD! -2JO7*:%A/<!1J]D8(&);K;R<TR.-MXV;$V_3=2TI]*
MJL:U7G),R5O8&@3T95M ,0T>^X?<P1+&8DSVFRNK3$.9TMT<N^-AJ*75:;JW
M%2UA@JOC(&^#E[H>G7I1'/TGW?-'BJ!O+](FD;J3>W"_Y6]D4*BNXN%L*]/T
M\E^SA_#2RY.P?T.5XX]P WZ)/6RPWRRH'!.P'JHW,3+8$+8)EFBW_*/3J.;G
M"#POP,!S#/"Y#+^?8!*4\5A\$@J;3H)YS]9?GG;2Q.2I(@ _H5+ZA6G6Y%ZG
M^T]'2:G\\H/,/PBK(Q%Y/0S7[X2C. 3G_"*%_()82PQ)_O\[]KF+@8]HFO>^
M"/>6&5V,.&IQ[#?T\AZ&,OI+/8LY8ZW5@HZ4_=FB IFF!<7_J\J0K!VL1=J[
M<\Y4R0[W\FO@KR9Q,CXBK-9K_5![$.#G4EANL>&JTSAIL%.T5OKEON0 @^\#
MX).F/_ER5 -^*'YV!&>_#KYU_DC"EX!>C(N0=#)Q^&6W/E.2^U.B8?L^2:!/
M@R!)_G1V(FKAG!M8X&Q_NEKDS.:JP4BHW0K\Y_AXN0_F7FKJ^HH O&7_TBKB
MUI$8' L]TI8N8'A#_WI/H<$O>CS'TFD.[^#Z;.PLRJ*LXAL;&W6?+]&>C<YB
M%;1+(../P#N"W<3V5Z\U+D@ZW_''V"UU"^)\\<9?AC>$DFZ/GQ0]^7.XI*3N
MN/ZO@B7+_.P:Z_]DAO\.LV)PMV&$4*(+0_D3V6LD1+[OOP/-,:AVMR(T+F:]
M1O(LG(GV9G?%R$G(5^L1KH\<^1M<C&[5!686NA-=0F(L2% !JTC9"@%ESFDW
MS#U@K3J6ZCC\7:EZ!SMO<W0S\\AI.F(M3G+I;G\NG+[)'Q)2&*>VI8K6+Y:'
M?FFA$B9MO2COKF\N<H#/5RW<+F"\EWEW[0SR74OK>;\*G$W1[I.)[JL'4XN:
M[]V?.!2\D5@()U":*G?61WFA8[$T_S1\;O+S$%?:@'2\[*++2DJ+3Z>==VV1
MOQ=/C_]H$,>: .JQL/VHC)A7OO8+SGU.HUK?K<WT2%<&]T)>,?=\Y>HIHC6P
MV?>P-D0ZAZ#"G)]=[,$EH0MT[N7MX@W(/EDYRY3WFN)L-QE)?>Y&G4M1#@[.
MM&KLY).8IY&E)0\S';!/23 0@$FG"67YD) AQ@CI$,KZ<IX- !540'U >="V
MH06_B,7\FTAA]"<2?67\!ZXGF:NNKK0ZO3O?X51/)1\L5&^W+E0&E=9WVT@*
M:]@]XA&^"$)?21[Q:'I;(>:QRW7*3BBZ"7P/[',2X4MI8B4GSQ.TR($;YL#T
MDQ  (+@%MM<HMLFU,KQ3M%23]CS%,&&4_B7??:B1/QJUH]1ITSW/:0>D*.Q]
M4;H/\S*6T19E.Y60GD!IK7ME!RZO,TT<L+"":V$AV0C *ZXBJ-#GN5*O9,7P
MQ^[]\T_ _R2 5[%*4I2R9X)L@3@\?(( )>?K+PU-?V4#,YF%$OQVZAFY[ _A
MN[@..?%7+D0UN>2MH<<^P3'73!_E"N\67CJ9'I+KB*^UF)"ILZ=DO=F0[5/U
MTQJ\&\LRK53OLP;HX*)>FL-F)*RGNH7/=F'-;].?+STIFMTW+P/?7"^I1$Y&
MTL;KIF $@(%=Z@ _.BLN<8FIOM["++K?^@NJ.N.;VF8A$<=QDLS7K!\K:]]L
M'L:'Q9>QUS:-H$6D>)@=YFF^>LO7PYWCY"=N%B?LD.E,1K4^%<)8V51]7+17
MW!-@;##$&V-@)XD5(9G]"QKL3O\*M5$5%6T2[4K: /SFVZ3FAK4MM/91?/)
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MGV&MW!Y)9$'Y'+L[$,BX< 1J["YH^F48Y/SQ @*0E@?:CY01$%_LUO_$>K?
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MKQFN8$?J;K7W/O[+:-]4?P*2Y(4  *WA6PC !GW!2&[!*]4<]D9Y_1]W(3^
M53//7]4-^DU 4<I==^8JTYCJ6^?][,E%, *XZ#SL6%-5[O'<VZ34PN'T8/;X
MO>^M)I\S G"!J@/#.B;YHN%8@@3H]OH&*+Z8HMX.Z:95(W!@(VH- A!(,5$Z
M%)"" \[4#;W_H!"IE'A:BO.0;$3;49=+.JNI^!OG$HIQ2N51&B\;J]?:3Y=[
M'7V54%J7:T@F%01=A<*\B+=H2$8,&NMYDN332V<8P2V11U%B,M6-'DP=.=8V
M[7)<&L5S?H<"ZW4*>8Z%6SQ3LU]N>\6\'F-S;.Q 35,0- L_=3>L'.4H9AZ)
M?!UV](I#<6]9I8)P0PY]K>*]BJNIS3,;EZK+L,8O&,IJD%F\^0W+67=HD$&=
M=XPM[2Q1U3P_'S#)T;[3M 7=:%-W-+E(+%E9<(Y]8.Q3LG7I,N<KW0H$ #(-
MOMQJ^JJ.S.2'A]Q7ZQ=C4CG7WM,(P+@:W+#"F3*7P[^O;Z0;E[",FR$9@[R0
MN79<?O$BO#N#?\Q9=DK&H"QWYD4JX#0S6#5%_O'T&R%&CV706&;9108_#0KS
M&\QGO*Q&J61K05\ZZ0.DJ<EH MX I1[9.MLZ#7,V=+,_H@M^GB-"Y:RRWY5K
M?6HMOK5;1%L?+C<.HD^M65@X$=H/?X__]5.9=%0W6WIAU+(G2J^!@=D&ZP5_
MC7C,K40&_D@L3-D1D1)G+"'0Q^M<0B;R3.G;TI^8V9IOV8]0A&L'OK2+DLU?
M,>9VX,6TWXP"/0#$\9O&80U%8_YK[8$_ZJJ, .@2P.RULJ8J]DU\* B9FN+G
ME(\;@N/J^(,;-!.D+<?3+) ! +ZX-;@^!1Y(@S_FUX4RQ[BRK86.EH@/PU\C
M&SRZC &D3]- UX'F]3M4!;7JH8F5/P>[0]..UQ& 2#Q2+S\DU:!ZPY7BQ3$R
M] (@/ZG3]TL=BE>UV/XD"5]MID!*ZW@7M#Z  -!3B/XD#OG<TE,?8UZ@YY5S
M?8$ K#R2^8?8=4)8PZ&(Q.H?G?ZAYKK"8MM32R_Z1R>:G]12\P:KNCT5+O^-
MGV/BH3K$TRN_G9^P@'DR@YP#2ZA0\5SZ%'2QE'9VH)&IVVM#P3E67WX[\CC2
M9U/M>EO_X@AT=C 64<)$',63YY_#6BL(\^I,0P!:!?.0*988 6CRA?QB\,%]
MK.EX!;R_F-%?B=2: 0$ X^F/,4\,;#E=(0#Z]DAM#\*VP,?MH/V%' *<K6P&
MYFB:;RURQUA:^PU72&'??9*M6?2Y;7TGC3N^5O_>:4OF(=&.@&_._.451!B9
M3FU5D#D>V=6#,8#_L"J1^+=GTY!B]57^(@/]!QF;FY62!3&O=+ B9P.5!OA?
M -/,>?G]4%?E4=D[159<AK!"38BZD&BBWNA'"X&R&A1KEV1!\9=B^<"?T!<*
M)[D^N% .EOMO4.H@H\GOVZ](R^3[_H+HX_=A"M_#9DD?W#D-KFNZQ,X__>@J
M\&DF8JP^G#3M7GCKQW],>S];Q2:GN_5'X!7VRT21(JI/0.?'X+,^DW]&O-KD
MIISF">?FL-VL%TB1V4OZ)I_F $,N;#KME*2(49)^SYXI8+A$'$CRNMUN=/K=
MN2([Y;74ALEY)",8=TO^%E-?O0%!#BC+W7\@4.Y@Q<.]FEXCD#FAAH2%0,=Y
M@&3'2QJ[ZZ282/W<Y=-,MWV6(O%#"4?TWA@=!, )6CSE("]MKRGV-47PZ;N'
MY>_4K=XQ=GSV6+">.-^<IXWP.K!Z=/7@CGO"^[D7.FD"])IVN9/=;+PH6"4Z
MP5YI/LZ:14L5H\YJ=W@B7L>[,T\S:MABI%169JJ7MH:@RU<2D0/4GIB_(VWL
M)U48JA2!*0N7&-\5(DMR$T2#2#L(=0'#7$L?T_K0ZP7S**JJDJG=% .T<YJQ
MZE@X&X^E'5[9(A.'QD4P.-!I?60UG$@H8)0+-SH959M\ZIXT3W1TVA.37QDU
M98FE^&Y-  N1&U]7FPL'88\-=!8R5+M>.RYCF[;A&+GAJ"/)5!CGX74<*/7I
MZ;#)DIKZ\_OA.]@#-:(4MM<,2V9NQ5P[;_.QXK!KUNAQC1=<+I3>+9\6D?'+
MIW!61*);N\4V)X!&.QZ]FB( F!70.%C.U&D*7H9MOY 43C ,YQ>1-":?<0RO
M-1HO9A>A/'9/P%LLV&2NBAKSU"^78G'3!.[E)/954-'<CQ"B=>YWRSMY=G=9
M4?$NSK:V111V<W7U>Z&$]\"4:MPWD]3"S=M:%%Y%NR7OUC\1+NTJ/PM_\7+V
MR+'SZ6V^<%Y\=CI^/$G.5+)7B^'FZ\=&M;RX$7F?^,E6T'R2H7UW<.;E$Q_0
MA-R/=B+3#PG<XWR33/TA :7_M'F%^BNO5SY*EJ61K"YMKV'$=-M@9DO_A7L7
M.AA39J[#8W2663I)L0F/J2U:$N^]RS?2Z9B67B. !Z?J.^G:"M_3J![6D*!$
M%AK]F"F9=7O03KYWQ0N-D?S/=Z(.*MJFL5/\)(F58V6QX@L?1FY]K .[A;]O
M._BZZ52"&^NCD]_RH,>UK8 #4H9EI^9[90 MZA.?6QM^4N-#:US+-H3I\(&_
M*+J9"H#_0$,HE73,(&!(R$1*5\Q8WKJDG\JWLXK,=\&Q&6TL! _$.W]-/SXX
M'2=G(!C/9NQB>-.=[GZ:]1=0D226?TDZ.TOBI$.G<0@S3U[4?10[ /P.&1G5
M:$N652N&;653HL]C2],+B2_1J;4KZ<>I& (510K\X>1,L8J@&V%7,3PL!O;?
M,*2V9RKOX'Q>?GE0N,N/NJ(-2[D?E*YA2HJ+!C\LOY:Q6Y[>5-FXQ("G%70Z
M\Y<]P$9W*'/XVL;F$QH:+I-'TSRNX,XXI++ZV+$T/9@MZ#_*X,@^D:Y8>(K
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MKX.>R=2U0Y*CC8_*;R1&Y1PI!F(D%4 6_"1@:HI2"/T>.X=!%)H(S_ILD("
MTG_=)"QCR;(K0=44.CNN'<A>"C2!O)'=U3E+8KX^ 5]MC$LM"\U6Y@9G$$)?
M7 !21_LO>)$5CQG933]S&:JF%RV4@A4V/NJ+AGN 8"?FQ\;(^@)! +PH1!/
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M]S%()D%!@KBAR(Y? 8\47PG\'SID##O7ZRJ5/*8;T9)5"@G%TO-V/E5^A(L
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M6><B"^CDYS%%5%TNDB7+'C?T@2^P#*><=67OE?FGACV4NKZJ?/Z&'IT2,'(
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M+]LYU .GD[:^K!S_QL/[*I"3IY*/V'WXEK#F^=?1W%4V\@62<97VO&S#*1F
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MO/R:)%<[56)4Z<OW?9^8*GYKZR8=D?ICI"3^678%5[-%1LROK4\\/A__V*U
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M[8F[Q+0QM2A7,'^U976>=8IM]&2B7,1[#*$=DX#;G2;SSG@#4?VT%RO1_J7
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MCGB6:,/=0B,HN_P+8V?)Y0DVK6=G$[%C[O!:>:\H1GMMN+-GH3B.?CE?%TM
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M?=U8?J8=32$[*:"^L_9Q&EN?/<OOVRS4+WIT*="1;@[ SB\B2XSN\:!\K\<
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M]#&?]?'\F<S^3W5?&157MVU9!*D0" 1-\ 0)!'?7$*1P=_>B @1WBI  P2U
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M ;B[:%*\(V9X*\4"LXY^/JA/Q5=0- G0I##70>)"G^MS:8>W"&%[NYQ(4!L
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M[X',TQ,!!KY!+T5"#:A-L-\(#Y_UJSDNXQ^T"W P'3)X_^.5.*C(MO6&"VM
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M#W%+?2PKD\3.=!T)40.*G5\B/<MB<X(+],HJ<\B:7<X$R4"&J99$&TE\/1%
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MOKV:#3&VWC KYUJ3'K_O*%TVNQBI]W&Y-GJI<2QKI_*^+/D@HNP_=?XH'6<
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MZE\-F&A502[<$(:!Z[L_%%?>1>"1OM?)W<]@H$U!/<]XKL=$"N_6X\UR=G"
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M'7>OS@5ID39 X\5)_/\)79:(!V6KM05;V%;6:/KW2 UG9=TEO:;:AI9$-I9
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M/0-64.)N%,"=.]^> =?=%1]<DY%R,(MR"!]PE ZW2AY6 K?/=$Q!I\^ (,N
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MY[Z?''T> 7??B\RW*,CD/<G^?M.'S60Y7M\5L.!;L!KK2K NZ-*^9V&=OU
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M59#=HVJV=V>=#LU"2.#H@IBC/RF-Q+Z\"+MKO2UX(/M/;U7QYI3@6DQ52]A
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MNLFR#;U->U:2 1O<&<27'E)CQK":JEKC]40.83<G=8%%K[I2Q/R<[ERW\+L
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M  #TD   #0   &EM86=E7S P-"YJ<&?<NV547,O6-KI($UR"NP1W=Y?@04.
MX.X2W"40W)L "2% <'=MW(.[I/$FN!-<+WN/<[^SSWO.>>W^NE_UF&.M45VK
MNF9US3F?9U:MQ_G'5>"%HJR"+  '!P<8/WV QP5 &D!"0$!$>(Z$B(B(C(R$
M@H:+CH:*BD:$C8.)2T9,04Y&3$I*2<-&3TG%0DU*RL#/R,+!R</#0T$O*"K
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M[:8SGB7=Y[U0%' 1]0?N8?[XQ)_U;8B__=)-^2""G]CMSMN2X?*%5@<8PGW
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M<DBDCG'<YRUH?6%V([4*IT.O[H94.N5"5-TERE:+\MK>B.VZ4O/4.6TE9*K
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M"H@\</C%21!,QY'>]P[NY]E9J>K_5_18#(T=UO)QF)F>(C0-HTO\I0X.>J8
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M7X.=@17P3P7H#7V >/\-J+7D==2*%QTTF1:\D9,?&A*-GJ%9S D8M;IQ^*F
M/*_8EFZ>_3N-LKF?=\*:$Y\$K"J-UT<H^C8VI,-2.5.S-H1;='"ZDXPT=F"6
M,L81RO[2YCG7&*[X>7I:ZM0, (+70&3O"E&Z?(I2K.Y4VA .$G5'@UY$?PY3
MALGT"F60=S;J09R.&-64K#4]E>/ ^XPD2J@?9*1.#(.@8U*EZJ"^+8NFD;[
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M>&4%X^P,:@E^'/N[XCPW-L?!M1B$?:TA$"4G0C,_[79#!(CZ1\2M<=ZT>:2
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M!;?;>?(^S'FN*^!&5B( 3WY3$A9@?OCI"PQRO#0F!9I:M",>,R7;'_/GL3I
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MN)T/.^GK_#JV\CN3#($-]\K:C",$B7$%M8,O:GL@C=SJ*4WQ[]NQ].ZM2:^
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M!<W7@MKX=<PAV)\S@%@G()V33\%"I-PA)Z?4C2T1%_RI/GFDB8%1NQF):8=
M4#37Z#=.< B(#2K@O*=4<@/.0>&L2(@@:\9UY*O5T:A1*_<MG"(NM<08.P)2
MR&V?U?%<UR,2IRP2$$RLSD#;,@86<>5/9C=U2+5GW^[<72G$^@UGD9?](:;'
MR(HOR;1LM7!%5DRGKPW_S7\%BS34UX8NV^>;,#!$M\##;@5F_:HP[UQ%*YSR
M!QG-&8.S4(J_6U$Z26WM5O7/@IB$<.<E2PXPEP[XRNN<0&:34"5+)=_ANJ%7
MS$>2!V_VU0C79;(Q]!:9ZTNBU2 J<*LW(7WS@4Z*6*O!8 ?!\[1PQ>]%H[-%
MXD2+V)*H9^,I3<M/#S:GA?VRN7>4G\^>7P&++H>6E-G?Y$88N!$J81\UQ'6)
M__;EB(5T;"75(B8_.KLC39]HCB*_RR%EW^XV?+PJ7Z;IJ'.^:^]13U&V#NI:
M/%HUIE%I5.//HSY;?+%S7-H 1QEC6Y01<9;-5#)[U3CYKA05*>G;M",[KJ?:
MZNA.CU:5A\JNUB_9.E#!A8ZQP] EW8Q:7;6C<MS,'!=&*LXD=%+$F]7S%0RR
M\3)4!WO^PNMV7!6:D:!Q%W=(%D;EN*OXE':I.%,4(7VK0W&0PK#5#Y:8]!E+
M/4%U/CU61>@*?@4@=D&(W95?%E"1VAY]^R8%_L37_NE?NO?7!ER5,GS/?M.A
M!W#&^ $!R(TU/VACZ2"%:JC?KHOPS\!BZ,,NY!="UR%5NK(E6%!=:MO!9MK*
MG7) +\#PY7+G/E#@82. _X!AB#,[;%-FW(4CYE:[:9K@973EQ@.,DB$5=4!M
MVSR@*"'OK;YP9_#MN:D>1FG&OU:\6LSZN<BY8:3AW6/+GTT["<$]F);<!@;[
MD!LZS^*6A^0RZI:*PDG6DJ5@Z.^ ()^Q=*;$L0KZJCO5['DWG%WMZ=$"PBZ[
MBG80,]>?WX%Q<*LA2VR"M2(DT>(.T6?="GQ+[BC%!]WR.']BK9]+G!L+&/.%
M3MEYD/&,5\KZSVK@:F:,?0U4K</SD\I-":('< 94894%QM*M3;:N1P!>Q-B[
M-4^,]=9R=)0SU^)9^,;6^^AY3N)#<.33&.S;PX9;+GWT[G??BC+-\*<49U(4
M-(FIZEZF&Y<F<92!S7\& /!XI]E6@).]2L8) 1CTW+:/H=Z95OCDT]3!"@ER
M$EMPL4-195 M]E"_&G<%Z1^?&+[O/ZA:EEM%NL+&$^[[@^RD&A4;XJ!V?)IC
M>8G_-M$!U>=3%<'F$K&D&I]EG:J.P3%_9I=>3\KRCCF<%-Y-:?M9:=Y+[S39
M"V1&&$3M&5TP=A/=-X\=?M&I=V>;!W@[($&"B+6*-[MI'<TXL](N=^C96B&?
M/I'.='L'$#(?OGSWYD@^/=$_8AQ/.3[GE;X"S)Y3R< O4XW+NW:CSRMFCO51
MB@B>XI[C=QJD-_)%2+.N8KX<B>D,L<>$43IEYD-P;^=CCS^FJR3\/:5[A>PL
M'^("*:^8"^7O\U[8B2J*)Q]F8 78H3PH(N1._).^LN!-8NU3B;/#I?G[SP?2
MO^O#MY4'\1/$Y7H<X[C-L1/S[T:.7>C,YG"LTR-]/WO#IRC4)BB11_]84H+!
M'B"Z&7'5CLDT+[.\U#18+.@M[[:)YQGX-G>_-N4RPMPO/K59/74\N3(KD"1^
M34.5X$F5("\'\*P,$G NT%RTMF:JJ^C3L[HPO0 UKB)/8D)U$9$J>A(?YH9M
MQ(;9V?;VO#^XZ'!^[)FLP/?@$?C>#_O^3KTRA!'TR*_W91_R4^-\V8H;U^Z<
MKTHROAYK*'&*L\2\4,ORP:,*5!=#*-K\GJSKJ2?Y:9#F/ ==U4?E;*'FT4).
M$^+I9Y_]G.2X?=3G;K<099PQ.7PNVYU\$WI@,K-9!V#]=546D"J(+F/<4)%C
MR862]PHP0='LR][RS3ZZNQ< -KMM3A$IN19H&EB:?VT"Q^A01(3"XROGX>'=
M=#P5PZ1F;_B' >.U/5Q_)&50_.)(#X$+[X"AF\X"Y!J$OY#46R1;N/Z :%QL
M8N0OH1T'N445T0 RO#4T/(VMBR6)W!VH!HE*V!#PNW^C J]A8<1G0H"'BX)_
MD!AT9#Y^KWJ,@2(,:\.+[0O@E;S+7M\KBD"BF,6TK-V6@,AUF'<,=BR,(N@J
M^M'<>>@"J\,T<5%#Q7_L<Q-&!$&1V8RR20I=S\@50717("LC=K'.UNT#/V.,
MEUCF'V+HM+MFP%C3J(AVDQ]#S/K_O(N3>492]$<&;(?UM,(56(2T@4P446@G
MF9V@1I$(^==>5.??-O%:&R*/U(SKV>&%MN1&JPY L.QR<) DN9Y:EBW:#[*5
M.-%D4DM2UMIV" 9DYB3VJPMGFNR-6WH1;^\1M+8D'+H#_5%M*8(6XW$1V2]1
MR7A)0%"9"#VO  S=W]X>KN&*K)\G]KE186"">.1SHM[+16YDA^Z"<!T**ZFK
ME;M,)BN0#5WY@XRQ9Q?F(?MG(/4X*M:66 9Z5.BCWM1G::II-XA<2-9/CF9K
MJ=QJS3]&<'B*1;QX5UOC"(Q^='>V-FV0P3(4A4\CEZ-)CK5F[,UN?XR)=C*%
M>S'0%T5WQW"JL00PV.0^KFLD +8*>:DP^IK,)FU()5X&K*5B,K=0_&LWMRXZ
M(+@DJ1O9WH4+!UP?ARY6>('ARD:.\4F&P_?O,-9%B$"K'YX$;2C9>\N_4#D2
M>*;)=9T83TBH)/C2)K[IR.\$VNTP3<E?=7W _"7H7=@UM(P,:(^KBM)+!= T
M+/3)\L=W7Q-[6\Q-(IS*!3L+&JK!30UU61Z8TK:Z@S!5.USTJO%WF,($@,M*
MW"?=B:ME3(OCXT^0FW5\\HB341W7;U&LP\6C;#PDN3EGYGUH'U\!DJ&3-Y,W
M@I]76(!H!?GU4/$.,$\1#OS.*ZTH:F<O\15XHR5%G6Y&DE_8*MS"^HZ\S"V>
M2@7YN],^ANYS91?I:',HIHKEKOT8MB/+_GJI'U09^I"8N_9<Q'E?6="L\W B
MGLUY^OM'.^853ORFCJ]%D[%3-,4N0]8O0I["[G/A[CDA\WB<ZD_).]P+^4M<
M<\2JZSR4DW4Y39- ,$[KRPQ8&+*B6:_"%OAQ(C8Q.YWW6!O'R[<P>_<Y89G\
M\<N(0#,\]\"J9VQCI4#M2.4+->'AO!WHKY:A\/F^"^VOY7^PDSI@H>=W<VZ
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ML%@*KUO>V1\9V"Z4^28.7_J\ H[*8C_]JQMH*I-C[NN6(W %ECLL! R1BX9
MA5/Y466/)C[2=S^2/E(>5;\"S.])S1Z%A!08[)8;KOJQH(9'_A9%^G8\KCV
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M:&R.MF/N_5WK>=3CIYEESSCX#N$V'BH*IW.4C0%"C//%Q!6UG$5T3]SIYA6
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M9\M!QRIRU0V&-&WQ"8R;472\3_((TQ&3 &@I&!H@U=0$+KU3A'+"Q/'NU*4
M\E0OW^",'6>Q:Z"_GPL/CF=HEIJ-NRX&"Q:I3X[94^.^SAP)VSGRG9UUJNNC
M65W]]%?6 WLK"NL!GZI5,D,5\E'V#IZ-5A^*X+B\BSRCXT60[1MW'A!(V.QI
M:HGV+K:,OO%NCA2D,9F" .Z3-=17VL4RS*,FN"-;)$V%;TQOZHF;Q,K&+![*
M-.&7RC!;++=CV'I_#%Q5ZM 7E<8.U7">HEKJ4T; 3G]S8Y$RB9 JL,C$B\+$
MEQ*(H84N"KC6&;'OY#/+*Y:A;L[$&UCG@A:KVE\,8,@K;7++MLS?GWWPC6)
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M[@E$=OACPR, ;VKLW2:M.:87NN5^\MF*J_OZ;#;#<QT=Y@FP*E%^1A1T/K?
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MI8KK^M3?PM^'>CT#"2'@-:/D4:,_YZ.^T5RJNXPU?<[$;-X4S,*6D"*(((1
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M9@GZUN 9U9E^75-*U)QNP!@U5RMH13R9M*;J7R3^W-+\<1O)35C_4UB7CRS
MZV<@.RH_R6=[']IL_=1Q$87(M@5RS( 1J-"JW0LTPN_\2G!I5B24\YRM:T15
MSX)+94\S=[*._LZ"DW0@:#<1#MS]& "9>COVB]R\CY"UG4GME$4S:/I4<Z)K
M:@798?&J.@#=0X2#I,5H.V/INM. :(:I GA6VY 7M7>P)I=H]*T'H,?*IQH
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M/8Z0FM?$SRCLXZ>QR-.V8=K7G?:Z^6-<A9?+"PW1RNW<YM+ZH-R6<?J+>_W
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M^ZC?X:%AB!6\XE-N4JXRP^J WENI=-NV"ZMVX?B,9;L-/@X'G?BB).E64#/
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M=^@1[W-455+V<TP[L.@-0"RML%AAVL^/FE3@42C:!)Z\1:M=.4Z,ERLB+/3
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M QS_59#*OPI"WGH";!4_1^SKW<97O-8=",Z8)T!T#LXA"]KCFP",@,FIW"?
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M!9_9M4G?LZ&*"? $*+NNV&'+B=>UD#?7?4LS/!Q(3&/B((J 0VUUEP>L&TI
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M.Z]\\EE-RXTQQG5 ](C_LG\9%!]#E.<DU59CKVCZGC?N;IV#'@W%*OOQE^G
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MK?D0M(\&UXSR!-"/^/K6\ZJ?6BWB4>0,]E"845N\G@!+-QQ_*A'DEX_PE(<
MJ1T"-8/^_S#\\I7'C+5VPD&.7XW.*!A_12JI__?="Y5-/3XY7<4;7I]OTZOJ
M5Y4G:=4+(M=PP3$ N JAK:OCVE0A[CG/XH$';62[_*&QG90$D12]-:O9.LN.
MW5QY_#X]A'ZQE5@!_H6M$%KU>#9"[9SSM]Q/7.$\N6;@5?/KCUI2B@HU!*P6
M(N>7_)\\19!"U/C3X(WOWAM(HG18J=Y9:+3+:/<#*3&85> 2^".YGF76+2]C
MN>4:1@?V!);1$Y(-++\*1S"<SP9]OG+$1D 6U&88LW11.(>:0PQ2+@;(+W@N
M'87H*WB6RZT7Q%A_@?R%1/8+Y?_H_>HUU1A;>P)X?&UMM"K7G2F[-X/6URUX
M*-C/=5HKEHCIKF?VXNKXGR:>2E F$^ZUA*?!@XH/!;38R$?H;E2%86&?U>@Y
M:=VO^B<E]RKYIA"FUS8===0:'LRIJ.2@@[H:CG,X<@F#'P'5%5+'/U6V\S]!
MS6"YRPM9T@7;16K=BT%U. !9?4IBQF:5U/@L=E_\"G7F"7!&*=[=_,"Q&1]6
M:%MX]S>5)ORAK_NG+,]Q_-SRE&Z+*HB_0?C=+DDI^)NYVG,L^ 38>"3B'@BO
M8Z2)(^M\/4BW*MY==NCMZUV8SA=:,81]5*/4=),DSOV /BC67SZEE9LRN)NI
M.P%/\B_O&*O-R.[RUE^Q=6^(^4/N)[OP^U+&/OIG8H8@R=VBX"V2\GP;K6E%
M5VF?&^O(PP\"<$ILX!3!:GT"/.22;-^Z\(OS7[&7,Q45V\U>)\@=RX(HYMR!
M&/T?BL?%UW@?M#M;WOXT9VP..S:2D%:TH_\X!LE/P90P<X_/65"4 ;@D>7X8
M]ZJ *J:'$'2KL+/&2IW6U9;T X=#QIU<CC2&-F.\ZM[5#9TPIAZ_B8G:I?60
MO^NYX'KV2N:4+,[1@/XY$6'4G"JO-Z*Q"661E0ZE8D  +J>L4.=>-6&JRP8Y
M><3W<M@Y2S>=)%G.>R3U9L&1C9S^WW#HD74.-E8VEO2?.Y]5;O@=_Q8M.QP%
M_6.A4FO,BP_W(=#@ +3R[L$]S5;%HF9B8^LX5<X$*;-!DLZ-O2-#/@*D :-[
M\1"UZ8V9D_IWRR1T$ (L I.7OBZQ)IPLF:M>CGJ)]R]M%6^\PV;M6-?L#U]0
M\Q"CNI'2!Y)&PNO=ZE31*,2H=+U28A?^LC:4%?)92C?:E],%@A-'3.#%R*+O
MNSW)AMCP88:P8T4?12=_@ZW5D9*#V93=%B@S<N(3("S #(3?5^D [7%@:+P!
MTWN) <W B<D#R+'1"Y.\6'XOEG5RF,=8PMUU\%DW3)P"<4/*[:;^HUS%O\$Y
MBR5""K+_ME)DO;TN@:].H7<X\O-E,H5)?.:EH:$+U;MT*?U543YYAN9F?+RW
MO!QA:UT"_(*/[,\_ - PE.MVL+(I;+H\!>4%;:59LIM_<RIM.AT'P[1$!^YI
M6^J3_+ZJI:JT6??>+#[:EOC"'0T@\*!Q$G>^HD(]3_H[!2'0J_0>[EQBB'K_
M1S/ S5?S[#W%O(,L\O8Y-V$2WA)3ZX5AFT]C=YU?&VE.AI,M 51-+P*YK9X
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MI6%XIVR>9-K5W6Z/*\*Y>*8.AC5OGN0JB6',[8,$>*"F3I8 >*'=6_?GSKC
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MR4LU6T7\,,X/;XG^><";9GT#BQ8,\&&3C[.HR4%U\.Q"]16HE6M?#6??--R
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M Q8J(DKX!NP8 Q0+ $5V8 N!&W8\$@H=VN%907<.P^<(=;8A]$4O)'\\-TZ
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MDOUC#X?BO>V@$ OJ9@=-68).C=5CS;8,CM$ISF8-[@@GLO]M2R."^=(+7(_
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M3=2EZ'$?RT5RNH3?<9P5)UJ_V]\SJGT70YI'YKAEA3CJ=*Z%5U3<';GOU?E
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M_V]P RZ!A"%['.GP+\,RL\F?Z[A<6=;D\(1Z*"+AIW"UU%1B.EO#!]'>3L0
M4DWQM/;1/OHSNWJ?V=TFWBP'2G 4I[^$>T8$ET;/EV\!)R",)A<B3J7YI826
M"ZXF,Z7XK)CX%V"C4DS/NB9NW(7 T25NVC(,0HO88GV#>@9/9;8%7."^8,"M
M&K(28:X</6,H,@F4(6=23_K831/)5<:FN[?A*T#,1'[0X:(NB?=1MIA&CJ/?
M'+G(O@>NM.J9^<J"R(UR8"_V(_<5G*^QZX'2=&2^7?I)(<!4;45U@T58!W:O
MT>NC>-T].R65D5__::%1][FZ$5Y7G#0M7R'9\3@E\^A+OE$P9;!1V%,JH*"
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M95\P,#<N:G!GI+=G5)/=]^>-!9$NO8-([]*K< ,")@A(Z%U 2A)Z#1! Z26
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MF.[,96YJI,/:1JI_Q?NS&A>_VPSY6"0 V/Q6_42MTNSQW)/*[.==\N@MULY
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MSQLVY@D<LVC,Y7&>\SQDVAA6MPE['=1,+\1KE7Z'9+G1M 566X=-UJ<TS]D
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MUVYMI!V@BB@VI+#7^+=^J0LTB$@65=B,DV3NU_@D<AV+8EU?-TR]2QH[=BW
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M! ?S*V,/D +ENW#:;K.('EF6L3?_G+.=1/B\J[2?+'WX [-JZ!ZIR=.Z=OE
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MV]\+YWG1TZXY&C)/@83HS8AVL'H3O*"VHRULL;#:T<GB,!AC%TRF6O+V1J#
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MS)--#\06GX4BM/,5U$86/-+[R1-ZP=?WN]!9JQD>BZL4+%!X+4895LC1I;H
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M7S2^_M@->;7HB;)>+46 V,P+&@#!55[,A!Q[.(B-_I-/L\B9]S[2Q55X:;M
M]A$^Z:H!+OK"K/YGSH\\5;C23-7D)I2MBQ-@%N>Q,"RD%/QXI5*7.C<6NVPW
M/S\,EBN.'RGBK^?XLZW;$+PW53%B*))>&5)>>:R+5-3*#.-3-$U3\L\X5O5Y
M4+#/8E9UK\=1]=Q/<0B2$D08FERC^=+:@FL++WB=]>L-V3MS!9S.T3P')WJN
M2P1O<>!R(4ST,F.:[V9M4J>SU^K/5\84Q&QP)<LWU"FXHGRAUX_PXOG2J;%4
MSY_Y2+_WDC?_EXCE1$Y84T4O@=;(HGQJ:2V7GMPQP1WMF^(KCPSS7,1$I0V*
ME_2$Z:'F#V_OQ:#R+.3"^]MLRU_U5?NPMLZD5+8'!+<QRH^-*+Z*<Z5VF\U(
M]Q8I=4'Q8ZJG&/>PD:5)@*F\)Q,TKN-;Z1TNUD%\XF;YO[YLA(N<B'"]V5LL
M2@[W'7RJI?3?$ D^6JFP@K]-3&2(.<<0Z1V,V#4%M<<^A39W)+U@M9+N^YK"
M:*% ]ECHVR].[2VWMG]@E'3UW_K,^I3:8^+&!DV/\M(.I IT0^+AL##]+Y'H
ML^,'+*GS>*D]QOV<1J<\&N9UKJ3X4$?OH 5VP1:B)1(7Q>'_ND'5Z;NX+E_@
M6CJ#LMZ*=Z\?,7NT'Z0B((2&-?[\-V(2O*ULB)_([4ZEUW4OROFJZ6UEZY*$
M6,./A3\Q!>K6L!5(WTHLWVF=0U^\4:D4-!!LMJ"PZBLI$A"151*7-EQL^?0]
M9WJ\H:*O69])F3K_Y>^YH*H^CA^0M:_])MNQKHR<KH+F)K"VG,G"+H=;D3(
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M &&%QYG\F]_.%@O-^3"E5 )3MOD8=I72MS+/UBB(\@/VG)/8#$QA<LT?D,%
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M)D9A_X-I$=N'YY8@@(+O!WNP1E,DV#*]A]C]PV_Q:947OA?6EYJSLB'M^2H
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M DZG<GG"I0YY2))N2 !<4#79%N('W$9/U$/121<4OC9611D;&R>=[#;W)]=
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M-YZ-*A5%HN:0\/>^C<6\BQNF@&*/\ G)I4@^]YTRX6EECU^DT14J:CTK1_T
MB:_"T!R(8 K3(B6N"J_5(B>Z'K+Y]JXQ@:/0;%S)0>$T;%;$YG];)3A[X*U<
M:Q36M]321G8\IUTSMMU[1,]/(O4S!(Y2C]J9!O#<?L!3_IB#R_@=^/(_!77=
MOVDT@]M.PH;WOU^>'ZMVXO_4?L!2,K$_14]0I<96367NF)U6SL(T36+;?L\
MBXV!IJ4RB'N5]D\!)6EZ0A.!\6FI+BJ1_"W2"S.E!W@@7U(&PBH 6+*1$/QD
M?U?+Q"0:P=+,GPF<^'ZRH4X46D.7<CZZ*E)W,XJ):JIK#(Z_9I;8_XYWT22Z
M(KVR)O]#F<U?TUXZI+V<.F@.K]-'9:VRX?65WD@?ZGG8Z;P]58>NT4?R[YT^
M7 )<R%X:XFRK+>35%/'9?2(12HLO4I"]N%K8I6E50\7$D>B?Y(:?&$/P1>'S
M'"ZF[GZ8M)6:]W:L2E34YR66V2?@H,0@;Q[3J<]^_[U,J0KV&[22!SQV:LLE
MH?S6(>L"DF:!)Y(I>B-4\>_)#*]7C&1;R)'Z3*R;?QLYABL_5Y0:T7-0\P68
M%<4C =K,*F(J9A7#\+?F@8'E64G%S:L*"#TIN,IX%MDM0Y9/SMR53JL2%+)*
M"J,^Y U5T5#^&EHSJ,"=!*.,=#8MD[*V99?U;J8.VC*:6YX%PJ@?,B-&C"\)
M9,8=TV497(XYWCE)_+]:;%".QI1E<R*)#Z7OS_RRV/X[#U4Y< H6]%GDT_MX
M"*DK49+QX:(=9F$TT1Y^-@Q56*>,A%Y/493;@)4UY*"N]9R/+;K3N7M=A-P%
M?G8<E]QBS<O/O399ES!-NKR<DSVBUZY^ 7)"+ QG=)!GE&4S($5TAANRG,LD
MM<*4G[-\E\6S5CMQ>#NXW-<0EX)4"(, SQ4! ^)Z ("ZOS908"3D ..N-LQ8
M=."D7!D4R5(1.%Z]VVRLT*IK,KTPF[D",(0D?@_0Y(R/"N<7#5U:8(UJ7 _-
MTI.1GN!%BC2=?/OY5%=K69DDY%WX"9I8Z] ^_>9.F?ZT[I,6DUS'1-SHU)G'
M[?J77.+K .?/>1;>50:/9KYU>78>5%.0#M\?&WW%G:9&(OG(27D#_LK5PN7@
M)_A7LZK:DOF[Q97HR4/*U&K2#PJD9"8!SV\E]+);NC]..I9-R?C5;F2>T84*
MM<OH6@PQGQ6WGLHL$JP(&(%KB36UZ$I\*L6#O'W=:@[_0A QEZ;5M@ZR<;,+
MK=$ZKA]Y$^E%#5A(#\SUA24%GNBF;-0H_E9Q<L=^_TO%=2$RSL0L%V*L8LX"
M,S\'N6:68C68GO,2D#YX)CX^K5L!O75C NBY2*ZF]EDZ]MS^1-MCLV4'%?#K
MZ0/&D,O4)>LML[O."<I?F8^G.KL)GE,= *R=5W_[83WID:NWKS@;EH0[Z?!0
MIVN,L;WA'=*G'+M 0D/*(]+LY2GCGE ;7PKH59K=F0JL(!,<F,V G9F:9"#N
M*C5L3@KR"2&$%$ZFRO8"_@5Z;5/M!)^PP=@T0O=I7LGU2#**>\L_K:L4I"5E
M^N>15#>&_D=0(2K11$_Y/MTU5J&D</_PA71G3Z+=E,*+N^G/JBN:H-C.P#ZE
MK^"DGM*XF;<)X5;B;\3?;-E\%)_B<Y'Q_T[[.NRAB.-M*SM]GUO?V*@P[J)^
MB"X2CI34>^ )I[VE&J^!0[4[D!=X]0%O^;ZU!W\EZ"XE<:&)'<K5GH6/.KQ*
MDU_B;D@N>9[ZUAMP]89D\(R47 +G?VF_VUM\UI1L.,F))1!MEYL_&BV&'5>K
M&>_O.CMI*(:0YR(2^RL,J5ET7L4AV.3[=9LMNW09ZF;V1FCMD:(R0MJ+PL2(
M1Z+CK% V2WU&6V\5<^$":DM*D5\#NF"XDIFK(=+U+U WKZ*RM9WX'5,4AS;I
M=W&U-OZ,^]EY]787,P+ETY :/X&U"4#)6'A:#V;^U"A=&-3/5[M-_5U10MM,
M'L;P#4"+22U: D6$2)L"XH%^#Q9W6BS']7T0I)$EEQ1$ "X*<QHO8T1''%Q<
MU*O*389Q]66U+\LK(0L^E/T>;3$&<(\W4N1KO$P>+;B^&,NE9(UT^S!1<_GJ
MJD"%"Z^M,ROQYZL1Q>_VE6$;(PP7K4=6K3OC0/O+TH-FHO>[YBYHZ F3D-,[
M Q^HO$/^(W:\Z-H.5X\EM>@@3LLETTVANI@BL< H?QONE.7\=/219]TK)$>D
M@<V>PO""[2,=3+U"H6M"G&Y--<BQG@%T,GNEE!:];)"&63OXZ?STS%E*P2(1
M_7H*%F;T*+[Q:E;4SMJ_=X06J!6 B*_2E82K&7E;9^ZVFEP^QTW$7C^^5 OT
MQQD-*@<EV)5$Q46JMW7,=O (X]NY:+R>E,Q!1/<EZW@#[$"3&)>':.KC"%_]
MJS(5M6DN:HC!5+-ZK+VD98D_ ES_H4.YLIJV<40>"K'Q1.C,.?],Q??8+YZ]
MCQJJN&75J8>-VM_&B_18:WV][=!;>E4SM:$WW1'X686M&1'?7%7.?B&W=3Z,
M85GZ>*BO[]B%HE#A^Q#IKG\9CCOGHH5$H>9DCF Y(7'>-R3DZ'YIL)$]4>\U
M;P>J#1^9[\6Y]@B<@]UEV2K4G3_82K/'&<(1_Y4M+=@-!0<&1T3<U@;]M?*E
MW%18)FW-Z.L2'BY.[_,Y>V0]>[)*BY078(SOP?P&9OGWS0HD=+$Y_"2V.@:<
M(_68T6;E[3+U7)DN?I^VJ3;*7S?VN5G9JW7P"8>YN6I%+?C(3.5[5(PWUF9?
MJ(B<KW#MG[?FL+1;0"D>F 3A12@D#JAP1CV%3=#$XC%LKDTGEV4]K!0WD?A&
MWW]/CHGYM7X6"B3<)/\V8O=C#5]#'M?C;YQD@*=#9\OXKCBL!#GXAJ0_DG-N
M/6?X1'-.HNFBE<]!5$NL#(R-@*4M?R=)U0LUKL>"1U\.:JF7VD@L[&&S_O/G
M<+C=G%M+:Z6"'B$:;"3Z-AN(H=4EP5[]PP)S$#4C$8[0P0O#E*QT6VVV+Q=D
MZ-IW#@V%_6N);QWB;DC>3$!S+-!<R5GI-F79ZT=);U^VZZLI0!DL="[E\;3\
MS;CN%)G-]]4"1M!S.SVZI6=S(+X^,5^;@8[XN)T.&E;'>EO9G$H3*/-=%4,N
MJ9% Q39K&IX)OV$%RA=(BRP)JIP?F.7OPA^")9NW'PQ'U1!=!MH&35.LM$*A
M R8C_LV@J3YG*3C(=!C7NJ-KM("1]IPLS3[&;ICX* 9#M"A8=LM5Y-@ZK680
M)J>7[!O%Q+EY0ACQ>XWG#T^FZSMXL@$/KAXDN %95A181GP[/C*@E)KZ^LR^
M?PV)C)W2(#6*<@FZY0X;BWK&&(.)HB#Z]JIQ3:D(8*@H +@):! %2] *\[,?
M^V)-8P)Z=2B[NL6?/Q>U&3L[!)^&#,8$-BIGA;@ISUY.]"_,GZ,+W3[-SV[$
M64&%YE(? 0#3L:"I8@-#_Q2SW?:@)\*-QKI 5[ELX>2HJ2/SU<6X?_SY,)4+
M*]$?1081Q)4>P3K"JF#TZ+<1<]FN_A$$O:5M^?8Y!*AXQ_R]U0[AU");GGD1
M_A=9\K"7-/5X]#/EZ_G$U>N%&Y+&R,*2W^VS0_TR%YQ?Y1,/#HICT%U"[3-O
MRG!F+0^)];*=_$N:V68_TN*7S*;73*[GFIHN5.2-#0,IR&H:"6E$S?)+/^+K
MU5O3LO ? H6##M27+^00A$[=OBUV&C+B]C.\83%383F(+YB"RF1K!%"P9M#9
M BZ8(UBZ/1VL'.^Z\P]=%[0'NNCQH3$=IA>**T0!_2RT!G$$ ?Y^+;9[K817
MJ\ :A&/_#L5N=^+C""T-GHO=";+A<CC,B>-<\'UL:_)^UH<)4MI'A8HYSJW1
MJ?P(0B0-C<4=PU2:T_1B4]JD?,^_E=H/?[^"BE!6:5,9/H3KC"-)BX&Z]!4*
MK;6)$_67KG%#\]>#(W[@E,I4=K&K/W5__3_%V9I+T-NS#,7U3HU*BM ;W=&"
ML\XA3+H8!9T9=F:0YM1YD4UX@8$TZ.I#8H3 @"\=>!Z]:(0NF1)KGL5'C!>3
M3-8$??U-M]6W-;S)&H>?X4Z7=KK[.0?[MR15V:/DPZR1 V=S*0!AM;NVR%0/
M6HRK9LX*M:#G:S*UL>U!27XK"TF[]3DX@PH*5'24],=_NDJ-',(Q6Q,5:?H-
M? =H]7"&:YAX:% 4ZZ+'O#K-I336Z]'M".'IH7:U9.\O(TA03E-VX(@_#\SK
MU05?!Y(QUE]):Z.4.'LAY\G%K**.>X'.5LJ*X\_&3=E9.]#]]*S?-;$"QRY?
MBN"9HYNZ&P>\8/^,<LTS*S,687Y!7K]S\9Z]--&PVVY\P[ 4X&J6-T=&9E+
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M0BB91:[LJ\597(>.7%#ZPZ"\-3B?$/2@<:+?X#(:]F)BG8IPE10.5E2WQ7P
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M4DA%E*=]OHEOY-7$FS'\IV]!&-,3/7KQP I[E)"&4L('%Y;T4U-?\M;N8[?
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M=4<Z^0MCV>]-RXY6]L_8*\'M^86&:BJUAHTT=OHT2V(@T^@[[5XKT[/YIB?
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MJ1H,WOZ-#'35SR#<+HK\P:[C8+'\/:^@M[RUKH\R1O9(ZV'M"?C#P+60F6-
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M<A\TZ-6#J!UONC)TE 7KCJE+Z0O;,R$DJ]HC]9[DJ;I>RX"6B6[6[.]AUMN
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M_W@)!#P" C(2,CX*"C[;!^(/;/_C]M8)8,!#L$*Y04%\!" Q(* P(-YZ 3(
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M"P5TD'&3UF6) \9+]S:B5=+*,Y)5OM2_1>G[K(M)X,1YB,,5<(22<LR3F5I
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M/*P;R\_@?2@UQ,UDBT679X%$U=6&,[(32'8-E&$M8P[GFN P51IQHCK2G/;
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M&PG%.T+Q1]:+-\^ -JF77YZW5V/$SX !\O&V1>@+?#IM.AVD<3\#8H6S?1I
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MG^.#_S8C/_U;6<)+]%8T85W_#M?)Y_X\^1D@PGF:ZS7[;W\ G-M>MVT6W?K
MF^K@OM/C\+_/@',5PY?*<]2__S#+>QH&ERT/?LFPR6<70Y?\".L90$-+_H#Z
M\JF9@@ W0:^84W^XC*3?,T!'_QD@R>EIHV_L2241MT8;$,Y6BN1_>4'FRY\2
MI<U(!W^_@$4O%5)!I>EW@>GL'S-V55P+^:S%T?NN:]3GBQ\OX?7EO7JL4FW4
M*7/!@J165B@CVW_YEJX"4-"B!9%?8Z0,N*<FZ'O4"=L1+](*KG?! 3>;UJ[+
MC3(;4_3" &6-/\-K%4FI7(!;?N?=94<9M"6WN9)]_J[BUY6_!Y%$-%?C9<0=
MB1=H!C3L3:3(47<N/>+89A$\&D\L 92>'^5=%CHK5\A ++2"Y9:%Y2Y:<9>I
MP) 7-UD4=6SYSR5T2]*QM:6\,D=>->I?YYC^AN8G?G!%QU(1V2C#TE%"]AC#
MMTQRRL''+W9 32&$T 4DO,YFVD1?$Q&T? :<0BR> ;!QRR&G1LNW#(V%7XZ=
M%D.!>;+GR+8JKAK=7VQ:0SMEL#5/2E<KV,O V8D8?Z@W"%$I/H1/77NCS_RX
M GJP V(7CFHU(ERIB;^+X_5^\SJ,Y=D@X$"H_G=O[L;:/8:Y#TDC;YBB/5/(
M=K*R*9W3E"$Q^DSDV-ZOLVH>Z:%1^H\-X:OZ'P3L7/)<K^6(I6DC>1!#[!SH
MV?&4^Q%\"<8(2$'C0U7WB?=E\=QF\?TI4VKS^]YTE3:X"R-97>C8,,GV)8[N
M0";>USD.,1UT=;+Z2*[*GE0Y+=$_IPE_F4.PNP?G]A?:1#42E"8]^=>204U1
M;,M_*;&UY"J8QT8B908V)SF> 806?"DJ0V#/MU]%P(/?-^\1>1\94K])53A:
MYA^>+)2G7\'-*C-Y62VR8,<V&LS"X<KE"NDV./*.F]0F.MD8W=&8"&,$ [C%
M3]EN3L\ ,BY,?+C[(OS(!_FA[QRWQP).5.F_SC%;M023.7<;(#%!V*ZD\&5?
MB+N=,BR8K%G2"]US2W7\)#;AQ,>8_?='*?;@.(6*9J16E+KQ -V^50^.!A*X
MJ3JB=FGNA3,#_L/)?D>!YE57T1QB4;PZQ$8_>P;LY\" "02R^F\;O$.W',O)
M+)-JBY(\^;]&VN:/BJ>Q]V(),BIV:P^[2P9[.59+[/2@\7VT?2-8A*O)TT"7
MQ6?ZL_QM938/])/VBB"&>\^97CY*U-I0\4*R<WW(9R).<,ZFWTP]%O+M#7#F
MQ0]5"H"$;N?CM7X&]O+2X<(.],CY>N,$M%MZNO?;R6G_@I%0*TYN9V3KH'E+
M[*UY.J<\]>)XTS76"PM#-G]WX"2W26/JC8W0T%%I,PDV0C*CA=]U:/Y[20MM
M9RVI064PA](&VQXYXEP=XREG@<N2*)1;.OD*CQ"ZBJ:+1%QR*V7?ILBW,7\W
M<+M<XSKQ(S;0VJJ;Q3[1,06F)EML%%)<Z(SF6CE"DA:OC0.'*A/OP_X4Y#IY
MP^O,&X:<;&S>#@F<21#NCJY);5O4-=8UJ<S,OO^6_=/8MMU;;2?]/0NTA:J+
M:X'5R,02%XU:TX@K#4LYU'\M^%?9RK<671%=11SK,.(^S%5_5/\:LT:ABGA]
ML_%-'^-!3?SP@+B9F;N%_JNW# ':,\EL[%)N'\"OXIG]^RK+;&1O$[*M[IOY
M?KQ;+*D6ZC%'JQ-._;'?H<7=L*/:OF[U2?8=6,J+BY^/,>%,*I))@-D)HV78
MACHV[Q2_8E20T5QBVG#F,I&3V/:K*J*(4'?4GOSWL+A0]RSS@/*W7\KIH6]^
M/"3L9H56__Z?6YK+A6IOHYC'(E@N+RNC'O"(M;8C3[^L? GP?9"2;^A_9.1;
M67>NP\&[:82$6$'<XW_7N;O$L+,_^G\T?64K37$F0I8K8>NN$67-29@QV:E%
M? *M<?A6]1X0:/?00[T)H;.*W"2773[#"J\11AM"UX9.BE/OCV$S?=OJW.!Y
MBU4*L%'6"1#&%N N#$MT3%7X5!8[?FRT0OQKD6'S(M)N$5."B?R=HW3II>L5
M\2[D0;DNT@!RUD2!%8YM%Z_BCM<#<)K2X =OI&,NW?KN1J\<MRR/1RU52#KM
M%]W"--V18!5.Y+]J6\G.X+FY(!<02BIN#K:(.IX99O<QTW<25@5%1%]!Q- =
M:T^'M0=Y>PQ*CSY@X2"3^8 /4P*A<ANQO3?4K^11NEJ(?OQ2'ON,)DU>&<PJ
M+M;C;%B'[!WP$U7, NFOQ7]R<0@C:L?+B(7@<_\,:'D&3!2"W"L\R9\!%/C/
M@/*'E2<&B*^0ZO]&=<PDA EOVL\*'WZT>P9D$U6#A3?.L>YWVT;;7++A)^2G
MY4\T9,#%>[I_7LF^*@]_Z=..-C=YSX!YQ@'0FKW/#8_G,X#]\EOUTXRP\/ U
M5I#P.<7+. _3?\*!;J(6ENO_)PO:FN0W*5*W"9M,=&<'[N7]NYXO'IJJ-?XE
M2EMFZ4K8RCGW2ZGT9%X&V19#UP]P*2]&>)./.+ -OVW3QA_>'/<,$'=G\.D?
M)%_S251\NO_'.G:[1IGK"EP:'@'?*H>'E5/]^^+U,Z"Q/'WSQ14.6Q,_^F1N
M0/]5@C"6?[]]D0[D27U/#F%W4.^7;#@4\]=9[_#4[KPM+EK^-U,1#*,O5J?"
MRW]1A/;/@%VSXI?T^L46X(WE%[C^MW"?P@/59X"+_IK^O:Q@V[I^Z)4B.FWR
M4](9*\QSG"XQN?5XV'CRA.A\\VRF/NXN:R,F_),Y8\>H76.3342ZB_C]V#.@
MYF" L1I?W:I:)IVW:XZ$X_Q6P7'2^L9Y1=TC*OA1W&==/PCVM)TU7M.?\!Z)
M"$S\E>(9P ;:9+C/;B<_EWF4N&IX,3J:/N-L<7!</'VMMT^*:B"3EZ:JNLQN
M0A:_?H#^N9JG\(OA%UX$D=7N,\#"Y^[3YV? '!_KTYN#E']=-B^+NG[10K%Q
M6$_^+W+V;UJ=0/7 P:%-@)7^B][)#(U#\NTJ>-JXT">9G7T&H%VA";*N+H=X
M%.B*@T DS*V6*90LI@9LBDBQJ!LBI(K7$CL0_ >S ]L(56?\6$P7QWTI7/<)
M&- L<<"):5UJ,>N;I_]?8ZA=G3ZA)X*Y$TUSVL>(5,PW06],Q"]-5;!601E_
M'PW75K#9\J)*YI=EC2\\$S?)C,I$!L0O,*7W^:<*<L ,D['5CPEWQ([*$LJ_
M_JOGJM68C3@3)%HC?K,U8^9JR_O^Q$)N\K(ZLEOFFX+*$:=BDK(-/8B6E9F$
M O'BC8$!YW.KU>@ /C@.PO CWQ]PLY+C"G/<T^M&Y!DXS$\<(:*MTPUW_ZKG
M5@AVO:"<*+_*SXK5.WYA9^.$$SCJO?<:H<_]B!Z0%?K_!J3_Y0:<?.VI.*EQ
M&TY"0ESF=3;LNSYRV8OR\%;&R9(:F\,WGI-N'-$Z+--W8CE%?72[>357;>\[
MUFV0EO7%2O$BJ*F_1&-Q>=M!-030KWC'<ITFNP89.(MI"^N:8 ,'UMLQN2I@
MR;='L*%9HP3_5MHEUVVX%]?$!#%O/-H?PB&PB,@BJL.8["ZK)X*Q6R%P!=IU
M=[UCS]\=N= 4*[V3YE4\XHTCG^'JH=L4LTT_T2F2MB9V2(AJP1\!NDU>]\XU
M+U\$[JFV7\OY1AH.[+)'NI4=ZK&CO3W6?%.@"BT[*:XM-AN]YR43RE4TY@/+
M,!XLG OBZX7**RHF2]9*[T TKP?/G^9FIS9N6Y#53WV"I((=QVV8\/)L[<VC
M:%+2=2XORXQ[[@]@M[2$CB$VV%K4$9N-WQD(8N(@@HH516WHS5)%.EP93OAM
MK1)OPK'8S?66?!C.<A-?.FFUU)K[XG&DUJ_[@.)/U'$+Q2"%ZSNR4B7FU*)Z
MI]H 'E[T=^:<ZLPN\C&AR;D1?=]_XU"=<@:"SQB[N#7&85(N='^H#I&S/CI<
M718X99-#06EJ G@,+IOY=.##/[-J8+&C'QP'87VO2K[4!&#>$I8+OXB@J'(.
M_B:>&F"8)>YX>$[9XSM)WF(8\G+EACZ*#,WTXKLW$.F0D,_ .NI+<MFAA9Z!
MR<C=(RUY;<>/8:6F"O+N)[#E;Z-AZ\/<T4LY7&G?!Y &/O#V4Z.'SPJE?X!&
MJ'0IU_TQ"@\SLU@F&!5'Y+N8J'$4#E0%ZO7/-@;F5#2SDE%25RQ^29.R6OD+
M)[)T%YR:'+"WQI9.HI4D(%80?"J.D,+EUQ??-0=^['+PX!R^!+G<MDUM"1'=
MIJLFZ]6'[B[I]5P[@V-\NTF'QJCM1IR]V<X\88K!R^NC:(DLGCW*.V(B'0=C
ML@OCS?S9%I/-C3]>Q_*M_>+E&;52?+?K#/\XD=2Y-T_%0FSOJR UT_A1MN03
MSXIJ?_<V =%= .B!7USNL6[<PG5IK)O9_:'K8GM?,T]FH[L2T/QN'I5<]$Y#
M^71,?]:)&"P^@FV%K/MY4@'?''6AQ7K.%:TKB?GWF5ZS"]X%F_D1S7?$ACXJ
MDG.0A]BDHR#?IX2OD?/OYP@%@I?B%@221N/?#EJIQLQ'C=CO&>Z(8\FY.!XF
MV"3&RI3SD=9>?PDG;Z'Z\H3L2NL']N(./<K"8N#_]KUBAQ2TQV#Q%?7C=_)<
M,!#KB,AE[J+J<&=?J1!77LC)>F9EYB&-?$T8>;EK?4&J";#0NUDWP'!"K"CV
MW>>+7IW36@O+AD)]-9 'YUL@&LX X<V!]J6:2E=GBH[+E[X=@G!3S6F;^++E
M.IX3#%?$V:[&RK9(TYCK*E^JA?"-Y2:B;_Y_0R.WM]%XB#S^9 ?A/HQ1(2M?
MT4(#J) MLOT_A):&I->4,K:$6!2IN[<F%_2/S^LOZ#2&5W4Q5"+-^BN/K&,0
M+:]E)*M519KP:W.GBB/M2EJ-&H'%%8-5:Q\$MCH_Q%6L3CHNL:W(UITS#QT^
M \#5H;6ZB$%,F8IBBCA%^QL,'<&5(RQJ'E<<U]6;URZ3E:I*DZ4G1Z8RX/68
M^;?%?(B24J5NY,&M1 =<:=30^B9YR/A 0RHY*LEE1W^Y159EH1@NT>]&LD@T
MSFZ#O=%XP=R5[9J',>:S'=]R)WFQ92_^T7AUP7#2NIBQ0LY)5^.NI*"XM0,Y
MP\(QG,J@X1^AWTU#=GUZ&P<_26&]'AFQ[M/@[E;K$L=@M.\;NC]V]8F\TL>>
M<\VSH)JRKGW]UQ]@HI?VL\6E*U:.->ARGL[<4GL)K?IIW6ZY1F'Q(OQALO6W
M:M8:-^/R1N^V<O?:WOCW*1V^8E!N$^LP?8GSF61LZZ>H+A\KC,)F9N'?S4?*
M^QYDMX57&!YR$Z,+3?T3XA,4+OQ>./:@C',,HLCU]W9@)IH_7W\I5:6\CPF/
M<N^&3\\XD7&,4"QTN^M8T9EO$=Q%;=36,F.O\VO.')LFV0JYX7(A>@5; 2Z:
M6 -"\@^NZ]Z!$LXM_\[+6QDDR0\C79,8V_!2S>2?GO@Z1? ]?/-258,V0<?!
M.763F9'8N?[H9BJ*= !,P8/BL)XT\C3@[OK,CS^'HJ ,6O(&I$(;V1]DGT^W
M1A-AO_FFX^:9?M*F?.,J3O--Z_7E%11?R[EQ?O^JH8:[FE!HGDH\X.X4(4)J
M:0X%_V(?E-EVVCVK1SL!Y6A09.@=]# JRZG&!Z",K8W(HT9Z,CI>#Z"TY???
ML!@'JMLE&,Y][^I9)@5_MS36KGIPB\_$@UNL-#OIN/]%I0&=KE^OR/YE@B_]
M 'Z;/"XE_4G"+YN#0M8E,%ES@@!J9-[Z?6]6;N97PGQ8'C"S-?#>+O%N@R(-
M6IQU>SQJ@S56=##+Y6Y/\WC]2^NZ^(=]=KD]LF;SK?_:$"GHVR3-%"6;U9>[
MZ,&RM\:W]@Z/4GXB)'G!IWD;7\],N->W)[8[B?L:HT;8[@J ='Y-9J*"=OVE
MI0[ML]JUN>MA!<>KHB66(<;O3*A[AU+BCL:L]BC/6$*$:NX%M$NS]V529SI%
MFXW+<0Y.WEO S++!^2M6SK4W"73ONJA]V2\BD0%N\,S3-JW6,\Z\K/LI11"8
MN:80Q^\\30E0Y.N\NIJR(3!UO8+I5 S6:\?0'JD)P]"%\AA^)N<Y8=+2JH[D
M)M&P(P_AL%29WY@Z^F.=XYKQ\1DPPV=N'Z7RV>&R:-QUMHM=6V>IKTRSI:5"
ME>.GX:\;K\4G6PLDY]">A!XXJ;]L\/<$[2HYPH4?JG\D9X5\9[KMJ2M+8BI,
M# @U27YBN0.<_GGWB\%M5/<'B_,Y[?GYW*6C@\8>DC@W4(#8H9S!-0&)$V>+
M9AK%Z0-(17-Q89DS=2NN29P50F+X-QLQGS1J&QF@F >:T8:$&1;>%=J0'K[A
MHQ[%]37 %$9?KQ:@*M"B#=B?A:P^M5ZN#K9=7+&V\#XBK167LLI73''4LTXJ
MU %=R;9</BL!GNR2RI\!;[O:GP&73)8K-_N^0@9G.K^6/\_,Z\HFW_53;)(O
M<YK!JL+ZA0SAE1X/LY/>]+?&:\IKS"9[:035\+]X[%[)@V$[%\ZD35X7X=]A
M6%WD;\@Q]X(>NO#T?W#%N,%-]+G_5%B/M3KH.V"R_K8L\,#-JNO9LNYC[SKP
M2-0G.&$V"Y8Z+S/TY)A?H.!YB-\2^J%_,2Y\DJG_@CV=%:?"3VA$+D_W92#I
M6].UBXTQ;.:5P*.VJ@#U=$-6K.,;L ^[^4:=<*"KZ[>UM8(BG82Z]$>DW<_S
MR9DRJELMS;V/',W0J';W1ADGQ,HD'91H1!_'UJO-(,TJ'_?TF[_E&6UKFJ[D
M\, (?OB3!O=&5) >N2XB>Y:KWMS24]6*R_S:D)NWU<DCUX[0E-(H*4,\@[U^
MZHI7&R#W3Z-#RITWG=<H:OO-.[H(CEJW;+4/]G*^J"BU<&9=X-#Z'!'_KU3O
M7G^&U6< \6SV/Y<E&XX;[/>"'YJ3;2?3V*/$W;UMM /%^FW]9&9+3L $4Y#.
MW<5(&-R=[NF2<<83Y&'U#'A]Z3JSC6<+:5"FH/8^F<@Y->]B1HC3@\^?]M13
M:3?BI7GR/ ,D^\^O7P13^'JCS:TZ&>H+CADK/ /:U(:2C)>%8O,VABX:RJ^;
MKJ?VSSTQ'XX]CW:DG@&"'^#WN/OD*#;,F<W3PW6?,[[T1(RBN%GM6<,);K^[
MQLF]=S4:.Y0DCA+^H<]RLG0XUK;<MZ&=?EHB@/4,$.M-?09X%^_0K\;S%E[\
M<'<+_C!$& 0AG:CC!M[ESYV"G5VC?CE1THAA3-5_#+X94:]*^NCSXUL('.KS
MRSWT9J@MB P-3S6Q^4O^71KP1[?.#HF:UX>UJ  %_WSB%73-IQ)8SXY;C.?"
M=<3\S:@5F5ZYMTW[?A3^@*K2-2/(4T_]T,&'\*7]Z.(/-@2>FH_.(_3=-YY'
M\0G?[?ZC;K-\_J-NU4W(T3T_/0/>2-SZH&MY!1^J+ZL;W0F,7)STM0HTPW%S
M?V 7<PL9Q[&L6QI4C'<5:4"O6NI<#@UN,<^GA7!O_<BV<9VY>50I7L&W0%O[
M#W+_7(.FMU%K48$:7W_O+>-7<PN9 #T+6G^XA34] TC'UG0=,P]7L^?NAIWI
M#C1#9JT61Z\?VOKO)M<X0O![F)$WG;Y^J-6*!-P1MSCJU^",*YX1X0=]C_&I
M7B>.\2-W>V)<^:="*/]+1ZWAQ0H#[0*3BWUN327\C]Z[+8MYG[@NO4"QR&79
MCM1+)Q5W*'XJ[[PV1#[#6UC?&#S?>&A=J//F+57\Y];Q'>$,[#Y[>"; ]0QX
M9Z-GJ<()'XXVG:,?^X-?Z@YI.AT2(>,XS:@\;6F[MHP]>! ?"M[LBWMXP>A3
MEK2K29__:-49F&G$0\#@3QC#;)\)/Y)\Z5M352>+6#W!='4_.[Z,()L87-OX
M4A.=]T9%E&HO6IAA\;_^K$72>'95-25$-9[:7NCW_O_D+T 9WT[OA.BZ<P60
M!];).%="DSPL9) DP92#;FS1B^4-JBR3W>A@Y X!*@./(+%Z$E[,=?$7'..%
M:ET[@3O4QG7:@+56MEN%%56(H,^#RNL 1'Y+2H&ZX0=1\K"W;5B=3WQC7?K&
M83JQ<E QKK# ]_SFPHZ7Q7#>6V"V5:/$<*-DH(636YEQ?"YS3<7%]WY[!5[=
M:6/-6\$U_ELPI$\.6NEZ; R1^LJ\+8DU0KZ\REWJ--T[4QP<263?3.7!JK_W
MM'UY]B&7AL]=3E[]'OSDM&^7AG1:_JOF267[_D6YL#(U?\F=VO(W\*M'F+OF
MC-CP(M?U(1:KF%L0<#E&>3!._.O+'BGIN@-UURL\]>A,J+8\,<_3GB]MF1CB
M*S%M'2=X13 VTD[MGVX%? ;X+W]HF*HY" .SS,"689*@7[AO\ %E #H7 H'9
MY"MWG>;:O\=:O;SJ3M-2P]/E>2M.;8A1835>(/U3CJ2OU7O67RTH@6ZOH]DN
M><T 'C,:G2VH^J>00.YDLI0$#4PRTZ:&NWY2'%QJ=(_[60FG4Y?..%"2UR:?
M:0F7\Q[#F!D5C34:0DU<4T2]<"I3.FHS[3)%T)WCD%JEG'/$82UIV>9/<OY&
MOSZ%JY8HYH$6K7*N%OYN5:6_L=]W,5J&5>$\1M"+&?^2]O1WI276S#GG&\U=
M7'_G <\ 1_=[C=KRCI6W6.]EO!V'5 UFBM_.W9E;]1/$T;HX4?B%.V>MK)X$
M9,V6L^9,E%)7)]%/,(H3(N+I'!LXC-H+,PSF$GRW'/CALL;.I(#-%DBH)>?=
M C\:95\_"<VK@TZ6<40PHRM;:V%,9S!DQ(0[]'&.NXH] X#-IZ^<JRT;3>0%
M5-R2CSVC.ZK/ Y2C[58XJ\D[%5%9,NT$DFARHJ5_4?D6=IN8T_&>Q-RI !^I
M3ATU7.R'LK3E<$KRZ$/?40(,_,9X!:;/<TZ,8V8*Z<]Y^9V;ZA;=7/Q;R0]F
MB(*@M)E44A]$:9H1RL2#U$F.[CI&>5#B.EJ19S/"='2UU]?4-?5@'YF*MB:I
MXI]6N\@^>T6XFR6?9G<6"F78>/*:]<]2+YC$_;HN0]7C'<.Q?#$[G3GGP[(E
MI"Y$< #RRH3J\&P5@>"N ?#3ARB;*N)6;4W0IVM2?TEWF:9T*KU)W%5=XHO_
M E:'H+MS67$?GW=;Z:W"\:"@^L#6#PZ0V3=[:U2JU"4&+_(7 Q\R[T0^?(.V
MQ1Q3QU [,B@3;*F>."KW<$O?\JX!24E@*Y8S=;/ '&$KU\$4=NQLXJBE5UB=
MO@)]$J?XOSC)@Y/B\[+9H5N3.2'(BT,-LL<PM3_U^PY][H>M>+<:6J<)P2:_
MEC6U='5X(":))8&1GU'4ZMN?9$J;R/V]\>I.U^=T]JYGN=?QQ+W'HWM&;6^7
M%JC:K"QNV=?LUI3SDHF-"]&4WTQY5M</U+T,L$L.H^PBI @M9V]7T4H115?8
M^.+ND\[2L7HVKF[]:7)GBKV8XQO88@1N(Z:K:\B3(Y\!\>Y"F:>@SAL]HCA%
M:$4M=(H(.<().1RB03"TX>))]K0_?=+)BKIH&0M<V)V!W*#[J:\IQ>;/$F9@
ML9WJA6PP"I/+</8LS<XS:R9Z+]EZ0A8QN0U';86:-W+=>XM@1]<Q;E8WC5SS
MF29"XO7>4J>I2UX,T)M.191%;3?U>YK<YJ;QYO:<%!3D8+W5][<SYF'>V+L?
M=DTYL+"T^KQVNEU0/IVC$M_1/31D8+*O^00)J.;>AL+WGP'*20N#&*]872@@
M7(2O4FP.)LDCW"6;<E;V[S&V(K:;0%XD9[^Y]G#L;,8>OJ:X[\"*#LA1/3_Y
MD&;-[4%JF7&G'&3[ YOGIA['TY-]E]@E\U\ZM4O<WHGEBXO);>F'.&H./'QU
MI>CUMD:1YKW.P#1?"_9E%6#$.(%=(5<TI+;- A=[:"]1 SMTHO2@R>OZ@;/:
MY=VO.1-W:M-F;4'!D/W/$U67_")]@O#X17U/TM/4T<*\Q867K&=F1H_L?E3&
MLHCJT/_#/8T[O.3L ()PQUA"*N;;8YFNC=C4[=O!U,<;UE@[(H1M[P4$BP_2
ML"$3&-;\#<:&U%^^AGQ  6QLH_/T2GY9+G[\/,[Y#,!P->EC'@GG5FU+9M ;
MU WI0_I8WWX$5'Q)&[Q.4)[P#0K$K;5(ZC.$3>"]DDE=$MD@.!%[^:R,,YRZ
MHSQMJ+]V":/Q5FHQA=&W/TM3/U&^P'RY3)K/WJMD'70=ONX0,@GU277#"OCQ
M:&=SAJGL4J G8VK1\U=7YSW:,:KUL2*IE[M&UL(CZ6F*]M;19J-N2:U#'U&7
MF5)@8 )_(NGB<?]CT;#^&P&BA!OVUA"+TQ?7$?#B.JP7'=+NR.,!MCYX/YH-
M"XF)1[@\9=,;+2X7(#!Q;N0J*=[KLMG.KNY&_: 2IHCEV",<5[.6/\/=F['
M5Y&M3U]4%CS_X7027IP.3 YG^,7I1%,BB% XC"H*1TCD>]*?9LD7$(]A:N&
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M$TQZU.VA-[A^#F#)# ,4R:YT#_W]T-_C_'_X*LG_&A!VVK"I9WJS,R+X* V
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M1I_T]>E=V1]Q#O1^7:Z+HK6EZ=G0'&T'%J=580(EO$I:Q33H5%5%G4":M_B
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M0<T(9*\@OS27@ZR?4E(H*P4!]9EZ?X%B>N3LRZTNU7)<U0+:]!E L:U)MOU
M\5NYX62]L%ZRTG.#/?F M.#XZMQBBV[2!A,"5JZ&G_!(YBR(]:MN$?C^-0 .
MV4C68D[3'SYII+Y'B;H8)0^@2_W=6:VX?JE"DT9=V&Q>O]A7KH.:W^,!QDKS
MX/C7'.#6,8^G@]Y]E\RYDVUNX;TG7#%8S2FRAXCD5N@[>J087;&9(VGE8>Q!
M6NLZ\W80<I]V4+<V&A":L2VNS'8E/H%^2E/DX5*L(O/:'_UJ&9X^&+JX(&#7
M!?CHHMAHAM9=(90,R&Y%I@]J<TL.5271G"9RH54 -^4Y)S*5OIGMV]9:S#]6
M&S\+]XFS.SQ+>B0R"12.[Y J<FOO*,40B/PPKLBL)9 'G7&B8M>WENV*35=B
M,?3353;GR1,W;RR&[#*DDE!GWVK)B8C2%#Y^/.LZ#5W</&DVD3S$#M^[07B6
M9Z;;PA0<!W@ GZJW<RF?=4MCH4A+^SQ(EU/3X#AY3K@&<&RR[Q<1/G1#S;>;
M""1QX"I@4!_Y^E(+!":<Y3(7*6>10&5N>5I\=25WS"*.X<IF>((<+=7_&"U?
M#:N\N 8 W&HMY!/*.#PD) ]U$MA9<<J%(LM;R<G'C.[6+),UC57ZFNOJ2%A^
MAAJB2X;QB<.#9UE154>T7166ETJ3)5'JLM,90CGV8% 1\MC5" "4OAAHBY0\
MKB'K=E,L\Q<I@0;[:_E0(2XT&$0TQ';7PF_4&RP7-=@_O9I,&[(MY>I%\+^@
M>\?A$Q60\P5JC!;,=S=..Z],@^HT]7T(4[ \+ UW]G2\!M!U#DN_,,-\99\=
MGZ(KQ::9\$Z@/SO+49S%#ZE&J=KZH)19%I?7WZ9&/+A:X2]&\L_Q]K#FZ;/5
M3[8KB_\T%+FDI3H)^-U&O?8(I]PID/@P];NSLWV0C(R0S''Q7][Y9>*;KYS'
M\]]JO5W.@21U?HX@EUICKH,'CN$WIN[9.TQ4O0EWZ+6EYM;Z."Z1GDR&N(D9
M.!TALUK6ON=%V347G@&]!WZ,#K$JN"A,TN7*]IR"O"K!N9G?J4J9GVW+X>U^
M%G*H([-!++TQUJ!")@U$-A Q?<]N7(&W-L<YD8C2<WO>]J55/,9Z*0[UX4,L
M3+EA'_RJ..VT<@V0C?;_&M?[1PBPJ5*)D@33:?V+#F[]![S_>KB(U9VO'2=B
M%A&;#ZV,:R)<BK>2<(OQ4ZL4>O</UV.)GOP&)8H9/;X&T*K7@ O1:;3DXS6K
M[=J1=W8CXTL4D-L=I6XG;46(U$ 4.7<R1YKT&F?4K4T5 #Y21ENPQYQI%]+,
M#FMTXQ,;+,:E/)=1.](1+8I=8K]/B'D]K6/FI,(H18]^H/BC,?W5D:18(D A
M;,=X\:LY:64BVEC:]8/W("*P::6S64F,)$E\+/$4V+W[?>X;V_-K@.NC--[?
MJVS#XP@]4C :G-_W$DI:E8;ETO9[ZQ!42PZB340-D149U!+2HHY+(8H8:66N
MT,HZ2; /WK]'=^&2_$8;Z4%/XN. 2>WJG:D'H3WV/D@-A0?EIRS=ST#$X$AR
M>DUL#0\V)-SK!\ %LQI!CIX:\+3WR*!;>P/C>"9IRL3')2!4J40Q>=#36A)4
MH)-@4O]6OD<=#*+,DAQY1H;Y$>7SB['N5%4M+@0V-4AN&]N5T+*6-TPV77:Y
MO9^6OW4N]/)NMF<3H47O!1C3GZ>"J0:<CY">_VT\LN+?<2:8PW0-J)$;7FO$
MFC!470/Z+ ]J_L 6(G@_DA!(VA^%0=8EW@7&#2KW)YW%?L45&T6A$E5]]&S,
M3F<A(E=]83+QYNJ1=%R#^4S\NG>>9Y#-9:PD,.XT6?,@I_JG1;&XO,,DJ4>6
M>?"9K%57[1E.*$I'E\/#G@.6JQVE23T2#<XS.9LHS^J)(5E**N%K!)C6RRZ/
M-M8[X-_E-L<7Q'>_.0J K%;O!E1626)[C+6<7&MQ*A (7](*W@P5^S00*+A-
M9/"U0F UXG9[=NE\A+T*[6RQD2$JUO9S+'=-0">)']GCO!6NVSO,N@7S,U@V
MX8VF3'#5'+ 5Q\W?L9N##M$C"3;"UY>?LE]=G0]IS>+[L;.",&OW8L8[.%L9
MTO;H3[L-"OH]VA3KE?MO4I/D?T/9 ,HQ,->H?1! LW-#FO%H51@&66Y)O96L
M&\]'=8#]+-Q-^N0#T9IM/>TI><4".T&QH&R'3JN<I[XY=:04_K[\K-W'J"<D
M!;"JL$G\ES]*R:Y'Q_O;0PPQ,-*^>!MG ^[LU78R]ZIE;=E#KML>4M.2!C/?
M!6'>3X:_6*DRX!F2C\04Y*@H2E9T[]AL!II,$;;Z]R#?\OQ#)>SI+]YR.GAC
MP2$K5L$[7X,;]PK%U ,]9$$&A3KZFH?P=$%HIQ#M6*1<OV#*"%JKS#WX\D1*
MDC^1/S%&W=MA;L;JVT$@;;I#H[_A_W3?]W\&(S._'9E&RK G%JYS^_-F/.D)
M&<1A2[3MI.;YD3)@>94(E@3@V)II=#8/G9K>S8#D 9' T-D7&$N'H\JR*R#K
MKT5>OY.+VT@C/:O0/EZS5+'%-<ODWW56PS-[\-G/S(2PPNI%*=?YA.<33\'C
MF6!'#P[?HQL@!]:!U].*7_B)T_[REWC;! A$2(0GVC Q([W,1HR2F'WI$K.^
MRNDKD!@*;OR@V] >)K+- =LG$19"Y %);K VP<BD5[_X%SRO,X;#LP!=GQW.
MR'H5R(JD+OAT#Y,>UJFL%[PTG!'EF&8DPEA>:M6/.6+++#3M4Q8T>=^&V]1'
MVWUI_Z 1L<#$F,O0, ML\XAG/Z"4>G$$Y]9*X=#][6WJ&T8=^,AMZE&IF3"W
MOQ$_L<8M"AW-<V\!+NU/J&*7!CBBV[/PXQFFHPK@RVPM'F-!N+&99@Y]%[)C
MZ(]T[,'M+U1#7V=1$4TX3GL#B $^6WK"\$Q&0:_; LUN,]+8K' SI6S3?VH;
M]?\%VNO9?P-02P$"% ,4    "  4B A;-B-+%_T+  #C8P  $0
M    @ $     871N;2TR,#(U,#8S,"YX<V102P$"% ,4    "  4B A;=E#2
M$:\)  "'8P  %0              @ $L#   871N;2TR,#(U,#8S,%]C86PN
M>&UL4$L! A0#%     @ %(@(6_1BA[WN(   OP\" !4              ( !
M#A8  &%T;FTM,C R-3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( !2("%LZE_6C
ME54  /N2!  5              "  2\W  !A=&YM+3(P,C4P-C,P7VQA8BYX
M;6Q02P$"% ,4    "  4B A;B#M"HTTC  "@4P( %0              @ 'W
MC   871N;2TR,#(U,#8S,%]P<F4N>&UL4$L! A0#%     @ %(@(6WCGS";\
MX $ R1 - !H              ( !=[   &5A,#(T.30S.2TQ,'%?86-T:6YI
M=6TN:'1M4$L! A0#%     @ %(@(6PD]A-)7!P  QB4  !X
M ( !JY$" &5A,#(T.30S.3 Q97@S,2TQ7V%C=&EN:75M+FAT;5!+ 0(4 Q0
M   ( !2("%O_S?AN6 <  +$F   >              "  3Z9 @!E83 R-#DT
M,SDP,65X,S$M,E]A8W1I;FEU;2YH=&U02P$"% ,4    "  4B A;0BY\I?P#
M   *#P  '@              @ '2H ( 96$P,C0Y-#,Y,#%E>#,R+3%?86-T
M:6YI=6TN:'1M4$L! A0#%     @ %(@(6Q7OGO( !   V \  !X
M     ( !"J4" &5A,#(T.30S.3 Q97@S,BTR7V%C=&EN:75M+FAT;5!+ 0(4
M Q0    ( !2("%NA'IKVXFH  'Y]   -              "  4:I @!I;6%G
M95\P,#$N:G!G4$L! A0#%     @ %(@(6SF1HI<'=   [H$   T
M     ( !4Q0# &EM86=E7S P,BYJ<&=02P$"% ,4    "  4B A;\YZ.VA^0
M   XG   #0              @ &%B , :6UA9V5?,# S+FIP9U!+ 0(4 Q0
M   ( !2("%L_VF,.YH$  /20   -              "  <\8! !I;6%G95\P
M,#0N:G!G4$L! A0#%     @ %(@(6^C-L<TP;@  FG0   T
M ( !X)H$ &EM86=E7S P-2YJ<&=02P$"% ,4    "  4B A; ]J<$^8W  #G
M00  #0              @ $["04 :6UA9V5?,# V+FIP9U!+ 0(4 Q0    (
M !2("%N)7['!L:\  $BQ   -              "  4Q!!0!I;6%G95\P,#<N
M:G!G4$L! A0#%     @ %(@(6_I?YNW+EP  8*,   T              ( !
G*/$% &EM86=E7S P."YJ<&=02P4&     !( $@";!   'HD&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>ea0249439-10q_actinium_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://www.actiniumpharma.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20250630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-06-15</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:OperatingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">atnm:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-8060">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0" id="ixv-34">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-8061">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-8062">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-50">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-61">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-67">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-77">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-82">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-100">100 Park Ave., 23rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-8063">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-8064">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-107">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-8065">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-8066">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-146">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-151">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-8067">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-8068">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-8069">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-189">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-197">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-205">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0" id="ixv-218">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-8070"
      unitRef="shares">31195891</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-8071" unitRef="usd">59928000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-8072" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-8073" unitRef="usd">1101000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-8074" unitRef="usd">1602000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-8075" unitRef="usd">61029000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-8076" unitRef="usd">74506000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-8077" unitRef="usd">985000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-8078" unitRef="usd">891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-8079" unitRef="usd">271000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-8080" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-8081" unitRef="usd">329000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-8082" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-8083" unitRef="usd">1373000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-8084" unitRef="usd">1685000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-8085" unitRef="usd">15000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-8086" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-8087" unitRef="usd">63017000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-8088" unitRef="usd">76899000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-8089" unitRef="usd">7714000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-8090" unitRef="usd">7568000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-8091" unitRef="usd">589000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-8092" unitRef="usd">569000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-8093" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-8094" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-8095" unitRef="usd">8314000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-8096" unitRef="usd">8148000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8097" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8098" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8099" unitRef="usd">685000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8100" unitRef="usd">984000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-8101" unitRef="usd">5000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-8102" unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-8103" unitRef="usd">44004000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-8104" unitRef="usd">44141000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-8105"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-8106"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-8107" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-8108" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" id="ixv-8109" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" id="ixv-8110" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-8111" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-8112" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-8113"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-8114"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" id="ixv-8115" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" id="ixv-8116" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" id="ixv-8117" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" id="ixv-8118" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" id="ixv-8119" unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" id="ixv-8120" unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-8121" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-8122" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-8123" unitRef="usd">417624000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-8124" unitRef="usd">408553000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-8125" unitRef="usd">-398642000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-8126" unitRef="usd">-375826000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-8127" unitRef="usd">19013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-8128" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-8129" unitRef="usd">63017000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-8130" unitRef="usd">76899000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c12" decimals="-3" id="ixv-8131" unitRef="usd">4879000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="-3" id="ixv-8132" unitRef="usd">8825000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-8133" unitRef="usd">12579000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c14" decimals="-3" id="ixv-8134" unitRef="usd">15460000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c12" decimals="-3" id="ixv-8135" unitRef="usd">2624000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c13" decimals="-3" id="ixv-8136" unitRef="usd">3593000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-8137" unitRef="usd">11562000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c14" decimals="-3" id="ixv-8138" unitRef="usd">6555000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c12" decimals="-3" id="ixv-8139" unitRef="usd">7503000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="-3" id="ixv-8140" unitRef="usd">12418000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-8141" unitRef="usd">24141000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c14" decimals="-3" id="ixv-8142" unitRef="usd">22015000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c12" decimals="-3" id="ixv-8143" unitRef="usd">-7503000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="-3" id="ixv-8144" unitRef="usd">-12418000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-8145" unitRef="usd">-24141000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c14" decimals="-3" id="ixv-8146" unitRef="usd">-22015000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c12" decimals="-3" id="ixv-8147" unitRef="usd">625000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c13" decimals="-3" id="ixv-8148" unitRef="usd">1065000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-8149" unitRef="usd">1325000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c14" decimals="-3" id="ixv-8150" unitRef="usd">1992000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c12" decimals="-3" id="ixv-8151" unitRef="usd">625000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c13" decimals="-3" id="ixv-8152" unitRef="usd">1065000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-8153" unitRef="usd">1325000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c14" decimals="-3" id="ixv-8154" unitRef="usd">1992000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-8155" unitRef="usd">-6878000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-8156" unitRef="usd">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-8157" unitRef="usd">-22816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-8158" unitRef="usd">-20023000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c12"
      decimals="2"
      id="ixv-8159"
      unitRef="usdPershares">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c12"
      decimals="2"
      id="ixv-8160"
      unitRef="usdPershares">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="ixv-8161"
      unitRef="usdPershares">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ixv-8162"
      unitRef="usdPershares">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-8163"
      unitRef="usdPershares">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-8164"
      unitRef="usdPershares">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ixv-8165"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ixv-8166"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c12"
      decimals="0"
      id="ixv-8167"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c12"
      decimals="0"
      id="ixv-8168"
      unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-8169"
      unitRef="shares">30103063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="0"
      id="ixv-8170"
      unitRef="shares">30103063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" id="ixv-8171" unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" id="ixv-8172" unitRef="shares">31195891</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c14"
      decimals="0"
      id="ixv-8173"
      unitRef="shares">28994775</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="0"
      id="ixv-8174"
      unitRef="shares">28994775</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c15"
      decimals="0"
      id="ixv-8175"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-8176" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-8177" unitRef="usd">408553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-8178" unitRef="usd">-375826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-8179" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c19" decimals="-3" id="ixv-8180" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c21" decimals="-3" id="ixv-8181" unitRef="usd">8874000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" id="ixv-8182" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="-3" id="ixv-8183" unitRef="usd">-15938000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c22"
      decimals="0"
      id="ixv-8184"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-8185" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-8186" unitRef="usd">417427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-8187" unitRef="usd">-391764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-8188" unitRef="usd">25694000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c27" decimals="-3" id="ixv-8189" unitRef="usd">197000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-8190" unitRef="usd">197000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c28" decimals="-3" id="ixv-8191" unitRef="usd">-6878000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-8192" unitRef="usd">-6878000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c29"
      decimals="0"
      id="ixv-8193"
      unitRef="shares">31195891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="-3" id="ixv-8194" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" id="ixv-8195" unitRef="usd">417624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" id="ixv-8196" unitRef="usd">-398642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-8197" unitRef="usd">19013000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-8198"
      unitRef="shares">27634213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-8199" unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-8200" unitRef="usd">373934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-8201" unitRef="usd">-337583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-8202" unitRef="usd">36379000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c37" decimals="-3" id="ixv-8203" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c39" decimals="-3" id="ixv-8204" unitRef="usd">1378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c36"
      decimals="0"
      id="ixv-8205"
      unitRef="shares">1752050</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="-3" id="ixv-8206" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="-3" id="ixv-8207" unitRef="usd">14694000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c39" decimals="-3" id="ixv-8208" unitRef="usd">14695000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c36"
      decimals="0"
      id="ixv-8209"
      unitRef="shares">10148</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c37" decimals="-3" id="ixv-8210" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c39" decimals="-3" id="ixv-8211" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-8212" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c39" decimals="-3" id="ixv-8213" unitRef="usd">-8670000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-8214"
      unitRef="shares">29396411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-8215" unitRef="usd">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-8216" unitRef="usd">390081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-8217" unitRef="usd">-346253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-8218" unitRef="usd">43857000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c45" decimals="-3" id="ixv-8219" unitRef="usd">1374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c13" decimals="-3" id="ixv-8220" unitRef="usd">1374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c44"
      decimals="0"
      id="ixv-8221"
      unitRef="shares">1154191</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c44" decimals="-3" id="ixv-8222" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c45" decimals="-3" id="ixv-8223" unitRef="usd">9955000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="-3" id="ixv-8224" unitRef="usd">9957000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-8225" unitRef="usd">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-8226" unitRef="usd">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c47"
      decimals="0"
      id="ixv-8227"
      unitRef="shares">30550602</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c47" decimals="-3" id="ixv-8228" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-8229" unitRef="usd">401410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-8230" unitRef="usd">-357606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-8231" unitRef="usd">43835000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-8232" unitRef="usd">-22816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-8233" unitRef="usd">-20023000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-8234" unitRef="usd">9071000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c14" decimals="-3" id="ixv-8235" unitRef="usd">2752000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" id="ixv-8236" unitRef="usd">409000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c14" decimals="-3" id="ixv-8237" unitRef="usd">405000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-8238" unitRef="usd">-501000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c14" decimals="-3" id="ixv-8239" unitRef="usd">-555000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-8240" unitRef="usd">147000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c14" decimals="-3" id="ixv-8241" unitRef="usd">1224000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-8242" unitRef="usd">-278000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c14" decimals="-3" id="ixv-8243" unitRef="usd">-259000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-8244" unitRef="usd">-12966000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c14" decimals="-3" id="ixv-8245" unitRef="usd">-15346000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c14" decimals="-3" id="ixv-8246" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c14" decimals="-3" id="ixv-8247" unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-8248" unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="-3" id="ixv-8249" unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c14" decimals="-3" id="ixv-8250" unitRef="usd">24652000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c14" decimals="-3" id="ixv-8251" unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-8252" unitRef="usd">-5000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c14" decimals="-3" id="ixv-8253" unitRef="usd">24722000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-8254" unitRef="usd">-12971000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c14" decimals="-3" id="ixv-8255" unitRef="usd">9365000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-8256" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="-3" id="ixv-8257" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-8258" unitRef="usd">60257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c50" decimals="-3" id="ixv-8259" unitRef="usd">86355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-2199">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. (&#x201c;Actinium&#x201d;, the &#x201c;Company&#x201d;,
or &#x201c;we&#x201d;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production,
final drug product manufacturing, preclinical research and development (&#x201c;R&amp;amp;D&#x201d;) and clinical development. We are deploying
our technologies, capabilities and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation
radiotherapies. We are focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline
of clinical and preclinical stage targeted radiotherapy product candidates are directed against validated cancer targets for indications
in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed
by currently available treatment options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;59,928&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. There
was no revenue for the three and six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt; There was no revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;There
was no grant revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no revenue for the six months ended June 30, 2025 and June
30, 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and six months ended
June 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;547&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,734&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the Financial Accounting Standards Board, (the &#x201c;FASB&#x201d;), issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740):
Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness of income tax disclosures. The amendments
in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income
tax disclosures. The Company is required to disclose additional information regarding reconciling items equal to or greater than five
percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required
to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds
received). &lt;span style="background-color: white"&gt;The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. The Company adopted this standard effective
January 1, 2025 and will report on it in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company
will update all required disclosures pursuant to ASU 2023-09 at that time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2025, FASB issued ASU
2025-04, &lt;i&gt;Compensation&#x2014;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer&lt;/i&gt;, which revises the Master Glossary definition of the term &#x201c;performance condition&#x201d;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#x2019;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#x2019;s goods or services from the grantor&#x2019;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#x2019;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#x2019;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting
periods, including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual
reporting period. The Company is evaluating the impact of ASU 2024-03 on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB issued
ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyPolicyTextBlock contextRef="c0" id="ixv-2203">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. (&#x201c;Actinium&#x201d;, the &#x201c;Company&#x201d;,
or &#x201c;we&#x201d;) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients
with advanced cancers. Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production,
final drug product manufacturing, preclinical research and development (&#x201c;R&amp;amp;D&#x201d;) and clinical development. We are deploying
our technologies, capabilities and intellectual property with approximately 240 issued and pending patents worldwide, to develop next-generation
radiotherapies. We are focused on developing highly differentiated and innovative first-in-class product candidates. Our current pipeline
of clinical and preclinical stage targeted radiotherapy product candidates are directed against validated cancer targets for indications
in hematology, solid tumors and conditioning for cell and gene therapies, which we believe have high unmet needs that are not addressed
by currently available treatment options.&lt;/p&gt;</atnm:NatureOfBusinessPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-2207">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements
furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for
a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the
full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-2211">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Annual Report on Form 10-K for the year ended December 31, 2024. The unaudited condensed consolidated financial statements
include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-2215">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited interim condensed
consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those
estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-2220">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Segment Information - &lt;/b&gt;The
Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating resources. The
Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated balance sheets
and net loss and its components in the consolidated statements of operations; research and development expenses, general and administrative
expenses, and interest income, for the purposes of making operating decisions, assessing financial performance, and allocating resources.
All assets are in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-2225">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. The Company holds most of its cash equivalents in a money market account comprised of US Treasury notes. Balances held by
the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;59,928&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-2244">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2025 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;59,928&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;329&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;60,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-8260" unitRef="usd">59928000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-8261" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-8262" unitRef="usd">329000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-8263" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-8264" unitRef="usd">60257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-8265" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-2294">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate office space.
Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on
a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-2298">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-2302">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. There
was no revenue for the three and six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0" id="ixv-2333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements
&lt;/b&gt;- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt; There was no revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-2338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue&lt;/b&gt; &lt;i&gt;&#x2013;
&lt;/i&gt;The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognizes
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;b&gt;&#160;&lt;/b&gt;There
was no grant revenue for the six months ended June 30, 2025 and June 30, 2024, respectively.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <atnm:LicenseRevenuePolicyTextBlock contextRef="c0" id="ixv-2344">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional. There was no revenue for the six months ended June 30, 2025 and June
30, 2024, respectively.&lt;/p&gt;</atnm:LicenseRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-2379">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-2384">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -
&lt;/b&gt;The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model.
The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-2388">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share
&lt;/b&gt;- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number
of shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and six months ended
June 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;547&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,734&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-8266">For the three and six months ended
June 30, 2025 and 2024, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,420&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;547&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,734&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c51"
      decimals="-3"
      id="ixv-8267"
      unitRef="shares">240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c52"
      decimals="-3"
      id="ixv-8268"
      unitRef="shares">5420000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c53"
      decimals="-3"
      id="ixv-8269"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c54"
      decimals="-3"
      id="ixv-8270"
      unitRef="shares">305000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c55"
      decimals="-3"
      id="ixv-8271"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c56"
      decimals="-3"
      id="ixv-8272"
      unitRef="shares">9000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-8273"
      unitRef="shares">547000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c14"
      decimals="-3"
      id="ixv-8274"
      unitRef="shares">5734000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-2444">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the Financial Accounting Standards Board, (the &#x201c;FASB&#x201d;), issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740):
Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the transparency and decision usefulness of income tax disclosures. The amendments
in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income
tax disclosures. The Company is required to disclose additional information regarding reconciling items equal to or greater than five
percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company is required
to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds
received). &lt;span style="background-color: white"&gt;The amendments in ASU 2023-09 are effective January 1, 2025. Early adoption is permitted
for annual financial statements that have not yet been issued or made available for issuance. The Company adopted this standard effective
January 1, 2025 and will report on it in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2025. The Company
will update all required disclosures pursuant to ASU 2023-09 at that time.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-2468">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2025, FASB issued ASU
2025-04, &lt;i&gt;Compensation&#x2014;Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to
Share-Based Consideration Payable to a Customer&lt;/i&gt;, which revises the Master Glossary definition of the term &#x201c;performance condition&#x201d;
for share-based consideration payable to a customer to include conditions, such as vesting conditions, that are based on the volume or
monetary amount of a customer&#x2019;s purchases or potential purchases of goods or services from the grantor, including over a specified
period of time. The revised definition also incorporates performance targets based on purchases made by other parties that purchase the
grantor&#x2019;s goods or services from the grantor&#x2019;s customers. The revised definition of the term performance condition cannot
be applied by analogy to awards granted to employees and non-employees in exchange for goods or services to be used or consumed in the
grantor&#x2019;s own operations. ASU 2025-04 eliminates the policy election permitting a grantor to account for forfeitures as they occur
for share-based awards granted to a customer. Separate policy elections for forfeitures remain available for share-based payment awards
with service conditions granted to employees and non-employees in exchange for goods or services to be used or consumed in the grantor&#x2019;s
own operations. ASU 2025-04 further clarifies that a grantor should not apply the guidance in Topic 606 on constraining estimates of variable
consideration to share-based consideration payable to a customer. ASU 2025-04 permits a grantor to apply the new guidance on either a
modified retrospective or a retrospective basis. The amendments in ASU 2024-04 are effective January 1, 2027, for annual for annual reporting
periods, including interim periods within annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual
reporting period. The Company is evaluating the impact of ASU 2024-03 on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2024, FASB issued
ASU 2024-03,&#160;&lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures&lt;/i&gt;&#160;(Subtopic 220-40), to
improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures
in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments require
that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset
amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current
GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. The Company is evaluating the impact of ASU 2024-03 on its financial
statements.&lt;/p&gt;</atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-2483">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On March 27, 2025, a putative class action complaint (the &#x201c;Securities
Complaint&#x201d;) was filed by alleged stockholder Nitin Kohil against the Company and executives Sandesh Seth, Avinash Desai, Madhuri
Vusirikala, and Sergio Giralt (the &#x201c;Defendants&#x201d;), styled&#160;&lt;i&gt;Kohil v. Actinium Pharmaceuticals, Inc., et al&lt;/i&gt;., Case
No. 1:25-cv-02553 in the United States District Court for the Southern District of New York. The Securities Complaint alleges that the
Defendants made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims
against all Defendants pursuant to section 10(b) of the Securities Exchange Act (the &#x201c;Exchange Act&#x201d;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual Defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint
purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities
between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&#160; On June 24, 2025, the court in the
securities action appointed lead plaintiffs who intend to file an amended Securities Complaint on or before August 25, 2025. The Defendants
have not yet responded to the Securities Complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On May 5, 2025, a derivative shareholder complaint (the &#x201c;&lt;i&gt;Georges&lt;/i&gt;
Complaint&#x201d;) was filed against the Company and certain of the Company&#x2019;s directors and officers alleging derivative liability
for the allegations made in the Securities Complaint.&#160; On May 13, 2025, a second derivative shareholder complaint (the &#x201c;&lt;i&gt;Robinson
&lt;/i&gt;Complaint&#x201d; and, together with the &lt;i&gt;Georges &lt;/i&gt;Complaint, the &#x201c;Derivative Complaints&#x201d;) was filed against the Company
and certain of the Company&#x2019;s directors also alleging derivative liability for the allegations made in the Securities Complaint.
On June 24, 2025, the Court consolidated the Derivative Complaints (the &#x201c;Derivative Action&#x201d;). On July 29, 2025, the parties
to the Derivative Action filed a stipulation with the Court to stay the Derivative Action pending resolution of any motion to dismiss
the Securities Complaint. The Court has not yet entered that stipulation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
Company and other Defendants intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c57" decimals="-6" id="ixv-8275" unitRef="usd">1000000</atnm:MilestonePayment>
    <atnm:NetSalesPercentage contextRef="c57" decimals="2" id="ixv-8276" unitRef="pure">0.02</atnm:NetSalesPercentage>
    <atnm:LeasesTextBlock contextRef="c0" id="ixv-2513">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025, the Company
has two leases which have been capitalized in accordance with ASC 842, one for corporate office space and one for office equipment. The
Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date of July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible for certain other costs, such as insurance,
utilities and maintenance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Supplemental cash flow information related to leases
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: white"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 89%"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 10%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: white"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding six months ended June 30, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0" id="ixv-8277">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0" id="ixv-8278">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-5" id="ixv-8279" unitRef="usd">600000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-2525">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;The components of lease expense are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c12" decimals="-3" id="ixv-8280" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c13" decimals="-3" id="ixv-8281" unitRef="usd">173000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-8282" unitRef="usd">346000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c14" decimals="-3" id="ixv-8283" unitRef="usd">346000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c12" decimals="-3" id="ixv-8284" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c13" decimals="-3" id="ixv-8285" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" id="ixv-8286" unitRef="usd">5000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c14" decimals="-3" id="ixv-8287" unitRef="usd">5000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" id="ixv-8288" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c14" decimals="-3" id="ixv-8289" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c12" decimals="-3" id="ixv-8290" unitRef="usd">2000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c13" decimals="-3" id="ixv-8291" unitRef="usd">3000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-8292" unitRef="usd">6000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c14" decimals="-3" id="ixv-8293" unitRef="usd">6000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-8294" unitRef="usd">313000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c14" decimals="-3" id="ixv-8295" unitRef="usd">306000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" id="ixv-8296" unitRef="usd">5000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c14" decimals="-3" id="ixv-8297" unitRef="usd">5000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-8298" unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c14" decimals="-3" id="ixv-8299" unitRef="usd">5000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock contextRef="c0" id="ixv-2804">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: white"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Weighted average remaining lease term:&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 89%"&gt;&lt;span style="font-size: 10pt"&gt;Operating leases&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 10%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: white"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-8300">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-8301">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-8303" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-8304" unitRef="pure">0.062</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:LesseeLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-2848">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands) &lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2025 (excluding six months ended June 30, 2025)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,341&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:LesseeLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c58" decimals="-3" id="ixv-8305" unitRef="usd">318000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c59" decimals="-3" id="ixv-8306" unitRef="usd">6000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c58" decimals="-3" id="ixv-8307" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c59" decimals="-3" id="ixv-8308" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c58" decimals="-3" id="ixv-8309" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c58" decimals="-3" id="ixv-8310" unitRef="usd">1341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c59" decimals="-3" id="ixv-8311" unitRef="usd">17000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c58" decimals="-3" id="ixv-8312" unitRef="usd">67000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c59" decimals="-3" id="ixv-8313" unitRef="usd">1000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c58" decimals="-3" id="ixv-8314" unitRef="usd">1274000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c59" decimals="-3" id="ixv-8315" unitRef="usd">16000</us-gaap:FinanceLeaseLiability>
    <atnm:OtherRevenueTextBlock contextRef="c0" id="ixv-2927">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 - Other revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has a grant from
a government-sponsored entity for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognizes revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. There was no grant
revenue recognized for the six months ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (&#x201c;EUMENA&#x201d;), including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United
Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront, non-refundable payment
of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. The Company continues to retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its interim
unaudited condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The
Company&#x2019;s contract liabilities consist of advanced payments from licensees. Long-term license revenue deferred was $35 million at
June 30, 2025 and December 31, 2024; this deferred revenue will be recognized upon European Union&#x2019;s regulatory approval of Iomab-B
or provision of definitive feedback that Iomab-B will not receive approval in the European Union.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:NonRefundablePaymentReceived contextRef="c60" decimals="-6" id="ixv-8316" unitRef="usd">35000000</atnm:NonRefundablePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c2" decimals="-6" id="ixv-8317" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-6" id="ixv-8318" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-2954">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 - Equity&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company
entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, &#x201c;JonesTrading&#x201d;, pursuant
to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock.
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales
Agreement&#x201d;) with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;). The A&amp;amp;R Sales Agreement modifies the original
Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares of common stock
are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#x201c;Prior
Shelf Registration Statement&#x201d;). On August 11, 2023, the Company filed a new registration statement on Form S-3 (File No. 333-273911),
which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024, to replace the Prior Shelf Registration
Statement, including a base prospectus which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock,
warrants, units and/or subscription rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum
aggregate offering price of $200 million of common stock that may be issued and sold under the Amended Sales Agreement. On March 31, 2025,
upon filing of the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, the Company became subject to General
Instruction I.B.6 of Form S-3, pursuant to which in no event will the Company sell its common stock in a registered primary offering using
Form S-3 with a value exceeding more than one-third of its public float in any 12 calendar month period so long as its public float remains
below $75 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company did not sell any
shares of common stock during the six months ended June 30, 2025. During the six months ended June 30, 2024, the Company sold 2.9 million
shares of common stock, resulting in gross proceeds of $25.2 million and net proceeds of $24.7 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the six months ended
June 30, 2025, the Company granted newly hired employees options to purchase 26 thousand shares of common stock with an exercise price
ranging from $1.06 to $1.43 per share, a term of 10 years, and a vesting period of 4 years. The stock options had an aggregated fair value
of $29 thousand that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 4.0% to 4.5% (2) expected life of 6 years, (3) expected volatility range from 90.1% to 90.7%, and
(4) &lt;span style="-sec-ix-hidden: hidden-fact-67"&gt;zero&lt;/span&gt; expected dividends. During the six months ended June 30, 2024, the Company granted options to purchase 1,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 31, 2025, the Board
of Directors approved of the cancellation of stock options to purchase an aggregate of 4.9 million shares of common stock held by certain
current employees and directors that were initially granted under the Amended and Restated 2013 Stock Plan and the 2019 Amended and Restated
Stock Plan. Such cancellations were subject to the consent of the applicable holders of the stock options, which the Company received.
The cancellation of these stock options resulted in the recording of $8.8 million in stock option compensation expense for the six months
ended June 30, 2025. During the six months ended June 30, 2024, the Company recorded stock option compensation expense of $2.4 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2025
was $0.3 million related to unvested stock options, which is expected to be expensed over a weighted average of 2.2 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was determined based on the stock
price on the dates of the grant and is being recognized over three years. The unrecognized compensation expense at June 30, 2025 of $0.1
million is expected to be expensed over 0.1 years. During the six months ended June 30, 2025 and 2024, the Company recorded compensation
expense related to RSUs of $0.3 million and $0.3 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c61" decimals="-6" id="ixv-8319" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c62" decimals="-6" id="ixv-8320" unitRef="usd">500000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c62" decimals="-6" id="ixv-8321" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <atnm:AggregateMarketValueOfCommonStock contextRef="c63" decimals="-6" id="ixv-8322" unitRef="usd">75000000</atnm:AggregateMarketValueOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c64"
      decimals="-5"
      id="ixv-8323"
      unitRef="shares">2900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c64" decimals="-5" id="ixv-8324" unitRef="usd">25200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atnm:NetProceedFromIssuanceOfCommonStock contextRef="c64" decimals="-5" id="ixv-8325" unitRef="usd">24700000</atnm:NetProceedFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-2965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercisable, June 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c75"
      decimals="0"
      id="ixv-8326"
      unitRef="shares">5137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c75"
      decimals="2"
      id="ixv-8327"
      unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c76" id="ixv-8328">P7Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="0" id="ixv-8329" unitRef="shares">26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-8330"
      unitRef="usdPershares">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="0" id="ixv-8331" unitRef="shares">4923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-8332"
      unitRef="usdPershares">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" id="ixv-8333" unitRef="shares">240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-8334"
      unitRef="usdPershares">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-8335">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="0" id="ixv-8336" unitRef="shares">166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-8337"
      unitRef="usdPershares">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-8338">P5Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c65"
      decimals="-3"
      id="ixv-8339"
      unitRef="shares">26000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c65"
      decimals="2"
      id="ixv-8340"
      unitRef="usdPershares">1.06</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c65"
      decimals="2"
      id="ixv-8341"
      unitRef="usdPershares">1.43</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c66" id="ixv-8342">10 years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0" id="ixv-8343">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EquityFairValueDisclosure contextRef="c2" decimals="-3" id="ixv-8344" unitRef="usd">29000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c67" decimals="3" id="ixv-8345" unitRef="pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c68" decimals="3" id="ixv-8346" unitRef="pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-8347">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c0" decimals="3" id="ixv-8348" unitRef="pure">0.901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c0" decimals="3" id="ixv-8349" unitRef="pure">0.907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="c0" decimals="0" id="ixv-8350" unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c69"
      decimals="-5"
      id="ixv-8351"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="c0" decimals="-5" id="ixv-8352" unitRef="usd">8800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c70" decimals="-5" id="ixv-8353" unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c71" decimals="-5" id="ixv-8354" unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c66" id="ixv-8355">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-3150">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit (&#x201c;RSU&#x201d;) activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c77"
      decimals="INF"
      id="ixv-8356"
      unitRef="shares">300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c77"
      decimals="2"
      id="ixv-8357"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c72"
      decimals="INF"
      id="ixv-8358"
      unitRef="shares">300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c72"
      decimals="2"
      id="ixv-8359"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EquityFairValueDisclosure contextRef="c72" decimals="-5" id="ixv-8360" unitRef="usd">1800000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c72" decimals="-5" id="ixv-8361" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c73" id="ixv-8362">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c73" decimals="-5" id="ixv-8363" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c74" decimals="-5" id="ixv-8364" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-3229">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the six months ended June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Outstanding, January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c78"
      decimals="0"
      id="ixv-8365"
      unitRef="shares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c78"
      decimals="2"
      id="ixv-8366"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c79" id="ixv-8367">P4Y5M15D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c81"
      decimals="0"
      id="ixv-8368"
      unitRef="shares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c81"
      decimals="2"
      id="ixv-8369"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c80" id="ixv-8370">P4Y</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c81"
      decimals="0"
      id="ixv-8371"
      unitRef="shares">7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c81"
      decimals="2"
      id="ixv-8372"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm contextRef="c80" id="ixv-8373">P4Y</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c12" id="ixv-8374">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c12" id="ixv-8375">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c12" id="ixv-8376">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c12" id="ixv-8377">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c7"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c8"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c9"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c10"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c11"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c13"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c14"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c18"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c26"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c28"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c36"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c38"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c38"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c38"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c44"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c46"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c46"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c14"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c14"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c14"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c14"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="c59"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c75"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c2"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c2"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c73"
      id="hidden-fact-54"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c73"
      id="hidden-fact-55"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c73"
      id="hidden-fact-56"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c73"
      id="hidden-fact-57"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c73"
      id="hidden-fact-58"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c73"
      id="hidden-fact-59"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c78"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c80"
      id="hidden-fact-61"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="c80"
      id="hidden-fact-62"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c80"
      id="hidden-fact-63"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c80"
      id="hidden-fact-64"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c81"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c81"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-8448">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-8449">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-8450">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-8451">--12-31</dei:CurrentFiscalYearEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
